

SLC

British Journal of Pharmacology


November 1990

POST-NATAL CHANGES IN D-2 DOPAMINE RECEPTORS IN RAT AND POST-MORTEM HUMAN BRAIN.

K. Smith & K.M. O'Boyle*, Department of Pharmacology, University College Dublin, Belfield, Dublin 4.

Several studies have examined changes in D-2 dopamine receptors during ageing and senescence. Relatively few studies, however, have investigated post-natal changes in D-2 receptors. Increases in D-2 receptor density during the first 1-3 months of life in rats (Hyttel, 1987) and from birth to 2 years in humans (Seeman et al., 1987) have been observed but the patterns underlying these increases have not been examined across a large number of ages. The present study describes developmental changes in D-2 receptors in rat and post-mortem human brain.

D-2 receptors were measured in Sprague-Dawley rat striatal (aged 1-118 days) or post-mortem human caudate/putamen (aged 0.5-164 weeks) membranes by saturation analysis of ³H-spiperone binding as previously described (O'Boyle & Waddington, 1984). The relationships between post-natal age and D-2 receptor density are shown in figure 1. There were no changes in K_d with age.



At birth D-2 receptor densities in both rat and human brain are extremely low, being only 1/10 of the maximal values attained later on in life. In rats, B_{max} increases linearly after birth until day 20 and peak levels of D-2 receptors are achieved by post-natal day 30-40. Thereafter, B_{max} declines gradually up to day 118, the oldest age examined in this study. There was no difference in B_{max} between male and female rats of similar ages. In post-mortem human brain D-2 receptor density showed a similar linear increase from birth to 20 weeks of age. These developmental increases in D-2 receptors may be associated with the development of motor function in the young.

Hyttel, J. (1987) *Pharmac. Tox.* 61, 126-129.
O'Boyle, K.M. & Waddington, J.L. (1984) *Eur. J. Pharmac.* 98, 433-436.
Seeman, P., et al. (1987) *Synapse* 1, 399-404.
We thank Dr. B. Kierse, Our Lady's Hospital for sick children, Crumlin, for human brain tissue.

NO ALTERATIONS IN BRAIN IRON, COPPER, MANGANESE OR ZINC LEVELS IN PRESYMPTOMATIC PARKINSON'S DISEASE

D. T. Dexter¹*, F. R. Wells², F. Javoy-Agid³, Y. Agid³, S. E. Daniels², C. D. Marsden² and P. Jenner¹. ¹Parkinson's Disease Society Experimental Research Laboratories, Pharmacology group, Biomedical Sciences Division, King's College, Manresa Road, London, U.K. ²Parkinson's Disease Society Brain Bank, University Department of Clinical Neurology, Institute of Neurology, The National Hospital, London, U.K. ³Laboratoire de Medicine Experimentale, INSERM U289, Hopital de la Salpetriere, Paris, France.

Neuronal loss in Parkinson's disease (PD) is associated with a selective increase in total iron levels in substantia nigra, but a reduction in brain ferritin content, suggesting altered iron handling may occur in PD (Dexter et al, 1989, 1990). It is not known whether this represents a primary cause of dopamine cell death or whether iron accumulation is secondary to neuronal cell loss. For this reason we have determined the metal ion content of brains from control subjects who at post-mortem were found to have Lewy bodies and cell loss in the substantia nigra but who had not shown clinical symptoms of PD during life (presymptomatic PD). Post-mortem brain tissue was obtained from 6 normal control subjects with a mean age (68.3 ± 5.7 years), death to refrigeration time (2.9 ± 0.3hr), time between death and removal of the brain (14.3 ± 1.5hr) and from 6 Lewy body positive control subjects with a mean age (68.2 ± 5.8 years), death to refrigeration time (2.7 ± 0.4hr), time between death and removal of the brain (21.5 ± 2.2hr*). Brain tissue was freeze dried, solubilized by hot acid digestion and the metal ion content measured by Inductively Coupled Plasma (ICP) spectroscopy. No differences in the total levels of copper, iron, manganese and zinc were observed when the substantia nigra, cerebellum, cerebral cortex (Brodmann area 10) and globus pallidus from normal controls and Lewy body positive subjects were compared (see Table 1).

Table 1 Total copper, iron, manganese and zinc levels in normal controls and Lewy body positive subjects.
BRAIN AREA TOTAL METAL ION CONTENT (nmoles/g dry weight of human brain)

		COPPER	IRON	MANGANESE	ZINC
Substantia nigra	Normal(n=6)	897 ± 111	13729 ± 1854	41 ± 9	1132 ± 86
	Lewy body +ve(n=6)	906 ± 122	13258 ± 1174	39 ± 7	1026 ± 67
Cerebellum	Normal(n=5)	498 ± 82	4066 ± 504	25 ± 2	1483 ± 109
	Lewy body +ve(n=5)	295 ± 39	3146 ± 560	24 ± 3	1177 ± 103
Cerebral cortex	Normal(n=5)	422 ± 97	4578 ± 55	24 ± 4	1273 ± 227
	Lewy body +ve(n=5)	365 ± 100	4413 ± 303	30 ± 1	873 ± 57
Globus pallidus	Normal(n=5)	385 ± 80	13443 ± 1281	48 ± 3	1461 ± 244
	Lewy body +ve(n=5)	359 ± 43	13735 ± 1151	51 ± 4	997 ± 99

Values represent mean ± SEM. *P < 0.05 compared to normal controls (Student's t test).

There appears to be no accumulation of iron in PD in the early stages of the illness. This suggests that iron accumulation does not initiate dopamine neurone degeneration. It may however, contribute to the progression of the pathology.
Dexter, D. T, Wells, F. R, Lees, A. J, Agid, F, Agid, Y, Jenner, P and Marsden, C. D (1989). *J. Neurochem.* 52; 1830-1836.
Dexter, D. T, Carayon, A, Vidailhet, M, Ruberg, M, Agid, F, Agid, Y, Lees, A. J, Wells, F. R, Jenner, P and Marsden, C. D (1990). *J. Neurochem.* 55; 16-20..

EFFECT OF CARBIDOPA DOSE ON PHARMACOKINETIC AND METABOLIC HANDLING OF AN ORAL BOLUS OF L-DOPA IN RATS

P.J.E. Attwell, S. Rose*, P. Jenner and C.D. Marsden, Parkinson's Disease Society Experimental Research Laboratories, Pharmacology Group, Biomedical Sciences Division, King's College London, Manresa Rd, London SW3, U.K.

L-DOPA, when given in combination with the peripheral dopa decarboxylase (DDC) inhibitor, carbidopa, remains the treatment of choice in Parkinson's disease. Jaffe (1973) reported the optimal dose of carbidopa required to maximally inhibit systemic DDC in man to be 75mg/day. However, Cedarbaum *et al.* (1986) demonstrated enhanced L-DOPA efficacy when the dose of carbidopa exceeded the maximally effective dose. This was disputed by Contin *et al.* (1989) who found the AUC of L-DOPA and the clinical performance to be unaffected by increased dose of carbidopa. For this reason, we report the effect of increasing dose of carbidopa on the pharmacokinetic handling of L-DOPA in rats.

Male Wistar rats (306±4g) were cannulated in the carotid artery two days prior to experimentation. Rats were fasted 16h prior to drug administration. One hour prior to L-DOPA (50mg/kg po) administration, rats received carbidopa (3.125-100mg/kg ip). Blood samples were taken from the carotid cannula 15min prior to, and at intervals up to 300min after L-DOPA administration. Plasma levels of L-DOPA, 3-OMD, DOPAC and HVA were determined by HPLC with electrochemical detection.

Carbidopa pretreatment increased $t_{1/2}$ and decreased Cl_p of L-DOPA in a dose-related manner, with maximum effect at 25mg/kg (Table 1). Carbidopa pretreatment also tended to reduce V_d in a dose-related manner. Pretreatment with carbidopa increased $AUC_{0-\infty}$ for L-DOPA and $AUC_{0-300min}$ for 3-OMD, and decreased $AUC_{0-300min}$ for DOPAC and HVA in a dose related manner, with maximum effect at 100mg/kg.

Table 1 Effect of carbidopa (CD) dose on the pharmacokinetic handling of L-DOPA (Mean±sem, *p<0.05 compared to control, Dunn's test; n=5-6)

Dose CD (mg/kg)	$t_{1/2}$ (h)	V_d (L/kg)	Cl_p (L/kg/h)	$AUC_{0-\infty}$ (mg.h/L)		$AUC_{0-300min}$ (mg.h/L)		
				L-DOPA	3-OMD	DOPAC	HVA	
0	0.86 ± 0.16	5.1 ± 1.1	4.1 ± 0.5	8.9 ± 1.3	10.0 ± 1.7	1.4 ± 0.2	2.9 ± 0.3	
3.125	1.25 ± 0.21	3.7 ± 1.0	2.0 ± 0.2*	19.9 ± 2.0*	30.0 ± 1.7*	1.1 ± 0.2	2.5 ± 0.3	
12.5	1.36 ± 0.16	3.4 ± 0.5	1.8 ± 0.3*	25.9 ± 2.9*	48.0 ± 5.0*	0.7 ± 0.1*	1.8 ± 0.2*	
25	1.60 ± 0.15*	2.9 ± 0.9	1.1 ± 0.3*	39.5 ± 8.2*	72.7 ± 10.0*	0.3 ± 0.1*	1.5 ± 0.4*	
100	1.50 ± 0.21	2.2 ± 0.5	1.1 ± 0.3*	44.9 ± 7.4*	88.3 ± 13.0*	0.2 ± 0.0*	1.0 ± 0.3*	

Maximum bioavailability of L-DOPA was achieved after 25mg/kg carbidopa in the rat. Above this dose, peripheral decarboxylation of L-DOPA was decreased, but O-methylation to 3-OMD was increased. This suggests that, in agreement with Contin *et al.* (1989), increasing the ratio of carbidopa:L-DOPA does not increase the bioavailability of orally administered L-DOPA if DDC is maximally inhibited.

Cedarbaum, J.M., Kutt, H., Dhar, A.K., Watkins, S. & McDowell, F.H. (1986) Clin. Neuropharmacol. 9: 153-159;
Contin, M., Riva, R., Martinelli, P., Procaccianti, G. & Barruzzi, A. (1989) Clin. Neuropharmacol. 12: 75-81;
Jaffe, M. (1973) Adv Neurol 2:161-172

EFFECTS OF CHRONIC ETHANOL CONSUMPTION ON GABA_B MEDIATED RESPONSES IN THE ISOLATED MOUSE VAS DEFERENS

P.V. Taberner* and C.J. Watson, Department of Pharmacology, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, England.

GABA_B receptors are known to be present in a number of peripheral tissues. In the vas deferens they are responsible for the inhibitory effects of GABA and baclofen on electrically evoked twitches (Bowery *et al.*, 1981). Several studies have indicated that changes in GABA_A receptor sensitivity and number in the CNS are associated with ethanol tolerance and dependence (Taberner, 1989). Since tolerance to the direct effects of ethanol can be observed in vas deferens from mice pretreated with chronic ethanol (Hepper & Taberner, 1983), we have compared GABA_B mediated responses in control and ethanol-treated LACG mice.

The ethanol drinking schedule necessary to produce tolerance and mild dependence was as described previously (Unwin & Taberner, 1980). Vasa were removed and set up singly under 250 mg tension in a 5 ml bath in Mg⁺⁺-free Krebs Ringer bicarbonate medium (pH 7.4) gassed with 95% O₂ 5% CO₂. Isometric responses were recorded following electrical stimulation (60-100V, 0.1 Hz, 0.5 msec duration). After 60 min equilibration to establish a baseline response, drugs were added in cumulative fashion, with a 30 min washout between different drugs. IC₅₀ values were derived from dose-inhibition curves fitted to the logistic equation (Barlow, 1975). Results are means ± s.e. mean from 6 animals.

Inhibition of evoked twitches was obtained with GABA (IC₅₀ : 0.16 ± 0.02 μM) and baclofen (IC₅₀ : 0.15 ± 0.02 μM) but not 3-aminopropane-sulphonic acid or muscimol. The maximum inhibition observed after GABA or baclofen was 35% and 18% respectively. These values were slightly reduced in ethanol dependence mice. At the same time, the IC₅₀ value for GABA was significantly increased to 0.34 ± 0.07 μM (p<0.01, t-test). In tissue from mice after 4-6 h withdrawal, the GABA IC₅₀ was 7.06 ± 1.7 μM. Ethanol applied *in vitro* was inhibitory but, as found previously, no significant tolerance was observed: IC₅₀ control, 470 ± 48 mM; ethanol treated, 488 ± 33 mM. We conclude that peripheral GABA_B receptors, like CNS GABA_A receptors, are desensitized by chronic ethanol treatment and that this may account for some of the peripheral symptoms observed in ethanol dependence and withdrawal.

Barlow, R.B. (1975) Br. J. Pharmacol., 53, 139-142.
Bowery, N.B. *et al.* (1981) Eur. J. Pharmacol., 71, 53-70.
Hepper, A.D. & Taberner, P.V. (1983) Br. J. Pharmacol., 79, 245P.
Taberner, P.V. (1989) Comp. Biochem. Physiol., 93A, 241-245.
Unwin, J.W. & Taberner, P.V. (1980) Neuropharmacology, 19, 1257-1259.

CHANGES IN LONG TERM POTENTIATION IN HIPPOCAMPAL SLICES FOLLOWING CHRONIC BARBITAL TREATMENT

H. Frow, M. A. Whittington, & H. J. Little* Department of Pharmacology, The Medical School, University Walk, Bristol BS81TD

The physiological basis of the tolerance and the withdrawal syndrome caused by chronic barbiturate treatment is uncertain, although decreases in GABA inhibition have been suggested. Acutely, barbiturates have been shown to potentiate GABA-mediated inhibition, to block calcium channels and to increase chloride conductance. There has been little study of the electrophysiological effects of chronic barbiturate treatment.

Male mice, TO strain, 30 - 35g, were given barbital in powdered food for seven days: 3 mg barbital per g food for two days, 4 mg/g food for two days and 5 mg/g food for three days. Controls received a matched amount of powdered food only. At the end of the seven day treatment the mice were placed in clean cages and given powdered food without barbital for 24h. Our previous studies showed that the withdrawal syndrome was maximal at this time. Hippocampal slices, 400 μ m, were prepared and placed in an interface recording chamber. Extracellular recordings were made from area CA1, with Schaffer collateral/commissural stimulation, after 60 min equilibration of the slices. Threshold measurements were made every 10 min for 2h and input/output relationships established. Recordings were then made every 5 min for 60 min at 1.5 x threshold stimulation, a tetanus of 100 Hz for 1 sec applied and recording continued for another 60 min at 1.5 x threshold. Results are given as mean \pm s.e.m. (n)

The slices from the barbital treated mice showed significantly lower thresholds for production of single population spikes ($P < 0.001$, analysis of variance) compared with controls, and the input/output curves were shifted to the left. After 60 min thresholds were: controls $20.2 \pm 1.5 \mu$ A (5); barbital $15.2 \pm 0.7 \mu$ A (5). Paired pulse potentiation was unchanged by the barbital treatment. For 20 min following the tetanus, there were no significant differences between responses in slices from barbital-treated mice and controls, but during the next 40 min the responses after the barbital treatment were significantly smaller than controls ($P < 0.01$). For example, at 10 min after tetanus, responses were: controls $109.0 \pm 9.8\%$ (5), barbital $107.6 \pm 15.9\%$ (5) of pretetanus values. At 45 min after tetanus values were: controls $112.0 \pm 9.8\%$ and barbital $99.7 \pm 15.9\%$ of pretetanus values.

The results show that the chronic barbital treatment lowered the thresholds to stimulation in hippocampal pyramidal cells. This would be consistent with decreased GABA-mediated inhibition. However, such a decrease in inhibition would be expected to increase long-term potentiation (Wigstrom & Gustafsson, 1985). This was not seen, but the maintenance of long-term potentiation was decreased by the chronic treatment. An alternative possibility to explain all these results is that chronic barbital treatment caused some of the changes that produce long-term potentiation, so that such potentiation was already present at the beginning of our recordings.

H. Wigstrom & B. Gustafsson (1985) *Acta Physiol. Scand.*, **125**, 159 - 172

ADENOSINE ENHANCES RECOVERY OF SYNAPTIC TRANSMISSION IN RAT HIPPOCAMPUS AFTER ANOXIA

K. Donaghy & C.N.Scholfield, School of Biomedical Science, Queen's University, 97 Lisburn Road, Belfast, BT9 7BL.

In the central nervous system glutamate action may be important in determining anoxic tissue damage. Adenosine reduces glutamate release, stabilises electrical activity and is released from hypoxic and hyperactive tissue. Therefore adenosine might provide some protection from anoxia.

Transverse hippocampal slices were placed on a nylon mesh in a recording bath perfused with Krebs solution from a reservoir at 25°C continually gassed with the appropriate gas mixture. A pair of laquered tungsten stimulating electrodes (125 μ m separated by 100 μ m) were placed on the stratum radiatum of the CA1 region of the hippocampal slices and stimuli (10 V, 0.1 ms) continuously delivered at 0.05 Hz. Synaptically evoked potentials were recorded via a single saline filled glass micropipette (approximately 2 M Ω resistance) positioned in the stratum radiatum 1 mm away from the stimulating electrodes. Recordings were made via a capacitively coupled preamplifier, digitiser and computer or oscilloscope. Experiments were performed by superfusing the slice with oxygenated solution then changing to deoxygenated solution for a predetermined period. Following this, the slice was resuperfused with oxygenated solution. To assess the effects on evoked potentials, the peak height of the response was measured 30 min after reversion to oxygenated solution and this expressed as a proportion of the height before the test or before application of adenosine. To produce anoxia, the gas in equilibration with the solution was changed from 95% O₂/5% CO₂ and 2 mM glucose to 95% N₂/5% CO₂ glucose free for predetermined periods.

The evoked responses from the preparation were a negative population epsp and a superimposed positive population spike and the form of this remained constant for several hours. The O₂ free/glucose free solution was applied for periods between 3 and 33 min to 57 slices. For periods of up to 8 min, most of the slices fully recovered and the recovery was maintained for 1 hr or more. For more prolonged exposures, the amount of recovery was inversely dependent on the exposure time. The average exposure time required for a 50% recovery was 17.6 ± 1.8 min. In four of the slices, the evoked response transiently increased on reoxygenation followed by a decline to equilibrate out to a lower level.

In a further 28 slices, 100 μ M adenosine was present 5 min before and during the period of anoxia. At any exposure time, the amount of recovery was enhanced by adenosine. If the data from 8-33 min was pooled the difference between the two sets of data had a P value of 0.0001 (using the unpaired, two-tailed t-test). The anoxic exposure time for a 50% recovery in the response was increased to 29.0 ± 4.1 min. These results clearly showed a substantial and significant enhancement of recovery of the preparation when adenosine accompanied the period of anoxia.

We thank the Wellcome trust for financial support

CARBACHOL-INDUCED SUPPRESSION OF THE N-WAVE IN GUINEA-PIG OLFACTORY CORTEX SLICES: WEAK ANTAGONISM BY M₃-SELECTIVE MUSCARINIC ANTAGONISTS, HHSiD AND p-F-HHSiD

G. Bagetta* and A. Constanti. Department of Pharmacology, The School of Pharmacy, 29/39 Brunswick Square, London WC1N 1AX (U.K.).

Muscarinic cholinceptors are currently divided into M₁, M₂ or M₃ subtypes, based on their relative sensitivity to antimuscarinic compounds such as pirenzepine (Pz) and telenzepine (Tz) (M₁-selective), methoctramine and AFDX-116 (M₂-selective), or hexahydrosiladifenidol (HHSiD) and its para-fluoro-derivative (p-F-HHSiD) (selective for smooth muscle/glandular (M₃) over cardiac (M₂) receptor subtypes) (Hulme, et al., 1990). We have previously suggested that muscarinic suppression of excitatory neurotransmission in the olfactory cortex slice is mediated by presynaptic M₁ receptors located on lateral olfactory tract terminals, since this effect was competitively antagonized by nM doses of Pz or Tz, but not by methoctramine or AFDX-116 (see Bagetta & Constanti, 1990). It is conceivable however, that a component of our measured response was due to activation of M₃-type muscarinic receptors that might also be located presynaptically. We investigated this possibility by testing the effectiveness of the novel M₃-selective antagonists HHSiD and p-F-HHSiD towards the muscarinic inhibition of the N-wave in guinea-pig olfactory cortex slices maintained *in vitro*, using an extracellular recording method (see Bagetta & Constanti, 1990). Dose-dependent inhibition of the N-wave occurred following 2 min bath applications of carbachol (CCh; 25-150 μ M) as previously described. Pre-incubation of slices for 30 minutes with low doses of HHSiD (10-100 nM) or p-F-HHSiD (up to 1 μ M) produced no obvious inhibition of CCh responses. However, a clear reduction of CCh effects was observed in 250nM-1 μ M HHSiD or 10-50 μ M p-F-HHSiD. Longer (60 min) antagonist exposures did not lead to a further suppression of CCh responses. CCh dose-response lines were displaced in a parallel fashion by HHSiD or p-F-HHSiD, suggesting a weak competitive-type antagonism. Schild plot analysis (Schild slope constrained to unity) of pooled data yielded pA₂ values of 6.6 for HHSiD (n=9 slices) and 5.5 for p-F-HHSiD (n=9 slices) respectively. The expected pA₂ values for these antagonists acting on ileal M₃ receptors are ~ 7.9 and 7.8 respectively. In conclusion, our experiments show that muscarinic receptors involved in olfactory cortical N-wave suppression possess a low affinity for HHSiD and particularly for p-F-HHSiD. This suggests that peripheral M₃-type receptors are not significantly involved in mediating this presynaptic muscarinic response.

HHSiD and p-F-HHSiD were kind gifts from Professor G. Lambrecht (University of Frankfurt, FRG).

Hulme, E.C., Birdsall, N.J.M. and Buckley, N.J. (1990). *Ann.Rev.Pharmacol.Toxicol.*, **30**: 633-673.

Bagetta, G. & Constanti, A. (1990). *Eur.J.Pharmacol.*, **178**: 91-96.

THE PHORBOL ESTER TPA INHIBITS MUSCARINIC RESPONSES IN RAT LACRIMAL ACINAR CELLS BUT NOT IN RABBIT SALIVARY ACINAR CELLS

C.P.Berrie* & A.C.Elliott, Department of Physiological Sciences, University of Manchester, Manchester, M13 9PT.

The pathway by which agonists stimulate the production of inositol 1,4,5-trisphosphate (InsP₃) and diacylglycerol (DAG) in many different cell types has been well described (Berridge, 1987), as has the role of InsP₃-evoked Ca²⁺ release in mediating secretion in exocrine acinar cells (Marty, 1987). However, the possible role of DAG-stimulated protein kinase C in Ca²⁺-mediated secretion is less well understood. 12-O-tetradecanoylphorbol-13-acetate (TPA), a phorbol ester known to activate protein kinase C (Nishizuka, 1984), inhibits muscarinic responses in a number of exocrine glands. However, its effects are variable and may indicate differences in the level at which protein kinase C acts in the different cells. We have compared the effects of TPA on acetylcholine (ACh)-evoked changes in [Ca²⁺]_i and inositol phosphate production in acinar cell preparations from the rat lacrimal gland and the rabbit mandibular salivary gland in an effort to obtain further evidence on its mode of action in secretory epithelia.

Initial results demonstrated that ACh can elicit reversible and reproducible dose-related increases in [Ca²⁺]_i in both cell types. Incubation of the lacrimal acinar cells with 0.5 μ M TPA (5 minutes; 22°C) caused a decrease in the peak and plateau phases of the ACh-evoked [Ca²⁺]_i response by 50.6 (+/-7.6)% and 62.3 (+/-9.8)%, respectively. However, TPA had no significant effects on the ACh-evoked [Ca²⁺]_i response in rabbit mandibular acini. Investigations into the ability of TPA to inhibit ACh-stimulated inositol phosphate production under similar conditions demonstrated a 52.9 (+/-4.6)% reduction in rat lacrimal acini and no significant effect in the rabbit mandibular acini. These results clearly show that different exocrine acinar cells vary in their response to phorbol esters. They also indicate that in rat lacrimal acinar cells protein kinase C exerts an inhibitory action on muscarinic receptor-stimulated Ca²⁺ release at a level prior to InsP₃ production. This is consistent with the patch-clamp experiments of Llano and Marty (1987).

Berridge, M.J. (1987) *Ann. Rev. Biochem.*, **56**, 159-193.

Llano, I. & Marty, A. (1987) *J. Physiol.*, **394**, 239-248.

Marty, A. (1987) *T.I.N.S.*, **10**, 373-377.

Nishizuka, Y. (1984) *Nature*, **308**, 693-698.

THE DEVELOPMENT OF MICRODIALYSIS FOR THE MEASUREMENT OF THYROTROPHIN-RELEASING HORMONE IN RAT BRAIN *IN VIVO*

A H Waterfall*, R.W. Clarke¹ and G.W. Bennett, Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham NG7 2UH and ¹Department of Physiology and Environmental Science, School of Agriculture, Sutton Bonington, Leicestershire LE12 5RD

Microdialysis has recently found wider application with the measurement of neuropeptide release *in vivo* (see review by Kendrick 1989). We have used the technique with a sensitive radioimmunoassay (RIA) in attempts to measure the release of thyrotrophin releasing hormone (TRH) from regions of rat antero/lateral hypothalamus.

Concentric microdialysis probes with cellulose based (CEL O.D. -200 µm) or polyacrylonitrile (PAN, O.D. -300 µm) membranes. 2 mm in length were perfused with artificial CSF (0.4 µl min⁻¹) with or without BSA (0.05% w/w) or Bacitracin (0.1% w/w) and tested for relative recovery of TRH *in vitro* at room temperature over several hours. Samples were collected in the upturned tip of an Eppendorf tube and snap frozen for later RIA. Cellulose membranes generally exhibited better relative recovery than polyacrylonitrile membranes, although considerable variation occurred both within and between probes (CEL: mean = 17.5%, range = 13-24%, n=9; PAN, mean = 10%, range = 4-16%, n=9).

Probes with CEL membranes perfused as above were run *in vitro* for approximately 60 minutes then inserted stereotactically (Bregma: RC -1.3 mm, LAT -1.3 mm, DV -9.5 mm, Paxinos & Watson 1986) into the brain of urethane anaesthetised (1.3 g kg⁻¹) male Wistar rats (250 - 300 g) in two groups of n=10 (A and B). Group A was perfused with CSF containing BSA and no stimulus applied. Group B was perfused with CSF containing Bacitracin (0.1%) and a potassium stimulus (300 mM KCl in CSF + Bacitracin) was applied for 1 hour between 2 control periods. In all experiments samples were collected hourly following a 90 minute preliminary perfusion.

In group A no baseline levels of TRH were obtained. In group B both control and potassium stimulated release were measured in 4 animals (control release = 10.5 ± 1.8 fmol/sample (mean ± S.E.M.), potassium release = 19.6 ± 4.9 fmol/sample). For these animals probe recovery *in vitro* was 22.5 ± 3%, (mean ± S.E.M., n=4) whereas the recovery of the probes used in the remainder of the group was 11.2 ± 1.8 (n=6). This suggests the need to select probes by prior *in vitro* testing before their use *in vivo*.

This study indicates that the microdialysis technique is likely to be useful for the measurement of TRH *in vivo*, particularly if better relative recovery of peptide can be achieved and maintained. Further improvements in RIA sensitivity will also enhance the technique.

We are grateful to the Wellcome Trust for financial support.

Kendrick, K.M. (1989) *Neuroendocrine Peptides*. ed. P.M. Conn. Vol. 168, pp 182-205. London: Academic Press.
Paxinos, G. & Watson, C. (1986) *Stereotaxic Co-ordinates*. New York: Academic Press.

503P

IN VITRO STUDIES ON THE MECHANISMS BY WHICH CYTOKINES ACTIVATE THE HYPOTHALAMO-PITUITARY-ADRENAL AXIS

A.M. Cowell*, H.D. Loxley and J.C. Buckingham. Dept. of Pharmacology, Charing Cross and Westminster Medical School, Fulham Palace Road, London W6 8RF.

Observations that interleukins 1 and 6 (IL-1 and IL-6) stimulate the secretion of adrenocorticotrophin (ACTH) in the rat *in vivo* (Naitoh *et al.* 1988; Rivier *et al.* 1989) have led to suggestions that cytokines may play a role in the activation of the hypothalamo-pituitary-adrenal (HPA) axis in conditions such as septic shock. The sites at which these compounds exert their stimulatory effects are not clear. Accordingly, we have used *in vitro* models to examine the effects of various cytokines on the secretion of ACTH by the anterior pituitary gland and of the two major corticotrophin releasing factors, CRF-41 and vasopressin (AVP), by the hypothalamus. Hypothalamic and adeno/hypophyseal tissue were removed post mortem from chronically adrenalectomized rats and incubated *in vitro* as described previously (Buckingham & Hodges, 1977a; 1977b). Peptides released into the medium were measured by radioimmunoassay. Hypothalamic extracts (0.05-0.2 HE/ml) produced significant (P<0.02, n=8) concentration-dependent increases in ACTH release from the pituitary tissue but none of the cytokines tested were active in this respect. Thus, IL-1α (250 & 500pg/ml), IL-1β (50-200pg/ml) and tumour necrosis factor, TNF (312.5-1250pg/ml), alone or in combination, failed to influence significantly (P>0.1, n=6-7) either resting or hypothalamic extract (0.1HE/ml) - induced ACTH secretion when in contact with the tissue for 60 min, although in one instance IL-1β (200pg/ml) produced a small but significant (P<0.05, n=6) increase in peptide release.

Preliminary data (n=3-5) with the hypothalamus suggest that the cytokines influence the secretion of both AVP and CRF-41. IL-1α (50-1000pg/ml) and IL-6 (5-20ng/ml) produced, within 15 min, 2 to 3 fold increases in the release of AVP. TNF (625 & 1250pg/ml) was considerably more active in this respect and initiated approximately 30 fold increases in the secretion of the peptide. None of these responses appeared to be concentration-dependent. In contrast, IL-6 (5-20ng/ml) produced dose-dependent increases in CRF-41 release. The results support the concept that cytokines activate the HPA axis and suggest that their stimulatory effects are exerted predominantly at the level of the hypothalamus and that they may involve alterations in the release of both CRF-41 and AVP.

We are grateful to the Medical Research Council and Charing Cross and Westminster Medical School for financial support and to the National Institute for Biological Standards and Control for the cytokines.

Buckingham, J.C. Hodges, J.R. (1977a). *J.Endocr.* **72**, 187-193.

Buckingham, J.C. Hodges, J.R. (1977b). *J.Physiol.* **272**, 469-479.

Naitoh, Y., Fukata, J., Tominaga, T., Nakai, Y., Tamai, S., Mori, K. & Imura, H. (1988). *Biochem. Biophys. Res. Commun.* **155**, 1459-1463.

Rivier, C., Vale, W. & Brown, M. (1989). *Endocrinology*, **125**, 3096-3102.

PHOSPHATIDYL CHOLINE METABOLISM AND CONTRACTION IN ARTERIOLAR SMOOTH MUSCLE

Jane E. Nally*, S.B. Guild, T.C. Muir, Department of Pharmacology, University of Glasgow, Glasgow G12 8QQ

Simultaneous intracellular electrical and mechanical recordings from the proximal rabbit saphenous artery have revealed that noradrenaline (NA) produces a contraction independent of any membrane depolarisation (Muir & Nally, 1989). Biochemical mechanisms by which NA could act in this tissue include hydrolysis of phosphatidylinositol 4,5 biphosphate (PIP₂) or hydrolysis of phosphatidylcholine (PC), (see review by Löffelholz, 1989). The possibility that either or both of these mechanisms were involved in the contraction to NA in the rabbit saphenous artery was investigated.

Total inositol phosphate (IP) production from PIP₂ hydrolysis was measured in segments (2cm) of artery by the method of Akhtar & Abdel-Latif, (1984). PC hydrolysis was estimated by measuring glycerophosphocholine (GPC), choline phosphate (ChoP) and choline (Cho), using the method of Cook & Wakelam, (1989).

NA (10⁻⁷-10⁻⁴M) failed to raise IP content of the rabbit saphenous, but did so significantly in the rat tail artery (prepared as described by Burnstock & Sneddon, 1984). In the rabbit saphenous, however, NA (10⁻⁷-10⁻⁴M) produced a concentration-dependent increase in both ChoP and Cho, which was abolished by prazosin (10⁻⁶M). GPC levels were unaffected by these concentrations of NA. The increase in Cho levels was monophasic and maximal after 15-30s. The increase in ChoP was biphasic, with a small peak at 15-30s and a much larger increase 2-4 min later.

These results demonstrate, for the first time in this tissue, that NA utilises PC hydrolysis in this artery as a source of DAG, in the absence of PIP₂ hydrolysis. The early rise in Cho levels implies the activity of phospholipase D, although some small, simultaneous activity of phospholipase C, leading to ChoP production, cannot be precluded. The later, much larger rise in ChoP, however, is likely to result from phosphorylation of Cho and does not match, in time course, the contraction evoked by NA in this tissue. The lack of production of GPC implies that involvement of phospholipase A₂ in the response to NA in this tissue is unlikely.

We acknowledge the support of I.C.I. and the Wellcome Trust.

Akhtar, R.A. & Abdel-Latif, A.A. (1984) *Biochem. J.* **224**, 291-300.

Cook, S.J. & Wakelam, M.J.O. (1989) *Biochem. J.* **263**, 581-587.

Löffelholz, K. (1989) *Biochem. Pharmacol.* **38**, 1543-1459.

Muir, T.C. & Nally, J.E. (1989) *Br. J. Pharmacol.* **96**, 188p.

Burnstock, G. & Sneddon, P. (1984) *J. Physiol.* **357**, 130P.

POST-SYNAPTIC α -ADRENOCEPTORS DO NOT MEDIATE THE RESPONSE TO FIELD STIMULATION IN SHEEP MESENTERIC LYMPHATIC VESSELS

N.G. McHale*, H.R. Harty & K.D. Thornbury. School of Biomedical Science, Queen's University, 97, Lisburn Road, Belfast BT9 7BL

Bovine mesenteric lymphatic vessels have a noradrenergic innervation stimulation of which increases the frequency of spontaneous contractions. This excitatory response is converted to an inhibitory one by α -adrenergic blockers and no response persists in the presence of a combination of α and β blockers (McHale *et al* 1980). It was anticipated that sheep mesenteric vessels would have a similar innervation but in the present study this was found not to be the case.

Spontaneous isometric contractions were recorded in isolated rings of sheep mesenteric lymph duct. These contracted rhythmically at a frequency of 5.5 per min (\pm 2.4 S.D. n=14) and field stimulation (35 V nominal, 0.3 msec pulse width) at a frequency of 1 Hz increased this resting rhythm to 9.4 ± 4.0 . This acceleration in contraction frequency was abolished by 10⁻⁶ M tetrodotoxin but was not blocked by 10⁻⁶ M phentolamine, prazosin or yohimbine. Mean frequency of contraction increased from $8 (\pm 0.3, \text{SEM}, n=6)$ to 13 ± 1.0 before and from 9.2 ± 0.6 to 13.8 ± 0.7 in the presence of phentolamine. Similarly in the case of prazosin frequency increased from 6.1 ± 0.3 to 11.3 ± 1.2 before drug addition and from 7.1 ± 0.4 to 10.7 ± 1.0 in its presence (n=6). Yohimbine had similarly little effect since frequency increased from 9.5 ± 0.3 to 14.4 ± 0.7 before drug addition to 11.1 ± 0.5 to 14.3 ± 0.9 in its presence (n=7).

The effect of field stimulation was mimicked by the application of 10⁻⁶ M noradrenaline. Control frequency before drug addition was 5.9 ± 0.9 (S.E.M., n=4) and this was increased to 13.3 ± 1.1 during noradrenaline perfusion. In contrast to its effect on field stimulation phentolamine 10⁻⁶ M abolished the effect of exogenous noradrenaline (6.8 ± 0.7 contractions/min before drug addition, 6.5 ± 0.79 in the presence of both noradrenaline and phentolamine).

It can be concluded from these results that stimulation of intramural nerves in isolated sheep mesenteric lymphatics produces an excitatory effect similar to that observed in bovine vessels but in the sheep the excitation is not mediated via post-synaptic α -receptors.

Reference

McHale, N.G., Roddie, I.C. & Thornbury, K.D. (1980) *J. Physiol.* **309**, 461-472

FUNCTIONAL EVIDENCE FOR THE EXISTENCE OF POSTSYNAPTIC α_2 ADRENOCEPTORS IN THE RAT ISOLATED TAIL ARTERY

A. Fuglsang*, D. Pollock & T.W. Stone, Department of Pharmacology, University of Glasgow, Glasgow G12 8QQ, Scotland

In the rat isolated tail artery, field stimulation causes a contraction that may be the resultant of at least two components (Bao et al., 1989). Evidence for such a view comes from studies in which the major, noradrenergic component, can be abolished by the α_1 -adrenoceptor antagonist, prazosin, and the purinergic component can be blocked by α , β -methylene adenosine triphosphate (mATP), which desensitizes the P_2 -purinoceptor. The present study re-examined this hypothesis by investigating the effects of prazosin and mATP.

Wistar rats were stunned and killed by exsanguination. Segments of tail artery (3–4 mm) were attached to a fine stainless steel stimulating electrode inserted into the lumen of the vessel. The resting tension on each segment of artery was initially set at 1 g and the vessel was allowed to equilibrate in Krebs buffer (37°C, gassed with a mixture of 95% O₂/5% CO₂) for 1 hour, after which the tension was reset to 1 g and the tissue was allowed to equilibrate for a further hour. Isometric contractions were obtained to noradrenaline (NA), mATP, clonidine and field stimulation (trains of 10, 0.4 ms pulses at 10 Hz and 100 s intervals, 40 V), administered alone and in the presence of yohimbine, prazosin or diltiazem.

Field stimulation produced motor responses that were abolished by prazosin (0.1 μ M). Low concentrations of clonidine (50 nM) caused slow rhythmic contractions, which were abolished by yohimbine (10 nM) or by diltiazem (2 μ M). Higher concentrations of clonidine (250 nM–5 μ M) caused more rapidly-developing contractions, that were less affected by yohimbine (10 nM) or diltiazem (2 μ M). Clonidine (50 nM–5 μ M) inhibited motor responses to field stimulation. Prazosin (0.1 μ M) also reversed the effect of clonidine on the baseline tone but unlike yohimbine, prazosin also abolished the field stimulation-induced responses. mATP (2–4 μ M) produced transient contractions and increased the amplitude and reduced the duration of the field stimulation-induced motor responses. The duration of the field stimulation-induced response was reduced by diltiazem (2 μ M) and yohimbine (10 nM), both of which reduced the amplitude of the response by 10%. Immediately after washing out yohimbine, the field stimulation-induced response remained elevated for 20–30 minutes. These observations suggest that in the tail artery there may be postsynaptic α_2 adrenoceptors, which operate a Ca²⁺ channel that can be blocked by diltiazem. These α_2 -adrenoceptors may be activated by low concentrations of clonidine (50 nM), whilst higher concentrations of clonidine additionally activate α_1 -adrenoceptors, which will mainly be responsible for the nerve-mediated, noradrenergic response, and may operate a coupling mechanism that uses intracellular rather than extracellular Ca²⁺.

* Supported by the Danish Medical Research Council

Bao, J.X., Eriksson, I.E. & Stjärne, L. (1989) *Acta Physiol. Scand.*, **136**, 287–288.

IS 2-METHYLTHIO-ATP AN APPROPRIATE TOOL FOR THE IDENTIFICATION OF P_2 -PURINOCEPTORS?

I. A. Dainty *, J. E. Steptoe, S. E. O'Connor & P. Leff. Fisons plc, Pharmaceutical Division, Research & Development Laboratories, Bakewell Road, Loughborough, Leicestershire, LE11 0RH

2-methylthio-ATP (2meSATP) is a key agonist in the differential classification of P_2 -purinoceptors, showing higher potency than ATP at P_{2Y} -receptors and lower potency at P_{2X} -receptors (Burnstock & Kennedy, 1985). In some systems which, according to agonist potency orders, contain P_{2Y} -receptors, 2meSATP apparently exhibits partial agonism. For example, in cultured pig aortic endothelial cells, 2meSATP produced a lower maximum response than ATP in stimulating prostacyclin production (Needham et al., 1987). In principle, the analysis of partial agonists to obtain affinity and efficacy estimates provides a more quantitative means of classifying receptors than agonist potency order information. It was of interest therefore to analyse 2meSATP's agonist action on the vascular endothelium in more detail. ADP β S (Adenosine 5'-(2-thiodiphosphate)) was also studied since it too has apparently demonstrated partial agonism at the endothelial receptor (Martin et al., 1985).

3mm ring segments of thoracic aorta were obtained from male Sprague-Dawley rats (330–370 g.wt.) and prepared for isometric force recordings in Krebs' solution containing indomethacin (2.8 μ M) and the P_1 -receptor antagonist, 8-sulphophenyltheophylline (300 μ M), maintained at 37°C and gassed with 5% CO₂ in oxygen. Each preparation was pre-contracted with 35mM KCl and, in experiments using 2meSATP and ADP β S, 100 μ M α , β meATP was included to desensitise P_{2X} -receptors. Cumulative agonist concentration-effect (E/[A]) curves were then constructed to ATP. The preparations were washed and after 45 min an E/[A] curve to a test agonist was constructed. Potency ($p[A_{50}]$) and intrinsic activity (α) estimates were obtained by logistic curve-fitting. Partial agonist data were analysed using the operational model (Leff et al., 1990) employing ATP as reference full agonist. In some preparations an E/[A] curve to ATP was constructed in the presence of 100 μ M 2meSATP or ADP β S.

The resulting potency order ($p[A_{50}]$'s in parentheses) was 2meSATP (6.59) > ATP (5.57) > α , β meATP (> 4.00), apparently confirming the receptor as the P_{2Y} -type. 2meSATP and ADP β S behaved as partial agonists compared to ATP (α = 0.41 and 0.54 respectively) and the resulting affinity (pK_A) estimates were 6.30 and 5.27. However, 2meSATP at 100 μ M, which is 200 times higher than its apparent dissociation constant, failed to cause any rightward displacement of ATP E/[A] curves. This lack of competition between the two agonists suggests that they are not interacting with a common receptor. The same was true when ADP β S was used.

These results question the use of 2meSATP in the identification of ATP receptors at least on the vascular endothelium. They also have implications for the use of agonist potency orders in the subclassification of P_2 -purinoceptors.

Martin, W., Cusack, N.J., Carleton, J.S. & Gordon, J.L. (1985) *Eur. J. Pharmacol.*, **108**, 295–299

Burnstock, G. & Kennedy, C. (1985) *Gen. Pharmacol.*, **16** (5), 433–440

Needham, L., Cusack, N.J., Pearson, J.D. & Gordon, J.L. (1987) *Eur. J. Pharmacol.*, **134**, 199–209

Leff, P., Prentice, D.J., Giles, H., Martin, G.R. & Wood, J. (1990) *J. Pharmacol. Meth.*, **23**, 225–237

PHARMACOLOGICAL PROFILE OF *PHONEUTRIA NIGRIVENTER* VENOM ON RABBIT VASCULAR SMOOTH MUSCLE

Antunes, E., Marangoni, R.A., Borges, N.C.C., Fontana, M.D. & de Nucci, G.* Department of Pharmacology, Faculty of Medical Sciences, UNICAMP PO Box 6111, 13081 - Campinas - SP, Brazil.

Phoneutria nigriventer is a spider responsible for most human accidents of spider bites in the Center East and South of Brazil. *Phoneutria nigriventer* venom (PNV) has been described as neurotoxic, causing activation of sodium channels (Fontana & Vital-Brazil, 1985), leading to neuromuscular blockade or release of acetylcholine and norepinephrine by the autonomic nerve endings in the guinea pig auricles (Vital-Brazil et al., 1988). Here we investigated the involvement of both sodium and calcium channels on the PNV-induced contractions in rabbit vascular smooth muscle.

Male, New Zealand White rabbits (2-3 kg) were anaesthetised with thiopental sodium (40 mg/kg, iv) and exsanguinated via the carotid artery. Rabbit mesenteric (RbMesA), coeliac (RbCA) and pulmonary (RbPA) arteries, the vena cava (RbVC), mesenteric (RbMesV) and jugular (RbJV) veins were removed, placed in oxygenated Krebs' solution and cleared of fat and connective tissue. Spiral strips were denuded of endothelium by gentle rubbing of the luminal surface with a cotton bud and mounted in the cascade (Vane, 1964). The tissues were superfused with oxygenated (95% O₂/ 5% CO₂) and warmed (37°C) Krebs' solution at a flow rate of 5 ml/min. PNV and other agonists were given as single bolus. Antagonists were infused at a flow rate of 0.1 ml/min.

PNV (1-30 ug) produced dose-dependent contractions characterized by rapid onset and short duration in all vascular tissues assayed (n > 10 for each tissue). Venous tissues were more sensitive to PNV than arterial ones (see Table). Phenoxybenzamine (PBZ, 50 nM, infused for 0.5 h) did not significantly inhibit PNV-induced contractions (n = 3-5), although it caused a 100-1000 fold decrease in adrenaline sensitivity (n = 5 for each tissue).

PNV ED50 (ug)	RbVC	RbMesV	RbPA	RbMesA
Before PBZ	1.1 ± 0.3	4.2 ± 1.5	4.5 ± 1.1	5.2 ± 2.6
After PBZ	1.3 ± 0.2	9.8 ± 4.3	7.5 ± 2.1	9.6 ± 6.7

Tetrodotoxin (3.0 uM, n=3), an antagonist of voltage-dependent sodium channels, did not affect PNV-induced contractions but blocked those evoked by the sodium channel agonist veratrine (100-300 ug). Nifedipine (0.1 uM, n=3 for each tissue) and nicardipine (0.1 uM, n=3 for each tissue) abolished BAY K8644 (0.3-3.0 nmol)-induced contractions, without affecting PNV-induced contractions.

Our results demonstrate that PNV-induced contractions on vascular smooth muscle occur independently of both voltage-dependent sodium and dihydropyridine-sensitive calcium channels activation.

Fontana, M.D. & Vital-Brazil, O. (1985). Brazilian J. Med. Biol. Res. 18, 557
Vital-Brazil, O. Leite, G.B. & Fontana, M.D. (1988). Ciencia e Cultura 40, 181
Vane, J.R. (1964). Br J. Pharmacol. Chemother. 23, 360.

509P

RESPONSES TO ENDOTHELIN IN HYPERTENSIVE RABBITS

*Y.T. Huang, C.A. Hamilton, C.A. Howie, J.L. Reid.

University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT.

Endothelin (Et) has been intensively studied since its identification in 1988 (Yanagisawa et al). Despite this, questions remain as to its mechanism of action and role in pathophysiology. We have examined responses to Et in perinephritis hypertension in the rabbit. Animals were made hypertensive as previously described (Hamilton et al, 1987) and studied during development and in established hypertension (at 2 and 6 weeks after surgery). Pressor/depressor responses to iv Et 0.03-0.2 nmoles/kg were observed for 30 min in conscious animals. In addition, pressor responses to 0.1 nmoles/kg Et were examined before and after bolus doses of nifedipine (N) or verapamil (V) 0.1 mg/kg iv or during N infusions 0.072 and 0.096 mg/kg/hr.

MAP was increased in hypertensive animals (HT), MAP 77±5 in controls (C) compared to 97±9 and 105±17 mmHg in HT at 2 and 6 weeks post surgery. Et caused an immediate depressor response followed by a prolonged dose related pressor response which reached a maximum in 1-3 min and took 15-30 min to return to baseline. The maximum pressor response was greater in HT (Table 1), however when examined in relation to starting MAP this difference did not achieve significance.

Table 1 Increase in MAP (mmHg) 2 min after Et (nmoles/kg).

	0.03	0.05	0.1	0.2	
2 week HT	7±4	12±2*	18±8*	24±11*	
2 week C	5±2	7±3	12±3	15±5	mean ± SD
6 week HT	12±5*	14±7	23±8*	31±12	* p < 0.05 vs C.
6 week C	6±2	10±4	16±4	27±8	

N and V attenuated pressor responses to Et in HT and C but the effect was greater in HT and in many cases only a depressor response was observed. 0.1 mg/kg N decreased the response to Et at 2 min by 25±7 and 37±17 in HT and 12±9 and 10±6 mmHg in C at 2 and 6 weeks. V decreased the response by 20±18 and 1±6 mmHg in HT and C respectively at 6 weeks.

In contrast to the differential attenuation of pressor responses to Et N and V have similar effects on pressor responses to alpha adrenoceptor agonists in HT and C (Hamilton et al, 1987) suggesting differences in the mechanism of utilisation of extracellular calcium between alpha adrenoceptor agonists and Et. The differences in the effects of calcium antagonists on responses to Et in HT provides further evidence for anomalies in calcium handling in hypertension.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. Nature 1988; 332: 411-415.
Hamilton CA, Jardine E, Sumner DJ, Reid JL. Clin. & Exp. Pharmacol & Physiol. 1987; 14: 77-84.

EXOGENOUS HUMAN BIG-ENDOTHELIN IS CONVERTED TO ENDOTHELIN-1 IN THE RABBIT *IN VIVO*

P. D'Orléans-Juste*, P.S. Lidbury, S.J. Capper¹, T.D. Warner and J.R. Vane, William Harvey Research Institute, St.Bartholomew's Hospital Medical College, Charterhouse Square, London. ¹Amersham, Cardiff Laboratories, Forest Farm Whitchurch, Cardiff, Wales.

Endothelin-1 (ET-1) and the 38 amino acid precursor human big endothelin (Big-ET(h)) are equipotent as pressor agents in denervated rats, yet Big-ET(h) has only 1/100th of the potency of ET-1 *in vitro* (Kashiwabara et al., 1989). We have assessed the pharmacological activities of Big-ET(h), ET-1 and Big-ET(22-38) *in vivo* and monitored the changes in plasma levels of ET-1 in anaesthetized rabbits. In addition, we have assessed the *in vitro* effects of these peptides in guinea pig isolated perfused lungs. Rabbits were anaesthetized with sodium pentobarbitone, and a cannula placed in the left ventricle, via the right carotid artery, for measurement of left ventricular systolic pressure (LVSP) and administration of peptides and collection of blood samples (1 ml). The effects of Big-ET(h), ET-1 or Big-ET(22-38) on LVSP, ADP-induced platelet aggregation *ex-vivo* (Thiemermann et al., 1988) and the plasma levels of ET-1-like immunoreactivity (ET-1_i) were determined. The antisera for ET-1 had only 0.1% cross-reactivity for Big-ET. As in experiments with ET-1 (De Nucci et al., 1988), eicosanoid release induced by Big-ET(h) from guinea-pig isolated lungs was assessed by specific radioimmunoassays for 6-oxo-prostaglandin F_{1α} (PGF_{1α}) and thromboxane (TX) B₂ in the perfusion effluent from the lungs. Big-ET (h) and ET-1 induced similar pressor responses (1 nmol/kg, ΔLSVP; 19 ± 4 at 5 min and 20 ± 4 mmHg at 1 min respectively). At 3 nmol/kg, Big-ET(h) inhibited platelet aggregation by 60% at 5 min, whereas 1 nmol/kg ET-1 caused 70-80% inhibition of platelet aggregation within 1 min. As with ET-1, indomethacin (5 mg/kg) both potentiated the pressor responses and abolished the anti-aggregatory effects of Big-ET(h). Big-ET(h) at 1 nmol/kg caused an increase in circulating levels of ET-1, which remained elevated for 30 min (P<0.05), whereas bolus injection of ET-1 (1 nmol/kg) raised ET-1_i levels for only 5 min (P<0.01). Infusion of Big-ET (3 x 10⁻⁷M) induced release of PGI₂ and TXA₂ from perfused lungs (maximal release: 2.8 ± 0.3 and 3.0 ± 0.2 ng/ml respectively). Big-ET(22-38), the C-terminal product of the atypical chymotrypsin-like cleavage of Big-ET(h) (Yanagisawa et al., 1988), did not affect LVSP or circulating levels of ET-1 and did not release eicosanoids. We suggest that Big-ET(h) has a similar pharmacological profile to ET-1 in anaesthetized rabbits, due to its gradual conversion to ET-1 in the circulation.

PDJ is a Scholar of the Canadian Heart Foundation. The William Harvey Research Institute is supported by a grant from Glaxo Group Research Ltd.

Kashiwabara, T., Inagaki, Y., Ohta, H., Iwamatsu, A., Nomitsu, M., Morita, A. and Nishikori, K. (1989) FEB letters 242, 73-76.
Thiemermann, C., Lidbury, P., Thomas, R. and Vane, J.R. (1988) Eur. J. Pharmacol. 158, 181-182.
De Nucci, G., Thomas, R., D'Orléans-Juste, P., Antunes, E., Walder, C., Warner, T.D. and Vane, J.R., (1988) PNAS. 85, 9797-9800.
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yasaki, Y., Goto, K. and Masaki, T. (1988) Nature, 332, 411-415.

MEMBRANE PERMEABILITY IS A DETERMINANT OF ARRHYTHMOGENESIS FOLLOWING ANION SUBSTITUTION

P.D. Ridley*, M.H. Yacoub & M.J. Curtis, Department of Cardiac Surgery, Harefield Hospital, Harefield, Middlesex UB9 6JH and Department of Pharmacology, Kings College, Manresa Road, London SW3 6L.

It has been demonstrated that substitution of chloride by nitrate is a novel method of reducing ischaemia- and reperfusion-induced arrhythmias (Ridley et al, 1989). Natural membranes differ in their permeability to anions. In cardiac myocytes the order of permeability is Iodide> Nitrate> Bromide> Chloride> Methylsulphate (Hutter & Noble, 1961).

In a randomized study, 60 rat hearts (n=12/group) were perfused (Langendorff mode) either with standard chloride-containing solution (Constituents in mM, NaCl 118.5, NaHCO₃ 25.0, KCl 4.0, MgSO₄ 1.2, CaCl₂ 1.4 and glucose 11.1, gassed with 95% O₂ and 5% CO₂, pH 7.4, 37°C) or with a similar solution modified by the substitution of chloride with a different anion. The incidences (%) of ventricular tachycardia (VT) and fibrillation (VF) were determined during 30 min regional ischaemia and during 10 min reperfusion (Figure 1). Hearts were excluded from the reperfusion study, and immediately replaced, if arrhythmias were already present at the time of reperfusion. Heart rate and coronary flow were recorded. Occluded zone size was measured using dye. Anion substitution of chloride profoundly altered the incidence of VT and VF. The effect did not correlate with heart rate, occluded zone size or coronary flow (all p>0.05) indicating a direct mechanism of action. Statistically significant reductions in ventricular arrhythmias were seen with anions with membrane permeability greater than chloride. Conversely, the impermeant anion, methylsulphate showed a tendency to promote ventricular arrhythmias (the persistent high incidence of arrhythmias at 30 min in this group made study of reperfusion arrhythmias impracticable).

In conclusion, these findings support the hypothesis that altered membrane permeability may contribute to the antiarrhythmic activity of some anion substitutions.

Fig. 1.

* Indicates p< 0.05 vs chloride group

Anion	Arrhythmia			
	Ischaemia VT	VF	Reperfusion VT	VF
Methylsulphate	100	100	Abandoned	
Chloride (Control)	100	67	100	92
Bromide	92	8*	100	92
Nitrate	0*	0*	58*	0*
Iodide	50*	0*	75	17*

Hutter, O.F. & Noble, D. (1961) J Physiol. 157, 335-350
Ridley, P.D. Hearse, D.J. & Curtis, M.J. (1989) Circulation 79 Suppl II, 192

THE EFFECT OF DOPAMINE ON KININ RELEASE FROM RAT AND HUMAN ISOLATED RENAL CORTICAL CELLS

K.G. Marshall*, J.D.M. Albano & D.G. Waller¹, Department of Renal Medicine, University of Southampton, St. Mary's Hospital, Portsmouth PO3 6AD and ¹Clinical Pharmacology Group, University of Southampton, Southampton General Hospital, Southampton SO9 4XY.

In the kidney the kallikrein-kinin system is implicated in local blood pressure control and natriuresis and radioligand binding studies have localized specific kinin receptors on rat renal cortex epithelial membranes (Cox et al, 1984). Cortical dopamine receptors are also present in both rat and human kidney (Baldi et al, 1988) and it has been suggested that intra-renal dopamine participates in local vasodilatation and natriuresis. To investigate the relationship between renal kinin and dopamine we have examined the effect of dopamine on kinin release from both rat (female Wistar-Kyoto) and human isolated renal cortical cells. Cells were prepared by collagenase digestion. Superfusion was carried out in parallel teflon columns (Drury et al, 1986) at 37°C with oxygenated Krebs-Ringer bicarbonate glucose buffer containing 0.2% bovine serum albumin, at a flow rate of 0.25 ml/min. Fractions were collected over 5 minute periods. After an equilibration period of 90 minutes cells were challenged with 10 minute pulses of dopamine (10^{-10} - 10^{-6} M) with 30 minute recovery periods between doses. Kinin release into the superfusate was assayed by radioimmunoassay using a monoclonal antibody. Integrated response ratios (RR) were calculated by comparing the mean basal kinin release in the three fractions before stimulation and the three fractions in the immediate recovery period, with the mean stimulated kinin release.

Using rat kidney cortical cells, after the equilibration period, basal kinin release remained stable over the next 4 hours with a Coefficient of Variation (CV) of 5.2%. In subsequent experiments stimulation with dopamine gave a bell-shaped response curve between 10^{-10} and 10^{-6} M with a significant increase at 10^{-9} M (RR:143.5±18.55, $p<0.005$, $n=6$) and a maximal response at 10^{-8} M (RR:216.7±68.61, $p<0.01$, $n=6$). Using cells from macroscopically normal surgically removed human kidney tissue, stable basal kinin release was shown in one experiment during 4 hours of superfusion (CV=7.3%). In a second experiment a similar dose-related response to dopamine was observed with maximal kinin release at 10^{-8} M. The dose-related increase in kinin release, from both rat and human renal cortical cells, in response to dopamine suggests that kinins may play an important role in its natriuretic and vasodilatory actions.

The financial support of the National Kidney Research Fund is acknowledged.

Baldi, E., Pupilli, C., Amenta, F., & Manelli, M. (1988) Eur. J. Pharmac. 149,351-356.
Cox H.M., Munday, K.A., & Poat, J.A. (1984) Clin. Exp. Hypertens .Ab (10 and 11) 11893-11896.
Drury, P.L., Williams, B.C., Edwards, C.R.W. & Horne, B. (1986) Clin. Sci. 71, 581-587.

GENTAMICIN NEPHROTOXICITY IN PRIMARY RAT RENAL PROXIMAL TUBULAR CELLS

H. McGlynn* & M. P.Ryan. (Introduced by F. Martin) Department of Pharmacology, University College Dublin, Belfield, Dublin 4.

Nephrotoxicity is a dose limiting feature of gentamicin administration. The renal pathogenesis of gentamicin can be attributed to its selective accumulation within renal proximal tubular cells. Previous results from our laboratory have indicated that gentamicin affects ^{45}Ca transport and phospholipid metabolism in brush border membranes from rat renal cortex (Godson and Ryan 1988). The present studies concerned gentamicin toxicity in primary rat renal proximal tubular cells.

The proximal tubular cells were prepared by collagenase digestion of the rat renal cortex and isolation of the proximal fraction on a Percoll gradient. The cells were seeded into 6-well plates and maintained for the 5 days of cultures in DMEM supplemented with 10% foetal calf serum and 2 mM glutamine.

Gentamicin significantly reduced the incorporation of [^3H]-thymidine into the tubular cells at a concentration of 10^{-4} M or greater, at 10^{-3} M a reduction to $71 \pm 12\%$ of control values ($p<0.0005$) was observed. Gentamicin at 10^{-3} M significantly reduced the cell number ($39.3 \pm 3.1 \times 10^4$) compared to control values ($72 \pm 8.1 \times 10^4$, $p<0.005$). Gentamicin significantly reduced the incorporation of [^{14}C]-leucine into the tubular cells at a concentration of 10^{-4} M or greater, at 10^{-3} M a reduction to $86 \pm 4\%$ of control values $p<0.05$ was observed. The protein content in the cells over the 5 days of culture was significantly reduced by gentamicin ($p<0.005$ on all days). For example, on day 2, control cell protein content was 121.4 ± 6.41 mg/ml whereas in gentamicin treated cells, protein content was 54.6 ± 2.6 mg/ml. A significant decrease in ^{45}Ca uptake into the cells was also detected at concentrations of 10^{-4} M and 10^{-3} M gentamicin. For example at 20 min control uptake was 1.713 ± 0.141 nmoles/mg protein 10^{-3} M gentamicin caused significant reduction to 0.975 ± 0.141 nmoles ($p<0.0005$). ^{45}Ca efflux from preloaded cells was significantly impaired by gentamicin at concentrations of 10^{-4} M and 10^{-3} M. At 20 mins control efflux was $40.8 \pm 3.9\%$ of ^{45}Ca load whereas 10^{-3} M gentamicin reduced the efflux to $67.1 \pm 0.6\%$ ($p<0.0005$) of the ^{45}Ca load remaining in the cells.

These results show that gentamicin, a known nephrotoxin, significantly impaired cell growth, protein content and calcium movements in primary rat renal proximal tubular cells. These primary renal cell cultures may offer a good model for mechanistic investigations of cell toxicity.

This work was supported by EOLAS, the Irish Science and Technology Agency.

Godson, C. & Ryan, M.P. (1988). Br. J. Pharmacol. 95, 578P.

INVESTIGATION OF CISPLATIN TOXICITY IN RAT RENAL PROXIMAL TUBULAR FRAGMENTS

S. McGuinness & M.P. Ryan*. (Introduced by F. Martin) Department of Pharmacology, University College Dublin, Belfield, Dublin 4.

Cisplatin is a widely used drug in the treatment of a variety of solid tumours. The chief dose limiting side effect of cisplatin is its pronounced nephrotoxicity which is cumulative and is characterised by necrosis of the S3 segment of the proximal tubule. In this study, the *in vitro* nephrotoxicity of cisplatin was examined in rats using an isolated renal proximal tubule preparation.

Proximal tubules were isolated from male Wistar rats (200-250 g) using collagenase digestion followed by mechanical sieving and differential centrifugation in 45% Percoll. The tubule preparation was characterized by marker enzymes, transport capabilities and by transmission and scanning electron microscopy. Alkaline phosphatase (AP) and gamma-glutamyltranspeptidase (gamma-GT) marker enzymes for the brush border were enriched in this preparation. Levels of AP ($p < 0.05$) and gamma-GT ($p < 0.05$) were significantly increased in the tubular preparation compared to the starting suspension. Na dependent hexose transport was assessed by [14 C]-alpha-methyl-glucopyranoside (alpha-MG) uptake. With a 0 mM concentration of sodium the uptake of [14 C]-alpha-MG at 20 minutes was significantly reduced ($p < 0.0005$) compared to uptake in medium containing 118 mM sodium. Alpha-MG uptake was reduced by phloridzin. The release of the lysosomal enzyme N-acetyl- β -D glucosaminidase (β -NAG) was significantly increased ($P < 0.05$) at concentrations of 100 μ M and 1000 μ M cisplatin. Cisplatin caused a dose dependent reduction in basal oxygen consumption to 51.6% of control at 16 μ M and to 36.7% of control at 1000 μ M ($p < 0.05$). Transmission electron micrographs of tubules treated with 3.0 mM cisplatin showed enlarged mitochondria with distorted cristae. Cytoplasmic blebbing of the basement membrane indicative of an acute toxic insult was also evident. Isolated proximal tubules accumulated [195 Pt]-cisplatin over a 5 hour period. The uptake of [195 Pt]-cisplatin after 90 minutes in the presence of metabolic inhibitors (30 μ M) was reduced to $43.2 \pm 6.2\%$ of control. Addition of Cisplatin:Methionine complex (1:10) significantly reduced uptake of [195 Pt]-cisplatin ($p < 0.005$) compared to control.

These results provide some insights into mechanisms of cisplatin transport and toxicity and suggest that the isolated rat proximal tubule preparation may be a useful *in vitro* model for the study of cisplatin nephrotoxicity.

515P

INHIBITION OF [3 H]-PAROXETINE BINDING BY SIBUTRAMINE, ITS METABOLITES AND OTHER ANTIDEPRESSANTS CORRELATES WITH INHIBITION OF [3 H]-5-HT UPTAKE

S.C. Cheetham, J.A. Viggers, N.A. Slater & W.R. Buckett, Boots Pharmaceuticals Research Department, Nottingham NG2 3AA

Paroxetine, a potent and selective inhibitor of 5-hydroxytryptamine (5-HT) uptake, has been used as a radioligand for 5-HT uptake sites (Habert et al., 1985). We have compared the potency of sibutramine, its secondary (BTS 54 354) and primary (BTS 54 505) amine metabolites and various other antidepressants to inhibit [3 H]paroxetine binding and [3 H]5-HT uptake. In addition, we have determined the ability of sibutramine and these two metabolites to inhibit [3 H]noradrenaline (NA) and [3 H]dopamine (DA) uptake.

Inhibition constants (K_i 's) for [3 H]paroxetine were measured by displacement of binding at 30pM to rat frontal cortical membranes (1 mg wet-weight/tube). Specific binding was defined by citalopram (1 μ M). Inhibition of synaptosomal uptake was determined at 2nM [3 H]5-HT or 10nM [3 H]NA (rat frontal cortex; 2.5 and 1.25mg/tube respectively) or 2.5nM [3 H]DA (rat striatum; 0.625mg/tube). Specific uptake was defined by zimeldine, desipramine and GBR 12909 (10^{-5} M), respectively.

[3 H]Paroxetine binding was potently inhibited by 5-HT uptake blockers such as citalopram and fluvoxamine. A good correlation was shown between the potency of sibutramine, its metabolites and other antidepressants to inhibit [3 H]paroxetine binding and [3 H]5-HT uptake (correlation 0.971; $p < 0.002$). These data support the view that sites labelled by [3 H]paroxetine are associated with the 5-HT transporter complex (Habert et al., 1985).

Table 1 K_i values for inhibition of [3 H]paroxetine binding and [3 H]5-HT uptake

	Paroxetine	5-HT		Paroxetine	5-HT
Sibutramine	2135 ± 137	3131 ± 193	Amitriptyline	18 ± 1	49 ± 2
BTS 54 354	19 ± 1	18 ± 2	Dothiepin	31 ± 2	78 ± 5
BTS 54 505	18 ± 2	26 ± 2	Zimeldine	68 ± 6	57 ± 4
Citalopram	0.65 ± 0.04	3.5 ± 0.4	Doxepin	126 ± 14	201 ± 2
Fluvoxamine	4.2 ± 0.3	3.6 ± 0.2	Desipramine	152 ± 6	200 ± 7
Imipramine	14 ± 2	31 ± 1	Nomifensine	1256 ± 40	2260 ± 132

K_i values (nM) \pm s.e. mean (n=3)

The metabolites of sibutramine more potently inhibited [3 H]paroxetine binding and [3 H]5-HT uptake than sibutramine itself. Similar results were obtained for inhibition of [3 H]NA and [3 H]DA uptake (Sibutramine, 283 ± 25 ; 2309 \pm 104; BTS 54 354, 2.7 ± 0.3 , 24 ± 1 ; BTS 54 505, 4.9 ± 0.4 , 31 ± 2 ; K_i values (nM) \pm s.e. mean for [3 H]NA and [3 H]DA uptake, respectively). These results support previous findings that the pharmacological effects of sibutramine are, at least in part, mediated by its secondary and primary amines (Luscombe et al., 1989), and that these two metabolites are potent NA uptake blockers *in vitro*.

Habert, E., Graham, D., Tahraoui, L., Claustre, Y. & Langer S.Z. (1989) Eur. J. Pharmacol., 118, 107-114.
Luscombe, G.P., Hopcroft, R.H., Thomas, P.C. & Buckett, W.R. (1989) Neuropharmacology, 28, 129-134.

THE EFFECT OF RS-30199 ON ANXIETY AND HIPPOCAMPAL MONOAMINE OXIDASE ACTIVITY IN THE RAT

Brian Moulton & Alun Morinan*, Neuropharmacology Research Group, Division of Physiology & Pharmacology, Polytechnic of East London, Romford Road, LONDON, E15 4LZ.

The 5-HT_{1A} receptor ligand RS-30199 has been reported to induce anxiety in Sprague-Dawley rats tested in the elevated plus maze and modified holeboard (Redfern *et al.*, 1989). In the present study, we have confirmed and extended these findings using a different strain of rat.

Male Lister Hooded rats (300-400g) were injected (i.p.) with RS-30199 (0.3-30.0 mg/kg), buspirone (2.0 mg/kg BSP), chlordiazepoxide (5.0 & 7.5 mg/kg CDP) or saline (CON). Forty minutes later, locomotor activity (Panlab Actisystem), anxiety (elevated plus maze) and hippocampal MAO activity were measured (Morinan, 1989).

At 30 mg/kg, RS-30199 reduced locomotor activity by 90%, but at 3 mg/kg there was a significant anxiogenic effect without any apparent sedation (Table 1). CDP but not BSP reduced anxiety, although none of the drugs had any effect on MAO activity (Table 1).

Table 1. Effect of the drugs on behaviour and MAO activity.

Drug	Dose (mg/kg)	Total Entries	Open/Total Entries (%)	Open/Total Time (%)	Locomotor Activity (counts)	MAO Activity (nmol/mg/h)
CON	-	11.4 ± 0.8 (14)	26.4 ± 3.4 (14)	13.2 ± 2.3 (14)	641 ± 18 (22)	37.5 ± 3.0 (12)
CDP	5.0	7.5 ± 2.4* (6)	44.9 ± 10* (6)	17.8 ± 9.0 (6)	649 ± 18 (6)	28.2 ± 1.7 (6)
CDP	7.5	10.3 ± 1.5 (8)	40.9 ± 7.3* (8)	20.9 ± 4.2 (8)	386 ± 33* (8)	46.6 ± 4.3 (6)
BSP	2.0	8.5 ± 1.0 (6)	31.6 ± 4.4 (6)	11.9 ± 2.3 (6)	655 ± 24 (6)	35.5 ± 1.4 (6)
RS	0.3	10.1 ± 1.2 (8)	17.8 ± 5.9 (8)	10.2 ± 3.8 (8)	613 ± 37 (8)	39.7 ± 2.7 (6)
RS	1.0	12.3 ± 0.9 (6)	17.4 ± 7.1 (6)	19.4 ± 5.9 (6)	672 ± 47 (6)	37.4 ± 1.8 (6)
RS	3.0	10.3 ± 0.7 (8)	17.6 ± 5.2* (8)	7.3 ± 1.7* (8)	591 ± 18 (8)	34.1 ± 2.1 (6)

Each value represents the mean ± s.e.m. (n) *P < 0.05 compared to CON (Dunnett's t-test)

In conclusion, these results are in agreement with those of Redfern *et al.* (1989), confirming that the effect of RS-30199 is due to anxiogenesis rather than sedation.

The support of Syntex Research Centre (Edinburgh), and the British Pharmacological Society is acknowledged.

Morinan, A. (1989) *Br. J. Pharmac.* 96, 13P.

Redfern, W., Clague, R.U. & Spedding, M. (1989) *Br. J. Pharmac.* 98, 682P.

LOW DOSE INTERACTION OF THE 5-HT_{1A} LIGAND GEPIRONE WITH ATROPINE ON SPATIAL LEARNING IN THE RAT

R.P. Barrett* & M.J. Rowan, Department of Pharmacology and Therapeutics, Trinity College, Dublin 2.

Cholinergic and serotonergic systems have been proposed to have mutually important roles in learning and memory (Vanderwolf, 1987). The combination of a reduction in serotonin synthesis with low dose atropine results in a marked spatial memory impairment (Richter-Levin & Segal, 1989). Since the 5-HT_{1A} receptor ligand gepirone has been found to produce deficits on a similar task (Rowan & Barrett, 1990) it was of interest to determine whether or not there would be a low dose interaction with atropine.

Male Wistar rats (250-300 g) were trained in a Morris water maze (1m diameter) to find a platform submerged in opaque water (24 - 26°C). Animals received four training trials each day for three days. Each trial consisted of a swim (maximum 2 min) and a 30s period on the platform. On the fourth day a 2 min probe test with the platform removed from the maze was videotaped and analysed. Water (1 ml/kg), gepirone (2 mg/kg) and atropine (20 mg/kg) were given i.p. 30 min before the first trial on each day. ANOVA of the log transformed data was used for inter-group comparisons. (Table 1, values are the mean ± s.e. mean, n = 12 in each group)

Table 1 Water maze performance following gepirone and atropine

	Escape latency(s)			Probe test target quadrant bias (% time)	Swim speed (cm/s)
	2	6	10		
A. Water	57 ± 13	42 ± 11	22 ± 6	32 ± 3	18 ± 1
B. Gepirone + water	56 ± 12	30 ± 8	10 ± 2	28 ± 3	19 ± 1
C. Water + atropine	71 ± 14	39 ± 12	19 ± 8	25 ± 2	22 ± 1
D. Gepirone + atropine	108 ± 9	78 ± 13	61 ± 14	22 ± 2	23 ± 1

There was no significant effect of gepirone or atropine alone on the acquisition of the task whereas the combination group (D) were markedly slower in learning the hidden platform location as measured by escape latency during training trials (P < 0.05 compared to groups A, B or C). On the probe test gepirone had no effect whereas both the atropine group (C) and the combination group (D) were impaired as measured by target quadrant bias (P < 0.05 compared to group A or B). Swim speed was faster in the atropine group (C) and the combination group (D), (P < 0.05 compared to group A or B). It would appear that gepirone and atropine in combination can produce a marked deficit in the acquisition of a spatial navigation task at doses which alone had no significant effect. This supports the hypothesis of an interaction between cholinergic and serotonergic systems on spatial memory.

Richter-Levin, G. & Segal, M. (1989). *Brain Res.* 477, 404-407.

Rowan, M.J. & Barrett, R.P. (1990). *Eur. J. Pharmacol.* in press.

Vanderwolf, C.H. (1987) *Behav. Brain Res.* 23, 43-57.

ANXIOGENIC EFFECTS ARE ASSOCIATED WITH YOHIMBINE BUT NOT WITH RS-15385-197 OR IDAZOXAN IN THE RAT

W.S. Redfern* & A. Williams, Department of Pharmacology, Syntex Research Centre, Riccarton, Edinburgh, EH14 4AP.

RS-15385-197 is a potent α_2 -adrenoceptor antagonist *in vitro* and *in vivo* which readily penetrates into the brain (Clark *et al.* 1989, Brown *et al.*, 1990). As the α_2 -adrenoceptor antagonist, yohimbine, is anxiogenic in man (Holmberg & Gershon, 1961) and in rat (Handley & Mithani, 1984), we have investigated the behavioural effects of RS-15385-197, yohimbine and idazoxan in rats by observing their activity in an elevated X-maze and a partially-shaded holeboard (Redfern & Williams, 1989).

Male Sprague-Dawley rats (160-210g; 12 per group), which had been housed singly for 4-8 days before testing, were injected i.p. with drug or vehicle (1 ml/kg), and 30 min later each rat was placed for 5 min on an elevated X-maze (Redfern & Williams, 1989). The rat was then tested in a holeboard containing a small roof (12 x 15 cm) fixed 10 cm above the floor in one corner (Redfern & Williams, 1989). The rat was placed in the shaded corner and observations were made of the initial emergence latency and of general activities during forays from the shaded corner, over 12 min. In pentobarbitone-anaesthetized rats (250-440g; 6-10 per group), the ability of the 3 antagonists (administered i.p.) to block central α_2 -adrenoceptors was determined by reversal of mydriasis produced by clonidine (0.3 mg/kg s.c.).

Clonidine-induced mydriasis: At 3 mg/kg i.p., RS-15385-197 and idazoxan produced a rapid, sustained reversal of the clonidine response (by 86.6 ± 2.0 and $86.2 \pm 2.2\%$ respectively, 30 min after injection) whereas yohimbine produced a gradual reversal of only $42.8 \pm 12.8\%$. A higher dose of yohimbine (10 mg/kg) was required in order to achieve $77.1 \pm 3.6\%$ reversal of clonidine-induced mydriasis.

X-maze: Yohimbine (10 mg/kg) reduced the % time spent on the open arms (from 20.1 ± 3.2 to $8.7 \pm 2.3\%$; $P < 0.02$, U-test); total arm entries were reduced after doses of 3 mg/kg (from 9.5 ± 0.8 to 5.7 ± 0.9 ; $P < 0.02$) and 10 mg/kg (from 13.6 ± 1.1 to 5.1 ± 1.3 ; $P < 0.002$). RS-15385-197 (3 mg/kg) and idazoxan (3 mg/kg) did not affect any parameters in the elevated X-maze.

Holeboard: Yohimbine (3mg/kg) suppressed head dips (from 11.4 ± 1.4 to 3.6 ± 1.7 ; $P < 0.02$) and the number of holes explored (from 4.1 ± 0.7 to 1.8 ± 0.7 ; $P < 0.05$) without significantly inhibiting other activities. A higher dose (10 mg/kg) increased emergence latency (from 12.8 ± 4.4 to 73.7 ± 10.7 s; $P < 0.002$) and virtually abolished all activity (e.g. forays were reduced from 8.0 ± 0.9 to 1.7 ± 0.5 ; $P < 0.002$). RS-15385-197 and idazoxan (both at 3 mg/kg) did not affect emergence latency or holeboard activities.

In conclusion, yohimbine reduced exploratory activity in these tests whereas idazoxan and RS-15385-197 did not, even though the doses of yohimbine used were equipotent (10 mg/kg) or less effective (3 mg/kg) at blocking central α_2 -adrenoceptors. Taking the reduced open arm activity in the X-maze as an index of increased anxiety, it appears from the results of these tests that, unlike yohimbine, RS-15385-197 and idazoxan did not have anxiogenic effects. This suggests that acute blockade of central α_2 -adrenoceptors is not associated with increased anxiety in the rat and that the anxiogenic effects of yohimbine therefore may be due to some other property of this drug.

Brown, C.M., Clague, R.U., Kilpatrick, A.T., MacKinnon, A., Martin, A.B. & Spedding, M. (1990) *Br. J. Pharmac.* **99**, 272P.

Clark, R.D., Repke, D.B., Kilpatrick, A.T., Brown, C.M., MacKinnon, A.C., Clague, R.U. & Spedding, M. (1989) *J. Med. Chem.* **32**, 2034-2036.

Handley, S.L. & Mithani, S. (1984) *Naunyn-Schmiedeberg's Arch. Pharmacol.* **327**, 1-5.

Holmberg, G. & Gershon, S. (1961) *Psychopharmacologia* **2**, 93-106.

Redfern, W.S. & Williams, A. (1989) *Br. J. Pharmac.* **98**, 683P.

THE EFFECT OF SYSTEMIC 5-CARBOXAMIDOTRYPTAMINE ON EXTRACELLULAR LEVELS OF 5-HT IN THE FREELY MOVING GUINEA-PIG

*A.J. Lawrence and C.A. Marsden, Dept. of Physiology and Pharmacology, Queen's Medical Centre, Nottingham NG7 2UH, U.K.

The technique of *in vivo* microdialysis is well established for the measurement of neurotransmitters in the extracellular space (Ungerstedt 1984). Such experiments have been successfully employed to measure 5-HT in the anaesthetised guinea-pig (Sleight *et al.*, 1990). The present study assessed the ability of the technique to measure extracellular 5-HT in the frontal cortex of the freely moving guinea-pig and to determine the effects of the non-selective 5-HT₁ agonist 5-carboxamidotryptamine (5-CT) (Connor *et al.*, 1986).

Male Dunkin-Hartley guinea-pigs (300-400g) were anaesthetised with a mixture of Hypnorm (Janssen), water and midazolam (1:2:1, 8ml/kg i.p.). Dialysis probes were implanted stereotactically into the frontal cortex using the atlas of Luparello (1967). The animals were allowed to recover for 24 hrs., and then perfused with artificial CSF. Half an hour later 4 x 20 min. samples were collected for the measurement of basal extracellular 5-HT. Animals were then given 0.01, 0.03, 0.1 or 0.3 mg/kg i.p. 5-CT, dialysis samples collected for at least a further 2 hrs., and behaviour observed.

The basal level of extracellular 5-HT was 113 ± 17 fmol/20 μ l (n=11). While saline administration had no significant effect on 5-HT levels, 5-CT produced a dose-related decrease with 0.3 mg/kg i.p. giving a maximal inhibition of $39 \pm 8\%$ (n=3). 5-HT values returned to normal within 2 hrs. and there was no effect on extracellular 5-HIAA. The administration of 5-CT at all doses caused a behavioural response consisting of wet dog shakes and hind limb abduction with associated flat body posture.

These data suggest that systemically administered 5-CT can act centrally to reduce neuronal release of 5-HT. This effect is likely to be mediated via either a reduction of neuronal firing by action on the somatodendritic autoreceptor or by a direct action on the terminal autoreceptor. The occurrence of wet dog shakes suggests that 5-CT may also interact with 5-HT₂ receptors *in vivo*.

Ungerstedt, U., (1984) in *Measurement of Neurotransmitter Release In Vivo*, ed. Marsden, C.A., pp 81-105, John Wiley & Son Ltd.

Sleight, A.J., Cervenka, A. & Peroutka, S.J., (1990) *Neuropharmacol.* **29**, 511-513.

Connor, H.E., Feniuk, W., Humphrey, P.P.A. & Perren, M.J., (1986) *Br. J. Pharmacol.* **87**, 417-426.

Luparello, T.J., (1967) *Stereotaxic Atlas of the Forebrain of the Guinea-Pig*, S. Karger, Basel.

ACTION OF SOME TRYPTAMINE ANALOGUES THAT ARE AGONISTS AT 5-HT₁ RECEPTORS ON CENTRAL AUTONOMIC OUTFLOW IN ANAESTHETIZED CATS

S.L. Shepherd*, D. Jordan¹ & A.G. Ramage, Academic Department of Pharmacology and ¹Department of Physiology, Royal Free Hospital School of Medicine, Hampstead, London NW3 2PF

Central activation of 5-HT_{1A} receptors using compounds, e.g. 8-OH-DPAT, which are structurally unrelated to 5-HT but selective for the 5-HT_{1A} receptor, causes a hypotension which is associated with a characteristic and dose-dependent patterning of autonomic outflows (Ramage, 1990). The present experiments were carried out to determine if central administration of the tryptamine analogues 5-carboxytryptamine (5-CT), N N-di-propyl-5-CT (DP-5-CT), indorenate and 5-HT, the latter in the presence of the 5-HT₂ antagonist cinanserin, cause similar effects on autonomic outflow to those produced by 8-OH-DPAT. As these compounds have varying affinities for the various subtypes of the 5-HT₁ receptor it may be possible to discern different roles for the various subtypes in the control of autonomic outflow.

Cats, anaesthetized with α -chloralose (70 mg/kg) and pentobarbitone sodium (6 mg/kg), were artificially ventilated after neuromuscular blockade with vecuronium bromide (200 μ g/kg). Simultaneous recordings were made of renal (RNA), splanchnic (SNA), cardiac (CNA) and phrenic nerve activity (PNA), blood pressure, heart rate, femoral arterial conductance (FAC), tracheal and intragastric pressure. Cumulative doses of 5HT (20 - 640 nmol/kg), 5-CT (0.625 - 160 nmol/kg), indorenate (100 - 800 nmol/kg) and DP-5-CT (2.5 - 80 nmol/kg) were given by microinjection (20 μ l over 1 min) into the IVth ventricle. Cinanserin (0.1 mg/kg) was given into the IVth ventricle before the doses of 5-HT.

DP-5-CT, 5-CT, indorenate and 5-HT caused maximum falls in BP of 44 ± 4 , 38 ± 6 , 23 ± 8 and 22 ± 3 mmHg respectively by the last dose. This was associated with varying degrees of sympathoinhibition but with little change in FAC. DP-5-CT, 5-CT and indorenate caused sympathoinhibition in all nerves, indorenate affecting all nerves equally, while DP-5-CT and 5-CT had a greater effect on RNA and SNA than on CNA. 5-HT caused a decrease in RNA and SNA but had no effect on CNA. DP-5-CT and indorenate also caused a bradycardia reaching a maximum of 16 ± 4 and 33 ± 10 beats/min respectively. Only the bradycardia caused by indorenate was weakly attenuated by atropine methonitrate (0.1 mg/kg). All drugs had little effect on phrenic nerve activity. Cinanserin had little effect on the above variables except to cause a small increase in FAC.

These results support the view that activation of central 5-HT₁ receptors causes a differential sympathoinhibition, with cardiac nerve activity being the least sensitive and renal nerve activity being the most sensitive.

This work is supported by the Wellcome Trust.

Ramage, A.G. (1990) J. Cardiovasc. Pharmacol. 15 (Suppl. 7) S75-S85.

SHAPE CHANGES: A NOVEL METHOD FOR ASSESSING THE EFFECT OF AGONISTS AND ANTAGONISTS ON HUMAN PLATELETS?

M.A. Barradas*, S. O'Donoghue & D.P. Mikhailidis (introduced by J.Y. Jeremy), Department of Chemical Pathology and Human Metabolism, Royal Free Hospital School of Medicine, London, NW3 2PF

Agonists interact with specific platelet receptors, causing shape change followed by aggregation. Low concentrations of agonists, such as adenosine diphosphate (ADP), 5-hydroxytryptamine (5-HT) and collagen, only induce a shape change which involves the transformation of platelets from a discoid to a spherical form.

Platelet shape change in platelet rich plasma (PRP) has previously been investigated by monitoring light transmission/scattering in the presence of EDTA to prevent platelet aggregation (Born, 1970). We devised a sensitive procedure to investigate agonist-induced platelet shape change in the presence/absence of antagonists. The method involves the stimulation of stirred PRP (1000 rpm, at 37 °C, for 30 s), the fixation of the platelets with glutaraldehyde (4% w/v in saline) and the measurement of platelet count and median platelet volumes (MePV) using a Coulter Counter ZM coupled to a Coulter Channelyzer 256 (resolution: ± 0.07 fl).

5-HT and ADP stimulated platelet shape change (PSC) *in vitro*, in a dose-dependent manner with significant ($P < 0.004$) increases in MePV occurring at 0.1 μ M for both agonists (control = 5.46 ± 0.44 fl, 5-HT = 5.98 ± 0.50 fl, ADP = 5.55 ± 0.38 fl, $n = 27$). Near maximal ADP and 5-HT-induced PSC was achieved with 0.4 μ M and 1 μ M (6.15 ± 0.50 fl and 6.07 ± 0.50 fl, respectively). Noradrenaline, at relatively high concentrations (1 μ M) also increased the MePV (5.55 ± 0.40 fl, $n = 12$), whereas adrenaline was ineffective (5.40 ± 0.45 , $n = 12$). The simultaneous addition of ADP (0.1 μ M) + 5-HT (0.01 μ M) caused a synergistic increase in MePV. At all these concentrations of agonists there was no platelet aggregation as measured by free platelet count. All samples were obtained from healthy male and female volunteers.

We also assessed the effect of naftidofuryl oxalate (NAF), a drug used in the treatment of peripheral vascular disease. NAF, at concentrations of 50 and 100 μ M, has been shown to inhibit platelet aggregation induced, *in vitro*, by 5-HT and ADP respectively (Davies & Steiner, 1988). Using the above methodology, we observed significant inhibition of 5-HT-induced PSC following the incubation of PRP with 3.125 μ M NAF for 5 min. In contrast, ADP- and collagen-induced PSC was significantly inhibited at concentrations > 50 μ M. PSC induced with the combination of ADP + 5-HT was significantly inhibited at concentrations as low as 1.56 μ M NAF.

In conclusion, we have devised a sensitive method for investigating agonist-induced shape change, a phenomenon which precedes platelet aggregation. Using this methodology, NAF appears to be at least 16 times more potent as a 5-HT blocker when compared to ADP or collagen. This is considerably more discriminating than with platelet aggregation methodology (2 fold difference). Furthermore, our results show that the inhibition of PSC by NAF occurs at therapeutic concentrations (≈ 4 μ M) of NAF.

We are grateful to Mr Tim Brown and Lipha Pharmaceuticals (UK) for supporting this study.

Born, G.V.R. (1978) J. Physiol. 209, 487-511

Davies, P.T.G. & Steiner, T.J. (1988) *New Trends in Clinical Pharmacology* pp 111-115. London: John Libby & Co. Ltd.

AN EP₃-RECEPTOR MAY MEDIATE PROSTAGLANDIN E-INDUCED POTENTIATION OF AGGREGATION IN HUMAN PLATELETS

R.L. Jones* & N.H. Wilson, Department of Pharmacology, University of Edinburgh, Edinburgh EH8 9JZ

The pro-aggregatory action of PGE₂ on human platelets often appears as a potentiation of second phase aggregation (Shio & Ramwell, 1972), but enhancement of primary aggregation has also been reported (Andersen *et al.*, 1980). It has been suggested that a discrete PGE (EP-) receptor mediates these effects (Andersen *et al.*, 1980) and that negative coupling to adenylate cyclase may be involved (Ashby, 1988). In this communication we report on the potencies of seven PGE analogues as potentiators of aggregation in human platelets and as inhibitors of the field-stimulated guinea-pig vas deferens (an EP₃ preparation; Coleman *et al.*, 1987) (Table 1). Small reversible waves to PAF (10 - 30 nM) were obtained in human PRP in the presence of the TP-receptor antagonist GR 32191 (1000 nM) and the DP-receptor antagonist BW A868C (200 nM). PGE analogues were added 2 min before PAF: PC₂₀₀ is the concentration required to double the size of the PAF response.

Table 1 Equi-effective molar ratios (EMR) for PGE analogues on guinea-pig vas deferens and human platelets (n = 4)

Prostanoid	Vas deferens EMR	Platelet EMR	Comments on platelets
Sulprostone	1.0 (IC ₅₀ = 0.2 nM)	1.0 (PC ₂₀₀ = 20 nM)	
5,6-Dihydro sulprostone	0.80	1.3	
16,16-Dimethyl PGE ₂	0.96	1.2	
Misoprostol	3.8	18	
MB 28767	5.4	16	
PGE ₂	7.5	?	inhibition often seen (IP agonism)
17-Phenyl-ω-trinor PGE ₂	47	110	shallow log dose-response curve
11-Deoxy PGE ₂ -1-alcohol	73	?	inhibition often seen (IP agonism)

In washed platelet suspensions the pro-aggregatory action of sulprostone was not blocked by 12 μM AH 6809, suggesting that an EP₁-receptor is not involved (Coleman *et al.*, 1985) and this is supported by the low potency relative to sulprostone of 17-phenyl-ω-trinor PGE₂, a potent EP₁ agonist (Lawrence *et al.*, 1989). In spite of the difficulties associated with the high sensitivity of human platelets to IP-receptor agonists, the data suggest that an EP₃-receptor may mediate the potentiation of aggregation.

Andersen, N.H., Eggerman, T.L., Harker, L.A., Wilson, C.H. & De, B. (1980) Prostaglandins 19, 711 - 735.
Ashby, B. (1988) Second Messengers and Phosphoproteins 12, 45 - 57 .
Coleman, R.A., Kennedy, I. & Sheldrick, R.L.G. (1985) Br. J. Pharmacol. 85, 273P.
Coleman, R.A., Kennedy, I., Sheldrick, R.L.G. & Tolowinska, I.Y. (1987) Br. J. Pharmacol. 91, 407P.
Lawrence, R.A., Jones, R.L. & Wilson, N.H. (1989) Br. J. Pharmacol. 98, 796P.
Shio, H. & Ramwell, P.W. (1972) Nature 236, 1 - 5.

CHLORIDE TRANSPORT IN HUMAN PLACENTAL BRUSH BORDER MEMBRANE VESICLES

D. Faller*, G. Higgins & M.P. Ryan. (Introduced by F. Martin) Department of Pharmacology, University College Dublin, Belfield, Dublin 4.

A major component of chloride transport in epithelial cells is mediated by chloride channels. The possibility of chloride transport defects in cystic fibrosis has stimulated interest in such chloride channels. Membrane vesicles prepared from epithelial cells serve as a useful model to study regulation of chloride channels. In this study we have prepared brush border membrane vesicles (BBMV) using a magnesium precipitation technique, (Ganapathy *et al.* 1985) from human term placenta. We have used these membrane vesicles to study chloride channels and the effects of some inhibitors.

The purity of the BBMV was assessed using the marker enzymes, alkaline phosphatase was enriched 25.3 ± 4.8 (n=4) and gamma-glutamyltranspeptidase was enriched 53.4 ± 8.9 (n=5) over the homogenate. Transmission and scanning electron microscopy showed the vesicles to be closed spherical structures of varying sizes, with the brush border membrane facing outwards. Chloride uptake into the BBMV was measured in the presence of an outwardly directed Cl gradient (Landry *et al.*, 1987). Using this system, we have shown a time-dependent accumulation of ³⁶Cl within the vesicles. Initial uptake at 30s was found to be 8.6 ± 0.6 nmol Cl/mg protein, rising to 17.1 ± 0.8 nmol Cl/mg protein by 12 min. By 40 min this value had decreased to 11.6 ± 0.7 nmol Cl/mg protein (mean ± s.e.mean; n=6). Addition of 5 μM valinomycin during the uptake reaction resulted in a discharge of accumulated isotope. When valinomycin was added after 2 min, the uptake was reduced from 17.2 ± 3.6 nmol Cl/mg protein before addition to 7.6 ± 1.6 nmol Cl/mg protein after addition. The effect of N-phenylanthranilic acid and 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS) on Cl uptake was examined. Both drugs showed dose dependent inhibition, the I.C.₅₀ values being 0.83 ± 0.35 μM for NPA and 3.45 ± 0.37 μM for DIDS (mean ± s.e.mean; n=3). Linoleic acid also inhibited Cl uptake with I.C.₅₀ of 4.59 ± 0.51 μM.

These results show that BBMV prepared from human placenta can be used as a model to study Cl transport. The results with valinomycin confirmed that the uptake was dependent on a membrane potential. The Cl transport system was sensitive to NPA and DIDS, both of which have been shown to inhibit Cl transport in other systems to a similar extent. Since the basic defect in cystic fibrosis is known to be a defective regulation of epithelial chloride channels, this system may be useful in the study of regulation of Cl channels in both normal and cystic fibrosis tissue.

This work was supported by EOLAS, the Irish Science and Technology Agency.

Ganapathy, M.E., Mahesh, V.B., Devoe, L.D., Leibach, F.H. & Ganapathy, V. (1985) Am. J. Obstet. Gynecol. 153, 83-86.
Landry, D.W., Reitman, M., Cragoe, E.J. & Al-Awqati, Q. (1987). J. Gen Physiol. 90, 779-978.

M. Keen*, S.A.W. Pickering & J.A. Hunt, Department of Pharmacology, The Medical School, University of Birmingham, Birmingham, B15 2TT, UK.

Vascular endothelial cells release the vasodilator substances prostacyclin (PGI₂) and endothelium derived relaxing factor (EDRF) in response to a range of natural stimuli, such as bradykinin (Crossman et al., Kondo et al., 1989). In this study we have investigated whether EDRF can modulate release of PGI₂ from cultured endothelial cells. The effects of nitroprusside, which mimics the action of EDRF (Kondo et al., 1989) and L-N^G-nitroarginine (NOARG) which inhibits EDRF formation (Moore et al., 1990) have been examined the basal and bradykinin stimulated release of PGI₂ from the bovine aortic endothelial cell line AG476

AG4762 cells (passage 16-22) were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% foetal calf serum and 1.5mM glutamine and plated out onto 15mm multiwells. Confluent cells were incubated for 30 min in warm, gassed DMEM containing 0-100nM bradykinin in the presence or absence of 100µM nitroprusside or 100µM NOARG. The release of PGI₂ was then determined by radioimmunoassay (Crossman et al., 1987).

Bradykinin produced a dose dependent release of PGI₂. The maximal release obtained was ~350% of basal release. The EC₅₀ for bradykinin was ~3nM. In the presence of nitroprusside, the maximal response to bradykinin was reduced by ~40%. There was no effect of nitroprusside on bradykinin EC₅₀. In the presence of NOARG, the maximal response to bradykinin was increased by ~30% and there was no effect of NOARG on the EC₅₀ obtained for bradykinin. Nitroprusside and NOARG had no effect on basal release of PGI₂.

The bradykinin stimulated release of PGI₂ from cultured endothelial cells is inhibited by nitroprusside and enhanced by NOARG. This suggests a role for EDRF in the feedback control of PGI₂ release. Whether the release of other vasodilator compounds is similarly affected remains to be determined. The mechanism of the apparent effect of EDRF is unclear. EDRF and nitrovasodilators stimulate guanylate cyclase in endothelial cells (Martin et al., 1988), suggesting that PGI₂ release might be inhibited by cGMP. However, Martin et al., (1989) have reported that changes in cGMP levels do not affect PGI₂ release. Thus these effects might involve a cGMP independent mechanism.

Crossman, D., McEwan, J., MacDermot, J., MacIntyre, I. & Dollery, C.T. (1987) *Br. J. Pharmacol.*, **92**, 630-636.
Kondo, K., Mitchell, J.A. de Nucci, G. & Vane, J.R. (1989) *Br. J. Pharmacol.*, **98**, 630-636.
Martin, W., Drazan, K.M. & Newby, A.C. (1989) *Br. J. Pharmacol.*, **97**, 51-56.
Martin, W., White, D.G. & Henderson, A.H. (1988) *Br. J. Pharmacol.*, **93**, 229-239.
Moore, P.K., Al-Swayeh, O.A., Chong, N.W.S., Evans, R.A. & Gibson, A. (1990) *Br. J. Pharmacol.*, **99**, 40

A COMPARISON OF THE THROMBOXANE RECEPTOR LIGANDS [¹²⁵I]-PTAOH AND [³H]-SQ29548 BINDING IN CULTURED BOVINE AORTIC ENDOTHELIAL CELLS

J A Hunt*, M Keen, Department of Pharmacology, University of Birmingham, Birmingham, B15 2TT.

Thromboxane A₂ (TXA₂) is a potent vasoconstrictor and an effective inducer of platelet aggregation. We have previously shown that the stable TXA₂ mimetic U46619 initiates the release of prostacyclin (PGI₂) from cultured endothelial cells (Hunt et al., 1989). PGI₂ is antiaggregatory and a vasodilator, so this release may be important as a feedback control mechanism modulating TXA₂ activity. In this study we have attempted to characterise TXA₂ receptor binding sites on an endothelial cell line, AG4762, using two established receptor ligands [¹²⁵I]-PTAOH (Swayne et al., 1988) and [³H]-SQ29548 (Hedberg et al., 1988).

Binding assays were carried out as described previously (Hunt et al., 1990), using washed membranes from AG4762 cells (passage 16-22) at 50-100µg protein/tube. Non-specific binding of 0.1nM [¹²⁵I]-PTAOH was defined using 10µM U46619 and that of 2.5nM [³H]-SQ29548 using 100µM BM13505.

Total binding of [¹²⁵I]-PTAOH was typically ~2000dpm/sample of which 35% was specific. In self competition studies I-PTAOH displaced all the specific binding of [¹²⁵I]-PTAOH, with nH=1, K_d=0.4nM B_{max}=23 fmols/mg protein. The TXA₂ antagonists SQ29548, BM13505 and BM13177 (Swayne et al., 1988) displaced all the specific binding of [¹²⁵I]-PTAOH; BM13505 IC₅₀=30±12nM (mean±s.e.m., n=3), SQ29548 IC₅₀=2.1±0.6µM (n=6), BM13177 IC₅₀=0.1mM (n=2). In all cases the antagonist displacement curves were consistent with binding to a homogeneous population of sites. Total binding of [³H]-SQ29548 was typically ~260dpm/sample; 45% was specific. In self competition studies with SQ29548, nH=1, K_d=2.5nM, and B_{max}=26 fmols/mg protein. The TXA₂ antagonists again displaced all the specific binding and appeared to recognise a single population of sites; SQ29548 IC₅₀=4±2nM (mean±s.e.m. n=3), BM13505 IC₅₀=198±56nM (n=3) and BM13177 IC₅₀=13µM (n=2).

[¹²⁵I]-PTAOH and [³H]-SQ29548 labelled high affinity binding sites in AG4762 cell membranes. The density of both these sites appeared to be the same and both populations of sites were homogeneous with respect to antagonist binding. However the order of potency of the antagonists is different for the two ligands. The order of potency obtained in [¹²⁵I]-PTAOH studies agrees with that previously identified in functional studies on this cell line (Hunt et al., 1990), whilst that described for [³H]-SQ29548 agrees with functional and binding studies carried out on platelets by Swayne et al., (1988). The reason for these differences is at present unclear. Whether the 'specific' binding of either ligand represents a bona fide TXA₂ receptor on endothelial cells remains to be established.

Hedberg A, Hall SE, Ogletree ML, Harris DN and Liu C-K (1988) *J.Pharmacol.Exp.Ther.* **245** 786-792.
Hunt JA, Hallam TJ, and MacDermot J. (1989) *Br.J.Pharmacol.*, **96** 170P.
Hunt JA, MacDermot J, and Keen M (1990) Proceedings of XIth IUPHAR Congress, Amsterdam, 1-7 July.
Swayne GT, Maguire J, Dolan J, Raval P, Dane G, Greener M and Owen DA (1988) *Eur.J.Pharmacol.*, **152** 311

INDUCTION OF THROMBOXANE BIOSYNTHESIS IN GUINEA-PIG EOSINOPHILS STIMULATED WITH LEUKOTRIENE B₄

Klaus F. Rabe ^{*}, Mark A. Gienbycz., Gordon Dent and Peter J. Barnes. Department of Thoracic Medicine, National Heart and Lung Institute, London, SW3 6LY.

Leukotriene B₄ (LTB₄) stimulates respiratory burst in human neutrophils and in guinea-pig eosinophils, increases IgE-receptor expression and IgE-mediated cytotoxicity in human eosinophils and is found in bronchoalveolar lavage fluid and sputum from asthmatic subjects. There is, however, little information as to whether LTB₄ can also promote the biosynthesis of cyclo-oxygenase products in eosinophils. As TXA₂ may play a role in the pathogenesis of bronchial asthma, experiments were designed to determine whether LTB₄ stimulates TXA₂ production in eosinophils.

Eosinophils were harvested from the peritoneal cavity of human serum-treated male guinea-pigs and purified on discontinuous Percoll gradients. Cells with a purity greater than 96% and viability greater than 99% were resuspended in HEPES-buffered physiological salt solution containing 1.6 mM CaCl₂, equilibrated at 37°C (5 min) and then challenged (10 min) with either vehicle, LTB₄, PAF, serum-opsonised zymosan (SOZ) or the calcium ionophore calcimycin. The amount of TXB₂, the stable metabolite of TXA₂, released in to the bathing buffer was measured by RIA. Hydrogen peroxide generation was used as an index eosinophil activation and was measured fluorimetrically by horse-radish-catalysed oxidation of scopoletin (Root *et al.*, 1975).

LTB₄ (1 µM for 5 min) stimulated the biosynthesis and release of immunoreactive TXB₂ (from 0.84 ± 0.21 to 9.4 ± 1.8 pmol 10⁶ cells⁻¹, n = 5) from guinea-pig eosinophils. This effect of LTB₄ was concentration-dependent (EC₅₀: 164 ± 10.8 nM, n = 5) with maximum stimulation (ca. 12-fold) of prostanoid synthesis occurring at 1 µM LTB₄. The ability of LTB₄ to generate TXB₂ was rapid (t_{1/2}: ca. 12.5 s), transient and non-competitively antagonised by the selective LTB₄ blocking drug U-75302 (6-(6-(3-hydroxy-1E, 5Z-undecadien-1-yl)-2-pyridinyl)-1,5-hexanediol; Morris *et al.*, 1988). LTB₄ (1 µM) was significantly more effective than PAF (1 µM) and SOZ (500 µg) at promoting TXB₂ release and ca. equieffective with calcimycin (1 µM). Pre-treatment of eosinophils with the cyclo-oxygenase inhibitor, flurbiprofen (8 µM for 5 min), abolished LTB₄-stimulated TXB₂ release but did not antagonise the ability of LTB₄ to generate hydrogen peroxide at any concentration examined.

It is concluded that LTB₄ is an effective stimulant of TXA₂ generation in guinea-pig eosinophils which is mediated through an interaction with specific LTB₄-receptors. Furthermore, LTB₄-stimulated hydrogen peroxide generation in these cells is not dependent upon the concomitant generation of cyclo-oxygenase products.

Root, H.K., Metcalf, J., Oshino, N. & Chance, B. (1975). *J.Clin.Invest.*, **55**, 945-955.
Morris, J. & Wishka, D.G. (1988). *Tetrahedron Letts.*, **24**, 143-146.

POTENTIATION OF FMLP-INDUCED PLASMA EXUDATION BY PGE ANALOGUES: EFFECT OF THE THROMBOXANE RECEPTOR ANTAGONIST GR 32191

R.A. Armstrong*, J.S. Matthews & R.L. Jones, Department of Pharmacology, University of Edinburgh, Edinburgh EH8 9JZ

We have recently demonstrated that potentiation of bradykinin (BK)-induced plasma exudation by PGE₂ in the skin of anaesthetised rabbits (measured by leakage of ¹²⁵I-albumin) may have two components (Armstrong *et al.*, in press). The high potency (1-10 ng) component may be mediated by an EP₃ receptor and appears to be unrelated to dilatation, yet accounts for 50% of the maximum potentiation achieved with PGE₂ (1000 ng). PGE₂ not only potentiates directly-acting mediators of inflammation, such as BK, but also leucocyte-dependant mediators such as the chemotactic peptide FMLP (Wedmore & Williams, 1981). We have compared the ability of the EP₃ agonist M&B 28,767 to potentiate oedema induced by intradermal injection of FMLP (50 picomoles/site) with PGE₂, misoprostol and butaprost. M&B 28,767 has considerable thromboxane (TP) receptor agonist activity and so its true potency could only be assessed after TP receptor block by GR 32191 (2 mg/kg i.v.).

Table 1 Interaction of PGE analogues and FMLP on plasma exudation (ml of exudate) in rabbit skin (n = 4 or more, ± s.e.m.)

Intradermal injection	Control rabbits			GR 32191-treated rabbits		
	0	1 ng	1000 ng	0	1 ng	1000 ng
FMLP + saline	9.0 ± 1.0			15.0 ± 1.3		
FMLP + PGE ₂		12.8 ± 0.8	19.8 ± 2.1		17.7 ± 1.1	45.8 ± 7.3
FMLP + Misoprostol		13.0 ± 1.3	23.9 ± 3.5		19.1 ± 1.3	31.4 ± 10.6
FMLP + M&B 28,767					17.6 ± 1.9	16.9 ± 2.6
FMLP + Butaprost		11.1 ± 1.1	19.4 ± 2.7			

In control animals, PGE₂, misoprostol and butaprost showed a similar ability to potentiate FMLP-induced exudation, the effect being most marked at 100-1000 ng doses. The marked effect of PGE₂ at 1 ng in combination with BK is absent with FMLP. M&B 28,767 and sulprostone (data not shown) do not significantly potentiate FMLP, suggesting that EP₃ agonists cannot potentiate FMLP probably due to their inability to induce dilatation in rabbit skin. GR 32191 pre-treatment had no effect on BK-induced exudation or potentiation by PGE₂ but enhanced both FMLP-induced exudation and potentiation, particularly by PGE₂. A similar profile was seen with the NSAID, flurbiprofen (2 mg/kg i.v.). We suggest that FMLP induces a thromboxane-dependent constriction (see Crowell *et al.*, 1989); after TP-receptor block by GR 32191 dilatation could result in increased exudation.

Armstrong, R.A., Matthews, J.S., Jones, R.L. & Wilson N.H. (in press) Adv. Prostaglandin, Thromboxane & Leukotriene Res.
Crowell, R.E., Van Epps, D.E. & Reed, W.P. (1989) Am. J. Physiol. **257**, H107 - H112.
Wedmore, C.V. & Williams, T.J. (1981) Nature **289**, 646 - 650.

THE ANTI-INFLAMMATORY EFFECTS OF INHALED SALMETEROL AND SALBUTAMOL IN GUINEA-PIG LUNG

C.J. Whelan* and M. Johnson, Department of Peripheral Pharmacology, Glaxo Group Research Ltd, Ware, Herts, SG12 0DP

β -Adrenoceptor agonists inhibit both increased vascular permeability and oedema formation (Green, 1972; Persson, 1987), but the extent of this inhibition is limited by the short duration of action of these agents. The present report compares the new long-acting, β_2 -adrenoceptor agonist, salmeterol (salm; Bradshaw *et al.*, 1987), with the shorter-acting compound, salbutamol (salb), against histamine-induced plasma protein extravasation (PPE) in guinea-pig lung following aerosol administration.

Guinea-pigs received an intracardiac injection of iodinated human serum albumin ($0.5\mu\text{Ci}; 0.3\text{ ml}$) under isoflurane anaesthesia. On recovery, varying doses of the β_2 -adrenoceptor agonists or vehicle were administered by inhalation as described by Ball *et al.*, 1987. At intervals after dosing, guinea-pigs were placed in a perspex chamber and exposed to nebulised histamine ($\text{H}; 0.5\text{mg.ml}^{-1}$) for 30 sec, followed by a further 30 sec exposure in the chamber. After 30 min, the animals were killed, plasma samples prepared and the lungs lavaged with $2 \times 10\text{ml}$ heparinised (10U.ml^{-1}) phosphate buffered saline. The radioactive content of an aliquot of plasma and 5ml of lavage fluid (BALF) were determined, and PPE was calculated as $\mu\text{l plasma.ml}^{-1}\text{ BALF}$. Histamine challenge increased the albumin content of BALF from $0.80\text{ }\mu\text{l.ml}^{-1}$ (95% C.L. $0.60\text{--}1.08$, $n=10$) to $5.26\text{ }\mu\text{l.ml}^{-1}$ ($4.82\text{--}5.72$, $n=13$). Salm ($0.001\text{--}1.0\text{ mg.ml}^{-1}$) andhalb ($0.001\text{--}1.0\text{ mg.ml}^{-1}$), 30 min prior to H, caused a dose-related inhibition of PPE. Salm and halb were approximately equipotent in this respect, 0.1 mg.ml^{-1} reducing H-induced PPE to $1.08\text{ }\mu\text{l.ml}^{-1}$ ($0.92\text{--}1.28$, $n=6$) and $1.32\text{ }\mu\text{l.ml}^{-1}$ ($1.26\text{--}1.38$, $n=6$) respectively. However, while the duration of action of halb was short (1–2h), that of salm was substantially longer (6–8 h). Inhibition of PPE was not secondary to bronchodilatation since an equi-bronchodilator dose of PGE_2 (0.1 mg.ml^{-1}) had no effect. Pretreatment of guinea-pigs with propranolol ($1\text{mg.kg}^{-1}\text{ s.c.}$) abolished the inhibition of H-induced PPE by salm.

The experiments described show that inhaled salm and halb inhibit H-induced PPE in guinea-pig lung at bronchodilator doses (Ball *et al.*, 1987). However, the duration of action of salm is markedly longer than that of halb. In man, salmeterol results in at least 12 hr bronchodilatation, and unlike shorter-acting β_2 -adrenoceptor agonists, may also provide a clinically useful anti-inflammatory action in bronchial asthma.

Ball, D. I., Coleman, R.A., Denyer, L.H., Nials, A.T., Sheldrick, K.E. (1987), *Br. J. Pharmacol.*, **92**, 746P
 Bradshaw, J., Brittain, R.T., Coleman, R.A., Jack, D., Kennedy, I., Lunts, L.H.C., Skidmore, I.F. (1987) *Br. J. Pharmacol.*, **92**, 590P
 Green K.L. (1972) *Br. J. Pharmacol.*, **45**, 322–332
 Persson, C.G.A. (1987) *Am. Rev. Resp. Dis.*, **135**, 571–575

GLUCOCORTICOID INDUCTION OF RAT GROWTH HORMONE GENE PROMOTER FUNCTION

F. Martin and F. Ryan*. Department of Pharmacology, University College Dublin, Dublin 4. Ireland.

Previous studies in this laboratory (Treacy and Martin, 1987) resulted in the characterisation of cell-type independent glucocorticoid inducible enhancer activity in the proximal sequences (–523 to –12) of the rat growth hormone gene promoter. We have now investigated the role of two 15 bp sequence elements within this promoter, which closely resemble glucocorticoid response elements (GREs) in other genes (Beato, 1989), in mediating this glucocorticoid responsiveness.

Two sequences (–111/–97) and (–250/–264), within the rat growth hormone promoter, resemble GREs. Small deletion mutations were generated in either or both of these elements by oligonucleotide directed mutation using a method based on the gapped duplex DNA approach (Kramer *et al.*, 1984). The generation of the desired mutations was confirmed by DNA sequence analysis. The ability of the mutated rGH promoter fragments to mediate glucocorticoid induction of gene expression was then tested in a series of transfection studies: CV-1 cells, which are glucocorticoid receptor deficient were co-transfected with a glucocorticoid receptor expression plasmid and a plasmid containing the wild-type rat growth hormone promoter fragment (or one of the three mutation) cloned upstream of a basal promoter/reporter gene (chloramphenicol acetyl transferase (CAT)) construct. The glucocorticoid inducibility was determined by the ability of dexamethasone (10^{-6} M) to induce expression of CAT enzyme activity in the transfected CV-1 cells. The wild type rGH promoter sequences mediated dexamethasone induction of CAT gene expression ($p < 0.05$). However, mutation of both GRE-like sequences or the (–111/–97) sequence, alone, resulted in a loss of glucocorticoid responsiveness. Glucocorticoid inducibility ($p < 0.01$) was still seen with the promoter fragment bearing the mutation in the (–264/–250) sequence.

These results suggest that the GRE-like element (–111/–97) in the rat growth hormone promoter is necessary for the mediation of glucocorticoid responsiveness by this gene promoter.

Funded by the Health Research Board, Ireland.

Beato, M. (1989) *Cell* **56**, 335–344.

Kramer, W., Drutson, V., Jansen, H.W., Kramer, B., Flugfelder, M. and Fritz, H.J. (1984). *Nucl. Acids Res.* **12**, 9441–9456.

Treacy, M. and Martin, F. (1987). *Biochem. Soc. Trans.* **15**, 952.

R.D. Pleass* & J. Westwick, Department of Pharmacology, Royal College of Surgeons, London WC2A 3PN.

U937 cells are a continuous line of human cells of committed monocytic origin (Larrick, J.W. et al 1980; Ward, S.G. & Westwick, J. 1988). We have investigated the effects of agents which modulate GTP binding proteins and protein kinase C (PKC) to explore the signal transduction mechanisms involved in lipo-polysaccharide (LPS) and cytokine stimulated interleukin-8 (IL-8) generation.

A sensitive and specific ELISA (Ceska, M. et al 1989) was used to quantitate extracellular IL-8. Additions of LPS (0.1–100ng/ml), interleukin-1 α (IL-1 α) (0.1–10ng/ml) and to a lesser extent tumour-necrosis factor TNF α (3–30ng/ml) produced a dose-related generation of extracellular IL-8. U937 cells may be transformed into monocyte like cells using the following transforming agents, di-methyl sulfoxide (DMSO) 1.25% and di-butyl cyclic-AMP (cAMP) 0.8mM.

Untransformed, DMSO-transformed and cAMP-transformed U937 cells were all responsive to the above stimuli. Pre-treatment of U937 cells with pertussis toxin (100ng/ml) for 4h produced approximately 80% inhibition of sub-optimal LPS, IL-1 α and TNF α induced generation of IL-8. In contrast incubation for with cholera toxin (100ng/ml) for 4h produced a 10–40% enhancement of IL-8 generation induced by LPS, IL-1 α or TNF α . Additions of the phorbol ester tetra-phorbol acetate (TPA, 0.1–30nM), but not 4 α phorbol produced a marked stimulation of IL-8 formation. However, the addition of LPS or IL-1 α did not modify TPA induced IL-8 formation. Staurosporine (0.1–3 μ M) the non-selective PKC inhibitor, produced a dose related inhibition of basal, LPS and TNF α stimulated generation of IL-8. Low dose (0.1–0.3 μ M) staurosporine doubled the IL-1 α -induced formation of IL-8, although 1–3 μ M staurosporine produced a significant inhibition.

These results indicate that GTP binding proteins and PKC have a regulatory role in the generation of IL-8 derived from U937 cells.

Larrick, J.W., Fischer, D.G., Anderson, J. & Koren, H.S. (1980). *J.Immunol.*, 125, 6–12

Ward, S.G. & Westwick, J. (1988). *Br.J.Pharmacol.*, 93, 769–774

Ceska, M., Effenberger, F. & Peichl, P. (1989) *Cytokine* 1:136

B.E. Wood, S. E. O'Connor & P. Leff. Fisons plc, Pharmaceutical Divison, Research & Development Laboratories, Bakewell Road, Loughborough, Leicestershire, LE11 0RH

ATP, which is susceptible to degradation by ectonucleotidases, produces a transient contraction of the rabbit ear artery (REA) via P_{2X} -receptors. However, as in many P_{2X} -systems, ATP exhibits a very low potency ($p[A_{50}]$ 3.14) compared to stable analogues such as α,β -meATP ($p[A_{50}]$ 6.47) (O'Connor *et al.*, 1990). α,β -meADP is an inhibitor of 5'-nucleotidase, the enzyme which converts adenosine monophosphate to adenosine. Attempts have been made to use this compound to inhibit ATP metabolism (Pearson *et al.*, 1980, Morishita & Furukawa 1989) but these were apparently unsuccessful. We have studied the effect of α,β -meADP on responses to both stable and unstable purines in the REA.

Experiments were conducted using isolated rings of endothelium denuded ear artery from NZW rabbits. All contractions were expressed as a % of the maximum response to the standard P_{2X} -agonist α,β -meATP. Concentration effect ($E/[A]$) curves to α,β -meATP, β,γ -meATP, ATP and ADP were constructed alone and following 60 min incubation with α,β -meADP (30 μ M).

α,β -meADP caused a large leftward displacement ($\Delta p[A_{50}]$ 1.88 ± 0.17 $n=5$) of the $E/[A]$ curve to ATP and also changed the response from a phasic to a tonic contraction. In contrast, α,β -meADP resulted in only small leftward displacements of the $E/[A]$ curves to α,β -meATP, β,γ -meATP and ADP ($\Delta p[A_{50}]$ 0.15 ± 0.13 $n=5$, 0.41 ± 0.14 $n=5$, and 0.30 ± 0.15 $n=6$ respectively), and had no effect on the kinetic nature of the contraction in each case.

In contrast to the findings of Morishita & Furukawa (1989) we found that α,β -meADP had a profound potentiating effect on the response to ATP. In addition it produced only slight potentiation of the effects of the stable analogues α,β -meATP and β,γ -meATP. However, the effects of ADP, which like ATP is unstable, were not potentiated by α,β -meADP. These results imply that the effect on ATP was not due to inhibition of 5'-nucleotidase. The reduction in the fade of the contraction to ATP, induced by α,β -meADP, may explain the marked leftward displacement of the $E/[A]$ curves (Leff, 1986). However, this seems unlikely as the contractions to both β,γ -meATP and ADP, which produce rapidly fading responses, remained unchanged by pretreatment with α,β -meADP.

This selective potentiation and stabilisation of ATP responses by α,β -meADP in the rabbit ear artery requires further investigation to elucidate the mechanism.

Leff, P. (1986) *J.Theor.Biol.* 121, 221-232.

O'Connor, S.E., Wood, B.E. & Leff, P. (1990). *Br. Pharmacological Society, Sheffield Meeting.*

Morishita, H. & Furukawa, T. (1989) *Jpn. J. Pharmacol.* 49, 161P.

Pearson, J.D., Carleton, J.S. & Gordon, J.L. (1980) *Biochem. J.* 190, 421-429.

THE MECHANICAL AND BIOCHEMICAL INTERACTIONS OF INDIVIDUAL CO-TRANSMITTERS IN RAT TAIL ARTERY

J. Schwarze, S.B. Guild J.W. Craig & T.C. Muir, Department of Pharmacology, Glasgow University G12 8QQ

Sympathetic nerves innervating blood vessels may release more than one excitatory substance, noradrenaline (NA) and ATP or a closely related substance - the phenomenon of co-transmission (Burnstock 1976). While both substances play a role in transmission, the extent of their interaction in contraction remains unclear. We have investigated the interaction between noradrenaline (NA) and α, β , methylene ATP (α, β , MeATP) - a stable analogue of ATP - in contraction and on phosphatidylinositol - 4,5 bisphosphate (PIP₂) hydrolysis in rat tail arteries a tissue which exhibits co-transmission (Sneddon & Burnstock, 1985). PIP₂ hydrolysis is of major importance in NA-induced contractile responses (Abdel-Latif, 1986).

Changes in perfusion pressure produced by electrical field stimulation (N.S. 0.5ms 1-16 Hz supra maximal voltage 20 s), exogenous NA (10^{-6} - 10^{-4} M) and α, β , MeATP (10^{-7} - 10^{-5} M) were measured (Muir & Wardle, 1989). PIP₂ hydrolysis evoked by NA (10^{-6} - 10^{-4} M) and ATP (10^{-7} - 10^{-5} M) was estimated in segments (1cm. 5mg wet wt.) of artery by measuring total inositol phosphate (IP) production (Akhtar & Abdel-Latif, 1984).

N.S. increased perfusion pressure, this was largely (80%) blocked by prazosin (10^{-6} M) but unaffected by prior, repeated (5 times) addition of α, β , MeATP (10^{-6} M) in a concentration sufficient to desensitise purinoceptors. This confirmed that the contractile response to N.S. was largely adrenergic. Consistently, NA (10^{-6} - 10^{-4} M) increased perfusion pressure to only 80% of that evoked by N.S. and increased IP accumulation. α, β , MeATP (10^{-7} - 10^{-5} M), however, increased perfusion pressure to only 20% of that evoked by N.S. and did not increase IP accumulation. PIP₂ hydrolysis, therefore, may underlie stimulus-contraction coupling for NA but not that for α, β , MeATP. Moreover, α, β , MeATP at a concentration (10^{-5} M) which produced near maximal contractile responses, when acting alone, failed to potentiate NA-stimulated increases in perfusion pressure or IP accumulation.

These results demonstrate that, despite releasing two excitatory substances, sympathetic nerve-evoked vasoconstriction in rat tail arteries is largely adrenergic. No major contribution of the co-released ATP in either vasoconstriction or in the associated biochemical responses, was detected. Since no interaction was detected on either contraction or PIP₂ hydrolysis, the site and mechanisms responsible for the co-operative effect of NA and ATP in this tissue remain to be elucidated.

We acknowledge the support of the Scottish Home & Health Department the Wellcome Trust and Deutscher Akademischer Austausch Dienst (DAAD).

Burnstock, G. (1976) *Neuroscience* **1**, 239-248.

Sneddon, P. & Burnstock, G. (1985) *Eur. J. Pharmacol.* **106**, 149-152.

Abdel-Latif A.A. (1986) *Pharmacol. Rev.* **38**, 227-272.

Muir, T.C. & Wardle, K.A. (1989) *J. Auton. Pharm.* **9**, 23-34.

Akhtar, R.A. & Abdel-Latif, A.A. (1984) *Biochem J.* **263**, 291-300.

533P

ALTERATIONS IN SENSITIVITY, PHOSPHOINOSITIDE HYDROLYSIS AND CYCLIC NUCLEOTIDE SYNTHESIS IN ISOLATED AORTIC RINGS FROM SPONTANEOUSLY HYPERTENSIVE RATS

A.M. Sharifi, K.J. Morrison & D. Pollock, Department of Pharmacology, University of Glasgow, Glasgow G12 8QQ, Scotland

Some studies have reported that isolated blood vessels from hypertensive rats are supersensitive to vasoconstrictors, whilst others have reported subsensitivity. Conflicting results with vasorelaxants have also been reported (Winqvist et al., 1982; Bohr & Webb, 1988). Such discrepancies might reflect differences in the model of hypertension used or in the method of recording the responses of isolated vessels. This study examined the sensitivity of isolated aortic rings from spontaneously hypertensive rats (SHR) to noradrenaline (NA) and to sodium nitroprusside (SNP). In addition, the ability of NA to increase phosphoinositide (PI) hydrolysis and of SNP to increase cyclic guanosine monophosphate (cGMP) synthesis was examined in vessels from SHR and from Wistar Kyoto (WKY) controls.

Blood pressures of conscious SHR (190 ± 2 , mm Hg (mean \pm s.e. mean), $n = 10$) and WKY rats (109 ± 3 , $n = 10$), measured by the tail cuff method, were significantly different ($0.01 > P > 0.001$, Student's *t*-test). Isolated aortic rings (3-4 mm) were suspended under an initial resting tension of 1 g in 25 ml organ baths, containing Krebs buffer at 37°C. Concentration-response curves to NA (10^{-7} - 10^{-3} M) and to SNP (10^{-9} - 10^{-6} M) in the presence of NA (EC₇₅) were obtained in rings from SHR and WKY rats. NA-induced PI hydrolysis was measured in aortic rings, labelled with (myo-³H)-inositol ($8 \mu\text{Ci ml}^{-1}$) and then incubated in Krebs buffer containing lithium chloride (10 mM) and NA for 1 hour. Prior to measuring PI hydrolysis of cGMP synthesis, aortic rings were homogenised in Potter-Elvehjem homogenizers. Inositol phosphates were extracted, separated chromatographically on Dowex formate resin and measured in a liquid scintillation counter. In separate experiments cGMP was extracted in trichloroacetic acid (TCA) and washed with water-saturated ether. These extracts were neutralised with 200 mM sodium acetate buffer and their cGMP content was measured by radioimmune assay.

The sensitivity of aortic rings to NA was lower in SHR rings than in WKY rings. This reduced sensitivity in contractile responses was reflected in a corresponding reduction in NA-induced PI hydrolysis (WKY: 610 ± 44 , $n = 7$; SHR: 537 ± 17 , $n = 14$ (dpm g^{-1} tissue), $0.01 > P > 0.001$) at high concentrations of NA (10^{-3} M). In aortic rings from SHR, inhibitory responses to SNP were increased, particularly at high concentrations (10^{-7} M) and this increased sensitivity to SNP was reflected in a corresponding enhancement in the ability of SNP to increase cGMP levels (WKY: 2050 ± 550 , $n = 6$; SHR: 6200 ± 600 , $n = 6$ (cGMP pmol g^{-1} tissue), $0.01 > P > 0.001$). In aortic rings from SHR, concentration-dependent changes in sensitivity to NA and SNP occur and these are reflected in corresponding changes in the ability of NA to induce PI hydrolysis and of SNP to increase cGMP synthesis.

Bohr, D.F. & Webb, R.C. (1988) *Ann. Rev. Pharmac. Toxicol.*, **28**, 389-409.

Winqvist, R.J., Webb, R.C. & Bohr, D.F. (1982) *Fed. Proc.*, **41**, 2387-2393.

DIFFERENCES IN INOSITOL PHOSPHATE ACCUMULATION IN RESPONSE TO NORADRENALINE IN TAIL ARTERIES FROM SPONTANEOUSLY HYPERTENSIVE RATS

S. Jenkinson, S.B. Guild & T.C. Muir, Department of Pharmacology, University of Glasgow, Glasgow G12 8QQ

An enhanced contractile response to nerve stimulation in several arteries from hypertensive rat animal models is now well established (Muir & Wardle, 1989). Although presynaptic mechanisms were initially implicated in this phenomenon (Vidal et al, 1986), a postsynaptic site has now been emphasised (Muir & Wardle, 1989). Postsynaptic changes may involve alterations in signal-transduction systems including the polyphosphoinositide (PPI) cycle, already associated with the contractile response to noradrenaline (NA) (Abdel-Latif, 1986). Accordingly, the present investigation was an attempt to determine whether any alteration in PPI metabolism in response to NA could be detected in a hypertensive rat model.

The tail artery, a tissue in which NA produces a contractile response, was chosen for this investigation and was dissected by the method of Holman & Surprenant (1980). Age-matched Wistar Kyoto (WKY) and spontaneously-hypertensive rats (SHR) were used to compare the normal and diseased states. Changes in PPI metabolism stimulated by NA in artery segments (1 cm, 5 mg wet.wt) were estimated by measuring inositol phosphate (IP) accumulation by the methods of Akhtar & Abdel-Latif, 1984.

NA (10^{-6} - 10^{-3} M) increased total IP accumulation in both SHR and WKY rats. No significant difference was found in either the maximal response or the EC₅₀ values between these two populations. However, analysis of the individual IP's which contributed to the total revealed differences between SHR and WKY rats. NA (10^{-6} - 10^{-3} M) increased inositol trisphosphate (IP₃) accumulation in both SHR and WKY rats. This increase was significantly greater at each effective concentration of NA in SHR rats, the maximum response being 2-fold greater. In contrast, NA (10^{-6} - 10^{-3} M)-stimulated increases in both inositol bisphosphate (IP₂) and inositol monophosphate (IP₁) were not significantly different between SHR and WKY rats.

These results demonstrate an alteration in PPI metabolism in the tail artery of spontaneously hypertensive rats giving rise to an enhanced IP₃ accumulation in response to NA. Since IP₃ is involved in calcium mobilisation, an enhanced accumulation of this inositol phosphate could be partly responsible for the enhanced vascular contractile response to NA in the hypertensive state. This alteration in PPI metabolism may therefore be a factor in the development of the diseased state.

We acknowledge the support of the Scottish Home & Health Department and the Wellcome Trust.

Muir, T.C. & Wardle, K.A. (1989) *J. Auton. Pharm.* **9**, 23-34.

Vidal, M., Hicks, P.E. & Langer, S.Z. (1986) *Naunyn-Schmiedeberg's Arch Pharmacol.* **332**, 384-390.

Abdel-Latif, A.A. (1986) *Pharmacol. Rev.* **38**, 227-272.

Holman, M.E. & Surprenant, A.M. (1980) *Brit. J. Pharmacol.* **47**, 177-189.

Akhtar, R.A. & Abdel-Latif, A.A. (1984) *Biochem. J.* **263**, 291-300.

EFFECTS OF RESERPINE AND 6-HYDROXYDOPAMINE ON FIELD STIMULATION-INDUCED RESPONSES OF THE RAT ISOLATED TAIL ARTERY

D.M. Aidulis & D. Pollock, Department of Pharmacology, University of Glasgow, Glasgow G12 8QQ, Scotland

Field stimulation of the rat isolated tail artery produces a motor response that is predominantly noradrenergic but may also include a non-adrenergic component, mediated by adenosinetriphosphate (ATP) and possibly an unidentified "substance X" (Bao et al., 1989). Evidence for co-transmission in this blood vessel is indirect and is provided by experiments, in which alpha₁-adrenoceptor antagonists do not inhibit the field stimulation-induced responses completely but the residual response is blocked by alpha, beta-methylene adenosine triphosphate (mATP), which desensitizes purinoceptors. In such studies, where the smooth muscle is used to detect the released transmitter, the identification of the transmitter(s) depends on the specificity and concentration of the drugs used to block the various components of the motor response. This study re-examined the nature of neurotransmission in the rat tail artery by investigating the effects of drugs on field stimulation-induced responses of this vessel. Responses of arteries from rats pretreated with reserpine to deplete or 6-hydroxydopamine (6-OHDA) to destroy the sympathetic nerves were also examined.

Tail artery rings (3-4 mm) from Wistar rats were attached to fine stainless steel electrodes on a perspex rod. An initial resting tension of 1 g was applied to each ring, which was allowed to equilibrate for 2 hours in Krebs buffer (37°C, gassed with a 95% O₂/5% CO₂ mixture). Isometric contractions were obtained to field stimulation (0.5, 2, 20 Hz, pulse width 0.4 ms, 10 pulses, 70 V) or noradrenaline (NA, 0.01-100 μM), administered alone and in the presence of prazosin (0.1 μM), ATP (1-100 μM) or mATP (2 μM). Arteries from rats pretreated with 6-OHDA (2 x 25 mg kg⁻¹ day 1 and 2 x 100 mg kg⁻¹ day 3) were examined on days 4-5 and from rats pretreated with reserpine (0.5 mg kg⁻¹ for 3 days) were examined on days 4-5.

In arteries from control rats, field stimulation produced motor responses that were abolished by tetrodotoxin (TTX, 0.1 μM) and prazosin (0.1 μM). ATP (1-100 μM) produced no response and mATP (2-4 μM) produced small contractions that quickly showed tachyphylaxis and did not affect field stimulation-induced responses. Field stimulation of arteries from rats pretreated with reserpine, either produced no response or caused contractions that were little affected by prazosin, mATP or TTX, suggesting that these contractions, like the similar contractions obtained in the denervated vessels from 6-OHDA-pretreated rats, were not neurogenic.

DMA is a University of Glasgow Scholar.

Bao, J.X., Eriksson, I.E. & Stjarne, L. (1989) *Acta Physiol. Scand.*, **135**, 65-66.

ADRENALINE AND NORADRENALINE ACTIVATION OF α_2 -ADRENOCEPTORS IN HUMAN RESISTANCE ARTERIES

N.A. Parkinson, S.McG. Thom, P.S. Sever. Department of Clinical Pharmacology, Queen Elizabeth The Queen Mother Wing, St Mary's Hospital, London, W2 1NY.

Postjunctional α_2 -adrenoceptors have been identified in human subcutaneous resistance arteries using the α_2 -agonist BHT933 (Nielsen 1989) and noradrenaline (NA) (Nielsen 1990). This study sought to compare the actions of NA and adrenaline (Ad) and try to establish the relative contribution of α_1 - and α_2 -adrenoceptors to the contractile response.

In vitro studies were undertaken on human subcutaneous resistance arteries (internal diameter 160-550 μ m) in a microvascular isometric myograph. 13 resistance arteries were obtained from 11 patients undergoing surgery and mounted as ring segments bathed in Krebs solution at 37°C, bubbled with 95% O₂; 5% CO₂. The vessels were allowed to equilibrate and then set at a normalised internal circumference as previously described by Mulvany & Halpern (1977). They were then exposed to 118 mM potassium depolarising solution (KDS) and NA (10 μ M). Vessels which failed to produce an effective active pressure of 100 mmHg were discarded. Schild studies were performed, exposing the arteries to five sequential cumulative dose response curves (DRCs) to either NA or Ad in the presence of cocaine (1 μ M) and propranolol (1 μ M). Between each DRC there was a minimum incubation period of 10 minutes. The first DRC acted as a control to determine the reactivity to either NA or Ad. All subsequent DRCs took place in the presence of doxazosin (1 μ M) to determine the presence of α_2 -adrenoceptors. The 3rd to 5th DRC took place in increasing concentrations of yohimbine (30, 100, & 300 nM). pA₂ and pD₂ values were determined to establish potency.

Doxazosin reduced the maximal contraction to NA by $53 \pm 11\%$ and the maximum to Ad by $40 \pm 16\%$. Control pD₂ values for NA and Ad were 6.7 ± 0.4 and 7.0 ± 0.4 respectively. In the presence of doxazosin these were slightly reduced to 5.9 ± 0.8 and 6.5 ± 0.4 . Schild plot analysis calculated pA₂ values for yohimbine against NA as 8.3 and against Ad as 7.9. (The percentage reductions in the maximum are expressed as means \pm s.e.m.)

The equivalent yohimbine pA₂ values indicate that NA and Ad activate α_2 -adrenoceptors equally in human resistance arteries. The small effect of doxazosin on the pD₂ values suggests that the majority of the response to NA and Ad is due to α_2 -adrenoceptors in arteries of this size. It was noted that doxazosin elicited an apparent non-competitive action as it did not shift the DRCs to the right but reduced the maximum.

Mulvany, M.J. Halpern, W. (1977). *Circ. Res.* **41**, 19-26.

Nielsen, H., Thom, S.McG., Hughes, A.D., Martin, G.N., Mulvany, M.J., Sever, P.S. (1989) *Br.J.Pharmac.* **97**, 829-834.

Nielsen, H., Mortensen, F.V., Mulvany, M.J. (1990). *Br.J.Pharmac.* **99**(1), 31-34.

537P

FURTHER INVESTIGATION OF SUBTYPES OF PRE- AND POSTJUNCTIONAL α_2 ADRENOCEPTORS IN THE PERIPHERY

Sonia Connaughton, Theresa Walsh, D. Moore*, G. Shanik*, M. Sugrue*, E. Prendiville*, P. Burke* & J.R. Docherty, Dept. Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, and * St. James's Hospital, Dublin.

We have recently shown that the prejunctional alpha-2 adrenoceptors of rat vas deferens and rat atrium resemble the alpha-2 ligand binding sites in human platelet and rat kidney, respectively (Connaughton & Docherty, 1990), and can therefore be tentatively identified as alpha-2A and alpha-2B, respectively (Bylund, 1988). We now investigate subtypes of functional alpha-2 adrenoceptors prejunctionally in rat submandibular gland and postjunctionally in human saphenous vein.

In rat isolated submandibular gland, antagonist potency was assessed as the ability to produce 30% potentiation of stimulation-evoked overflow of tritium (EC₃₀) in tissues pre-incubated with [3H]-noradrenaline. In human saphenous veins obtained from varicose vein surgery, antagonist potency was assessed as a KB or pA₂ from the shift in the contractile potency of noradrenaline.

In rat submandibular glands, yohimbine and ARC 239 had EC₃₀ values of 7.35 ± 0.88 and 5.95 ± 0.95 (-log M, n=3 each), respectively, while prazosin (1 μ M) significantly increased the basal outflow of tritium so that an EC₃₀ could not be calculated but was <6.5. The low potency of ARC 239 and prazosin, both absolute and relative, suggest that the receptor resembles the alpha-2A subtype.

In human saphenous vein, yohimbine and prazosin had pA₂'s of 7.40 (95% limits of 6.75-8.03) and 6.45 (5.83-7.59) against noradrenaline, while ARC 239 had a KB of 7.54 ± 0.98 . The high potency of ARC 239 and prazosin seem to rule out the possibility that this receptor resembles the alpha-2A subtype. However, the correlation for a series of 9 antagonists between antagonist KB in human saphenous vein and antagonist Ki at alpha-2B binding sites in rat kidney yielded a relatively poor correlation (slope=0.52, r=0.65, n=9), so that these receptors do not seem to resemble the alpha-2B binding site.

Bylund, D.B. (1988) *Trends Pharmac. Sci.* **9**, 356-361.

Connaughton, S. & Docherty, J.R. (1990). *Br. J. Pharmac.* (in press).

8-OH-DPAT DISCRIMINATES BETWEEN SUBTYPES OF α_2 ADRENOCEPTOR

Meriel Borton, Sonia Connaughton & J.R. Docherty, Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin 2, Ireland.

The 5-HT-1A receptor ligand 8-OH-DPAT (Middlemiss & Fozard, 1983) has been reported to be an α_2 -adrenoceptor antagonist in guinea-pig submucous nerves (Crist & Surprenant, 1987). We have examined the actions of 8-OH-DPAT at subtypes of α_2 -adrenoceptor.

In ligand binding studies, K_i values were obtained for the displacement by 8-OH-DPAT and other agents of 3H-yohimbine binding to human platelet (α_2A) and rat kidney (α_2B) membranes (see Connaughton & Docherty, 1990). In functional studies, the actions of 8-OH-DPAT at prejunctional α_2 -adrenoceptors in rat atrium were assessed as an EC_{30} (concentration producing 30% increase of stimulation-evoked release of tritium in tissues pre-incubated with 3H-noradrenaline, and actions at postjunctional α_2 -adrenoceptors were assessed as a K_B from the shift in the contractile potency of noradrenaline in human saphenous vein.

Yohimbine had similar affinity for the α_2A ligand binding sites of human platelet and the α_2B ligand binding sites of rat kidney, with K_i values of 8.04 ± 0.10 and 7.93 ± 0.07 , respectively, whereas 8-OH-DPAT showed higher affinity for α_2B (6.41 ± 0.08) than for α_2A (5.44 ± 0.04).

In rat atrium, yohimbine and 8-OH-DPAT had prejunctional EC_{30} values of 7.89 ± 0.05 and 6.37 ± 0.17 , so that 8-OH-DPAT was approximately 30 times less potent than yohimbine. In human saphenous vein, yohimbine and 8-OH-DPAT had K_B values ($-\log M$) of 7.37 and 5.40 so that yohimbine was approximately 100 times more potent than 8-OH-DPAT.

In conclusion, 8-OH-DPAT shows moderate potency as an antagonist at prejunctional α_2 -adrenoceptors in rat atrium and as a ligand at α_2B ligand binding sites, and so shows selectivity for α_2B over α_2A ligand binding sites.

Supported by the Royal College of Surgeons in Ireland, The Health Research Board (Ireland) and by the Irish Heart Foundation.

Connaughton, S. & Docherty, J.R. (1990) *Br. J. Pharmac.* (in press).

Crist, J. & Surprenant, A. (1987) *Br. J. Pharmac.* 92, 341-347.

Middlemiss, D.N. & Fozard, J.R. (1983) *Eur. J. Pharmac.* 90, 151-153.

 β -INHIBITION OF SPONTANEOUS RHYTHM BUT NOT CONTRACTILITY IN SMOOTH MUSCLE OF THE SHEEP LYMPH NODE

Helen Harty, J.M. Allen, N.G. McHale & K.D. Thornbury. School of Biomedical Science, Queen's University, Belfast BT9 7BL and Biomedical Sciences Research Centre, University of Ulster, Coleraine BT52 1SA.

Stimulation of β -adrenoceptors in the smooth muscle of lymphatic ducts decreases the frequency and force of spontaneous contractions (Allen et al, 1986). This is evident either when the intramural nerves are stimulated in the presence of an α -adrenoceptor antagonist or when isoprenaline is applied alone (MCHale et al, 1980). Similarly intravenous isoprenaline in conscious sheep depresses lymph flow by inhibiting lymphatic pumping (MCHale & Thornbury, 1986). Sheep lymph nodes are also spontaneously contractile and are known to possess a noradrenergic innervation (Thornbury et al, 1990). It was the purpose of this study to assess the role of β -adrenoceptors in the modulation of both spontaneous and evoked contractions in the smooth muscle of the lymph node capsule.

Strips 2mm wide and 30mm long were dissected from the hilar region of sheep para-intestinal lymph nodes. Measurements were made of isometric tension in a water-jacketed organ bath maintained at 37°C and continually perfused with Krebs solution gassed with 5% CO₂, 95% O₂. Spontaneous contractility was rather less regular than in lymphatic vessels but when isoprenaline 10⁻⁷M was added to the perfusate frequency of contraction decreased in a manner similar to that found in lymph ducts. In a summary of seven such experiments mean frequency was approximately halved during drug addition (from 9.4 ± 1.1 , SEM, before to 5.3 ± 1.3) and remained depressed for up to 30 min thereafter. In contrast isoprenaline in doses as high as 3×10^{-7} M did not relax contractures induced by increasing external K⁺ and indeed at higher doses caused a contraction. Neither could any evidence be found of β -inhibition when the intramural nerves were stimulated by an applied electric field since the response to the latter stimulus was not significantly potentiated by 10⁻⁶M propranolol. These results suggest that β -adrenoceptors modify pacemaking in sheep nodal smooth muscle without depressing contractility. This is in contrast to the response in bovine lymph vessels where both are depressed.

Allen, J.M., Iggulden, H.L.A. & McHale, N.G. (1986). *J. Physiol.* 369, 401-411.

MCHale, N.G., Roddie, I.C. & Thornbury, K.D. (1980) *J. Physiol.* 309, 461-472

MCHale, N.G. & Thornbury, K.D. (1986). *J. Physiol.* 378, 109-118

Thornbury, K.D., MCHale, N.G., Allen, J.M. & Hughes, Gwen, (1990) *J. Physiol.* 422, 513-522.

EFFECTS OF PROPAFENE ON ^{45}Ca MOVEMENTS AND CONTRACTILE RESPONSES IN RAT ISOLATED VASCULAR SMOOTH MUSCLE

R. Carrón, F. Pérez-Vizcaíno, E. Delpón & J. Tamargo. Department of Pharmacology, School of Medicine, Universidad Complutense. 28040-Madrid. Spain.

Propafenone (P) is a class Ic antiarrhythmic drug which also inhibited the slow inward Ca current in cardiac tissues (Delgado et al., 1985). However, the possibility that the calcium antagonist properties of P may be responsible for the relaxation of vascular smooth muscle has not been studied yet. Therefore, the present study was undertaken to examine the effects of P on contractile responses and ^{45}Ca uptake in isolated rat aortic strips and portal veins.

Aortic strips and vein segments from Sprague-Dawley rats were incubated in Krebs-Henseleit solution (KS). Techniques employed to estimate ^{45}Ca uptake in aortic strips were as previously described by Barrigón & Tamargo, 1986.

P, 10^{-7}M and 10^{-4}M , inhibited the spontaneous myogenic activity in portal vein segments. Thus, at 10^{-5}M , P inhibited the amplitude of contractions by $44.6 \pm 9.9\%$ ($n = 7$) and at $5 \times 10^{-5}\text{M}$ it suppressed the spontaneous activity. In aortic strips P, 10^{-7}M - 10^{-4}M , inhibited the contractions induced by high K (80 mM) and noradrenaline (NA, 10^{-5}M), the IC_{50} s values for P depression being $2.5 \pm 0.7 \times 10^{-6}\text{M}$ and $8.7 \pm 0.8 \times 10^{-6}\text{M}$, respectively. Contractile responses induced by addition of Ca (1-5 mM) to 0Ca high-K KS were also inhibited by P ($\text{IC}_{50} = 2.5 \pm 0.8 \times 10^{-6}\text{M}$). In another group of experiments, the effects of P were studied on the phasic contractile responses induced by NA in strips previously incubated in 0Ca KS, then to 2.7 mM Ca KS ("Ca-loading") for 5 min and finally in 0Ca KS for 2-3 min. At 10^{-6}M and $5 \times 10^{-6}\text{M}$, P when applied after "Ca-loading" inhibited by $29.7 \pm 3.3\%$ ($p < 0.001$) and $81.0 \pm 1.7\%$ ($p < 0.001$), respectively, the magnitude of the NA-induced phasic contraction. At $5 \times 10^{-6}\text{M}$ and 10^{-5}M , P significantly decreased ^{45}Ca uptake stimulated either by KCl from 0.523 ± 0.02 to 0.378 ± 0.01 ($p < 0.05$) and 0.299 ± 0.18 mmol/kg aorta ($p < 0.001$) and by NA from 0.506 ± 0.024 to 0.361 ± 0.013 ($p < 0.01$) and 0.279 ± 0.012 mmol/kg aorta ($p < 0.001$). However, P had no effect on ^{45}Ca uptake in resting, non-stimulated aortic strips.

These results indicated that in isolated rat aortae and portal vein P inhibited Ca entry through voltage- and receptor-operated channels as well as Ca release from intracellular stores. As a consequence it would reduce the concentration of intracellular free Ca available at the contractile apparatus for vascular smooth muscle contraction.

Barrigón, S. & Tamargo, J. (1986) Br. J. Pharmac. 87, 763-770.

Delgado, C. et al. (1985) Br. J. Pharmac. 86, 765-775.

EFFECTS OF NAFENODONE ON GUINEA-PIG ATRIAL AND VENTRICULAR MUSCLE FIBRES

E. Delpón, R. Carrón, F. Pérez-Vizcaíno & J. Tamargo. Department of Pharmacology, School of Medicine, Universidad Complutense. 28040-Madrid. Spain.

Cardiotoxicity is frequently observed after overdosage and during therapeutic use of tricyclic antidepressants. In an effort to minimize undesirable cardiovascular effects, new antidepressants have been recently developed. The present study was made to determine the effects of nafenodone (N) on the electromechanical properties of isolated guinea-pig atrial and ventricular muscle fibres.

Guinea-pig atria and papillary muscles were incubated in Tyrode solution. Transmembrane action potentials were recorded through glass microelectrodes. Slow responses were elicited by isoprenaline (10^{-6}M) or histamine ($3 \times 10^{-5}\text{M}$) in fibres incubated in 27 mM K solution.

In right atria N, 10^{-8}M - 10^{-4}M , decreased the rate ($\text{IC}_{50} : 1.1 \pm 0.8 \times 10^{-5}\text{M}$) and amplitude of contractions ($\text{IC}_{50} : 5.2 \pm 0.8 \times 10^{-6}\text{M}$) and lengthened the sinus node recovery time. In left atria driven at 1 Hz, N, imipramine (IMI) and desipramine (DMI) caused a negative inotropic effect, the IC_{50} 's being $1.0 \pm 0.8 \times 10^{-5}\text{M}$, $1.0 \pm 0.2 \times 10^{-6}\text{M}$ and $2.9 \pm 0.8 \times 10^{-6}\text{M}$, respectively.

At concentrations $> 10^{-6}\text{M}$ N had no effect on resting membrane potential but it decreased ($p < 0.05$) the amplitude and V_{max} of the upstroke both in atrial and ventricular muscle fibres. In atrial fibres N at concentrations $\geq 10^{-5}\text{M}$ lengthened ($p < 0.05$) the action potential duration (APD). The lengthening of the APD was accompanied by a significant prolongation of the effective refractory period (ERP). In ventricular muscle fibres N slightly shortened the APD values ($p > 0.05$), while the ERP was slightly prolonged and thus, at 10^{-5}M and $5 \times 10^{-5}\text{M}$ it increased the ERP/APD ratio. IMI and DMI were more potent to inhibit amplitude and V_{max} of the action potential and following exposure to $5 \times 10^{-5}\text{M}$ of both drugs atrial and ventricular fibres became inexcitable.

N shifted the dose-response curve of Ca downwards and to the right and decreased the amplitude of the slow contractions induced by histamine ($\text{IC}_{50} : 4.5 \pm 0.7 \times 10^{-6}\text{M}$). At concentrations between 10^{-5}M and 10^{-4}M it reduced the amplitude and V_{max} and shortened the APD of the slow action potentials induced by isoprenaline, while exposure of ventricular fibres to $5 \times 10^{-5}\text{M}$ IMI and DMI suppressed the slow action potentials and contractions.

In conclusion, the present results indicated that N exerted in isolated guinea-pig atria and ventricular muscle fibres less cardiodepressant effects than IMI and DMI.

THE DEVELOPMENT OF AN *IN VITRO* ANIMAL MODEL TO EXAMINE MYOCARDIAL NORADRENALINE UPTAKE: PRELIMINARY RESULTS USING A SHORT DURATION ANGIOTENSIN II INFUSION

M.R. Arnott & A.D. Struthers, Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, DD1 9SY, Scotland.

Previous *in vitro* studies have shown that angiotensin II (AII) inhibits myocardial noradrenaline (NA) uptake (Peach *et al.*, 1969). More recently Sumners and Raizada (1986) reported that AII had a biphasic effect on NA uptake, being stimulatory in the short term and inhibitory in the long term. As angiotensin converting enzyme inhibitors have been shown to lower plasma NA and prolong patient survival in chronic heart failure (Cleland *et al.*, 1984) our aim was to develop an *in vivo* animal model to examine the effect of AII on myocardial NA uptake.

Male Sprague-Dawley rats (250-400g) were anaesthetized with Urethane (25% w/v; 6ml/kg) and jugular, femoral and carotid catheters inserted. The carotid catheter was connected via a transducer to a chart recorder to allow monitoring and recording of both heart rate and blood pressure. After anaesthesia the rats received a bolus dose of [³H]-NA (10 µCi/kg) again through the jugular line, the rats were then sacrificed by anaesthetic overdose at varying times (1, 2, 5, 10, 20 mins) after the bolus of [³H]-NA. The hearts were then removed, blotted, weighed and homogenized in ice-cold 0.4N perchloric acid before counting in the scintillation counter. In order to test that the model was capable of detecting uptake inhibition by known uptake inhibitors, preliminary experiments were performed in which the rats received 2mg/kg of both desipramine (an uptake-1 inhibitor) and corticosterone (an uptake-2 inhibitor). This was administered in a bolus injection through the jugular line thirty minutes prior to the [³H]-NA. In experiments where AII was used, the AII was infused through the femoral line for 10 minutes before the bolus [³H]-NA was given and continued until the animal was sacrificed 3.5 mins later.

The uptake of NA was significantly ($p < 0.001$) inhibited in the presence of desipramine and corticosterone showing that the model was valid and capable of detecting uptake inhibition by known uptake inhibitors. The addition of the blockers reduced the uptake from 186329 ± 7465 dpm/g wet weight tissue to 48852 ± 10846 after 5 minutes. In the experiments with short duration AII infusions we found that a low suppressor dose (20 ng/kg/min) produced no significant change in the myocardial uptake of NA over the control situation (saline only infused). However when a higher (pressor) dose of AII (80 ng/kg/min) was infused a significant ($p < 0.0001$) increase in the amount of [³H]-NA taken up by the heart was found. The level of [³H]-NA rose from 138608 ± 4350 dpm/g wet weight tissue in the control to 239698 ± 19965 in the 80 ng/kg/min infusion. This increase in the myocardial uptake is likely to result from the increased afterload placed on the heart by the pressor effect of AII. The increased afterload may cause the [³H]-NA to be retained within the heart cavity for a longer period of time before expulsion thereby allowing more [³H]-NA to be taken up by the myocardium.

Cleland, J.G.F., Dargie, H.J., Ball, S.G., Gillen, G., Hodsman, G.P., Morton, J.J., East, B.W., Robertson, I., Ford, I. & Robertson, J.I.S. (1984) *Br. Heart J.* 54, 305-312.

Peach, M.J., Bumpus, F.M. & Khairallah, P.A. (1969). *J. Pharmac. exp. Ther.*, 167, 291-299.

Sumners, C. & Raizada, M.K. (1986). *Am. J. Physiol.* 250, (Cell Physiol. 19), C236-C244.

EFFECT OF LEUKOTRIENE D₄ ON THE RESPONSES OF CYSTEINYL LEUKOTRIENES AND U46619 IN GUINEA-PIG HEART

J.D. McLeod* & P.J. Piper, Department of Pharmacology, Royal College of Surgeons, London WC2A 3PN.

The cysteinyl leukotrienes (LTs), C₄ and D₄, are potent vasoconstrictors of the vasculature supplying the cardiac muscle. If LTs have a role in coronary vascular disease in man, antagonists selective against LTs in the coronary vessels may be of therapeutic benefit.

We have investigated the actions of four new LT antagonists which are selective for LTD₄ in guinea-pig (GP) airways: ICI 198,615 (Snyder *et al.* 1987), SK + F 104,353 (Hay *et al.* 1987), CGP 45715A (personal communication), MK-571 (Jones *et al.* 1989) on LT-induced responses in GP isolated hearts.

Hearts from male Dunkin-Hartley GPs (350-450g) were perfused using the modified Langendorff technique with Krebs buffer gassed with 95% O₂, 5% CO₂. The hearts were perfused at a constant pressure (PP) of 40mmHg and the variable coronary flow (CF) was measured by means of a drop counter. The coronary vascular resistance (CVR) was determined by: peak PP/peak CF - basal PP/basal CF. Bolus doses of the agonists: LTD₄, LTC₄, U46619 were given and the antagonists were continually present in the perfusing buffer.

Both ICI 198,615 (3-30nM) and SK + F 104,353 (10-100nM), at similar concentration ranges to those required to inhibit the effects of LTD₄ in GP airways, antagonised the cysteinyl LT-induced vasoconstrictor responses in GP isolated heart. However, ICI 198,615 selectively antagonised only the responses to LTD₄ whereas both the LTD₄ - and LTC₄ - induced vasoconstriction was inhibited by SK + F 104,353. No effect was observed by either compound on the responses to U46619. CGP 45715A (30-100nM) and MK-571 (5.5-18.5µM) appeared to have no specific antagonistic effect against LTs in the GP heart, with the responses to U46619 also being inhibited. MK-571 had a greater effect on the responses induced by U46619 than those observed with the cysteinyl LTs.

Therefore, these LTD₄ receptor antagonists have a different spectrum of activity in the GP heart from that observed in the GP airways.

We thank ICI, Smith Kline and French, Ciba Geigy and Merck Frosst for the gift of their compounds.

Snyder, D.W., Giles, R.E., Keith, R.A., Yee, Y.K. & Krell, R.D. (1987) *J.Pharm.Exp.Ther.* 243(2), 548-556.

Hay, D.W.P., Muccitelli, R.M., Tucker, S.S., Vickery-Clark, L.M., Wilson, K.A., Gleason, J.G., Hall, R.F., Wasserman, M.A. & Torphy, T.J. (1987) *J.Pharm.Exp.Ther.* 243(1), 474-481.

Jones, T.R., Zamboni, R., Belley, M., Champion, E., Charette, L., Ford-Hutchinson, A.W., Frenette, R., Gauthier, J-Y., Leger, S., Masson, P., McFarlane, C.S., Piechuta, H., Rokach, J., Williams, H., Young, R.N., DeHaven, R.N. & Pong, S.S. (1989) *Can.J.Physiol.Pharmacol.* 67: 17-28.

EFFECTS OF SIMVASTATIN ON PLASMA CHOLESTEROL AND FAT DEPOSITION AND ENDOTHELIUM DAMAGE IN LARGE ARTERIES FROM CHOLESTEROL-FED RABBITS

N. Hassan, C.A. Hamilton, C.A. Howie and J.L. Reid.

University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT

Hypercholesterolemia is a major risk factor for cardiovascular disease. The HMG CoA-reductase inhibitor simvastatin (S) lowers plasma cholesterol in man (Mol et al, 1986) and attenuates cholesterol deposition in large arteries in animals (Ishida et al, 1990).

The aim of this study was to compare effects of S on plasma cholesterol, fat deposition and endothelium damage in arteries from cholesterol-fed rabbits. Animals were fed a 0.3% cholesterol diet plus 0 (controls) 1, 5 or 10 mg/kg/day S. Plasma cholesterol and triglyceride, mean arterial pressure (MAP), heart rate (HR) and weight were measured pretreatment and after 2, 4 and 8 weeks. Animals were killed and thoracic aorta and mesenteric artery removed for staining with sudan red for fat deposition and toluidene blue for endothelium damage. Similar increases in MAP and weight were observed in all groups. HR was slightly but significantly decreased in rabbits fed S, 5 and 10 mg/kg/day, being 192 ± 18 , 183 ± 22 , 178 ± 19 and 177 ± 15 beats/min at 8 weeks in the 0, 1, 5 and 10 mg/kg/days groups respectively.

There was a dose-related decrease in plasma cholesterol in S treated animals which reached significance with 10 mg/kg/day. Triglyceride levels were not altered by S. Both plasma cholesterol and fat deposition in the arteries varied widely between rabbits and although sudan red staining appeared to be reduced in the aorta from S treated rabbits, this did not reach statistical significance. There were no treatment effects on sudan red staining in mesenteric artery. In contrast toluidene blue staining was significantly reduced in both aorta and mesenteric artery with 10 mg/kg/day S. There was no relationship between plasma cholesterol and sudan red or toluidene blue staining in individual animals. Neither plasma cholesterol nor lipid deposition was related to weight.

TABLE: Effect of S on plasma cholesterol, sudan red and toluidene blue staining.

S, mg/kg/day	Plasma cholesterol mmol/L		% sudan red		% toluidene	
	0 weeks	8 weeks	aorta	mesenteric	aorta	mesenteric
0(n=7)	1.0 ± 0.3	20.0 ± 8.7	46 ± 28	26 ± 14	61 ± 23	58 ± 25
1(n=4)	0.9 ± 0.1	18.0 ± 3.5	30 ± 18	21 ± 20	52 ± 12	37 ± 12
5(n=7)	0.8 ± 0.2	14.8 ± 11.7	26 ± 28	15 ± 9	52 ± 18	31 ± 19
10(n=6)	0.9 ± 0.5	6.1 ± 4.4	16 ± 14	22 ± 5	25 ± 7	17 ± 13

mean \pm SD. * significantly lower than controls using ANOVA ($p < 0.05$)

In summary S attenuated the increase in plasma cholesterol and endothelium damage in cholesterol-fed rabbits. However there was a poor correlation between plasma cholesterol and fat deposition or endothelium damage in arteries from individual rabbits.

Ishida F, Watanabe K, Sato A, Taguchi K, Kakubari K, Kitani K, Kamei T.

Biochemica et Biophysica Acta 1990; 1042: 365-373.

Mol MJTM, Erkeleus DW, Gevers Leuven JA, Schonten JA, Stalenhof AFM. Lancet 1986; 2: 936-939.

EFFECT OF MORPHINE AND RUTHENIUM RED ON A C-FIBRE EVOKED BLOOD PRESSURE REFLEX IN THE ANAESTHETISED RAT

E. A. Campbell & M. N. Perkins, Sandoz Institute for Medical Research, 5 Gower Place, LONDON WC1E 6BN.

Close intra-arterial injection of capsaicin into the rat hind paw produces a reproducible fall in blood pressure (Donnerer and Lembeck, 1983) mediated by excitation of polymodal C-units which can be excited repetitively at low doses (Szolcsanyi, 1988). In the present study we investigated the effect of morphine infusion on this reflex and subsequent reversal with naloxone. We also studied the effect of Ruthenium Red, an inorganic dye which inhibits transmembrane and mitochondrial Ca^{++} transport and antagonises capsaicin-induced Ca^{++} uptake in dorsal root ganglion cells (Wood et al, 1988) and also protects sensory fibres from capsaicin desensitisation (Maggi et al, 1988).

Sprague Dawley rats were anaesthetised with sodium pentobarbitone (50mg/kg, i.p.). The left carotid artery was cannulated for measurement of blood pressure and the left epigastric artery cannulated retrogradely for injections into the femoral artery. Morphine was infused via a jugular cannula and in some preparations the contralateral femoral vein was cannulated for control injections. Injection of capsaicin (0.1nmol, intra-arterially) every 10 minutes caused a reproducible fall in blood pressure over several hours. At this dose it produced no systemic effects when injected intravenously. In confirmation of the reflex nature of the response section of the saphenous and sciatic nerves or application of local anaesthetic (10% procaine) abolished the depressor response. Infusion of morphine (75µM, 100µl/min i.v. for 1.75h) blocked the capsaicin evoked depressor reflex. Subsequent infusion of naloxone (1mM, 100µl/min) reversed this effect within 20 minutes. Ruthenium Red (10nmol) when co-injected with capsaicin abolished the reflex. It was ineffective at a dose of 1nmol.

The efferent pathway of this reflex consists of a loss of sympathetic vasoconstrictor tone with the reflex centre located in the brain stem (Donnerer and Lembeck, 1983). Morphine is most probably acting at the level of the spinal cord to inhibit substance P release from central terminals of sensory fibres (Donnerer, 1989). The Ruthenium Red block of the capsaicin-evoked response in the in vivo preparation described here is consistent with previously reported findings with in vitro preparations or in the isolated perfused rabbit ear (Amman and Lembeck, 1989). This block is specific for capsaicin as the response to bradykinin or acetylcholine is unaffected (Amman and Lembeck, 1989). This preparation therefore provides a useful in vivo model for the study of capsaicin and capsaicin analogues.

Amman, R. & Lembeck, F. (1989) European J. Pharmacol. 161, 227-229.

Donnerer, J. (1989) Br. J. Pharmacol. 96, 767-772.

Donnerer J & Lembeck, F. (1983) Naunyn-Schmiedeberg's Arch. Pharmacol. 324, 293-295.

Maggi, C.A., Patacchini, R., Santicoli, P., Giuliani, S., Gepetti, P. & Meli, A. (1988) Neurosci. Lett. 88, 201-205.

Szolcsanyi, J., Anton, F., Reeh, P.W. & Handwerker, O. (1988) Brain Research, 446, 262-268.

Wood, J.N., Winter, J., James, I.F., Rang, H.P., Yeats, J. & Bevan, S. (1988) J. Neurosci. 8, 3208-3220.

PHARMACOKINETICS AND METABOLISM OF 4-AMINOPROPIOPHENONE IN THE RAT

T.C.Marrs*, S.G.Wood¹, K.Fitzpatrick¹, R.H.Inns & J.E.Bright, CDE Porton Down, Salisbury, Wiltshire SP4 0JQ and ¹Huntingdon Research Centre, Huntingdon, Cambridgeshire PE18 6ES

4-Aminopropiophenone (PAPP) is a methaemoglobin forming cyanide antidote (Bright, 1987) whose action is reputedly dependent on the formation of 4-(N-hydroxyamino)propiphenone (Graffe et al, 1964).

In the studies ¹⁴C-carbonyl labelled PAPP was used in male rats and ring-labelled PAPP was used in female rats. For excretion studies 5 mg/kg PAPP was administered orally to 4 male and 4 female rats housed singly in metabolism cages for separate collection of urine and faeces. Urine was collected over the first 6 h and subsequent 18 h after dosing and faeces and expired air over the first 24 h period. Urine, faeces and expired air were then collected over 24 h periods until 120 h had elapsed from dosing. At 120 h animals were killed by cervical dislocation, the cages were washed and washings, carcasses, urine and faeces stored at -20°C. For estimation of plasma concentrations, PAPP (5 mg/kg) was administered to separate groups of 4 male and 4 female animals. Blood was sampled at 15 min intervals for 1 h and then at 2,3,5,7,10,30,48,72,96 and 120 h thereafter. The samples were centrifuged in heparinised tubes and then stored at -20°C. Total radioactivity was measured in the collected samples and the chemical nature of radioactive components in plasma, erythrocytes, urine and faeces was studied using a combination of TLC, HPLC, mass spectrometry and proton magnetic resonance spectroscopy (60 MHz) to elucidate the metabolism of PAPP.

In the excretion studies, males and females excreted 57.6±11.4% and 46.4±10.3% of the dose respectively in the urine in 6 h and 24.4±10.6% and 42.1±11.7% in the next 18 h. Over the 120 h period of the study, 83.7±0.4% and 92.2±4.1% was excreted in the urine of males and females (results \bar{x} ±SD). The remaining dose was found in the faeces and expired air. Peak levels of plasma radioactivity were seen at 15 min in the males and 1 h in the females. 4 major components were seen in methanolic extracts of rat plasma: about 10% of the radioactivity was accounted for by unchanged PAPP, 40% N-acetyl PAPP and 25% N-acetyl-p-aminobenzoic acid. Additional, chromatographically very polar material could not be identified. Urine contained 3 major components, PAPP (10%) and N-acetyl-p-aminobenzoic acid 60%. Polar material, accounting for about 30% was shown by enzyme treatment to be in part a conjugate of PAPP. A minor component in both sexes was N-acetyl PAPP, while N-acetyl-p-aminophenol was a minor component in the urine of females; it was not observed in males due to the position of the radiolabel. It was concluded that the major route of metabolism in the rat was N-acetylation.

Bright, J.E. (1987) in *Clinical and Experimental Toxicology of Cyanides* ed Ballantyne B. & Marrs T.C. pp 359-382. Bristol: Wright.

Graffe, W., Kiese, M. & Rauscher, E. (1964) *Naunyn-Schmiedeberg's Arch Exper Pathol Pharmacol.* 249, 168-175.

COMPARISON OF THE HEPATIC CLEARANCE OF (±) RP 49356 AND ITS ENANTIOMERS IN THE ISOLATED PERFUSED LIVER

S.A. Roberts, A. McCormack, P. Gunraj, R.E. Mackenzie & V. Facchini Biopharmaceutical Research, Rhône-Poulenc Ltd., Dagenham, Essex.

The extent of hepatic clearance of the racemate RP 49356 1RS,2RS - [N-methyl-2 (3-pyridyl) -2-tetrahydrothiopyran - carbothioamide-1-oxide], a novel antihypertensive agent, and its enantiomers (-) RP 52891 and (+) RP 61499 has been studied in the isolated perfused rat liver. A perfused liver can be a suitable model for determining differences in the hepatic clearance of a racemate and its enantiomers and for predicting the extent of first pass metabolism *in vivo* (Silver and Dauterman, 1989)

Isolated livers were prepared by the method of Miller (1973). After a 60 minute equilibration period, compounds (3 mg in DMSO) were added to the perfusate. Thereafter, sampling of perfusate occurred over a period of 120 minutes. Samples were centrifuged and the supernatants stored at -20°C until analysed.

Samples were initially assayed by a non-chiral h.p.l.c. method with internal standardisation, following extraction into dichloromethane containing 1% IPA at neutral pH. Extracts were evaporated to dryness under nitrogen at 50°C and reconstituted in 100µl of the mobile phase (methanol:water, 1:1 v/v) for analysis. The analytical column was a 250 x 4.6mm LiChrosorb 'Select B' cartridge (5µm, C8) protected by a 4 x 4mm C18 (7µm) guard cartridge. A flow rate of 1.0 ml/min was used and the compounds were detected by their U.V absorption at 275 nm. The racemisation of the enantiomers and any changes in the isomer ratio of the racemate with time were investigated using a chiral h.p.l.c. method which utilised a 250 x 4.6mm cellulose triphenylcarbamate column with a flow rate of 1.0 ml/min (mobile phase - IMS:hexane, 3:7 v/v).

Low hepatic clearance of (±) RP 49356, (-) RP 52891 and (+) RP 61499 occurred giving mean values of 0.024 ± 0.003, 0.0027 ± 0.003 and 0.019 ± 0.003 ml min⁻¹g⁻¹ liver respectively. The values were calculated for periods of equivalent bile flow rate (0.6 - 0.85 µl min⁻¹g⁻¹ liver) and revealed that the (-) enantiomer was removed from the perfusate at a rate about 30% greater than the (+) enantiomer. Mean half-lives for the removal of RP 52891 and RP 61499 were 195 and 300 minutes respectively. At the end of each perfusion with RP 49356, there was a mean decrease of about 14% in the quantity of RP 52891 present in the perfusate. As anticipated on structural grounds, there was no interconversion of RP 52891 and RP 61499.

It can be concluded that RP 49356 is likely to undergo some degree of stereoselective hepatic clearance which could influence its pharmacological activity and duration of action.

Miller, L.L. (1973) In : *Isolated liver perfusion and its application*. Barstock, I., Guaitani, A. & Miller, L.L. (eds), pp 10-52, New York, Raven Press.
Silver, I.S. and Dauterman, W.C. (1989) *Xenobiotica* 19 509.

AMELIORATION OF ACUTE RENAL FAILURE WITH 8-CYCLOPENTYL-1, 3-DIPROPYLBXANTHINE: DOSE DEPENDENCY

M.R. Panjehshahin, M.G. Collis*, C.J. Bowmer & M.S. Yates. Department of Pharmacology, Worsley Medical & Dental Building, The University of Leeds, Leeds LS2 9JT and * Bioscience II, ICI Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG.

8-Cyclopentyl-1, 3-dipropylbixanthine (CPX) is a selective A₁ adenosine antagonist *in vivo* and at a dose of 0.1 mg kg⁻¹ it ameliorates glycerol-induced acute renal failure (ARF) in the rat (Kellett *et al.*, 1989). In this study the beneficial effects of a range of CPX doses were compared. ARF was induced in male Wistar rats by an i.m. injection of 50% glycerol in saline (10 ml kg⁻¹) after which animals were treated with CPX (0.03, 0.1 or 0.3 mg kg⁻¹ i.v.) and treatment was repeated 12, 24 and 36h later. An additional group of rats was injected with glycerol and received no further treatment. Renal function was assessed by measuring plasma urea and creatinine levels and clearances of [³H]-inulin (C-IN) and [¹⁴C]-p-aminohippurate (C-PAH).

TABLE 1

	Plasma Urea (mg dl ⁻¹)		Plasma Creatinine (mg dl ⁻¹)		C-IN (ml min ⁻¹ 100g ⁻¹)	C-PAH (ml min ⁻¹ 100g ⁻¹)
	0h	48h	0h	48h	48h	48h
Group 1 No treatment	38 ± 2	247 ± 18	0.66 ± 0.08	4.51 ± 0.70	0.24 ± 0.05	0.89 ± 0.14
Group 2 CPX (0.03 mg kg ⁻¹)	59 ± 2	214 ± 29	0.55 ± 0.02	2.53 ± 0.52	0.35 ± 0.06	1.16 ± 0.18
Group 3 CPX (0.1 mg kg ⁻¹)	45 ± 1	97 ± 10***	0.62 ± 0.02	1.11 ± 0.12**	0.54 ± 0.06*	1.84 ± 0.20**
Group 4 CPX (0.3 mg kg ⁻¹)	49 ± 1	103 ± 13***	0.59 ± 0.02	1.14 ± 0.17**	0.66 ± 0.09***	1.94 ± 0.15***

Mean ± s.e. mean (n = 12); * P < 0.05; ** P < 0.01 relative to group 1; * P < 0.01 relative to group 2 (ANOVA).

Rats given 0.03 mg kg⁻¹ CPX showed small improvements in renal function, but these changes were not statistically significant when compared to the untreated group (Table 1). By contrast, treatment with either 0.1 or 0.3 mg kg⁻¹ CPX significantly improved renal function. However, there was no appreciable difference in the beneficial effects afforded by 0.1 or 0.3 mg kg⁻¹ CPX. These results show that in glycerol-induced ARF the protective effect produced by CPX is restricted to a narrow dose range.

Kellett, R., Bowmer, C.J., Collis, M.G. & Yates, M.S. (1989) Br. J. Pharmac. 98, 313-318.

MODULATION OF INTERFERON ALPHA 2c RECEPTOR EXPRESSION IN HUMAN BREAST CANCER CELL LINES BY ESTRADIOL, PROGESTINS AND ANTI-PROGESTINS

J.Martin, B.McKibben* & H.W. van den Berg, Departments of Therapeutics and Pharmacology and *Medicine, The Queen's University of Belfast, Belfast BT7, N.Ireland. (Introduced by Dr.B.Silke).

Recombinant interferon alpha 2c (IFN) increases estrogen receptor (ER) expression in ZR-75-1 human breast cancer cells and sensitises them to the anti-proliferative effects of the anti-estrogen tamoxifen, (van den Berg *et al* 1987). We have been unable to demonstrate induction of ER in a tamoxifen resistant, ER negative, variant line, ZR-75-9a1, (van den Berg *et al* 1989). In this study we have investigated the influence of estradiol, progestins and anti-progestins on IFN receptor expression. We have also examined the relationship between IFN receptor and steroid hormone receptor expression in ZR-75-1 cells, the tamoxifen resistant variant and an estrogen independent subline (ZR-PR-LT). The latter line lacks binding sites characteristic of the Type 1 ER but expresses elevated levels of progesterone receptor (PGR), (van den Berg *et al* 1990).

IFN was labelled with 125-Iodine using the Iodogen reaction and purified by HPLC to a specific activity of 298Ci/mmol. Binding of 125-I IFN to whole cells at 4°C was determined in the presence and absence of excess cold IFN. ZR-75-1 cells contained 1498±541 IFN receptors/cell which fell to 802±447 receptors/cell during a 5 day exposure to 10-9M estradiol (E2). This E2 induced reduction in IFN receptor expression was accompanied by a 6-fold increase in PGR concentration. There was no significant reduction in IFN receptor expression in ZR-PR-LT cells associated with their elevated basal PGR content. However, a 6 day exposure of ZR-LT-PR cells to the progestin Medroxyprogesterone acetate or the anti-progestin RU.38.486, which results in a marked down regulation of PGR in these cells, also results in a 30 -50% increase in IFN receptor expression. A similar inverse relationship between IFN and PGR receptor expression is apparent in the ZR-75-9a1 line which lacks PGR and expresses the highest concentration of IFN receptors (3443±389 sites/cell). This increased receptor expression is not associated with increased sensitivity of the tamoxifen resistant cells to the anti-proliferative effects of IFN.

We conclude that E2 and IFN appear to have opposite effects on the expression of each others' receptor in ZR-75-1 cells suggesting that an ER/PGR/IFN receptor axis exists. This proposal is supported by the observations that downregulation of PGR in the estrogen independent cell line is accompanied by an increase in IFN receptor expression and that IFN receptor content is highest in the tamoxifen resistant cell line lacking detectable PGR. The failure of IFN to induce ER in this line is not the result of failure to express IFN receptor.

Acknowledgement: This work was supported by the Cancer Research Campaign.

H.W.van den Berg H.W., Leahey W., Lynch M., Clarke R., Nelson J. (1987) Brit.J.Cancer 55, 255-257

H.W.van den Berg H.W., Lynch M., Martin J. Nelson J., Dickson G.R. Crockard A.D. (1989) Brit.J.Cancer 59, 522-526

H.W.van den Berg H.W., Martin J., Lynch M. (1990) Brit.J.Cancer 61, 504-507

PROGESTIN/ANTI-PROGESTIN ACTION TOWARDS HUMAN BREAST CANCER CELL LINES DIFFERING IN THEIR PROGESTERONE RECEPTOR CONTENT

H.W.van den Berg, J.Martin and M.Lynch, Department of Therapeutics and Pharmacology, The Queen's University of Belfast, Belfast BT7 1NN, N.Ireland. (Introduced by Dr.B.Silke).

Progestins such as Medroxyprogesterone acetate and Megestrol acetate have been traditionally used as second or third line treatment in hormone responsive breast cancer, although response rates have been reported equal to those for the anti-estrogen tamoxifen in unselected groups of patients. Recently novel anti-progestins such as RU 38.486 (Mifepristone) and ZK 98.299 have shown promising activity in experimental breast cancer, (Schneider et al 1989). The mechanisms by which progestins/anti-progestins exert their direct anti-proliferative effects on breast cancer cells are poorly understood.

We have studied the effects of the progestins Medroxyprogesterone acetate (MPA) and ORG 2058 and the anti-progestins RU 38.486 and ZK 98.299 on progesterone receptor (PGR) expression by and proliferation of ZR-75-1 human breast cancer cells and variants differing in their steroid hormone receptor profiles. The relative affinities of progestins/anti-progestins for PGR in an oestrogen (E2) independent variant of the ZR-75-1 line (ZR-PR-LT, van den Berg et al 1990) expressing high basal levels of PGR were: ORG 2058 = 100, MPA = 200, RU 38.486 = 44, ZK 98.299 = 30. A 5 day exposure of ZR-75-1 cells to 10-9M E2 in the presence of 10-9M MPA resulted in an almost complete blockade of E2 induction of PGR, whilst RU 38.486 (10-9M) lowered induced PGR concentration by 50%. ZK 98.299 (10-9M) had no effect on E2 induction of PGR. Progestins/anti-progestins also showed marked differences in their ability to down regulate PGR in the estrogen independent variant, ZR-LT-PR. MPA and RU 38.486 were equipotent, reducing PGR levels by 50% at a concentration of 10⁻¹⁰M, (IC₅₀). IC₅₀s for ORG 2058 and ZK 98.299 were 5x10⁻⁷M and 10⁻⁶M respectively. MPA was the most potent anti-proliferative agent in all cell lines tested, but the ZR-PR-LT line was only marginally more sensitive than the parent line despite expressing a 20-fold higher basal PGR concentration. Surprisingly, the growth inhibitory response to MPA, RU 38.486 and ZK 98.299 was greatest in a tamoxifen resistant variant (ZR-75-9a1, van den Berg et al 1989) lacking detectable PGR.

These results suggest that there is a poor relationship between affinity for PGR and ability to down-regulate the receptor - an indication of receptor activation. The reason for the marked differences in the ability of these agents to down-regulate PGR is not known, but it is of interest that the two most potent agents, MPA and RU 38.486, possess intrinsic glucocorticoid/anti-glucocorticoid activity respectively. Our results further suggest that PGR status will not accurately predict anti-proliferative response to these agents.

Acknowledgements: This work was supported by the Cancer Research Campaign.

Schneider M.R., Michna, H., Nishino, Y., El Etraby, M. (1989) *Eur.J.Cancer* 691-701

van den Berg H.W., Martin, J., Lynch, M. (1990) *Brit.J.Cancer* 61, 504-507

van den Berg H.W., Lynch M., Martin J., Nelson J., Dickson, G.R., Crockard A.D. (1989) *Brit.J.Cancer* 59, 522-526

TAMOXIFEN INHIBITS THYROTROPIN RELEASING HORMONE-INDUCED EXPRESSION FROM A MINIMAL RAT PROLACTIN PROMOTER

F. Martin and S. Tait, Department of Pharmacology, University College Dublin, Dublin 4. Ireland

Earlier studies from this laboratory (Whelan and Martin, 1987) indicated that the triphenylethylene antioestrogen, tamoxifen, suppressed oestradiol induced increases in prolactin mRNA levels in rat pituitary tumour cells in culture (GH₃ cells). In addition, these studies demonstrated that tamoxifen also suppressed thyrotropin releasing hormone (TRH) induced increases in prolactin mRNA levels. These findings suggested that tamoxifen may have some activities that are not mediated through the oestrogen receptor. Other groups (eg. Lam (1984)) have also demonstrated that tamoxifen can impair the action of elements of signal transduction cascades. We have now sought to demonstrate the inhibition of TRH induction of expression from a rat prolactin gene promoter construct that is nonresponsive to oestrogen, after transfection into GH₃ cells. GH₃ cells were maintained in monolayer culture. They were transfected with plasmids containing rat prolactin gene promoter fragments linked to a reporter gene encoding the bacterial enzyme, chloramphenicol acetyl transferase (CAT). The ability of hormones to induce expression from the rat prolactin promoter fragments was analysed by measuring the levels of CAT enzyme activity in GH₃ cell extracts at the end of the treatment period (48 h). All procedures have been previously described (Schuster et al., 1988).

When transfected into GH₃ cells, a construct prPrl(-1953)CAT containing the most proximal 1.95 Kb of prolactin promoter sequence was induced by oestradiol (10⁻⁸ M), as judged by expression of CAT enzyme (p < 0.05). The induction was suppressed by tamoxifen (10⁻⁵ M) (p < 0.05). An identical construct containing only the most proximal 75 bp of the rat prolactin gene promoter (prPrl (-75) CAT) was no longer inducible by oestrogen. Expression from prPrl (-75) CAT was, however, significantly, induced by TRH (10⁻⁷ M) (p < 0.05) and this induction was completely suppressed by tamoxifen (10⁻⁵ M) (p < 0.05). Tamoxifen alone had no effect on CAT gene expression.

These findings provide further evidence that tamoxifen inhibits TRH induction of prolactin gene expression by a mechanism that may not involve the oestrogen receptor.

This work was funded by the Cancer Research Advancement Board of the Irish Cancer Society.

Lam H.Y.P. (1984) *Biochem. Biophys. Res. Commun.* 118, 27-32.

Schuster, W., Treacy, M.N. and Martin, F. (1988). *EMBO J.* 7, 1721-1733.

Whelan, J. and Martin F. (1987) *Biochem. Soc. Trans.* 15, 952.

¹P.E. Hoaksey, ²S.A. Ward, ^{1,2}G. Edwards, ¹Department of Pharmacology and Therapeutics, University of Liverpool and ²Department of Parasitology, Liverpool School of Tropical Medicine.

A combination of the macrocyclic lactone ivermectin (IVM) and a benzimidazole carbamate has been proposed for the treatment of onchocerciasis. Inhibition of hepatic drug oxidation has been demonstrated with these classes of compounds (Ward *et al.* 1985, Miura *et al.* 1989). The efficacy of ABZ is limited by poor bioavailability. Any metabolic interaction resulting in increased plasma and/or tissue concentrations of ABZ or its active sulfoxide metabolite (ABS) may be beneficial. We have evaluated the metabolic interactions between IVM and ABZ in rat liver microsome preparations and the isolated perfused rat liver (IPRL). In microsomes, ABS production was inhibited non-competitively by IVM as evidenced by no change in K_m but a progressive fall in V_{max} with increasing concentrations of IVM. In the IPRL although there was a significant increase in the AUC of ABS after co-administration of ABZ and IVM ($p < 0.01$ unpaired t-test) the pharmacokinetic parameters of ABZ were unchanged, in contrast to results obtained in microsomes. ABZ had no effect on the disposition of IVM. The conversion of ABZ to ABS is mediated by P-450 and FAD dependent processes, whereas the conversion of ABS to ABZ sulphone is mediated only by P-450 (Rolin *et al.* 1989). Selective inhibition by IVM of P-450 isozymes offers one explanation of this apparent contradiction. The increase in plasma ABS in the presence of IVM without a corresponding decrease in ABZ concentrations might improve efficacy due to the higher concentrations of pharmacologically active compounds.

Table 1: Summary of the Pharmacokinetic Parameters of ABZ and ABS in the IPRL Clearance (Cl); apparent terminal elimination Half-life ($t_{1/2}$); Volume of Distribution (Vd); and Area Under the Curve (AUC)

Compound	Co-admin- istration	AUC ₀₋₄ ($\mu\text{g}\cdot\text{min ml}^{-1}$)	AUC _{0-∞} ($\mu\text{g}\cdot\text{min ml}^{-1}$)	Cl (ml min^{-1})	$t_{1/2}$ (min)	Vd (ml)
ABZ	-	117 (20)	128 (17)	7.9 (1.2)	48 (18)	512 (211)
ABZ	IVM	105 (20)	108 (20)	9.5 (1.8)	33 (11)	425 (125)
ABS	-	531 (114)	-	-	-	-
ABS	IVM	790 (174)	-	-	-	-

Miura, T., Iwasak, M., Komori M., Ohi, H., Kitada, M., Kamataki, T. (1989). J. Antimicrob Chemother 24 551-559.

Ward, S.A., Mihaly, G.W., Tjia, J.F., Back, D.J. (1985). J. Pharm. Pharmacol. 37, 62-64.

Rolin, S., Souhaili-El Amri, H., Batt, A.M., Levy, M., Bagrel D., Siest, G. Cell Biol. Toxicol 1989, 5 1-14.

S.J. Paterson, Department of Pharmacology, UMDS, St Thomas's Hospital, London, SE1 7EH

Although three types of opioid receptors, μ , δ and κ , have been identified using binding assays, *in vitro* bioassays, electrophysiological recordings and behavioural experiments, there is increasing evidence that the non- μ , non- δ binding of non-selective opioid ligands is heterogeneous (Zukin *et al.*, 1988; Hunter *et al.*, 1989). In the present investigation, the κ -binding of [^3H]-U-69593 was compared with the non- μ , non- δ binding of [^3H]-bremazocine, [^3H]-ethylketazocine and [^3H]-diprenorphine in brain, cerebellum and spinal cord obtained from New Zealand white rabbits.

The μ -sites were labelled with [^3H]-[D-Ala²,MePhe⁴,Gly-ol⁵]enkephalin, the δ -sites with [^3H]-[D-Pen²,D-Pen⁵]enkephalin and the κ -sites with [^3H]-U-69593. The non- μ , non- δ binding of [^3H]-bremazocine, [^3H]-ethylketazocine and [^3H]-diprenorphine was determined in the presence of unlabelled [D-Ala²,MePhe⁴,Gly-ol⁵]enkephalin and [D-Ala²,D-Leu⁵]enkephalin to prevent μ - and δ -binding.

The proportions of μ : δ : κ sites were 51:31:19 in rabbit brain, 84:6:10 in rabbit cerebellum and 88:0:12 in rabbit spinal cord. In rabbit brain, the binding capacity found with [^3H]-U-69593 was 2.28 ± 0.16 pmol g⁻¹ (n=6) whereas that of [^3H]-bremazocine after suppression of μ - and δ -binding was 4.44 ± 0.84 pmol g⁻¹ (n=4). In the cerebellum, the binding capacity of [^3H]-U-69593 was 1.14 ± 0.08 pmol g⁻¹ (n=5) and the non- μ , non- δ binding capacity of [^3H]-bremazocine was 1.58 ± 0.08 pmol g⁻¹ (n=3). In spinal cord the binding capacities were 0.42 ± 0.05 pmol g⁻¹ (n=4) and 1.09 ± 0.14 pmol g⁻¹ (n=3) respectively.

Thus in rabbit brain, cerebellum and spinal cord [^3H]-U-69593 labels less opioid sites than does [^3H]-bremazocine after suppression of μ - and δ -binding. These findings will be compared to those obtained with [^3H]-ethylketazocine and [^3H]-diprenorphine.

Supported by a grant from St Thomas's Research Endowments Committee.

Hunter, J.C., Birchmore, B., Woodruff, R., & Hughes, J. (1989) Neurosci. 31, 735-743
Zukin R.S., Eghball, M., Olive, D., Unterwald, E.M. & Tempel, A. (1988) Proc. natl. Acad. Sci. USA 85, 4061-4065

ANTIDEPRESSANT INHIBITORY ACTIVITY IN THE ABDOMINAL CONSTRICTION ASSAY IS COMPETITIVELY BLOCKED BY OPIOID ANTAGONISTS

A. M. Gray, R. D. E. Sewell and P. S. J. Spencer, Dept. of Pharmacology, Welsh School of Pharmacy, University of Wales College of Cardiff, P.O. Box 13, Cardiff CF1 3XF.

Some antidepressants possess clinical efficacy in analgesic therapy. They also produce antinociception in rats (Isenberg et al., 1984) which is only partially naloxone-reversible when higher doses of the opioid antagonist are employed. The present study examines the possibility that amitriptyline [AMI] and (+) oxaprotiline [(+) OXPN] (Waldmeier et al., 1982) produce graded antinociceptive effects in the abdominal constriction test which may be competitively blocked by low doses of the opioid antagonists naloxone and MR2266 (Millan, 1989).

Male ICI-GB1 (WSP) mice ($20 \pm 2g$; $n = 8$) were pretreated with antidepressants at 30min and naloxone or MR2266 (both at $0.5mg/kg$ sc) at 5 min before 1% acetic acid (ip). Abdominal constrictions were evaluated over 20 min and both AMI and (+) OXPN produced linear dose related inhibitory actions in the assay. These dose-response relationships were shifted rightwards in a parallel manner by both antagonists.

Table 1.

	Alone	ED ₅₀ (mg/kg) Naloxone	MR2266	Blockade of antidepressant activity in the abdominal constriction assay
AMI	2.6 (1.9 - 9.61)	7.8 ^a (5.8 - 17.7)	27.2 ^a (5.2 - 39.9)	Results are expressed as means (95% confidence limits) and dose-response lines analysed using ANCOVA followed by Neuman-Keuls test. ^a , ^b $P < 0.01$ from antidepressant alone
(+) OXPN	14.8 (6.7 - 39.1)	91.0 ^b (85.9 - 155.6)	56.9 ^b (15.0 - 109.4)	

Since both antagonists completely blocked the inhibitory actions of the antidepressants in this test, it might be hypothesised that the antidepressants directly interact with opioid receptors (Isenberg et al., 1984) and/or release opioid peptides (Sacerdote et al., 1987) to play a more important role in inhibiting this type of nociceptive stimulus.

Isenberg, K.E. & Cicero, T.J. (1984) *Europ. J. Pharmacol.* **103**, 57 - 63.

Millan, M.J. (1989) *J. Pharmacol. Exp. Ther.* **251**, 334 - 341.

Sacerdote, P., Brini, A., Mantegazza, P. & Panerai, A.E. (1987) *Pharmacol. Biochem. Behav.* **26**, 153 - 158.

Waldmeier, P.C., Baumann, P.A., Hauser, K., Maitre, L. & Storni, A. (1982) *Biochem. Pharmacol.* **31**, 2169-2176

ARE OPIOID RECEPTORS OR α_2 -ADRENOCEPTORS INVOLVED IN BENZODIAZEPINE-INDUCED HYPOTHERMIA IN MICE?

Helen C. Jackson & P.J. Weinberger, Reckitt & Colman Psychopharmacology Unit, Department of Pharmacology, School of Medical Sciences, University Walk, Bristol, BS1 8TD.

Benzodiazepines (BDZ) decrease body temperature in mice (Taylor et al., 1985). Other compounds which produce hypothermia in these animals include opioid (Rosow et al., 1980) and α_2 -adrenoceptor agonists (e.g. UK 14,304; Bill et al., 1989). In the current study we have examined whether the hypothermia induced by the BDZ agonist lorazepam involves the release of endogenous opioids or noradrenaline using the opioid antagonist naltrexone and the selective α_2 -adrenoceptor antagonist RX811059 (Doxey et al., 1985). Body temperatures of male TO mice, 25-35g, were recorded at 15 min intervals using a rectal probe (inserted 2 cm) and digital thermometer (BAT-12, Sentsortek). Drugs were dissolved in 0.9% saline - except for the BDZ antagonist Ro 15-1788 (Taylor et al., 1985) which was suspended in Tween 80 solution - and administered i.p. Antagonists were injected 15 min after lorazepam and 15 min before morphine or UK 14,304. Treatment group means ($n=8$) were compared using ANOVA and Dunnett's test. The decrease in body temperature produced by lorazepam (3 mg/kg) was significantly attenuated by 10 mg/kg of Ro 15-1788 (vehicle 37.9 ± 0.1 ; L $36.1 \pm 0.3^*$; L+Ro $37.7 \pm 0.2^{\$}$ at $t=15$ min) but not altered by either naltrexone (0.3 mg/kg) or RX811059 (0.5 mg/kg). The antagonists did not modify body temperature themselves. However, naltrexone and RX811059 blocked the hypothermia induced by morphine (30 mg/kg) and UK 14,304 (1 mg/kg) respectively. Thus, the thermoregulatory effects of BDZ do not appear to be mediated through either opioid receptors or α_2 -adrenoceptors. The results with naltrexone contrast with studies implicating endogenous opioids in the effects of benzodiazepines on food intake - a behaviour which like body temperature is under hypothalamic control (Cooper, 1983).

* $P < 0.05$ -v-vehicle; $\$P < 0.05$ -v-drug control group

Bill, D.J., Hughes, I.E. & Stephens, R.J. (1989) *Br. J. Pharmac.* **96**, 133-143.
Cooper, S.J. (1983) *Life Sci.* **32**, 1043-1051.
Doxey, J.C., Lane, A.C., Roach, A.G., Smith, C.F.C. & Walter, D.S. (1985) in *Pharmacology of Adrenoceptors*. eds. Szabadi, E., Bradshaw, C.M. & Nahorski, S.R. pp13-22. New York: Macmillan.
Rosow, C.E., Miller, J.M., Pelikan, E.W. & Cochin, J. (1980) *J. Pharmac. Exp. Ther.* **213**, 273-283.
Taylor, S.C., Little, H.J., Nutt, D.J. & Sellars, N.A. (1985) *Neuropharmacology* **24**, 69-73.

Bill, D.J., Hughes, I.E. & Stephens, R.J. (1989) *Br. J. Pharmac.* **96**, 133-143.

Cooper, S.J. (1983) *Life Sci.* **32**, 1043-1051.

Doxey, J.C., Lane, A.C., Roach, A.G., Smith, C.F.C. & Walter, D.S. (1985) in *Pharmacology of Adrenoceptors*. eds. Szabadi, E., Bradshaw, C.M. & Nahorski, S.R. pp13-22. New York: Macmillan.

Rosow, C.E., Miller, J.M., Pelikan, E.W. & Cochin, J. (1980) *J. Pharmac. Exp. Ther.* **213**, 273-283.

Taylor, S.C., Little, H.J., Nutt, D.J. & Sellars, N.A. (1985) *Neuropharmacology* **24**, 69-73.

HISTAMINE H2 ANTAGONISTS AND NOCICEPTION IN THE MOUSE

Patricia Freeman & Gillian Sturman, Neuropharmacology Research Group, Division of Physiology & Pharmacology, Polytechnic of East London, Romford Road, London E15 4LZ

Considerable evidence suggests that histamine is involved in nociception. Centrally- but not peripherally-acting H1 antagonists have been shown to potentiate antinociception induced by morphine in mice (Freeman, Sturman & Tang, 1989). The existence of H2 receptors in the c.n.s. has been demonstrated and stimulation of them in the rat dorsal raphe area has produced antinociception (Glick & Crane, 1978). The recent development of centrally-penetrating H2 antagonists facilitates further investigation into histamine's role in nociception. Groups of ten female T0 mice were pretreated with antihistamine or vehicle and tested for response to nociceptive stimuli before and after morphine injection as previously described (Freeman & Sturman, 1989). Neither zolantidine nor cimetidine (H2 antagonists which penetrate the c.n.s. to varying degrees) nor ranitidine (a non-c.n.s. penetrating H2 antagonist) alone affected responses to nociceptive stimuli, and only cimetidine potentiated morphine's effects, possibly nonspecifically due to its p450 inhibitory action (Table 1)

Table 1	Pretreatment (mg kg ⁻¹ s.c.)	Morphine sulphate (mg kg ⁻¹ s.c.)	Median Latency	
			Hot plate (30 min)	Tail clip (30 min)
	Cimetidine (200)	5	15.7 **	1.0
	Cimetidine (100)	5	9.6	2.0
	Zolantidine (10)	5	13.1	1.0
	Zolantidine (5)	5	11.6	2.0
	Ranitidine (100)	5	15.6 NS	1.5
	Ranitidine (50)	5	10.9	1.5
	Cimetidine (200)	10	20.0 NS	30.0 *
	Cimetidine (100)	10	14.2	1.5
	Zolantidine (10)	10	15.7	2.0
	Zolantidine (5)	10	10.5	8.5
	Ranitidine (100)	10	13.3	7.5
	Ranitidine (50)	10	18.2 NS	30.0 NS

Significantly different from control by Kruskal Wallis analysis * $p < 0.05$, ** $0.02 < p < 0.05$

Thus although the H1 receptor appears to influence the nociceptive response, these results suggest that there is no evidence of an involvement of H2 receptors in these models.

We wish to thank Smith Kline Beecham for the gifts of zolantidine and cimetidine.

Freeman, P. & Sturman, G. (1989) Br. J. Pharmacol., **97**, 486P.

Freeman, P., Sturman, G. & Tang, M-F.R. (1989) Br. J. Pharmacol., **98**, 933P.

Glick, S.D. & Crane, L.A. (1978) Nature, **273**, 547-549.

557P

MEASUREMENT OF STIMULATED ENDOGENOUS 5-HT RELEASE IN RAT BRAIN SLICES USING FAST CYCLIC VOLTAMMETRY

¹J. J. O'Connor & ¹Z.L. Kruk, Department of Pharmacology, The London Hospital Medical College, Turner Street, London, E1 2AD, UK.

We have used fast cyclic voltammetry (FCV) to measure 5-HT release *in vitro* using methods previously described (Palij, et al., 1988, 1990). Rat brain slices (350µm) containing the dorsal raphe nuclei (DRN) or caudate putamen (CPu) were superfused with oxygenated ACSF at 32°C. Stimulating electrodes were placed centrally in the DRN and 80µm below the surface. 5-HT release was monitored with a carbon fibre microelectrode 100 to 200µm from the stimulating electrodes. 500ms trains of square waves (0.1ms; 50Hz; 20V) were applied every 5 minutes. Reproducible evoked release of 5-HT could be measured for 6hr. Concentrations of 5-HT greater than 10⁻⁸M were readily detectable. Omission of calcium from the perfusion medium reversibly abolished the electrochemical signal. Ro 4 1248 (10⁻⁷M and 10⁻⁶M) irreversibly attenuated the signal in a concentration-dependent manner. The effects of 5-HT uptake inhibitors on evoked 5-HT overflow and reuptake are shown in table 1. Benztropine (10⁻⁶M) had no effect on the signal detected in the DRN while in the same bath there was a large increase in the evoked DA overflow detected in slices of CPu (0.39±0.1µM to 1.22±0.4µM; n=3)

Table 1		Effects of 5-HT blockers (all 10 ⁻⁶ M) on evoked 5-HT overflow and reuptake.			
		Citalopram	Clomipramine	Fenfluramine	Fluvoxamine
Peak 5-HT release (nM±sem (n))	Control	58±13 (4)	63±11 (5)	84±8 (3)	55±10 (3)
	+Drug	142±16 (4)*	122±23 (5)*	112±14 (3)	92±17 (3)
t _{1/2} (seconds±sem (n))	Control	4.9±0.5 (4)	6.3±1.1 (5)	4.5±1.0 (3)	3.8±0.3 (3)
	+Drug	7.4±1.1 (4)*	13.2±1.6 (5)*	11.3±3.9 (3)*	7.8±1.1 (3)*

* P<0.05 (paired Student's t-Test). t_{1/2}: time in seconds for the overflow to decline to 50% maximum.

Supported by Glaxo (JJOC).

¹Present address: Department of Pharmacology, Queen Mary & Westfield College, Mile End Road, London, E1 4NS, UK.

Palij, P., Bull, D.R., Kruk, Z.L., Sheehan, M.J., Stamford, J.A., Millar, J. & Humphrey, P.P.A. (1988) Br. J. Pharmac. **94**, 347P

Palij, P., Bull, D.R., Sheehan M.J., Millar, J., Stamford, J.A., Kruk, Z.L. & Humphrey, P.P.A. (1990) Brain Research, **509**, 172-174.

EFFECTS OF THE PUTATIVE 5-HT_{1A} AGONIST ANXIOLYTIC, IPSAPIRONE, ON BENZODIAZEPINE WITHDRAWAL IN RATS

A.J. Goudie & M.J. Leathley, Department of Psychology, University of Liverpool, P.O. Box 147, Liverpool L69 3BX, U.K.

Two studies investigated the effects of ipsapirone in animals being withdrawn from the benzodiazepine (BZ) chlordiazepoxide (CDP). Rats were injected b.i.d. for 21 days with saline or CDP at doses up to 40 mg/kg/injection. Subsequently, controls continued to receive the treatment administered previously, other subjects received saline during CDP withdrawal. Further subjects received ipsapirone (3, 10 or 30 mg/kg b.i.d.) during withdrawal. Withdrawal indices recorded were body weight and food intake. Significant withdrawal signs were seen after CDP withdrawal, food intake and bodyweight measures fell and then recovered. At the high dose of 30 mg/kg (b.i.d.) ipsapirone potentiated CDP withdrawal in both studies. Potentiation of withdrawal was not seen in animals treated with ipsapirone at 3 and 10 mg/kg (b.i.d.). In a third study, ipsapirone induced a conditioned taste aversion, a possible index of drug-induced "malaise", at doses as low as 7.5 mg/kg. Therefore, a possible explanation for the potentiation of CDP withdrawal in subjects treated with high doses of ipsapirone was that drug-induced "malaise" reduced food intake and body weight, rather than ipsapirone causing a true potentiation of BZ withdrawal. However, in a fourth study we showed that the ipsapirone treatment regime that potentiated BZ withdrawal (30 mg/kg b.i.d.) did not significantly reduce food intake or body weight, suggesting that high doses of ipsapirone potentiate CDP withdrawal by a mechanism that does not simply involve nonspecific "malaise". The most plausible mechanism to account for the observed potentiation of withdrawal involves actions of the ipsapirone metabolite (1-(2-Pyrimidinyl)-Piperazine) on α_2 -adrenoceptor systems, which have been implicated in BZ withdrawal. However, the precise mechanism involved in the observed potentiation of BZ withdrawal remains uncertain at present. At no dose was there any evidence that ipsapirone attenuated BZ withdrawal, it is therefore likely that patients being withdrawn from BZs will inevitably experience withdrawal if treated with ipsapirone as an anxiolytic; and that if treated with very high doses of ipsapirone (and related agents) withdrawal signs may be exacerbated. These data may be related to clinical reports that buspirone-type anxiolytics are poorly tolerated by patients with a history of BZ treatment (Ashton et al. 1989; Harto et al. 1988; Schweizer et al. 1986).

Acknowledgement: Supported in part by a grant from Bayer AG, F.R.G.

Ashton, C.H., Rawlins, M.D. & Tyrer, S.P. (1989) *J. Psychopharmacol.* 3, 90P.

Harto, N.E., Braconnier, R.J., Spera, K.F. & Dessain, E.C. (1988) *Psychopharmacol. Bull.* 24, 154-160.

Schweizer, E., Rickels, K. & Lucki, I. (1986) *New Eng. J. Med.* 314, 719-720.

THE ABILITY OF 5-HT_{1A} LIGANDS TO MODIFY FEEDING BEHAVIOUR IN THE COMMON MARMOSET (*CALLITHRIX JACCHUS*)

Carey, G.J., Costall, B., Domeney, A.M. & Jones, D.N.C., Postgraduate Studies in Pharmacology, The School of Pharmacy, University of Bradford, Bradford, West Yorkshire, BD7 1DP

It is now well established that 5-hydroxytryptamine (5-HT) neurons are involved in the control of feeding behaviour (Blundell, 1984; Nicolaidis, 1986). The role of 5-HT appears to be inhibitory and generally 5-HT agonists and drugs which release 5-HT decrease food intake in both animals and man. It was therefore unexpected when Dourish *et al.* (1985) showed that the novel 5-HT_{1A} receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) increased food intake in non-deprived rats. However this effect is consistent with the inhibitory role of 5-HT as this drug has been shown to decrease serotonergic neurotransmission via an agonist action on 5-HT_{1A} autoreceptors in the raphe nuclei (Dourish *et al.*; Hutson *et al.*, 1986). The present studies investigate the ability of 8-OH-DPAT, gepirone and buspirone to modify firstly a model of free feeding, and secondly a model of satiated feeding in the common marmoset (*Callithrix jacchus*).

The studies used adult, non-food deprived marmosets weighing 330±20g. For free feeding studies marmosets were transferred to individual testing cages (identical to their home cages and to which they had been habituated) 45 min following subcutaneous treatment with vehicle (saline 1ml kg⁻¹), 8-OH-DPAT (10-100µg kg⁻¹), gepirone (0.25-1.0mg kg⁻¹), or buspirone (0.25-1.0mg kg⁻¹). Animals were presented with 25±0.1g of highly palatable food (syrup coated brown bread cubes), and the quantity consumed in a 10 min test period was recorded.

For satiated feeding studies marmosets were presented with 15±0.1g of the same palatable food in their home cages. Immediately following the satiating period marmosets received either drug or vehicle. Following a 45 min pretreatment marmosets were transferred to the test cages and presented with a further 15±0.1g of food. The quantity consumed in a 10 min test period was recorded.

8-OH-DPAT (10-100µg kg⁻¹ s.c.) and gepirone (0.25-1.00mg kg⁻¹) both failed to modify free feeding, but both caused a decrease in satiated food intake. 8-OH-DPAT (100µg kg⁻¹) reduced food intake from 4.88±1.23g, vehicle, to 1.68±1.00g. Gepirone (1.00mg kg⁻¹) reduced food intake from 4.45±1.16g, vehicle, to 1.66±0.85g. Buspirone (0.25-1.00mg kg⁻¹ s.c.) failed to modify food intake in both models.

These data suggest that 5-HT_{1A} receptor ligands may have an inhibitory effect in a model of satiated feeding in the marmoset.

This work was supported by Glaxo Group Research.

Blundell, J.E. (1984) *Neuropharmacology* 23, 1537-1551

Nicolaidis, S. (1986) (ed) *Serotonergic system, feeding and body weight regulation*, Academic Press, London

Dourish, C.T., Hutson, P.H., Curzon, G. (1985) *Psychopharmacology* 89, 197-204

Dourish, C.T., Hutson, P.H., Curzon, G. (1986) *TIPS* 7, 212-214

Hutson, P.H., Dourish, C.T., Curzon, G. (1986) *Eur. J. Pharmacology* 129, 347-352

5-HT₃ RECEPTOR AGONIST EFFECTS OF ZACOPRIDE IN THE FERRET

Vicki C. Middlefell, Tracey L. Price & I.A. Thomson (introduced by R. Spokes) Department of Biomedical Research, Wyeth Research (UK) Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire. SL6 0PH.

Zacopride is a potent and selective antagonist of 5-HT₃ receptors (Smith et al 1988) which has been shown to be effective against the emesis caused by cytotoxic agents in dogs and man, (Cohen et al 1989; Smith et al 1986). In the ferret however, zacopride was found to produce retching and vomiting at doses of 10-100 µg/kg i.m. We have investigated the cause of this emetic effect, using the 5-HT induced Bezold-Jarisch (B-J) reflex in the urethane anaesthetised ferret as an indicator of 5-HT₃ receptor activity.

Zacopride is a racemic mixture of *R* and *S* stereoisomers, both of which are 5-HT₃ receptor antagonists. In urethane anaesthetised rats *S*-zacopride was approximately 3 fold more potent than *R*-zacopride against the 5-HT induced B-J reflex. We have shown that *S*-zacopride but not *R*-zacopride (at doses of 10-100 µg/kg i.m.) possessed emetogenic activity in the ferret. The emesis produced by both zacopride and by its *S*-enantiomer was blocked by prior administration (using a 15 min pretreatment time) of the 5-HT₃ antagonist, ondansetron (1 mg/kg i.m.) but not by atropine (0.1-1.0 mg/kg i.m.).

In the urethane anaesthetised ferret a B-J reflex was elicited by 5-HT (10 µg/kg i.v.) administered via a jugular venous cannula. The carotid artery was cannulated to record blood pressure and heart rate. The B-J reflex was quantified by measuring the change in heart period (H.P.) from predose over 4 consecutive beats, starting at the point of apnoea. 5-HT induced a mean increase in H.P. of 703 ± 113 ms which was blocked by zacopride (3 µg/kg i.v.). Zacopride itself evoked a pronounced increase in H.P. in this preparation, an effect which was investigated further using its two enantiomers.

S-zacopride (0.3 µg/kg i.v.) evoked a B-J-like response with a mean increase in H.P. of 7232 ± 3530 ms. This was approximately 15 fold that produced in the same animals by 5-HT (10 µg/kg i.v.). A subsequent B-J reflex response to 5-HT was not attenuated following the administration of this dose of *S*-zacopride. The responses to both 5-HT and *S*-zacopride were blocked by the 5-HT₃ antagonist ondansetron (30 µg/kg i.v.). In contrast, *R*-zacopride, when administered over the dose range 1-100 µg/kg showed no inherent agonist activity but produced a dose dependent inhibition of both the 5-HT and the *S*-zacopride induced increases in H.P.

Neither zacopride or its enantiomers produced a B-J reflex in the urethane anaesthetised rat.

In conclusion, the *S*-enantiomer of zacopride appears to possess 5-HT₃ receptor agonist properties in the ferret which are blocked by both the *R*-enantiomer of zacopride and by ondansetron.

Cohen, M.L., Bloomquist, W., Gidda, J.S. & Lacefield, W. (1989) *J. Pharm. Exp. Ther.* **248**, 197-201

Smith, W.L., Jackson, C.B., Proakis, A.G., Leonard, C.A., Munson, H.R. & Alphin, R.S. (1986) *Proc. Am. Soc. Chem. Oncol.* **5**, 260.

Smith, W.W., Sancilio, L.F., Owera-Atepo, J.B., Naylor, R.J. & Lambert, L. (1988) *J. Pharm. Pharmacol.* **40**, 301-302.

ONDANSETRON DOES NOT AFFECT HEMICHOLINIUM-3 INDUCED DISRUPTIONS IN A T-MAZE REINFORCED ALTERNATION TASK

J. Coughlan, B. Costall, M.E. Kelly, R.J. Naylor and ¹M.B. Tyers, Postgraduate Studies in Pharmacology, University of Bradford, Bradford, BD7 1DP and ¹Glaxo Group Research Ltd., Ware, Hertfordshire, SG12 0DP

There is considerable evidence that cognitive performance critically depends on the normal function of the cholinergic system (Perry 1986). When this is disrupted by scopolamine, 5-HT₃ receptor antagonists (e.g. ondansetron) can inhibit the impairments (Costall et al. 1990). Hemicholinium-3 (HC-3) infused intracerebroventricularly (ICV) persistently also disrupts performance of the T-maze task (Costall et al. 1989). Here we report on the effects of 5-HT₃ receptor antagonists on the HC-3 disturbance in cognition.

HC-3 (25 µg/day for 9 days, dose chosen from preliminary observations) was infused persistently into the lateral ventricles of Lister hooded rats via chronically indwelling cannulae stereotaxically located (Ant. 5.8, Vert. 2.5, Lat. ±2.0) and coupled to subcutaneously implanted Alzet osmotic minipumps.

Rats were trained on a food reinforced alternation task using an elevated T-maze (see Costall et al. 1989, 1990). Food was withdrawn 2 days prior to the test, and throughout testing animals were food deprived for 23hr/day (water available *ad libitum*, 85% normal body weight maintained). Rats were allowed 10 min habituation to the maze on day 1 (both arms baited - banana flavoured pellets) and were subject to a pretraining period of reinforced alternation on days 2-5 of the test, with training on days 6-9. All training consisted of paired trials (each pair constituting a "run"), the first being 'forced' in that one arm was blocked while the other was baited. The second was a choice trial in which reward pellets were placed in the arm opposite to that reinforced in the first trial of the pair. A correct choice was when the rat entered the arm containing the food on the choice trial.

HC-3 (2.5 µg/day) disrupted performance, reducing correct responses (compared to control) over the 9 day test period [$F(4,16) = 32.6$ $P < 0.01$].

The 5-HT₃ receptor antagonists, ondansetron at 10ng/kg i.p. b.d. and zacopride at 10ng/kg i.p. b.d., failed to influence the HC-3 impairments, e.g. control, HC-3, HC-3 + drug % correct responses were, respectively, on day 9, 89.9, 54.4, 52.2 (ondansetron) and 86.7, 51.1, 42.2 (zacopride). In contrast, arecoline (30mg/kg/day i.p.) was shown to significantly attenuate the hemicholinium response (82.2, 45.5, 62.4 respectively, as above).

The present data indicate that the 5-HT₃ receptor antagonists do not influence the cognitive impairments caused by HC-3 implying that the action of 5-HT₃ receptor antagonists to improve cholinergic transmission may be a result of an interaction with the release mechanisms of the cholinergic neurone.

This work was supported by Glaxo Group Research Ltd.

Costall B., Coughlan, J. and Kelly, M.E. (1989) *Br. J. Pharmacol.* **86**, 47P

Barnes, J.M., Costall, B., Coughlan, J., Domeney, A.M., Gerrard, P.A., Kelly, M.E., Naylor, R.J.,

Tomkins, D.M. and Tyers, M.B. (1990) *Pharmac. Biochem. Behav.* **35**, 955-962

Perry, E.K. (1986) *Br. Med. Bull.* **42**, 63-69

ONDANSETRON ATTENUATES THE SCOPOLAMINE DEFICIT IN A WATER MAZE TASK

J. Coughlan, B. Costall, M.E. Kelly, R.J. Naylor and ¹M.B. Tyers, Postgraduate Studies in Pharmacology, University of Bradford, Bradford, BD7 1DP and ¹Glaxo Group Research Ltd., Ware, Hertfordshire, SG12 0DP

The muscarinic receptor antagonist scopolamine has been widely used to produce experimental cognitive deficits in both animals and man. Since a disruption in central cholinergic function has traditionally been associated with age related memory disorders (Bartus, 1982) scopolamine was used in the present studies to produce an experimental deficit in performance of a water maze task. Previous studies have shown that the 5-HT₃ receptor antagonist ondansetron attenuates a scopolamine-induced deficit in a T-maze task (Barnes et al., 1990). The present studies were designed to investigate the effects of ondansetron on the scopolamine induced deficit of a water maze task (Morris, 1984).

Male hooded Lister rats (250-300g, Bradford strain) were trained in a 2 day paradigm in the water maze. On day 1 each rat was pretreated with test compound or vehicle and placed on the island (located 2cm below the surface of the water) for 30 s immediately before testing commenced. The island was kept in a constant position for each rat (the position was randomised and balanced across the groups) but each rat began the trial at a different corner in the pool (the positions balanced across the groups). A training trial began with the animal being lowered into the pool, close to and facing the corner designated for the trial. The timer and tracking device was started and the time recorded for the animal to escape from the water onto the platform. The rat remained on the platform for 2s before being placed in the pool for trial 2. On each trial the rat was allowed a maximum 100s to find the island and the latency to find the island was noted. If the rat failed to find the island within 100s it was placed on the island for 10s. Each rat received 6 trials on day 1. A 7th trial with a black, visible island was also carried out to ensure no visual disturbances were influencing performance. The same procedure was carried out on day 2 on which drug effects were usually detected. Thus, increase in escape latency was attenuated by arecoline, 5.0mg/kg i.p., (the latencies being control, scopolamine, scopolamine + arecoline 26.0, 58.0 and 40.0s respectively, scopolamine response $P < 0.05$ compared to control and arecoline + scopolamine $P < 0.05$ compared to scopolamine). Ondansetron caused similar changes to arecoline (on day 2 latencies vehicle, scopolamine, scopolamine + ondansetron, 10µg/kg, were respectively 28, 45 and 35s).

These are preliminary data that support previous observations using the rat T-maze in which ondansetron inhibited scopolamine impairment in cognitive performance. The data further support a role for 5-HT₃ receptors in the modulation of cholinergic deficits in cognition

This work was supported by Glaxo Group Research Ltd.

Bartus, R.T., Dean, R.L., Beer, B. & Lippa, A.S. (1982) *Science*, 217, 408-417

Barnes, J.M., Costall, B., Coughlan, J., Domesney, A.M., Gerrard, P.A., Kelly, M.E., Naylor, R.J., Onaivi, E.S., Tomkins, D.M. & Tyers, M.B. (1990) *Pharmacol. Biochem. Behav.* 35, 955-962

Morris, R. (1984) *J. Neurosci. Meth.* 11, 47-60

THE ABILITY OF BTG 1501 TO INHIBIT THE SUPPRESSED BEHAVIOUR ASSOCIATED WITH WITHDRAWAL FROM DRUGS OF ABUSE

B. Costall, M.E. Kelly and ¹T.W. Smith, Postgraduate Studies in Pharmacology, University of Bradford, Bradford, BD7 1DP and ¹British Technology Group, 101 Newington Causeway, London, SE1 6BU

BTG 1501 has been shown to release suppressed behaviour in rodent and primate tests in a manner consistent with that of an anxiolytic agent (Costall et al., 1990a).

Using a mouse black:white test box, an 'anxiogenesis' of withdrawal has also been observed following cessation of treatment with drugs of abuse, alcohol, nicotine and cocaine. The present studies were therefore carried out to determine whether BTG 1501 had a capacity to inhibit the adverse behavioural phenomena associated with withdrawal from these drugs of abuse. The light:dark test, briefly, comprised a two-compartment box, one compartment being painted white and brightly-lit, the other being painted black and dimly lit. Naïve mice were placed individually into the centre of the brightly-lit compartment which they normally find aversive. Thus, after a 7-10 sec delay mice will move from the light to the dark compartment where most exploratory behaviour is exhibited.

Groups of mice (n = 5) received alcohol (8% w/v for 14 days in their drinking water), nicotine (0.1mg/kg i.p. b.d. for 7 days) or cocaine (1.0mg/kg i.p. b.d. for 14 days). During treatment with these drugs of abuse mice showed reduced aversion for the brightly-lit compartment of the black:white box, which is consistent with an anxiolytic profile of activity (latency for the initial move from the white compartment was delayed for some 15-28 sec for all compounds, $P < 0.001$). In contrast, 8-48 hr following cessation of alcohol intake or treatment with nicotine or cocaine, the normal suppression of behaviour in the novel white compartment was enhanced, and animals moved within 2 sec into the black compartment ($P < 0.001$). Naïve animals were used on all test days and behaviour was analysed from remote video recordings.

Groups of mice withdrawn from alcohol, nicotine or cocaine were given BTG 1501, 10mg/kg i.p. b.d., during the periods of withdrawal and the behaviour of separate groups of mice was analysed 8, 24, 48, 96 and 240 hr after withdrawal from the drugs of abuse. In each situation, the first dose of BTG 1501 was given at the actual time of withdrawal (last dose of nicotine or cocaine, or time of removing alcohol). BTG 1501 was shown to prevent the enhanced suppression of behaviour, interpreted as anxiogenesis, during the periods of withdrawal from alcohol, nicotine or cocaine. Thus, latencies of withdrawn animals (<1 sec-2 sec) were delayed for some 15-30 sec ($P < 0.001$), and this was associated with increased time spent in the light compartment with increased rears and line crossings in the light.

It is suggested that BTG 1501, which presents with a novel anxiolytic profile, also prevents the behavioural consequences of withdrawal from chronic treatment with drugs of abuse.

Costall, B., Domesney, A.M., Gerrard, P.A., Kelly, M.E., Smith, T.W. & Tomkins, D.M. (1990a). This meeting.

THE ANXIOLYTIC ACTION OF BTG 1501 REVEALED IN RODENT AND PRIMATE TESTS

B. Costall, A.M. Domeney, P.A. Gerrard, M.E. Kelly, T.W. Smith¹ and D.M. Tomkins, Postgraduate Studies in Pharmacology, University of Bradford, Bradford, BD7 1DP, and ¹British Technology Group, 101 Newington Causeway, London, SE1 6BU

BTG 1501 (3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione, monohydrochloride) was tested in 4 tests for anxiolytic potential using both rodent and primate species.

Mice (male, Albino BKW) were placed in the centre of a brightly-lit environment in a two-compartment box having a dark section simultaneously available (Costall et al., 1988). Normally mice move rapidly (5-10 sec) from the light to the dark where they spend most time exploring. This suppressed behaviour is released by known anxiolytic agents such that animals spend more time in the white environment (latency delayed for 15-25 sec). BTG 1501 (0.1µg/kg-100mg/kg s.c.) also released the suppressed behaviour (latency 17-28 sec, $P < 0.001$) and more time was spent exploring the light compartment.

Male Sprague-Dawley and Lister hooded rats were used in the social interaction (SI) and elevated X-maze test respectively. For SI pairs of unfamiliar rats were placed in a brightly-lit arena and time spent in SI determined (Costall et al., 1988). Normally, under these test conditions, rats spend the majority of a 10 min test period avoiding each other. Known anxiolytic agents enhance active SI. This was also observed for animals treated with BTG 1501 (10ng/kg-100mg/kg, SI increased from 50-70 sec to 155-200 sec., $P < 0.001$). In the X-maze animals were placed facing an open arm in a situation where 2 closed and 2 open arms were available for exploration. Normally rats spend most time in the closed arms. An anxiolytic agent will release this suppressed behaviour such that rats spend more time on the open arms, particularly in the furthestmost section (Costall et al., 1989). BTG 1501 caused a maximum effect indicative of anxiolytic action in this test at 0.01mg/kg i.p. Thus, time spent on the open arms increased, particularly on the end sections of the open arms (15-25 sec increased to 40-55 sec, $P < 0.001$). All rodent tests used remote video recordings, $n = 5-6$. Oral efficacy was confirmed for BTG 1501 in the rodent tests. Sedation was not observed in any test.

Common marmosets confronted with a human threat normally retreat to the cage back and exhibit characteristic postures. Under the influence of an anxiolytic agent marmosets spend more time forward and posturing is reduced (Costall et al., 1988). At 0.1µg/kg-1mg/kg s.c. BTG 1501 increased time forward in a 2 min test from 20-25% to 45-55%, and reduced postures from 8-12 to 2-7 ($P < 0.001$, $n = 4$).

In all tests described BTG 1501 caused changes in behavioural profiles consistent with those determined for known anxiolytic agents. It is therefore proposed that BTG 1501 may present as a novel non-sedative anxiolytic agent which is orally active over a wide dose range.

Costall, B., Domeney, A.M., Gerrard, P.A., Kelly, M.E. & Naylor, R.J. (1988) *J. Pharm. Pharmacol.* 40, 302-305

Costall, B., Kelly, M.E. & Tomkins, D.M. (1989) *Br. J. Pharmacol.* 96, 312P

USE OF THE STONE MAZE AS A TEST OF COGNITIVE FUNCTION IN THE RAT

A.M. Bratt, B. Costall & M.E. Kelly, Postgraduate Studies in Pharmacology, The School of Pharmacy, University of Bradford, Bradford, West Yorkshire, BD7 1DP

The Stone maze or multiple unit T-maze (Stone, 1929) has previously been used as a test of reference memory in the rat (Knowlton, 1985) and is distinct from models which use spatial cues, such as the Morris water maze. The present experiment investigated the use of the Stone maze and the effect of scopolamine on Stone maze performance which is of particular interest since a cholinergic deficit has been documented in dementia and memory disorder (Bartus, 1982).

The apparatus consisted of a large square perspex maze (144cm x 144cm) having inner walls forming alleys 12cm wide and 42cm high. The maze had only one correct route from the enclosed start box, to a food reward with fourteen blind ending error points between. Four perspex guillotine doors separated the maze into five equal areas. The measurement of learning ability was taken as the time required to reach the food reward and the number of errors made in deviating from the correct route. The experiments were carried out in white light, in a sound proofed room, with no extra maze cues.

Male Lister Hooded rats, food deprived to 85% of normal body weight received either scopolamine (0.125-1.0mg/kg i.p. b.d.), methylscopolamine (0.5mg/kg i.p. b.d.) or vehicle (0.9% saline) throughout the period of testing. The rats were given one 5 min exposure to the maze each day for fifteen days. The rat was placed in the start box and allowed access to the maze. The time (s) taken to reach the food reward, and the number of errors (maximum 14) were scored for each rat on each day of testing. To prevent retracing, the doors were lowered as the rat passed through the maze.

Scopolamine (0.25-1.0mg/kg) increased the latency to complete the task. 1.0mg/kg scopolamine increased the latency from $14.7 \pm 0.95s$ to $176.1 \pm 39.05s$ ($P < 0.05$ ANOVA) and the number of errors increased from 2.1 ± 0.2 to 4.5 ± 0.9 ($P < 0.1$ ANOVA) on day 9 of testing. Methylscopolamine (0.5mg/kg), a selective peripheral muscarinic antagonist, had no effect on maze performance. Pupillary diameter was measured to indicate the peripheral effects of scopolamine and dilatation was observed at 0.125-1.0mg/kg. However, methylscopolamine (0.5mg/kg) which induced maximal pupillary dilatation failed to influence performance of the task.

These results suggest that the Stone maze is a suitable apparatus in which to train rats to perform a task. Scopolamine produced a learning deficit in that it increased the latency to perform the task and number of errors made. It is concluded that the Stone maze may be a suitable model in which to study some aspects of cognitive function.

Bartus, R.T., Dean, R.L., Beer, B. & Lippa, A.S. (1982) *Science* 217, 408-417

Knowlton, B.J., Wenk, G.L., Olton, D.S. & Coyle, J.T. (1985) *Brain Res.* 345, 315-321

Stone, C.P. (1929) *Gen. Psychol. Mono.* 5, 9-129

J.M. Barnes, B. Costall, S. Hogg, M.E. Kelly & J.R. McCurrie, Postgraduate Studies in Pharmacology, University of Bradford, Bradford, West Yorkshire, BD7 1DP

Following the induction of focal or global cerebral ischaemia many animals suffer gross neurological deficits which compromise behavioural testing. We propose a simple yet effective method for the induction of global cerebral ischaemia following which the rat is able to perform in a behavioural test which has previously been used to demonstrate the learning ability of rats, the Morris water maze (Morris, 1984).

Bilateral occlusion (45 min) of the common carotid arteries was performed in male Lister Hooded rats under ketamine anaesthesia (100mg/kg i.p.) with sham operated animals acting as controls. For 7 days following surgery the animals were examined to assess their neurological status and were given a "neurologic deficit score" (max. 274) according to a revised schedule of Cahn et al. (1988). Behavioural assessment was performed on days 7-16 in the Morris water maze. Using a fixed island position for individual animals, each animal performed six trials per day for a 10 day period; escape latency was used as a measure of learning ability and the animal's swim speed was used as an indication of locomotor activity. Biochemical analyses were made of cholineacetyltransferase (ChAT) activity (Fonnum, 1975) in the amygdala, entorhinal cortex, frontal cortex, hippocampus, septum, striatum and tuberculum olfactorium on tissue taken from animals subjected to 10 days training (initiated at 7 days post-op) and on tissue which was taken 7 days after occlusion or sham operation.

The escape latency was significantly increased in the occluded group when compared to the sham operated controls throughout the test period (54.6 ± 5.3 s and 8.3 ± 1.3 s on day 4 of training with $n = 10$ and 7 respectively, $P < 0.001$ ANOVA). Whilst a consistent and significant neurologic deficit was observed in the occluded rats as compared to the sham operated animals (7.9 ± 0.2 and 0.2 ± 0.1 , $n = 10$ and 7 respectively, $P < 0.001$ ANOVA), no significant changes in locomotor activity were recorded, hence the apparent reduction in learning ability is not directly related to changes in locomotor activity. The biochemical assays revealed no significant changes in ChAT activity at the end of the 10 day training period. However the analysis performed 7 days after occlusion revealed a significant reduction in ChAT activity (sham vs occluded) in the striatum and tuberculum olfactorium (779.0 ± 64.8 reduced to 465.5 ± 50.5 nmol/min/mg protein and 504.9 ± 52.3 reduced to 352.2 ± 20.0 nmol/min/mg protein respectively, $P < 0.05$, $n = 8$, T-test)

The present method would appear to produce a reproducible deficit in learning ability in the Lister Hooded rat. Lower activities of ChAT in the striatum and tuberculum olfactorium at the start of testing warrant further investigation.

Cahn, J. Borzeix, M.G. & Cahn, R. (1988) *New Trends in Clinical Neuropharm.*, ed. D. Bartko et al., John Libbey & Co. Ltd., pp27-38

Fonnum, F. (1975) *J. Neurochem.* 24, 407-409

Morris, R. (1984) *J. Neurosci. Meth.* 11, 47-60

C.A. Jones & H.J.E. Symington (introduced by A. Angel). Department of Biomedical Science, University of Sheffield, Sheffield S10 2TN.

A wide variety of chemically dissimilar general anaesthetics share the ability to potentiate the effects of GABA receptor stimulation. However, adrenergic mechanisms may also have a role in anaesthesia, possibly via modulation of cortical arousal, wakefulness and processing of sensory stimuli (Mason & Angel, 1983). A previous report (Jones, 1990) described preliminary results that indicated that high concentrations of methohexitone decrease the K^+ -stimulated release of [3 H]noradrenaline from rat cerebral cortex slices. Effects at lower concentrations were not clear. As part of the further investigation of these effects the present experiments compare the actions of three barbiturate anaesthetics on the release of [3 H]NA. The results are presented in Table 1.

Table 1 Effects of barbiturates on K^+ -stimulated [3 H]NA efflux

Concentration	Methohexitone	Pentobarbitone	Thiopentone
10^{-7} M	108.7 ± 17.6	-	-
10^{-6} M	70.7 ± 10.0	70.5 ± 18.0	70.7 ± 23.0
3×10^{-6} M	96.9 ± 23.7	81.6 ± 23.6	110.3 ± 13.3
10^{-5} M	$56.3 \pm 7.7^{**}$	120.1 ± 11.8	119.0 ± 7.0
3×10^{-5} M	129.3 ± 19.0	81.3 ± 11.2	$53.4 \pm 9.0^*$
10^{-4} M	$54.0 \pm 8.6^*$	66.5 ± 13.3	$34.8 \pm 9.4^{**}$
3×10^{-4} M	$33.6 \pm 8.3^*$	$16.6 \pm 2.7^*$	$13.8 \pm 1.3^{**}$
10^{-3} M	$6.5 \pm 1.8^{**}$	$4.8 \pm 1.5^*$	$4.5 \pm 0.4^{**}$

Results are % control, mean \pm s.e. mean, $n = 4-11$. * $p < 0.05$, ** $p < 0.01$, Student's t test.

At the highest concentrations studied, all three barbiturates significantly decreased [3 H]NA release in a dose-dependent manner. As would be expected, thiopentone appears to be more potent than pentobarbitone. However, although clinically methohexitone is more potent than thiopentone there is no obvious correlation with inhibition of [3 H]NA efflux. This may be due to the different concentration-response profile seen at lower concentrations with methohexitone, as compared to thiopentone and pentobarbitone. The effects seen may be due to multivariate processes and further studies will focus on possible component mechanisms.

Mason, S.T. & Angel, A. (1983). *Eur. J. Pharmac.* 91, 29-39.

Jones, C.A. (1990). *Br. J. Pharmac.* 100, 393P.

CHANGES IN DIHYDROPYRIDINE BINDING IN THE CEREBRAL CORTEX FOLLOWING CHRONIC BARBITAL TREATMENT

M. Rabbani & H. J. Little Department of Pharmacology, The Medical School, University Walk, Bristol BS81TD

We have previously shown that long-term ethanol treatment increased the number of central binding sites for dihydropyridines, thought to represent voltage-sensitive calcium channels. Their possible causal role in ethanol dependence was suggested by the prevention of the development of ethanol tolerance, the ethanol withdrawal syndrome and the upregulation of binding sites by chronic administration of dihydropyridine calcium channel antagonists, concurrently with ethanol (Dolin & Little, 1989; Whittington & Little, 1989). Ethanol and barbiturate withdrawal syndromes show many similarities, both types of compound block calcium channels acutely, and a calcium channel antagonist gave protection in barbiturate withdrawal (Rabbani & Little, 1990). We have therefore now investigated the effects of chronic barbiturate treatment on central dihydropyridine binding.

Male mice, TO strain, 30 - 35g, were given barbiturate in powdered food for seven days: 3 mg barbiturate per g food for two days, 4 mg/g food for two days and 5 mg/g food for three days. Controls received a matched amount of powdered food only. At the end of the seven day treatment the mice were placed in clean cages and given powdered food without barbiturate for 24h. Our previous studies showed that the withdrawal syndrome was maximal at this time. The mice were killed by cervical dislocation and the cerebral cortices removed and frozen. Tissues were homogenised in Tris HCl 50 mM, centrifuged and the pellet washed twice more before duplicate binding determinations using [³H]-nitrendipine. Tubes were incubated for 45 min at 25°C and the binding terminated by filtration through Whatman GFB filters. Nonspecific binding was defined by displacement with cold nimodipine (1 µM).

The tissues from the barbiturate treated mice showed an 82% increase in B_{max} values for dihydropyridine binding, compared with concurrently treated controls. Values: controls 525 ± 67; barbiturate treatment: 953 ± 135 fmol/mg protein (P < 0.01 by analysis of variance; n = 22, 19 respectively). The K_d values were also increased by the barbiturate treatment: controls 5.89 ± 0.82 nM; barbiturate 11.83 ± 2.38 nM (P < 0.02 by analysis of variance; n = 22, 19).

The results suggest that the number of voltage-sensitive calcium channel was increased by chronic barbiturate treatment. The pattern differed from that after chronic ethanol treatment in that the affinity of the sites was decreased. Barbiturates have been shown to have a small affinity for these binding sites (Harris et al; 1985), but the barbiturate concentration in the CNS would have been very low after 24h withdrawal (P.V. Taberner, personal communication). This type of calcium channel may be involved in the barbiturate withdrawal syndrome.

S. J. Dolin & H. J. Little (1989) J. Pharmacol. Exp. Ther., 250 985 - 991

Harris, R. A., Jones, S. B., Bruno, P. & Bylund, D. B. (1985) Biochem. Pharmacol., 34, 2187 - 2191

M. Rabbani & H. J. Little (1990) Br. J. Pharmacol. In Press.

M. A. Whittington & H. J. Little, 1989 Br. J. Pharmacol., 94, 479P

INSULIN ACTION ON 2-DEOXYGLUCOSE UPTAKE IN NORMAL AND DIABETIC CBA/CA MICE FOLLOWING *IN VIVO* AND *IN VITRO* ETHANOL

M. Al-Qatari* and P.V. Taberner, Department of Pharmacology, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, England.

Previous studies have indicated that chronic ethanol treatment in mice increases glucose uptake into brain, muscle, and white adipose tissue (Connelly et al., 1987); the effect being greater in hyperglycaemic mice (C57) than in normals (LACG). Since insulin-stimulated glucose uptake in the periphery is reduced in both streptozotocin-diabetic mice and in non-obese diabetic mice as a result of decreased insulin sensitivity (Goto et al., 1988), it was of interest to compare the effects of chronic ethanol in normal and insulin resistant obese diabetic CBA/Ca mice (Connelly & Taberner, 1989).

Normal and diabetic male CBA/Ca mice were from the Bristol colony. Ethanol (24% v/v) was administered in the drinking water over 4-6 weeks. The uptake of the non-metabolizable substrate 2-deoxy-[³H]-glucose (2-DG) into isolated soleus muscles was measured as described by Cuendet et al. (1976). Briefly, soleus muscles were dissected, weighed, then preincubated for 2h at 37°C in Krebs-Ringer bicarbonate solution containing 2% defatted bovine serum albumin to remove endogenous insulin. One muscle was used to measure basal uptake; the other was incubated in the presence of 2.5 mIU/ml insulin. 2-DG (10 mM, 1 µCi) was then added. After 15 min the muscles were removed, rinsed in saline, and dissolved overnight in NaOH prior to liquid scintillation counting.

Normal untreated CBA/Ca mice showed higher basal and insulin-stimulated 2-DG uptake compared to LACG and C57 strains. Chronic ethanol treated mice showed a significant increase in basal 2-DG uptake over control levels (means ± SEM (n), nmoles/mg wet wt/hr): untreated lean, 3.85 ± 0.34 (20); ethanol treated lean, 5.56 ± 0.46 (8) (p < 0.01, t-test). Insulin-stimulated uptake was significantly increased (p < 0.01) in the ethanol-treated group; untreated, 5.22 ± 0.55 (9); ethanol treated, 8.49 ± 0.58 (8). Obese CBA/Ca mice showed significantly lower uptake of 2-DG compared to lean animals, but did not respond to the chronic ethanol treatment. 2-DG uptake in control obese mice was: basal, 3.73 ± 0.14 (8); insulin-stimulated, 3.85 ± 0.14 (8). After chronic ethanol, the rates were: basal, 4.07 ± 0.19 (8); insulin-stimulated, 4.22 ± 0.39 (8). Ethanol (0.3 - 100 mM) *in vitro* had no effect on basal or insulin-stimulated uptake. Similarly, acute ethanol (2.5 g/kg I.P.) was without effect on the uptake rate. In conclusion, ethanol appears to increase insulin-stimulated 2-DG uptake only when given chronically, and does not potentiate the action of insulin in an insulin-resistant animal model of diabetes.

We gratefully acknowledge the financial support of the Al Tajir trust.

Connelly, D.M. et al. (1987) Alcohol & Alcoholism suppl 1, 301-305.

Connelly, D.M. & Taberner P.V. (1989) Pharmacol. Biochem. Behav. 34, 255-259.

Cuendet G.S. et al. (1976) J. Clin. Invest. 58, 1078-1088.

Goto, Y. et al. (1988) Metabolism, 37, 74-78.

DOES CENTRAL ADMINISTRATION OF THE GABA_B RECEPTOR AGONIST BACLOFEN PRODUCE HYPERPHAGIA IN RATS?

I.S. Ebenezer, School of Pharmacy and Biomedical Sciences, Portsmouth Polytechnic, Hants.

We have previously demonstrated that intracerebroventricular (ICV) administration of the GABA-B agonist baclofen will produce a short lasting hyperphagia in satiated pigs (Ebenezer and Baldwin, 1989). More recently we have shown that systemic administration of low doses of baclofen to rats will cause a short-term stimulation of feeding (Pringle and Ebenezer, 1990). The present study was undertaken to investigate the effects of ICV administration of baclofen on food intake in rats.

Male Wistar rats (280-350g, n=10) were implanted under equithesin anaesthesia with guide tubes directed at the lateral cerebroventricle for subsequent chronic ICV administration of drugs. After recovery from surgery, the rats were given 6-8 daily training sessions during which time they were placed separately in cages where they had free access to water. The rats were allowed to habituate to the cage for 30 min before being presented with food for 2 h. The food was placed in a shallow cylindrical container in the centre of the cage. The animals were not food deprived. During the experimental sessions the rats were injected ICV with either physiological saline (control) or baclofen solution (0.1, 1, 2.5 and 5 nmol) at the end of the 30 min acclimatization period. The amount of food consumed was measured 15 min, 30 min, 60 min and 120 min after vehicle or drug administration.

Baclofen (0.1 - 5 nmol ICV) caused a dose-related increase in food intake in these rats. The 0.1 nmol dose had no significant effects on feeding compared with control data. In contrast, the higher doses of baclofen increased feeding ($P < 0.01$ in each case) during the first 30 min after administration. For example, the rats (n=9) ate 3.81 ± 0.26 g of food during the first 30 min after baclofen (5 nmol) compared with 0.18 ± 0.63 g after saline. Eating usually began about 1-2 min after administration, and this effect was particularly spectacular with the 5 nmol dose. All rats given baclofen (5 nmol) showed signs of ataxia and other motor side effects about 10 min after administration, and these effects were also noted in some of the rats given the 2 nmol dose. Nevertheless, the rats kept on eating despite these motor abnormalities. They eventually went into a sleep-like state for up to 2 h. The effects of baclofen (5 nmol) on feeding could be abolished by pretreating the animals with the GABA-B antagonist phaclofen (40 nmol, ICV). Furthermore, phaclofen pretreatment almost completely prevented the motor side effects associated with 5 nmol of baclofen.

The results of this study extend previous findings in the pig (Ebenezer and Baldwin, 1989), and show that ICV administration of baclofen produces a hyperphagic response in rats by acting at central GABA-B receptors.

Ebenezer, I.S. and Baldwin, B.A. (1989) *Br. J. Pharmacol.* **98**, 678P

Pringle, A.K. and Ebenezer, I.S. (1990) *Br. J. Pharmacol.* **100**, 420P

INTERACTION OF GABA AGONISTS AND GENERAL ANAESTHETICS ON IONIC CURRENTS OF TRANSMITTER RELEASING AXONS OF RAT OLFACTORY CORTEX

J. McGivern & C.N.Scholfield, School of Biomedical Science, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL.

The interaction of some general anaesthetics with the GABA receptors involved in inhibitory transmission has been well documented. Many authors have presented evidence indicating that general anaesthetics act by reducing excitatory transmitter release. Presynaptic GABA receptors are thought to be present on some central axons (Cain & Simmonds, 1982; Steel & Scholfield, 1985) and anaesthetics could interact with endogenous GABA to activate these receptors and reduce excitatory transmission. In the present study, by using a suction electrode technique, we have measured the electrical activity generated in unmyelinated axons which give rise to transmitter releasing varicosities *en passant*.

Slices of rat olfactory cortex of 150-250 μ m thickness were placed in a recording bath through which Krebs solution flowed. A suction electrode was connected to a current amplifier and by applying positive polarisation to the tissue, a crude estimation of the Na and K currents generating the action potential could be obtained (Scholfield, 1989). Effects on axonal Ca currents could be observed by blockade of the K-currents in these axons (Scholfield, 1988).

Pentobarbitone (0.1 to 5 mM) progressively depressed the Na, K and Ca currents in a dose-related manner. In the presence of the GABA_A antagonist, bicuculline (10 μ M), the depressant action of pentobarbitone was reduced (the ID₅₀ concentration increased from 0.72 ± 0.13 to 2.3 ± 0.5 mM). Axonal Na, K and Ca currents were depressed by the GABA_A agonist, muscimol (0.5-5 μ M), by up to $78 \pm 5\%$. Further increases in muscimol produced no further depression. Muscimol enhanced pentobarbitone action: the ID₅₀ concentration for pentobarbitone was decreased from 0.72 ± 0.13 mM to 0.1 ± 0.03 mM. Bicuculline reduced and muscimol enhanced alphaxalone sensitivity whereas halothane and ketamine were unaffected. The GABA_B agonist, baclofen, had no effect on any of the axonal currents, nor did it affect the depressant action of pentobarbitone.

These results confirm the presence of presynaptic GABA_A receptors on the transmitter releasing axons and that activation of these can depress axonal Na, K and Ca currents. Furthermore, the activation of these receptors (by muscimol) enhances the depressant actions of some general anaesthetics. This can partly explain the effect of some general anaesthetics at excitatory synapses.

We thank the Wellcome Trust for support.

Cain, C.R. & Simmonds, M.A. (1982). *J. Physiol.*, **332**, 487-499.

Scholfield, C.N. & Steel, L. (1985). *Neurosci. Letts.*, **56**, 33-38.

Scholfield, C.N. (1988). *Pflugers Arch.*, **411**, 180-187.

Scholfield, C.N. (1989). *Brain Res*, **507**, 121-128

ALTERATIONS OF DOPAMINE D2 RECEPTOR DENSITY FOLLOWING UNILATERAL INFUSION OF MPTP IN THE COMMON MARMOSET

N.M. Barnes, C.H.K. Cheng, B. Costall, P.A. Gerrard & R.J. Naylor, Postgraduate Studies in Pharmacology, The School of Pharmacy, University of Bradford, Bradford, West Yorkshire, BD7 1DP

Following peripheral MPTP treatment, the density of dopamine D2 receptors has been reported to be unchanged in the common marmoset (Jenner et al., 1986) and increased in the cynomolgus monkey (Joyce et al., 1985). The present study investigates the acute and chronic effects of a unilateral intranigral infusion of MPTP on striatal dopamine D2 receptors in the common marmoset, and considers whether changes in D2 receptors correlate to the behavioural recovery observed in such animals (Jenner et al., 1986; Gerrard, unpublished data).

Male or female common marmosets (*Callithrix jacchus*) weighing 350-400g were subjected to a unilateral infusion of MPTP (20 µg/24h) or vehicle (0.9% w/v NaCl) into the substantia nigra (see Barnes et al., 1987). The MPTP infusion was continued until severe parkinsonism motor deficits were apparent (7-14 days). The animals were killed by decapitation at various time intervals after the MPTP treatment and the caudate putamen were dissected out. Saturation studies were carried out using [³H]spiperone (11 concentrations between 0.005-5.0 nmol/L); non-specific binding was defined by 10 µmol/L (-)sulpiride.

Table 1. Effects of unilateral intranigral infusion of MPTP on [³H]spiperone binding to the caudate putamen of the common marmoset at various time intervals following withdrawal of MPTP treatment.

	Side	Post-infusion times					
		Vehicle	1D	3M	5M	8M	18M
B _{max} /Kd	Ipsilateral	504±74/36±3	308±24*/36±1	381±45/34±4	561±95/39±1	443/35	378/36
	Contralateral	438±61/33±3	363±44/36±1	388±32/35±3	458±60/38±4	510/33	455/42

Data are the mean ± S.E.M. (n = 3-5) or mean (n = 2), D = day, M = month. B_{max} is represented as fmol/mg protein and Kd as pmol/L. Significant difference in B_{max} values compared to the respective vehicle value is indicated by *P<0.05 (Mann-Whitney U test).

The unilateral intranigral administration of MPTP caused a significant reduction in the density of [³H]spiperone binding sites in the ipsilateral hemisphere at day 1 after the termination of MPTP treatment. No significant changes over all other post-infusion times were apparent in the ipsilateral or contralateral hemispheres. The results suggest that the initial reduction in ipsilateral striatal dopamine D2 receptors induced by MPTP infusion is reversible and that behavioural recovery does not appear to be the consequence of the development of total striatal dopamine D2 receptor supersensitivity.

Barnes, N.J.G., Costall, B., Domeney, A.M. & Naylor, R.J. (1987) *Neuropharmacol.* 26 (9), 1327-1335

Jenner, P., Rose, S., Nomoto, M. & Marsden, C.D. (1986) *Adv. Neurol.* 45, 183-186

Joyce, J.N., Marshall, J.F., Bankiewicz, K.S., Kopin, I.J. and Jacobowitz, D.M. (1985) *Brain Res.* 382, 360-364

THE EFFECT OF HALPERIDOL PRETREATMENT ON VASOPRESSIN, OXYTOCIN AND CORTISOL RELEASE IN SHEEP BY CHOLECYSTOKININ (CCK)

I.S. Ebenezer¹, R.F. Parrott & S.N. Thornton, AFRC Institute of Animal Physiology and Genetics Research, Cambridge.
¹School of Pharmacy, Portsmouth, Hants

Substances, such as CCK, that cause nausea in mammalian species with emetic reflexes also produce increases in plasma vasopressin but not of oxytocin (see Ebenezer et al; 1989). These results suggest that plasma vasopressin levels may be used as a marker for nauseogenic agents. Recently, we showed that administration of CCK to sheep, at a dose level that inhibits feeding but does not cause emesis, increased plasma levels of vasopressin (Ebenezer et al; 1989). As it has been demonstrated that dopamine antagonists have antinausea and antiemetic properties (Niemegeers, 1982), we decided to investigate the effects of the dopamine antagonist haloperidol on the CCK-induced release of vasopressin. We also measured plasma cortisol to provide an indication of non-specific stress.

Adult Clun forest sheep (n=10, 5M, 5F, mean b.wt. 64 kg) were used. The sheep were injected with the following: physiological saline followed by saline (control), haloperidol (80 µg/kg) followed by saline; saline followed by CCK (1 µg/kg); haloperidol (80 µg/kg) followed by CCK (1 µg/kg). The 1st injection was given s.c. 60 min before the 2nd injection (given i.v.). Blood samples were taken by jugular venepuncture before (-10, 0 min) and after (5, 10, 20 min) the 2nd injection. The plasma was analyzed by radioimmunoassay for vasopressin, oxytocin and cortisol concentrations as described previously (see Ebenezer et al; 1989).

Administration of CCK resulted in a transient but significant elevation of vasopressin levels after 5 min (148% ↑ from base-line; P<0.05) with no effect on oxytocin levels. There were also significant increases in cortisol levels starting 5 min after CCK injection, with maximal increases occurring at 10 min when plasma levels were approximately 170% above baseline (P<0.001). These results are consistent with those reported previously (Ebenezer et al; 1989). In contrast, pretreatment with haloperidol almost completely prevented the increases in plasma vasopressin concentrations that were evident when CCK was administered alone. Interestingly however, haloperidol pretreatment had no effects on CCK-induced cortisol release. Saline or haloperidol plus saline had no effects on the release of these hormones.

The results of this study indicate that haloperidol pretreatment causes a dissociation between the effects of CCK on cortisol (non-specific stress) and vasopressin (possible marker for nausea) release. Furthermore, these results suggest that CCK may cause the release of vasopressin via a dopaminergic mechanism. It is not possible at present to speculate as to whether blocking the increase in plasma vasopressin will lead to a decrease in the nauseogenic properties of CCK.

Ebenezer, I.S., Thornton, S.N. & Parrott, R.F. (1989) *Am. J. Physiol.* 256, R1355-R1357

Niemegeers, C.J.E. (1982) *Psychopharmacology*, 78, 210-213.

REVERSAL OF CCK-INDUCED HYPOLOCOMOTION IN THE MOUSE BY THE CCK-A ANTAGONIST DEVAZEPIDE BUT NOT BY THE CCK-B ANTAGONIST L-365,260

M.F. O'Neill*, C.T. Dourish & S.D. Iversen, Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Essex, CM20 2QR.

Intraperitoneal (i.p.) injection of cholecystokinin octapeptide (CCK) reduces locomotor activity in rodents (Crawley et al, 1981). It is unclear, however, whether this response is due to a peripheral or a central action of the peptide and whether it is mediated by CCK-A or CCK-B receptors. This study addressed both of these issues by comparing the effects of i.p. and intracerebroventricular (i.c.v.) injection of CCK on locomotor activity and determining the ability of the CCK-A antagonist devazepide (Evans et al, 1986; Chang & Lotti, 1986) and the CCK-B antagonist L-365,260 (3R(+)-N(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N1-(3-methylphenyl)-urea) (Bock et al, 1989; Lotti & Chang, 1989) to block these effects. Male BKTO mice (20-25g) were housed in groups of four prior to testing. On test day they were randomly assigned to treatment groups and injected with devazepide (0.001-1.0 mg/kg), L-365,260 (0.0001-0.1 mg/kg) or 0.5% methylcellulose vehicle (s.c.) 30 min prior to cholecystokinin octapeptide sulphated (i.p. or i.c.v.). After the second injection the mice were placed in individual Perspex boxes fitted with 4 pairs of infrared photocells linked to a CUBE microcomputer system. Locomotor activity was measured as number of photocell interrupts.

Devazepide and L-365,260 had no intrinsic effect on activity. CCK dose dependently reduced levels of activity when administered i.p. [$F(3,28) = 14.1, P < 0.0001$] and i.c.v. [$F(4,44) = 4.56, P < 0.005$]. The minimum effective doses for reducing activity were 10 ug/kg (i.p.) i.e. 0.2 ug in a 20g mouse, and 3.5 ug (i.c.v.). In mice treated with CCK i.p. activity was reduced within 5 min of injection, whereas after i.c.v. infusion of CCK the latency to onset of the sedative response was 15 min. Devazepide at a dose of 0.1 mg/kg reversed the sedative effect of 10 ug/kg CCK injected i.p. [$F(4,118) = 4.95, P < 0.005$] and of 3.5 ug CCK injected i.c.v. [$F(3,84) = 4.95, P < 0.005$]. In contrast, L-365,260 had no effect on hypolocomotion induced by centrally or peripherally administered CCK.

These findings indicate that CCK injected i.p. or i.c.v. induces hypolocomotion via an action at CCK-A receptors. Larger doses of CCK were required to reduce locomotion when injected i.c.v. than when injected i.p. Furthermore the latency to onset of the sedative response was longer following i.c.v. CCK than after i.p. CCK. These observations suggest that hypolocomotion induced by i.c.v. CCK may be caused by leakage of the peptide to the peripheral circulation (see Passaro et al, 1982) and subsequent activation of CCK-A receptors.

Bock, M.G., DiPardo, R.M., Evans, B.E., Rittle, K.E., Whitter, W.L., Veber, D.F., Anderson, P.S. & Freideinger, R.M. (1989) J. Med. Chem., 32, 13-16.

Chang, R.S.L. & Lotti, V.J. (1986) Proc. Natl. Acad. Sci. USA, 83, 4923-4926.

Crawley, J.N., Hays, S.E., Paul, S.M. & Goodwin, F.K. (1981) Physiol. Behav. 27, 407-411.

Evans, B.E., Bock, M.G., Rittle, K.E., DiPardo, R.M., Whitter, W.L., Veber, D.F., Anderson, P.S. &

Freideinger, R.M. (1986) Proc. Natl. Acad. Sci. USA, 83, 4918-4922.

Lotti, V.J. & Chang, R.S.L. (1989) Eur. J. Pharmacol. 162, 273-280.

Passaro, E., Debas, W., Oldendorf, W., & Yamada, T. (1982) Brain Res. 241, 335-340.

BEHAVIOURAL AND NEUROCHEMICAL EVIDENCE FOR AN INTERACTION OF CCK WITH D1 DOPAMINE RECEPTORS

C.T. Dourish*, P.H. Hutson, S.J. Kitchener, M.F. O'Neill, N. Suman-Chauhan and S.D. Iversen, Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR.

Cholecystokinin co-exists with dopamine in a subpopulation of mesolimbic neurones and has been shown to modulate brain dopamine transmission (Crawley, 1988). Brain dopamine receptors are heterogenous and have been classified into two types namely D-1 and D-2 receptors (Kebabian and Calne, 1979). It is known that CCK modifies the behavioural response to a mixed D-1/D-2 agonist such as apomorphine (Crawley, 1988). To date, however, the effects of CCK on the response to a selective D-1 agonist have not been examined. D-1 dopamine receptor stimulation produces a characteristic pattern of behaviour and increases the formation of cAMP by stimulating the enzyme adenylate cyclase (Waddington and O'Boyle, 1989). In the present study, we examined the effects of CCK on the behavioural responses and the increase in cAMP overflow induced by the selective D-1 agonist SKF 38393. For behavioural studies, male SD rats (300-400g) were habituated to 2.5h to Perspex observation boxes. CCK (0.001-10.0 ug/kg i.p.) was injected 10 min prior to (\pm) SKF 38393 (10-80 mg/kg s.c.). Beginning 75 min after injection of SKF 38393, animals were observed for a 15 min period and behaviour recorded using a keypad interfaced to a CUBE microcomputer. Striatal cAMP overflow was measured in vivo, in a separate group of rats, by intracerebral dialysis, as previously described (Hutson and Suman-Chauhan, 1990).

Preliminary studies revealed that 20 mg/kg SKF 38393 was the minimum dose required to induce the characteristic D-1 agonist syndrome (Waddington and O'Boyle, 1989). Therefore, this dose of the drug was used for the CCK interaction studies. CCK attenuated SKF 38393-induced mouth movements at doses of 0.01-1.0 ug/kg (ANOVA, CCK main effect: $F(5,142) = 2.45, P < 0.05$) and SKF 38393-induced sniffing at doses of 1.0-10.0 ug/kg (ANOVA, CCK main effect: $F(5,142) = 2.70, P < 0.03$) but had no effect on grooming induced by the drug. Similarly, CCK (1-10 ug/kg i.p.) attenuated the increase in cAMP overflow in striatal dialysate induced by SKF 38393.

These results provide the first evidence of a functional interaction between CCK and D-1 dopamine receptors. As the mouth movement response induced by SKF 38393 has recently been proposed as an animal model of tardive dyskinesia (Rosengarten et al, 1982) our data suggest that CCK (or a CCK agonist) may be a potential therapy for this disorder. Interestingly, CCK attenuates mouth movements induced in rats by withdrawal from chronic neuroleptic treatment (Stoessl et al, 1989). Furthermore, there is preliminary clinical evidence that the CCK analogue ceruletide alleviates symptoms of tardive dyskinesia in schizophrenic patients (Nishikawa et al, 1986).

Crawley, J.N. (1988) in *Cholecystokinin Antagonists*. ed. Wang R.Y. and Schoenfeld R. pp 243-262. New York: Liss.

Hutson, P.H. and Suman-Chauhan, N. (1990) *Neuropharmacology* in press.

Kebabian, J.W. and Calne D.W. (1979) *Nature* 277, 93-96.

Nishikawa, T., Tanaka, M., Tsuda, A., Kuwahara H., Koga, I. and Uchida, Y. (1986) *Psychopharmacology* 90, 5-8.

Rosengarten, H., Schweitzer, J.W. and Freidhoff, A.J. (1983) *Life Sci.* 33, 2479-2482.

Stoessl, A.J., Dourish, C.T. and Iversen, S.D. (1989) *Psychopharmacology* 98, 372-379.

Waddington, J.L. and O'Boyle, K.M. (1989) *Pharmacol. Ther.* 43, 1-52.

EVIDENCE THAT THE ANXIOLYTIC-LIKE EFFECTS OF THE CCK ANTAGONISTS DEVAZEPIDE AND L-365,260 IN THE ELEVATED PLUS-MAZE PARADIGM IN RATS ARE MEDIATED BY CCK RECEPTORS

S. Ravard*, C.T. Dourish & S.D. Iversen, Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR.

Recent data indicate that cholecystokinin (CCK) antagonists induce anxiolytic-like effects in two animal models of anxiety, conditioned suppression of drinking and the light/dark exploration box (Hendrie and Dourish, 1990a,b; Dourish et al, 1990). The present study was designed to examine the effects of three CCK antagonists L-365,260, devazepide and L-365,031 in an another animal model sensitive to benzodiazepine anxiolytics, the elevated-plus maze paradigm (Handley and Mithani, 1984). Male Sprague Dawley rats (250-300g) were individually placed in the centre of an elevated-plus maze for a single 5-min session. During the test session, the number of entries into and the time spent in the open and closed arms were recorded for each rat. To validate the elevated-plus maze as an anxiety model, the effects of diazepam (0.5, 1 and 2 mg/kg, i.p., 30 min before testing) were studied in the first experiment. In experiments 2, 3 and 4, we examined the effects of the CCK antagonists L-365,260, devazepide and L-365,031 (0.01-100ug/kg in all cases, s.c., 30 min before testing). In all studies, 0.5% methylcellulose (i.p. or s.c. as appropriate, 30 min before the test) was used as a vehicle control. In an additional experiment the effects of diazepam, L-365,260 and devazepide on exploration in a four hole box were examined to determine whether the effects observed in the maze were due to an increase in exploratory behaviour.

Vehicle-treated rats exhibited a low percentage of entries into the open arms and spent significantly less time in the open than in the closed arms ($p < 0.01$). Diazepam significantly increased the percentage of entries into and the time spent in the open arms ($p < 0.05$ for all doses), as previously described (Handley and Mithani, 1984). In subsequent experiments with CCK antagonists, diazepam (2 mg/kg) was used as a positive control and was observed to increase the total arm entries. L-365,260 dose-dependently increased the percentage of entries into and the time spent in the open arms, significant effects being observed at 1 and 10 ug/kg ($p < 0.01$ and 0.05, respectively). A dose of 1 ug/kg of L-365,260 also increased the total number of arm entries. Devazepide significantly increased the percentage of entries into the open arms at 1 and 10 ug/kg ($p < 0.01$ and 0.05, respectively). The percentage of time spent in the open arms was increased only by 1 ug/kg, a dose which significantly increased the total number of arm entries. L-365,031 had no effect on any of the parameters measured in the test. Diazepam (2 mg/kg), L-365,260 and devazepide both at a dose of 1ug/kg did not increase the number and the duration of nose pokes and the number of rears in the four hole box model of exploration. Thus, the present results suggest that devazepide and L-365,260 have anxiolytic-like properties in the elevated-plus maze paradigm. Both L-365,031 and devazepide are selective CCK-A antagonists whereas L-365,260 is a selective CCK-B antagonist (Freidinger, 1989). Since devazepide and L-365,260 but not L-365,031 induced anxiolytic-like effects in the elevated-plus maze paradigm, the results indicate mediation of the behavioural response by CCK-B receptors.

Dourish, C.T., Rycroft, W., Dawson, G.R., Tattersall, F.D. & Iversen S.D. (1990) Eur. J. Neurosci. in press.

Freidinger, R.M. (1989) Med. Res. Rev. 9, 271-290.

Handley, S.L. & Mithani, S. (1984) Naunyn-Schmiedeberg's Arch. Pharmacol. 327, 1-5.

Hendrie, C.A. & Dourish, C.T. (1990a) Br. J. Pharmacol. 99, 138P.

Hendrie, C.A. & Dourish, C.T. (1990b) Eur. J. Neurosci. in press.

BLOCKADE OF CCK-B RECEPTORS BY L-365,260 INDUCES ANALGESIA IN THE SQUIRREL MONKEY

M.F. O'Neill, S.J. Tye, C.T. Dourish & S.D. Iversen. Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR.

Blockade of CCK receptors has been shown to enhance opiate analgesia in a variety of pain models in rodents, primates and humans (Baber et al, 1989; Dourish et al, 1990). A novel series of non-peptide CCK antagonists has recently been developed which has helped to clarify the role of CCK receptor subtypes in the mediation of CCK/opiate interactions. Thus, it was demonstrated that the rank order of potency of these antagonists to enhance morphine analgesia (L-365,260 > devazepide > L-365,031) correlates with their relative affinities for the CCK-B receptor (Dourish et al, 1989). This suggested mediation of CCK/opiate interactions in rodents by CCK-B receptors. To date there have been no reports that CCK antagonists have intrinsic analgesic properties in rodents or primates. In the present study we determined the effects of the potent and selective CCK-B antagonist L-365,260 in the squirrel monkey tail withdrawal test, and observed that the compound induces analgesia in this model. Six male squirrel monkeys (*Saimiri sciureus*) were habituated to sitting in Perspex chairs with their tails suspended in cool (35°C) water. Pain threshold was measured as the latency to remove the tail from warm (55°C) water. L-365,260 [3R(+)-N(2,3-dihydro-1-methyl-2-oxo-phenyl)-1H-1,4-benzodiazepin-3-yl)-N1-(3-methylphenyl)-urea] was suspended into 0.5% carboxymethyl cellulose and injected i.p. 30 min prior to testing. Tail withdrawal latencies were measured at 30 min intervals for 120 min beginning immediately after injection of the drug. L-365,260 significantly elevated tail withdrawal latencies [L-365,260 main effect: $F(7,35) = 3.97$, $p < 0.001$] and induced significant analgesia across a 1000-fold dose range from 100ng/kg to 100ug/kg (see Table 1). Levels of analgesia were significantly raised throughout the two hour test period.

Table 1 Effect of L-365,260 on Tail Withdrawal Latency in The Squirrel Monkey

Dose/kg	Vehicle	1ng	10ng	100ng	1ug	10ug	100ug	1mg
Mean	1.62	3.13	4.70	4.30*	9.78*	9.04**	9.02**	6.44
S.E.M.	0.28	0.91	1.28	0.96	1.71	1.18	1.37	1.41

Data are mean latencies (S.E.M.) for 6 monkeys during a 120 min test. Significant differences from vehicle were determined by planned contrasts following significant ANOVA, * $p < 0.05$, ** $p < 0.01$.

These data provide the first evidence that blockade of CCK receptors induces analgesia in primates. Previous studies have indicated that the selective CCK-A antagonist devazepide has no intrinsic analgesic activity in this test (Dourish et al, 1990). This suggests that the analgesic action of L-365,260 is mediated by its action on CCK-B receptors.

Baber, N. S., Hill, D.R., & Dourish, C.T. (1989) Pain, 39, 307-328.

Dourish, C.T., O'Neill, M.F., Schaeffer, L.W., Siegl, P.K.S. & Iversen, S.D. (1990) J. Pharmacol. Exp. Ther. in press.

Dourish, C.T., O'Neill, M.F., Coughlan, J., Kitchener, S.J., Hawley, D. & Iversen, S.D. (1989) Eur. J. Pharmacol. 176, 35-44.

LACK OF EVIDENCE FOR CHEMICAL COMPLEXATION BETWEEN NEUROTENSIN AND DOPAMINE

R. Rivest*, F.B. Jolicoeur¹ and C.A. Marsden. ¹Department of Psychiatry, Faculty of Medicine, University of Sherbrooke, PQ, Canada J1H 5N4 and Department of Physiology and Pharmacology, Queen's Medical Centre, Medical School, Nottingham, UK, NG7 2UH.

It is recognized that central administration of neurotensin produces neuroleptic-like effects but the mechanism of action of the peptide has not been clearly established (Jolicoeur et al., 1985; Nemeroff, 1986). However a recent *in vitro* study reported that neurotensin could block the action of dopamine by forming a complex with the amine (Adachi et al., 1990). We have investigated this proposed mechanism of action by examining the effect of NT on the dopamine signal recorded *in vitro* using the method of differential pulse voltammetry with carbon fibre micro-electrodes. If neurotensin binds to dopamine in the solution, a diminution of the dopamine peak height and/or a shift in its oxidation potential would be observed after the addition of neurotensin.

The working electrodes were made from single 12 μ M carbon fibres electrically pre-treated as previously described (Sharp et al., 1984). A working, reference, (Ag/AgCl) and auxiliary (silver wire) electrode were immersed in a solution of artificial cerebrospinal fluid (pH 7.4) containing dopamine (10^{-5} M). After recording the dopamine oxidation peak every 2.5 min for 20 min, saline or neurotensin (10^{-4} M to 10^{-6} M) was added and voltammograms recorded every 2.5 min for a further 30 min and both the dopamine oxidation potential and its peak height were measured before and after the addition of neurotensin. The dopamine peak height after the addition of neurotensin was compared with the mean height of the peak obtained from the last scans before addition of the peptide. The results were analysed using ANOVA and individual differences were assessed by means of Dunnett's test * $p < 0.05$ ($n = 4$ /groups).

The height of the dopamine (10^{-5} M) oxidation peak was attenuated after the addition of the neurotensin (10^{-5} M = 38% and 10^{-4} M = 65%) into the solution while saline had no effect. However when the electrode was removed from the solution for 20 min just before the addition of neurotensin, there was no reduction in the height of the dopamine peak at the first measurement after replacing the electrode in the solution but the peak was reduced in subsequent recordings. Moreover, the oxidation potential (the time to reach the maximum height for the dopamine peak, $33.8 \text{ sec} \pm 0.19$) was not changed by the presence of neurotensin (10^{-5} M) ($33.9 \text{ sec} \pm 0.19$). Therefore, the reduction of the dopamine peak was caused by an effect of neurotensin on the recording properties of the electrode rather than a real diminution of the free dopamine in the solution. Together, these results do not support the recent hypothesis of a chemical complexation between neurotensin and dopamine being involved in the pharmacological effects of the neuropeptides.

We thank the Wellcome Trust, MRC and FCAR for financial support.

Adachi, D.K. Kalivas, P.W. and Schenk, J.O. (1990) *J. Neurochem.*, 1321:1328.
Jolicoeur, F.B., Rioux, F. and St-Pierre, S. (1985) *Hdbk. Neurochem.* 8, 93-113.
Nemeroff, C.B. (1986) *Psychoneuroendocrinol.* 11, 15-37.

THE PHARMACOLOGY OF NEUROTENSIN AND NEUROTENSIN ANALOGUES ON DOPAMINE NEURONES IN THE RAT SUBSTANTIA NIGRA PARS COMPACTA

K.D.KEEGAN, G.N.WOODRUFF and R.D.PINNOCK.
Parke-Davis Research Unit, Addenbrookes Hospital Site, Cambridge CB2 2QB.

Autoradiographic studies indicate that high densities of neurotensin (NT) binding sites occur on dopamine neurones in the substantia nigra and ventral tegmental area and electrophysiological studies have shown that NT excites dopamine neurones in the substantia nigra (Pinnock 1985; Seutin, et al 1989). In this study, we have compared the effects of NT to those of NT1-11, NT1-8, Acetyl NT8-13, NT8-13, NT9-13, LANT6-the avian derivative of neurotensin (LANT6) and Neuromedin N (Nn), which is spliced from the same mRNA as NT (Minamino et al 1984) and kinetensin. We have also investigated the actions of thyrotropin releasing hormone (TRH) on NT activity since TRH has been inferred to antagonise NT induced responses in a multiplicity of physiological and behavioural situations (Nemeroff et al 1979).

The preparation of, and extracellular recording from, slices of rat brain containing substantia nigra was as described previously (Pinnock, 1985). Slices were perfused at 4 ml/min with ACSF at 37°C. Drugs were applied directly dissolved in ACSF.

Neurotensin excited 74/79 dopamine neurones on which it was tested. The neurotensin analogues LANT6, Nn, NT 8-13, Acetyl NT8-13 and NT9-13 when applied at submicromolar concentrations, all excited neurotensin sensitive neurones. Kinetensin, NT 1-8 and NT 1-11 (10μ M) were inactive when applied to these neurotensin sensitive neurones. Exposure of the preparation to 10μ M TRH ($n = 3$) had no effect on the response to submaximal doses of neurotensin. TRH had no action of its own.

The results of this study show that NT9-13 contains within it the amino acid sequence required to excite dopamine neurones. Peptides such as neuromedin-N and avian neurotensin in which the arginine at position 9 has been substituted by isoleucine and asparagine respectively are active on neurotensin sensitive neurones. Substitution of the arginine at position 9 with histidine and the isoleucine at position 12 as in the peptide kinetensin results in loss of biological activity. The lack of effect of TRH on neurotensin responses suggest that the behavioural actions of TRH as a neurotensin antagonist do not extend to a physiological or pharmacological blocking action at the single neurone level in the rat substantia nigra.

Minamino, N. Kangawa, & K. Matsuo, H. *Biochem. Biophys. Res. Commun.* 1984 122 542-549
Nemeroff, C.B. Loosen, P.T. Bissette, G. Manburg, P.J. Wilson, I.C. Lipton, M.A. & Pinnock, R.D. (1985) *Brain Res.* 338 151-154.
Seutin, U., Massotte, L & Dresse, A. 1989 *Neuropharmacology* 28 949-954.

BINDING OF NEUROTENSIN ANALOGUES TO NEUROTENSIN RECEPTORS FROM RAT BRAIN

A.R. Aldalou, G.B. Irvine, C. Shaw¹, D.J.S. Guthrie, J. Nelson & B. Walker. Division of Biochemistry and ¹Department of Medicine, The Queen's University of Belfast, Medical Biology Centre, Belfast BT9 7BL, N. Ireland, U.K. (Introduced by JM Allen)

Neurotensin (NT), a tridecapeptide originally isolated from bovine hypothalamus (Carraway & Leeman, 1973), is widely distributed in mammalian brain. Specific NT binding sites have been identified in the central nervous system and in the gastrointestinal tract of mammals (Kitabgi *et al.*, 1985). The C-terminal hexapeptide comprises the minimum structure necessary for many of the biological actions of NT. We have synthesised several analogues of this region and in each have replaced isoleucine-12 by N-methylisoleucine (MeIle) to produce derivatives with potentially increased metabolic stability (Aldalou *et al.*, 1990). In this report we present data on the specific binding of NT and one of these analogues to plasma membranes from rat brain.

NT and NAc-NT (8-13) were purchased from Peninsula Laboratories (St. Helens, U.K.). The peptide NAc-[MeIle¹²]NT (8-13) was synthesised by solid phase methods as previously described (Aldalou *et al.*, 1990). Plasma membranes were prepared from 3 rat brains by a modification of the method described by Nelson *et al.* (1986) in 10 mM Tris/HCl buffer, pH 7.4, containing 1.0 mM MgSO₄, 1.0 mM dithiothreitol and 40 mg/L bacitracin. [3-[¹²⁵I]iodotyrosyl³]-NT (2000 Ci/mmol) was purchased from Amersham (U.K.). Routinely, 100 µl of the membrane suspension were mixed with an aliquot (100 µl) of radiolabelled NT in the presence or absence of NT or an analogue and the mixture was incubated for 60 min at 37°C. The final concentrations of peptides were in the range 8x10⁻¹¹ - 8x10⁻⁷ M. The tubes were then centrifuged for 30 min at 4000 r.p.m, and the pellet was washed with buffer at 4°C and recentrifuged. The radioactivity remaining in the pellet was determined using a gamma counter. Specific binding was found to be 89% of total binding.

The radiolabelled NT was displaced from the membrane suspension by NT, with an ID₅₀ value of 9.1 and by NAc-NT (8-13) and NAc-[MeIle¹²]NT (8-13) with IC₅₀ values of 8.25 and 8.35 respectively. It seems, therefore, that MeIle does not cause a significant decrease in affinity for receptor binding.

This work was supported by a grant from the SmithKline (1982) Foundation. A. R. Aldalou thanks Arab Student Aid International, New Jersey, USA, for financial assistance.

Aldalou, A.R., Irvine, G.B., Murphy, R.F., Shaw, C. & Walker, B. (1990) *Biochem. Soc. Trans.* **18**, 318-319.
Carraway, R. & Leeman, S.E. (1973) *J. Biol. Chem.* **248**, 6854-6861.
Kitabgi, P., Checler, F., Mazella, J. & Vincent, J.P. (1985) *Rev. Basic Clin. Pharmacol.* **5**, 397-404.
Nelson, J., Clarke, R., Dickson, G.R., Van Den Berg, H.W. & Murphy, R.F. (1986) *J. Steroid Biochem.* **25**, 619-626.

BINDING OF NEUROKININ A ANALOGUES TO NK-2 RECEPTORS FROM GUINEA-PIG BRAIN

A.A. Abu Shanab, J.M. Allen¹, D.J.S. Guthrie, G.B. Irvine and B. Walker, School of Biology and Biochemistry, The Queen's University of Belfast, Belfast BT9 7BL, N. Ireland, U.K. and ¹Biomedical Sciences Research Centre, University of Ulster, Coleraine, BT52 1SA, N. Ireland, U.K.

The tachykinins, substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), have been identified in the central nervous system (Kimura *et al.*, 1983). Three different classes of tachykinin-binding sites have been characterised and named NK-1, NK-2 and NK-3, showing binding preferences for SP, NKA and NKB respectively (Burcher, 1989). We have previously reported the syntheses of some analogues of NKA, two of which were specific antagonists of the action of NKA on guinea-pig tracheal smooth muscle (Guthrie *et al.*, 1990). We now report that these two compounds displace [¹²⁵I]-NKA bound to isolated membranes from guinea-pig brain.

The peptides 1) [Ala⁵, Aib⁸, Leu¹⁰]NKA (2-10), and 2) [Ala⁵, Aib⁸, Leu¹⁰]NKA were synthesised by solid phase methods as previously described (Guthrie *et al.*, 1990). [¹²⁵I]-NKA (2000 Ci/mmol) was purchased from Amersham (U.K.). Male guinea-pigs (250-300 g) were sacrificed by decapitation. Brains were rapidly removed and the cerebellum was discarded. Plasma membranes were prepared according to a modified procedure of Viger *et al.* (1987). Routinely, 100 µl of the membrane suspension were mixed with an aliquot (100 µl) of [¹²⁵I]-NKA (35000 cpm) in the presence or absence of NKA or an analogue and the mixture was incubated for 20 min at 25°C. The final concentrations of analogues were in the range 10⁻¹¹ - 10⁻⁵ M. At the end of the incubations, the tubes were centrifuged for 30 s at 10,000 g, and the pellet was washed once with the incubation buffer. The radioactivity remaining in the pellet was measured using a gamma counter. Under these conditions, specific binding was found to be 68% of total binding.

Bound [¹²⁵I]NKA was displaced from the membrane suspension by NKA, with an ID₅₀ value of 9.0 and by peptides 1 and 2, both with an IC₅₀ value of 8.5. Substance P and peptides not related to NKA did not significantly displace the label. Many antagonists of tachykinin activity have been reported, but generally they have much reduced receptor affinity and also lack specificity (Burcher, 1989). Peptides 1 and 2 are highly specific antagonists of NKA with receptor affinity almost equal to that of NKA.

This work was supported by a grant from N. Ireland Chest Heart and Stroke Association. A.A. Abu Shanab thanks Arab Student Aid International, New Jersey, USA, for financial assistance.

Burcher, E. (1989) *Clin. Exp. Pharmacol. & Physiol.* **16**, 539-543.
Guthrie, D.J.S., Abu Shanab, A.A., Allen, J.M., Irvine, G.B., McFerran, N.V. & Walker, B. (1990) *Biochem. Soc. Trans.* (in the press).
Kimura, S., Okada, M., Sugita, Y., Kanazawa, I. & Munekata, E. (1983) *Biochem. Biophys. Res. Commun.* **114**, 533-540.
Viger, V., Beaujouan, J.C., Torrens, Y. & Glowinski, J. (1983) *J. Neurochem.* **40**, 1030-1039.

J.J.S.Treanor, S.J.Allen, S.H.MacGowan, G.K.Wilcock & D.Dawbarn

Department of Medicine (Care of the Elderly), University of Bristol, Bristol Royal Infirmary, Bristol BS2 8HW.

Alzheimer's disease (AD) is the most common cause of dementia in the elderly and is characterised by memory loss and a progressive global impairment of intellect. It involves loss of central cholinergic function associated with degeneration of cholinergic neurones in the nucleus basalis of Meynert (nbM) in the basal forebrain.

β -Nerve growth factor (β -NGF) has been shown to induce choline acetyltransferase (ChAT) activity and promote growth and survival of cholinergic neurones *in vivo* and *in vitro*. Infusion of β -NGF has been shown to prevent death of septal neurones after fimbrial fornix transection and to reverse spatial memory impairment and shrinkage of cholinergic neurones in a sub-population of aged rats. Colocalization studies have shown that the majority of basal forebrain cholinergic magnocellular neurones are β -NGF receptor positive in human brain. Receptor binding studies on neoplastic cells and chick embryo sensory ganglia cells, have suggested that there are two sub-types of the β -NGF receptor, a fast dissociating low affinity (1nM) and a slow dissociating high affinity (20-50pM) low capacity receptor.

The aim of this study was to measure the dissociation constants and capacities of β -NGF receptors in membrane preparations of basal forebrain from AD and age-matched normal subjects. [125 I]NGF was found to bind in a specific fashion indicative of a single receptor and is not displaced with μ M concentrations of cytochrome C, insulin or epidermal growth factor (EGF). Steady state saturation analysis of basal forebrain membranes from normal and AD with radiolabelled NGF revealed one binding site which corresponded to the low affinity site previously reported in other species. There was no significant difference in mean Kd or B-max between normal and AD brain tissue. The mean Kd values \pm S.E.M. for normal and AD basal forebrain membranes were $3.02\text{nM} \pm 0.93$ and $3.67\text{nM} \pm 1.16$, the mean B-max values were 0.548 ± 0.143 and 0.516 ± 0.147 fmoles/ μ g membrane protein. In AD, mean ChAT values were reduced from 68.6 ± 9.86 to 16.4 ± 5.50 pmoles acetylcholine produced / μ g protein /minute.

These results show that there is no decrease in receptor number or affinity between AD and normal basal forebrain and in agreement with studies mentioned above this suggests that NGF may have a therapeutic role in AD.

SEPARATION OF THE *IN VIVO* VOLTAMMETRIC OXIDATION PEAK OF SEROTONIN, 5-HYDROXY-INDOLACETIC ACID AND URIC ACID: A NUMERICAL METHOD VERSUS NORMAL RECORDINGS

Gonzales-Mora¹, J.L., Crespi², F., Mobius², C., Guadalupe¹, T. and Mas¹, M.

¹ Department of Physiology, University of La Laguna, Tenerife, Spain and ² Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham, NG7 2UH, U.K.

The use of numerical methods for the analysis of *in vivo* voltammetric signals has been demonstrated recently for the mathematical separation of dopamine (DA) and its metabolite 3,4-hydroxyphenylacetic acid (DOPAC), components of the "catechol peak" or Peak 2 as obtained with 12 μ m diameter carbon fibre micro-electrodes (CFE) associated with differential normal pulse (DNPV) voltammetry (G.-Mora *et al.*, 1988). Voltammetric Peak 3, seen *in vivo* with specifically pretreated CFE (Crespi *et al.*, 1984) is the result of the oxidation of a mixture of serotonin (5HT), its metabolite 5-hydroxyindolacetic acid (5HIAA) and uric acid (UA) all having an oxidation potential (Ox-P) between +250 and +300 mV (Crespi *et al.*, 1983 & 1984). We have here investigated the specific Ox-P of UA, 5HIAA and 5HT using classical paper recordings and the computerised numerical method simultaneously. With both of these analytical procedures we observed that in conscious freely moving rats prepared for DNPV in the striatum (G.-Mora *et al.*, 1988) injection of the monoamine oxidase inhibitor (MAO-I) pargyline (75 mg/kg i.p. n=4) reduced Peak 3 to approximately 60% of pre-injection control values. In addition, this treatment, which is responsible for the disappearance of 5HIAA from the extracellular fluid of conscious rats (Crespi *et al.*, 1984) was followed by a shift in the Ox-P of Peak 3, of +8 to 10 mV at its beginning with a smaller change of +4 to 6 mV at its top. Two hours later, injection of allopurinol (15 mg/kg i.p.) further decreased the size of Peak 3 down to approximately 10% of its initial size within 90/120 min., thus confirming that striatal Peak 3 is mainly determined by the oxidation of a mixture of extracellular 5HIAA and UA (allopurinol blocking the formation of this purine catabolite) (Crespi *et al.*, 1983) and that these two compounds have a very similar, but possibly separable Ox-P, when the numerical system is applied. After the removal of UA via allopurinol, a larger shift of the Ox-P than that recorded after pargyline alone (which removes 5HIAA) was also seen: +15/25 mV and +10/20 mV at the beginning and top of the signal respectively. At that moment, injection of 5HTP (15 mg/kg i.p.), which stimulates the synthesis and release of 5HT, doubled the size of the signal without any change in the potentials, suggesting that the peak remaining after MAO-I and allopurinol treatments is mainly due to the oxidation of extracellular 5HT whose Ox-P seems then more clearly distinguishable from that of UA and 5HIAA.

Crespi, F., Paret, J., Keane, P. & Morre, M. (1984) *Neurosci.Lett.* **52**, 153-164

Crespi, F., Sharp, T., Maidment, H. & Marsden, C.A. (1983) *Neurosci.Lett.* **43**, 203-207

Gonzales-Mora, J.C., Sanchez-Bruno, J.A. & Mas, M. (1986) *Neurosci.Lett.* **86**, 61-66

EFFECTS OF CALCIUM CHANNEL-BLOCKING DRUGS ON VERATRIDINE-EVOKED RELEASE (OVERFLOW) OF GLUTAMATE FROM CEREBELLAR SLICES OF WISTAR RATS

B.G.M. Dickie & J.A. Davies, Department of Pharmacology & Therapeutics, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN.

The ability of veratridine to evoke neurotransmitter release is well recorded (see Nicholls, 1989). We have shown that veratridine increased glutamate release from cerebellar slices in calcium-free medium and that this was followed by a further increase when the slices were returned to calcium-replete (2mM) medium (Dickie and Davies, 1990). At least three types of voltage-sensitive Ca^{2+} channels have been identified (L-, N- and T-type) (Tsien *et al*, 1988). In this study we have investigated the effects of the Ca^{2+} channel blocking agents amiloride (T), verapamil (L) and w-conotoxin (N & L) on veratridine-evoked glutamate release.

Parasagittal slices (250 μm) were superfused (0.5 ml·min⁻¹) with artificial cerebrospinal fluid (ACSF), gassed with 95% O_2 /5% CO_2 at 37°C. Two-minute aliquots of ACSF were collected and assayed for glutamate by HPLC.

Stimulation of the slices was carried out by perfusion with a one-minute 'pulse' of veratridine (1×10^{-5} M) in Ca^{2+} -free ACSF, which produced a significant increase in glutamate release ($p < 0.001$), followed by another significant increase ($p < 0.001$) when the slices were perfused with Ca^{2+} -replete ACSF 5 minutes post-stimulation. The Ca^{2+} channel blocking agents were added either with the veratridine pulse or with the Ca^{2+} -replete ACSF. When added with the Ca^{2+} -replete ACSF w-conotoxin (1 μM) and verapamil (10 μM) did not affect glutamate release. Verapamil, however, significantly inhibited release when added with veratridine ($p < 0.001$). Amiloride (100 μM), when added with the veratridine pulse, significantly increased Ca^{2+} -evoked release ($p < 0.05$).

These results show that veratridine can stimulate glutamate release in Ca^{2+} -free conditions, and that this can be inhibited by verapamil, probably by a blocking action on Na^+ channels (Nachshen and Blaustein, 1979). The Ca^{2+} -evoked release was unaffected by w-conotoxin and verapamil, and was increased by amiloride. This suggests that neither N-, L- or T-type Ca^{2+} channels are involved. The increased release observed in the presence of amiloride is probably due to an effect on Na^+ exchange mechanisms.

Dickie, B.G.M. and Davies, J.A. (1990) *Neurosci. Lett.* 538, S77.

Nachshen, D.A. and Blaustein, M.P. (1979) *Mol. Pharmacol.* 16, 579-586.

Nicholls, D.G. (1989) *J. Neurochem.* 52, 331-341.

Tsien, R.W., Lipscombe, D., Madison, D.V., Bley, K.R. and Fox, A.P. (1988) *Trends in Neurosci.* 11, 431-437.

MICROINJECTIONS OF DLH INTO THE RAT PERIAQUEDUCTAL GREY MATTER INDUCE A DOSE-DEPENDANT DEFENCE RESPONSE ATTENUATED BY MIDAZOLAM

S.R.G. Beckett, C.A. Marsden & P. Marshall*, Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham, NG7 2UH. *ICI Pharmaceuticals, Bioscience II, Mereside, Alderly Park, Macclesfield, Cheshire. SK10 4TG.

Chemical stimulation of the dorsal periaqueductal grey matter using the excitatory amino acid D,L Homocysteic acid (DLH), (Hilton & Redfern 1986) elicits a series of cardiovascular, autonomic and behavioural effects, collectively termed the defence reaction. This response is in part under the modulatory control of GABA (Schenberg *et al* 1983). The present study determined whether there is a relationship between the dose of DLH, the magnitude of the defence reaction and its attenuation by midazolam.

Rats anaesthetised with a halothane, $\text{N}_2\text{O}/\text{O}_2$ mixture had stainless steel guide cannulae chronically implanted 2mm above the DPAG (AP -6.07, ML +0.2, DV -3.0 relative to bregma). Seven days post surgery the animals were placed in a circular arena and received a microinjection (0.2 μl) of saline or 2, 4, 8 or 16 nmol DLH (pH 7.5) into the DPAG, and the resulting behaviour recorded using visual observation and contrast computer tracking. Each animal was given the four doses over eight days, 48 hours later this process was repeated following administration of midazolam (1mg/kg, i.p.) 20 minutes before DLH. Subsequently, rats were anaesthetised with urethane and blood pressure and heart rate measured, and the effect of DLH (40nmol) alone and 20 min after midazolam recorded. The injection site was verified with dye.

Administration of DLH into the DPAG resulted in behaviour characteristic of the defence reaction (jumping, running and vocalisation) the duration of which was dose dependant (37.1 \pm 2.8 s. with 2nmol to 145.6 \pm 8.6 s. with 16nmol, $n=10$). The number of jumps and revolutions around the arena were also dose dependant and none of the behaviours were observed in saline controls. DLH significantly increased blood pressure and heart rate in the anaesthetised rat (+41 \pm 5mmHg⁻¹ and +63 \pm 9 bpm). Midazolam significantly shifted the behavioural dose response to the right (ANOVA $F=34.11$ $p < 0.001$) and attenuated the cardiovascular components (+16 \pm 5mmHg⁻¹ and +22 \pm 5bpm). These results demonstrate that DLH placed in the DPAG induces the defence reaction dose dependently and that both the behavioural and cardiovascular components are partially antagonised by the benzodiazepine midazolam.

S.R.G.B. is a SERC CASE student in collaboration with ICI Pharmaceuticals.

Hilton, S.M. & Redfern, W.S. (1986) *J. Physiol.* 378, 213-228.

Schenberg, L.C., DeAguiar, A.C. and Graeff, F.C. (1983) *J. Physiol. Behav.* 131, 429-432.

CHARACTERISATION OF THE NMDA RECEPTOR THAT STIMULATES RELEASE OF α -MELANOCYTE-STIMULATING HORMONE FROM THE RAT HYPOTHALAMUS

C.P. Wayman & J.F. Wilson, Department of Pharmacology & Therapeutics, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN

α -Melanocyte-stimulating hormone (α -MSH), a tridecapeptide derived from processing of the pro-opiomelanocortin (POMC) precursor, is synthesised in perikaria of the arcuate nucleus of the hypothalamus and is postulated to be a neurotransmitter or a neuromodulator. Release of central α -MSH is under both dopaminergic and serotonergic control, and the presence of a glutamergic influence on the POMC neurone has been identified by the demonstration of N-methyl-D-aspartic acid (NMDA)-stimulated release of α -MSH (Tiligada & Wilson, 1990). In this study we have further characterised the NMDA receptor mediating this latter response.

Two hundred and fifty μ m thick coronal slices of hypothalamus obtained from 150-200g male Wistar rats were superfused with oxygenated artificial cerebrospinal fluid (aCSF) at 37°C and 0.5ml/min under an atmosphere of humidified 95% O₂/ 5% CO₂. Two minute samples of superfusate were collected commencing 30min after the start of the superfusion, frozen immediately and freeze-dried at -25°C. The dried samples were reconstituted and their content of α -MSH determined by radioimmunoassay (Wilson & Morgan, 1979). The response to zero, 1 and 5mM Mg²⁺ ion concentrations, to ketamine and to the NMDA glycine site antagonist 1-hydroxy-3-amino-pyrrolidone-2 (HA-966) were investigated by comparing the total release of α -MSH over a 10min period following the administration of a 4min pulse of 10⁻⁴M NMDA in the absence and then the presence of the drug or modified aCSF. Responses to the second pulse of NMDA were compared to the second of two sequential NMDA pulses in unmodified aCSF.

Superfusion of hypothalamic slices with a 4min pulse of NMDA resulted in a significant ($p < 0.001$, one-way analysis of variance) increase in release of α -MSH. A second pulse of NMDA in normal aCSF (1mM Mg²⁺) produced a stimulation of α -MSH release that was not significantly different ($p > 0.05$) from that to the first pulse, being $107 \pm 8\%$ (\pm s.e.mean) of the first pulse. When slices were superfused with Mg²⁺-free aCSF, there was no significant change ($p > 0.05$) in either basal or NMDA-stimulated release of α -MSH. However, NMDA-stimulated peptide release did not return to basal release levels as in control experiments but remained elevated until the end of the experiment. Treatment of slices with aCSF containing high (5mM) Mg²⁺ ion concentrations caused a significant reduction in both basal ($p < 0.001$) and NMDA-stimulated ($p < 0.001$) release of α -MSH. Ketamine 10⁻⁴M similarly inhibited both basal ($p < 0.001$) and NMDA-stimulated ($p < 0.001$) release. Superfusion of slices with 10⁻⁴M HA-966 produced no significant change ($p > 0.05$) in either basal or NMDA-stimulated release of α -MSH.

These data demonstrate that the NMDA receptor that mediates the stimulatory glutamergic action on release of α -MSH from the rat hypothalamus shares features in common with other central NMDA receptors being blocked by high Mg²⁺ ion concentrations and by ketamine. We were unable to show the presence of glycine potentiation of the NMDA receptor response by blockade of endogenous glycine with HA-966.

Tiligada, E. & Wilson, J.F. (1990) *Life Sci.* **46**, 81-90

Wilson, J.F. & Morgan, M.A. (1979) *J. Pharm. Methods* **2**, 97-116

THE EFFECT OF CHRONIC ADMINISTRATION OF COCAINE ON LOCOMOTOR ACTIVITY AND ON A COGNITIVE TASK: EVIDENCE FOR DIFFERENTIAL DEVELOPMENT OF TOLERANCE AND SENSITIZATION

G.R. Dawson,*R. Banks, G.Bentley, A. McCreary, C.T. Dourish & S.D. Iversen, Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex. CM20 2QR.

It is well established that chronic administration of cocaine results in a progressive increase in locomotor activity and stereotyped behaviour in rodents (Post and Rose, 1976). The development of paranoid psychosis as a result of chronic cocaine administration has been presented as evidence of a similar effect in humans (Angrist, 1983). It has been suggested that this 'behavioural sensitization' may be due to an increase in dopaminergic transmission as a result of repeated stimulation of dopaminergic pathways (Peris et al., 1990). It might be expected that the development of sensitization would result in a progressive deterioration of the ability to perform complex tasks while under the influence of cocaine. Somewhat surprisingly, the development of sensitization is often paralleled by a development of behavioural tolerance, provided that the initial behavioural disruption results in reinforcement loss (Woolverton et al., 1978). We examined these paradoxical effects of chronic cocaine administration in rats by monitoring their locomotor activity and their behaviour on a complex cognitive task, delayed-matching-to-position (DMTP). In order to obtain food reward, rats in the DMTP task were required to press a 'sample' lever in an operant chamber, and to choose to press it again, after a variable delay, when it was presented alongside a second lever. Initially, a 10 mg/kg dose of cocaine induced a significant deficit in the total number of trials completed indicating a behavioural deficit, and in the number of trials successfully completed, indicating a cognitive deficit. However, by the third administration of this dose, there was no evidence of impairment on either measure compared to vehicle treated rats, demonstrating not only the development of behavioural tolerance, but also the development of tolerance to the cognitive disrupting effects of cocaine. In contrast, the locomotor activity measure yielded evidence of sensitization rather than tolerance. When the rats that had been tested on the DMTP test were given a fourth dose of 10 mg/kg cocaine, they showed a significantly greater elevation in locomotor activity than a separate group of rats injected with either 10 or 30 mg/kg of cocaine for the first time. These results are interpreted as indicating that cocaine disrupts cognitive as well as behavioural processes and that tolerance can develop to each. However, it remains to be determined whether reinforcement loss is a necessary requirement for the development of tolerance to the cognitive disrupting effects of the compound.

Angrist, B., (1983) *Neuropharmacology* **29**, 475-486.

Peris J., Boyson, S.J., Cass, W.A., Curella, P., Dwoskin, L.P., Larson, G., Lin, L., Yasuda, R.P., & Zahniser, N.R. (1990) *J. Pharmacol. Exp. Ther.* **253**, 38-44.

Post, R.M. & Rose, H. (1976) *Nature* **260**, 731-732.

Woolverton, W.L., Kleven, D. & Schuster, C.R. (1978) *J. Pharmacol. Exp. Ther.* **9**, 327-337.

THE ANGIOTENSIN CONVERTING ENZYME INHIBITORS ENALAPRIL AND CAPTOPRIL INHIBIT APOMORPHINE-INDUCED ORAL STEREOTYPY

R.J.A. Banks*, C.T. Dourish & S.D. Iversen, Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR.

Recent studies have suggested a functional interaction between the brain renin-angiotensin system and dopaminergic neurotransmission. Angiotensin II injected intracerebroventricularly potentiates apomorphine-induced stereotypy (Georgiev *et al*, 1984) whereas the angiotensin converting enzyme (ACE) inhibitor captopril attenuates the response (Sudilovsky *et al*, 1989). We have now compared the effects of the ACE inhibitors enalapril and captopril on apomorphine-induced stereotypy to those of the classical neuroleptic haloperidol.

In the first study the effects of captopril on apomorphine-induced behaviour were compared to those of haloperidol. Rats were habituated to observation boxes for 45 min and injected with 10 mg/kg captopril i.v., 0.2 mg/kg haloperidol i.p. or appropriate vehicle. The animals were returned to the boxes for 60 min (captopril) or 20 min (haloperidol) and injected with 0.03, 0.3, or 3 mg/kg apomorphine or vehicle (0.5mg/ml ascorbate in saline) s.c. The duration and frequency of cage crossing, grooming, rearing, sniffing, immobility, licking and gnawing were recorded for 30 min, beginning immediately after the second injection, using a keypad linked to a BBC microcomputer. Captopril had no effect on apomorphine-induced sniffing but significantly decreased apomorphine-induced gnawing and licking. Similarly, haloperidol had no effect on apomorphine-induced sniffing but blocked the licking and gnawing response.

In the second study dose response curves for inhibition of apomorphine-induced oral stereotypy by two ACE inhibitors (captopril and enalapril) were determined. Rats were allowed to habituate to observation boxes for 45 min and injected with 1, 3, 10 or 30 mg/kg captopril i.v. or 1, 3, 10, 30 or 100 mg/kg enalapril i.v. or s.c. or saline vehicle. The animals were returned to the boxes for 50 min and then injected with 1 mg/kg apomorphine or vehicle s.c. Behaviour was recorded for a period of 10 min beginning 10 min after the second injection. Captopril (3 and 10 mg/kg i.v.) attenuated oral stereotypy induced by apomorphine, but was ineffective at any other dose. Similarly, enalapril injected s.c. blocked apomorphine-induced gnawing at doses of 10 mg/kg and 30 mg/kg. Enalapril injected i.v. attenuated apomorphine-induced gnawing at 3 and 10 mg/kg, and abolished the response at 30 mg/kg. The selective blockade of apomorphine-induced oral stereotypy by haloperidol observed in this study is consistent with a previous report by Ljungberg and Ungerstedt (1978) that 0.2 mg/kg haloperidol blocks apomorphine-induced gnawing but has no effect on apomorphine-induced locomotion and sniffing. Furthermore, the results suggest that the effect of ACE inhibitors on apomorphine-induced stereotypy are similar to those of a classical neuroleptic as captopril and enalapril selectively blocked apomorphine-induced oral stereotypy.

Georgiev, V., Gyorgy, L., Getova, D. & Maskovksa, V. (1985) *Acta. Phys. Pharmacol. Bulg.* **11**, 19-26.

Ljungberg, T. & Ungerstedt U. (1978) *Psychopharmacology*, **56**, 239-247.

Sudilovsky, A., Turnbull, B. & Miller, L. (1989) *Soc. Neurosci. Abs.* **15**, 1065.

INHIBITION OF HISTAMINE RELEASE FROM HUMAN BASOPHILIC LEUKOCYTES BY THE PROTEIN KINASE C INHIBITOR STAUROSPOURINE

E. Ulrich Amon, Kai R. Dietz, & Franz W. Bauer, Department of Experimental Dermatology, F. Hoffmann-La Roche Ltd, Basel, Switzerland (Introduced by J.F. Waterfall)

Mast cells and basophilic leukocytes are involved in allergic/pseudoallergic reactions and local inflammatory responses, mediated by the release of histamine. Cross-linking of cell-bound IgE-molecules and hence cross-linking of IgE-receptors (FC_εR1) leads to a variety of cellular signal transduction processes, involving phosphoinositol hydrolysis, Ca²⁺ - influx, and protein kinase C (PKC). We therefore performed experiments to study the influence of PKC-inhibition on histamine release from basophils.

Suspensions of human basophils were obtained from healthy donors by dextran-sedimentation. Cells were challenged in HEPES-buffer with goat anti-human IgE in different dilutions for 30 min at 37° C. Cells were preincubated with different concentrations of the PKC-inhibitor staurosporine (1x10⁻⁹-1x10⁻⁵M) for 15 min before being triggered with anti-IgE. Histamine was measured spectrofluorometrically using an autoanalyzer.

Thousand-, hundred-, and then-fold dilution of the anti-IgE stock solution yielded a histamine release of 8.7±2.1%, 43.2±2.0%, and 35.1±2.4%, respectively (n=10). Preincubation with staurosporine exerted concentration-dependent inhibition of the IgE-mediated histamine release at an optimal dilution of anti-IgE (hundred-fold, table 1).

Table 1 Inhibition of IgE-mediated histamine release by staurosporine (in %, n=5)

		Concentration of staurosporine (M)				
		10 ⁻⁹	10 ⁻⁸	10 ⁻⁷	10 ⁻⁶	10 ⁻⁵
anti-IgE	:	15.3±9.6	20.1±7.9	67.5±8.7	88.0±3.9	81.0±7.2

The present results show a strong inhibition of histamine release mediated through the FC_εR1 by staurosporine. The IC₅₀ was 0.047 μM. Staurosporine is a potent PKC-inhibitor (Tamaoki *et al.*, 1986). Our data suggest that PKC is involved in the stimulus-secretion coupling following cross-linking of IgE-receptors on the basophil surface.

Tamaoki, T., Nomoto, H., Takahashi, J., Kato, Y., Morimoto, M. & Tomita, F. (1986) *Biochem. Biophys. Res. Commun.* **135**, 397-402

VAGALLY-RELEASED ACETYLCHOLINE INHIBITS SYMPATHETIC NEUROTRANSMISSION IN THE GUINEA-PIG TRACHEA

Y. D. Pendry & J. MacLagan, Academic Dept. of Pharmacology, Royal Free Hospital School of Medicine, London NW3 2PF.

In the guinea-pig, parasympathetic and sympathetic nerves lie in close proximity and have opposing effects on the airway smooth muscle (Jones et al 1980). We have previously reported inhibition of pulmonary sympathetic neurotransmission by exogenously applied muscarinic agonists via activation of prejunctional muscarinic M3 heteroreceptors (Pendry & MacLagan 1989). In the present experiments, the effect of endogenously released acetylcholine on relaxations evoked by stimulation of the pulmonary postganglionic sympathetic nerves was investigated.

The guinea-pig trachea with the right sympathetic nerve trunk, and both vagi and recurrent laryngeal nerves attached was mounted in oxygenated Krebs's solution containing indomethacin ($5 \times 10^{-6} \text{M}$) and maintained at 37°C . Increases or decreases in intraluminal pressure (ILP) reflected contraction or relaxation, respectively, of the trachealis smooth muscle. When the ILP had been raised with the stable thromboxane analogue U46619 (10^{-8} - $3 \times 10^{-6} \text{M}$), stimulation of the sympathetic nerve trunk (40Hz, V_{max} , 0.2ms, 5sec) evoked relaxations which were directly related to tone but reproducible at any given ILP.

Sympathetic nerve-induced relaxations were reduced in the presence of concurrent submaximal vagal stimulation (20Hz, 0.2ms for 3 or 4.5mins) in 50% of the preparations. The involvement of postjunctional physiological antagonism was excluded by stimulating the vagi at parameters which caused no increase in ILP. In addition, neuropeptides released from nonadrenergic noncholinergic nerves which run in the vagal bundle did not appear to be involved, as the neuropeptides substance P, vasoactive intestinal peptide, neurokinin A and endothelins did not significantly alter sympathetic nerve-induced relaxations.

The anticholinesterase, physostigmine (10^{-8} - 10^{-6}M) induced an increase in tone of the guinea-pig tracheal tube preparation and potentiated the postjunctional contractile action of acetylcholine (10^{-5}M). In contrast, physostigmine (10^{-6}M) inhibited sympathetic nerve-induced relaxations; for example, at an ILP level of 300mmH₂O sympathetic relaxation in the absence and presence of physostigmine was 145 ± 22 and $42 \pm 12 \text{ mmH}_2\text{O}$ respectively ($\bar{x} \pm \text{s.e.m.}$, $n > 5$; $P < 0.005$). The muscarinic antagonist, atropine (10^{-7}M) antagonised both the contractile action of physostigmine on airway smooth muscle and its inhibitory effect on sympathetic nerve-induced relaxation.

These results suggest that, in the guinea-pig trachea, acetylcholine released from pulmonary parasympathetic nerves inhibits sympathetic neurotransmission via an action on muscarinic receptors, situated prejunctionally on the sympathetic nerve terminals. Anticholinesterase drugs potentiate this effect and have a sympathoinhibitory action, in contrast to muscarinic M3 antagonists, which have a sympathoexcitatory effect in the airways (Pendry & MacLagan, 1989).

We wish to acknowledge the financial support of Pfizer Central Research.

Jones, T.R., Kannan, M.S. & Daniel, E.E. (1980). *Can. J. Physiol. Pharmacol.* 58, 974-983.

Pendry, Y.D. & MacLagan, J. (1989). *Br. J. Pharmacol.* 98, 777P.

591P

THE EFFECT OF POTASSIUM CHANNEL OPENING DRUGS ON GUINEA-PIG PULMONARY NERVES

J. Cooper & J. MacLagan Dept. of Academic Pharmacology, Royal Free Hospital School of Medicine, Rowland Hill Street, London NW3 2PF.

The potassium channel opening drug cromakalim prevents bronchoconstriction induced by various spasmogens in animals and man. Hall & MacLagan (1988) reported that cromakalim inhibits transmission in pulmonary cholinergic nerves due to an effect at either the ganglia or the final nerve terminals. In the present experiments, the location of the neural effect was studied. Contractions of the isolated guinea-pig tracheal tube, measured as a change in intraluminal pressure (ILP), were elicited by either preganglionic vagal nerve stimulation (PGS) via a ring electrode or by transmural stimulation (TMS; 30 V, 30 Hz, 0.2 ms pulse width, 5 s duration, 40 s interval) of postganglionic cholinergic nerves in the presence of hexamethonium ($50 \mu\text{M}$). Indomethacin ($5 \mu\text{M}$) was present throughout to abolish prostaglandin-induced tone.

Cromakalim (3.2 to $12.8 \mu\text{M}$) did not significantly affect the dose-related rise in tracheal tone caused by the spasmogens acetylcholine, histamine or U46619. Table 1 shows that cumulative addition of cromakalim (0.1 to $26 \mu\text{M}$) caused inhibition of TMS-induced increases in ILP, reaching a maximum inhibition of $53.25 \pm 3.25 \%$ at $26 \mu\text{M}$. Cromakalim also inhibited TMS-induced contractions when hexamethonium and indomethacin were omitted, in contrast to the results reported by McCaig and Dejonkeere, (1989). The inhibitory effect of cromakalim was significantly greater on

Increase in ILP (mm H ₂ O) to transmural (TMS) and preganglionic (PGS) stimulation.				responses elicited by PGS, reaching a maximum of $65 \pm 1 \%$ at $26 \mu\text{M}$. The active (+) enantiomer lemakalim (BRL38227; 0.01 to $26 \mu\text{M}$) was more potent than cromakalim, and caused 100% inhibition of PGS and TMS at $12 \mu\text{M}$. Glibenclamide (Glib; $20 \mu\text{M}$), a specific blocker of ATP-operated K ⁺ channels, significantly reduced the inhibitory action of cromakalim on contractions elicited by PGS and TMS ($P < 0.005$).
	Control	Cromakalim $26 \mu\text{M}$	%Inhibition	
TMS	155.0 ± 39.3	82.2 ± 20.8	$53.3 \pm 3.3^{\text{a,b}}$	Nonadrenergic noncholinergic (NANC) relaxant responses of the trachea were elicited by TMS in the presence of hexamethonium ($50 \mu\text{M}$), atropine ($1 \mu\text{M}$) and propranolol ($1 \mu\text{M}$) when the tone was raised to $200 \text{ mmH}_2\text{O}$ with histamine. Cromakalim caused variable facilitation of these NANC-mediated relaxations of the trachea. PGS in the presence of atropine ($1 \mu\text{M}$), propranolol ($1 \mu\text{M}$) and histamine did not induce a relaxant response of the trachea, indicating that
TMS + Glib	102.0 ± 68.1	76.7 ± 54.5	$25.1 \pm 4.5^{\text{b}}$	
PGS	158.0 ± 45.3	102.0 ± 29.4	$65.0 \pm 1.0^{\text{a,c}}$	
PGS + Glib	126.7 ± 27.9	83.6 ± 21.0	$34.5 \pm 6.0^{\text{c}}$	
Mean \pm sem, n = 5 a,b,c - P < 0.005				

NANCergic fibres enter the trachea below the cervical vagal nerve trunk.

These results suggest that cromakalim inhibits transmission both at the ganglionic synapse and at the final terminals of pulmonary cholinergic nerves, and a proportion of the K⁺ channels involved appear to be ATP-sensitive. Cromakalim, however, causes facilitation of NANC-mediated relaxations. In contrast, pulmonary noradrenergic nerves are unaffected (Pendry & MacLagan, 1990).

We are grateful for the financial support of Rhône-Poulenc Ltd. UK and to Beechams for the gifts of cromakalim and lemakalim.

Hall, A.K., & MacLagan, J.(1988). *Br. J. Pharmacol.* 95:792P.

McCaig, D.J. & Dejonkeere, B. (1989). *Br. J. Pharmacol.* 98, 662-668.

Pendry, Y.D. & MacLagan, J. (1990). In Press.

COMPARISON OF THE BRONCHODILATOR PROPERTIES OF RO 31-6930, LEMAKALIM AND SALMETEROL IN THE GUINEA-PIG

P.M. Paciorek, I.S. Cowlick, A.M. Spence, J.C. Taylor & J.F. Waterfall, Dept. Biology, Roche Products Ltd., Welwyn Garden City, Herts AL7 3AY.

Ro 31-6930 2-(6-cyano-2,2-dimethyl-2H-1-benzopyran-4-yl)pyridine-1-oxide is a potassium channel opener with bronchodilator properties (Paciorek et al., 1989). The aim of this study was to further evaluate the bronchodilator properties of Ro 31-6930, in comparison with lemakalim (Arch et al., 1988) and salmeterol (Bradshaw et al., 1987) following i.v. and inhaled administration in the guinea pig.

Guinea pigs were anaesthetised with urethane (1.75 g kg⁻¹ i.p.). Drugs were administered via a jugular vein and mean arterial pressure (MAP) measured from a carotid artery. Animals were respired with air (10 ml kg⁻¹ body weight: 55 min⁻¹), and pulmonary inflation pressure (PIP) was measured from a side arm of the tracheal cannula. Bronchoconstriction was evoked by \approx ED₆₅ doses of 5-HT (2-20 μ g kg⁻¹ i.v.) or by construction of dose response curves to 5-HT (1-300 μ g kg⁻¹ i.v.). Test agents were administered cumulatively i.v. or by inhalation from a DeVilbiss ultrasonic nebulizer via the tracheal cannula. In a separate series of experiments lung resistance (R_L) and dynamic lung compliance (C_{dyn}) were measured using a Buxco model 6 Pulmonary Analyser. A submaximal dose of 5-HT (2-20 μ g kg⁻¹ i.v.) which increased R_L by \approx 250% and decreased C_{dyn} by \approx 70% was determined. Test agents were then administered cumulatively i.v. 10 min prior to each 5-HT challenge. Values presented are mean \pm s.e. mean, n = 4-5.

Ro 31-6930, lemakalim and salmeterol evoked dose related inhibition of the submaximal increases in PIP with ID₅₀ values of 36.8 \pm 11.1, 169 \pm 44.0 and 7.6 \pm 2.9 μ g kg⁻¹ i.v. respectively. Inhaled Ro 31-6930 (0.1, 0.3 and 1.0 mg ml⁻¹; 2 min) lemakalim (0.3 and 1.0 mg ml⁻¹ 2 min) and salmeterol (0.03 and 0.1 mg ml⁻¹; 2 min) evoked dose related inhibition of the response curve to 5-HT which was most marked following the lowest doses of 5-HT (43.2-100%) and least at the highest doses of 5-HT (15.9-75.3%). Mean pre-inhalation MAP was 30.6 \pm 1.2 mmHg (n = 28). Ro 31-6930 reduced MAP by 7.9 \pm 1.2, 7.6 \pm 1.7 and 5.4 \pm 1.5 mmHg and lemakalim by 7.1 \pm 1.2 and 7.2 \pm 2.4 mmHg respectively. Ro 31-6930, lemakalim and salmeterol evoked dose related inhibition of the effects of 5-HT on R_L and C_{dyn} (ID₅₀ values: 7.4 \pm 1.5 and 14.2 \pm 3.7; 103.4 \pm 25.6 and 157.8 \pm 33.6; 4.2 \pm 1.9 and 4.9 \pm 2.0 μ g kg⁻¹ i.v. respectively).

Ro 31-6930 is a potent bronchodilator which is effective by both the i.v. route and by inhalation.

Arch, J.R.S., Buckle, D.R., Bumstead, J., Clarke, G.D. & Taylor, J.F. (1988) Br.J.Pharmacol. 95, 763-770. Bradshaw, J., Brittain, R.T., Coleman, R.A., Jack, D., Kennedy, I., Lunts, L.H.C. & Skidmore, I.F. (1987) Br.J.Pharmacol. 92, 590P.

Paciorek, P.M., Cowlick, I.S., Perkins, R.S., Taylor, J.C. & Waterfall, J.F. (1989) Br.J.Pharmacol. 98, 720P

COMPARATIVE EFFECTS OF ENDOTHELIN-1 AND LEUKOTRIENE D₄ ON HUMAN AND GUINEA-PIG AIRWAY PREPARATIONS

D.M.Conroy,* M.N. Samhoun and P.J. Piper, Department of Pharmacology, Royal College of Surgeons, London WC2.

Endothelin-1 (ET-1) is a newly isolated 21-amino acid peptide with potent vasoconstrictor and bronchoconstrictor properties (Yanagisawa et al. 1988). Although the possible role of this peptide in physiological and pathological processes is unknown, its presence in bronchial epithelial cells suggests that ET-1 could affect adjacent bronchial smooth muscle tone. In the present study we have compared the effects of ET-1 with those of leukotriene (LT)D₄ on strips of guinea-pig lung parenchyma (GPP), human lung parenchyma (HLP) and human bronchi (HBr).

GPP were prepared from the major lobes of lungs from male Dunkin-Hartley guinea pigs and HLP and HBr from human lung tissue. The tissues were superfused in series in a cascade system with Tyrode solution (5ml/min) at 37°C. LTD₄ and ET-1 were administered as bolus injections. FPL 55712 (1.9 μ M), indomethacin (2.8 μ M), WEB 2086 (10nM) and a mixture of antagonists to ACh, histamine, 5-HT and α - and β -adrenoceptors were given as a continuous infusion. In addition GPP were also used in conventional organ baths. Following stimulation with LTD₄ and ET-1 the bath fluids were assayed for TxB₂ and 6-keto-PGF_{1 α} by RIA.

ET-1 (10-1000 pmol) induced dose-related contractions of GPP and was approximately 10-30 times less active than LTD₄ (1-30 pmol). The contractile response elicited by ET-1 had a long duration of action and was unaffected by antagonists to ACh, histamine, 5-HT, PAF and LTD₄. However these responses were attenuated in the presence of indomethacin. In organ bath, equiactive doses of ET-1 (100nM) and LTD₄ (1nM), induced the release of 303 \pm 51 and 1171 \pm 131 pg/ml TxB₂ and 75 \pm 23 and 237 \pm 35 pg/ml 6-keto-PGF_{1 α} respectively. The release of both cyclooxygenase products was completely inhibited by indomethacin. ET-1 (10-300 pmol) also contracted HLP and was approximately 10 times more active than LTD₄ on this preparation. In contrast this peptide was less active than LTD₄ on HBr. The action of ET-1 on both preparations of human airways was not inhibited by indomethacin.

These results show that ET-1 causes a long lasting contraction of GPP which is mediated in part by the release of TxB₂, as has been previously shown for LTD₄. In contrast the action of ET-1 on both HLP and HBr was not mediated by the release of cyclooxygenase products and like LTD₄, appears to be a direct effect on both vascular and bronchial smooth muscle in these preparations.

We wish to thank the Frances and Augustus Newman Foundation for financial support.

Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, M., Kobayashi, Y., Mitsui, Y., Yazaki, Y., Goto K. and Masaki T. (1988) Nature 332, 411-415

DOSE-RELATED EFFECTS OF ALPHA, BETA-METHYLENE ATP ON CANINE NASAL VASCULAR AND AIRWAY RESISTANCES

J.C.C. Wang & M.A. Lung (introduced by C.W. Ogle), Department of Physiology, Faculty of Medicine, University of Hong Kong, Hong Kong.

Sympathetic stimulation contracts nasal venous vessels via some non-adrenergic and non-cholinergic mechanisms (Lung & Wang, 1989). ATP has been shown to act as a co-transmitter in sympathetic neuro-transmission (Burnstock & Warland, 1987). This study demonstrates the action of alpha beta-methylene ATP, a potent P_{2x}-purinoceptor activator, on the nasal vascular and airway resistances.

In sodium pentobarbitone anaesthetized dogs (n=6), nasal vascular resistance (R_{nv}) was measured by constant-flow perfusion of the main artery to the nasal mucosa and nasal airway resistance (R_{na}) by monitoring the transnasal airway pressure with constant airflow through the nasal cavities. Alpha, beta-methylene ATP was infused intra-arterially via the perfusion circuit at the rate of 0.1 ml min⁻¹.

Table 1

Doses of drug (ug kg ⁻¹ min ⁻¹)	R _{nv} (% change)	R _{na} (% change)
0.05	+2±1.2	-2±1.1
0.5	+18±4.3*	-12±3.2*
5	+40±4.7*	-24±3.8*
50	+50±4.6*	-28±4.5*

Results are means±s.e.means of % change from controls. * P < 0.05.

Alpha, beta-methylene ATP increased R_{nv} and decreased R_{na}, suggesting contraction of both arteries and veins. Hence, it seems likely that ATP is involved in the non-adrenergic non-cholinergic sympathetic control of the nasal blood vessels. Supported by HKU Research Grants (335/034/0038 & 378/030/8111/4F).

Burnstock, G. & Warland, J.J.I. (1987). Br. J. Pharmacol. 90, 383-391.

Lung, M.A. & Wang, J.C.C. (1989). J. Physiol. 419, 121-139.

ADENOSINE-INDUCED BRONCHOCONSTRICTION IN THE CONSCIOUS GUINEA-PIG

J.R. Thorne & K.J. Broadley, Department of Pharmacology, Welsh School of Pharmacy, UWCC, PO Box 13, Cardiff CF1 3XF

Bronchoconstrictor responses to adenosine (ADO) have been reported in asthmatic patients (Cushley et al, 1983) and *in vitro* in isolated preparations taken from sensitised guinea-pigs (Thorne & Broadley, 1988, 1990). This study investigates the *in vivo* effects of ADO in normal and sensitised conscious guinea-pigs measured using a whole body plethysmographic technique.

Male Dunkin-Hartley guinea-pigs were sensitised to ovalbumen (OA) by ip. injections 14 days (5mg in 0.1ml of water for injections) and 12 days (10mg) before the first exposure to adenosine. Groups of six animals individually inhaled nebulized saline or solutions of carbachol or adenosine in saline for 1 min. Immediately afterwards, specific airways conductance (sGaw) was measured by constant volume plethysmography (Griffiths-Johnson et al. 1988).

In control (untreated) animals, saline caused an increase in sGaw peaking at 27±7% at 5 min. ADO (1mg/ml) caused a greater increase in sGaw of 34.8±8% at a 15 min peak, suggesting bronchodilatation, which remained elevated after 90 min. A similar effect was observed when repeated after 7 days. Carbachol (0.02mg/ml) caused a decrease in sGaw, indicative of bronchoconstriction. The peak reduction (18±5%) occurred after 5 min and returned to baseline after 60 min. This constriction was slightly reduced when repeated a week later.

In sensitized guinea-pigs, ADO (1mg/ml) induced a bronchoconstriction, the peak reduction of sGaw occurring (24±4%) after 15 min. The degree of bronchoconstriction was no greater when exposed to a higher concentration (3mg/ml) of adenosine (sGaw reduced by 18±5% after 15 min). Both doses induced similar responses when repeated 7 days later indicating that the tachyphylaxis demonstrated *in vitro* (Thorne & Broadley, 1988) was reversed within 7 days.

These results demonstrate that an ADO-induced bronchoconstriction may be observed *in vivo*, like *in vitro*, by prior sensitisation with ovalbumen.

Cushley, M.J., Tattersfield, A.E. & Holgate, S.T. (1983) Br. J. Clin. Pharmacol. 15, 161

Griffiths-Johnson, D.A., Nicholls, P.J. & McDermott, M. (1988) J. Pharmacol. Methods 19, 233-242

Thorne, J.R. & Broadley, K.J. (1988) Br. J. Pharmacol. 93, 278P

Thorne, J.R. & Broadley, K.J. (1990) Br. J. Pharmacol. 99, 185P.

D.J. Prentice¹ & J.W. Black, Analytical pharmacology unit, Rayne Institute, Kings College Hospital, London, SE5.

Most adenosine receptor antagonists are xanthine derivatives, many are also cyclic nucleotide phosphodiesterase inhibitors. Adenosine receptor antagonists based upon the structure of the natural ligand, 7-deazo-9-phenyladenines, have been shown in binding studies to have low affinities at both A₁ and A₂ receptors (Daly *et al* 1988a) and N⁶-substituted 9-methyladenines have also previously been investigated to a limited extent (Daly *et al* 1988b). N⁶-substitution enhanced affinity for the A₁ receptor. We have studied the effects of a series of N⁶-substituted 9-methyladenines upon responses elicited by 5' (N-ethyl)carboxamidoadenosine (NECA) in guinea pig left atrium (A₁-receptor assay) and guinea pig taenia caecum (A₂-receptor assay). The unsubstituted compound had no affinity for either the A₁ or the A₂ receptor, however all of the N⁶-substituted compounds behaved as simple competitive antagonists at the A₁ receptor and exhibited selectivity for this site. A pK_B value of 5.26±0.10 (Schild slope=1.15±0.18) was estimated for the pentyl substituted compound N-0837 (N⁶-(3-pentyl)-9-methyl adenine) and this compound was shown to interact with 8-phenyltheophylline in a manner consistent with simple competition indicating that both compounds act at the same site. The most potent compounds in the series were N⁶-(endo-2-norbornyl)-9-methyl adenine (N-0861: pK_B= 6.28±0.09 Schild plot slope=1.09±0.07) and N⁶-cyclopentyl-9-methyl adenine (N-0840: pK_B=6.17±0.11 Schild plot slope=0.95±0.08). These compounds were inactive in the A₂-receptor assay at 30 and 100μM respectively. For comparison, 1,3-dipropyl, 8-cyclopentylxanthine (DPCPX) was found to have a pK_B of 8.61 in the A₁-receptor assay. However, in the A₂-receptor assay DPCPX produced a complex mixture of antagonism and potentiation. A pA₂ of 6.8 was estimated indicating an A₁/A₂ selectivity of about 60-fold. Therefore, although of lower affinity than DPCPX, the N⁶-substituted compounds are more A₁ selective and should be useful probes in the classification of adenosine receptors.

¹Present address: Analytical pharmacology group, Biochemical Sciences, Wellcome Res. labs., Beckenham, Kent, BR3 3BS.

This work was funded by Whitby Inc., Irvine, USA.

Daly, J.W., Padgett, W.L. & Eger, K. (1988a) *Biochem. Pharmacol.* **37** 3749-3753.

Daly, J.W., Hong, O., Padgett, W.L., Shamim, M.T., Jacobson, K.A. & Ukena, D. (1988b) *Biochem. Pharmacol.* **37** 655-664.

Alyami, A.M., Patel, I.A. and Wood, D., Postgraduate Studies in Pharmacology, School of Pharmacy, University of Bradford, Bradford, West Yorkshire, BD7 1DP

γ-aminobutyric acid (GABA) and muscimol cause a transient contraction of ileum which is antagonised by bicuculline, tetrodotoxin and atropine, suggesting an action on GABA_A receptors to release acetylcholine from cholinergic nerves (Kerr & Ong, 1986). When investigating this GABA-mediated contraction, we noted that it could be inhibited by a preceding period of electrical field stimulation (EFS) and here we describe some of the characteristics of this inhibition.

Segments of guinea-pig ileum were suspended in Krebs Henseleit solution (37°C, 95% O₂/5% CO₂). Consistent submaximal isometric contractions were elicited in response to applications of GABA (0.1mM). Tissues were then subjected to EFS (0.1Hz, 0.2msec, supramaximal voltage) for 2-40 min and the subsequent (test) responses to GABA (0.1mM) were recorded immediately after stimulation. Periods of EFS of 10-40 min caused significant inhibition of GABA contractions (n = 8), the extent of the inhibition increasing with increasing periods of EFS. After 20 and 40 min periods of EFS, test responses to GABA were 52±3% and 12±2% respectively of control responses. Test responses to GABA were not inhibited by a 2 min period of EFS, or by a 2-40 min EFS-free interval between control and test response, or when tissues were washed between the period of EFS and the application of the test dose of GABA. A 20 min period of EFS caused similar and significant inhibition over the entire concentration-response curve for GABA (0.01-1mM, n = 6). Increasing the frequency of EFS (0.2, 0.4Hz) significantly, and in a frequency-dependent manner, increased the inhibition of submaximal GABA responses observed with all periods of EFS: a 20 min period of EFS at 0.4Hz virtually abolished the subsequent response to GABA (0.1mM) (n = 4).

To establish whether this phenomenon of EFS-provoked inhibition was specific for GABA responses, experiments were conducted where submaximal control and test responses to muscimol, acetylcholine, dimethyl 4-phenylpiperazinium iodide, nicotine, 5-hydroxytryptamine, histamine and KCl were examined (n ≥ 6). EFS inhibited test responses to muscimol and to GABA similarly, but was without effect on responses to the other agents. Antagonists or synthesis inhibitors for a range of putative neurotransmitters or modulators were unable to protect the responses to GABA from the inhibitory influence of EFS (n ≥ 6, equilibration period 20 min). Agents used included theophylline, naloxone, indomethacin, propranolol, prazosin, yohimbine, methysergide, ritanserin, ascorbic acid, glutathione, catalase and superoxide dismutase.

The results suggest that EFS of guinea-pig ileum releases a substance or initiates a process which selectively inhibits GABA_A-receptor mediated contractions. The effect is time- and frequency-dependent, is reversed by washing and is not susceptible to a range of antagonists for putative neurotransmitters or modulators.

Kerr, D.I.B. and Ong, J. (1986) in *GABAergic Mechanisms in the Mammalian Periphery*, eds Erdö, S.L. & Bowery, N.G., pp 153-174, New York, Raven Press

DIFFERENCES IN THE MECHANISMS OF ACTION BETWEEN EXEPANOL AND 5-HT₃ AND 5-HT₄ RECEPTOR AGONISTS TO CAUSE CONTRACTIONS IN THE GUINEA-PIG ILEUM

J.M. Barnes, D.M. Ellender & R.J. Naylor, Postgraduate Studies in Pharmacology, School of Pharmacy, University of Bradford, Bradford, BD7 1DP

Exepanol is a benzoxepine derivative that can facilitate muscle contraction in the oesophagus and other regions of the gastrointestinal system (Wolf, 1985). Its mechanism of action is not known and in the present study we investigate a 5-HT₃/5-HT₄ receptor involvement.

Isolated ileal segments (2cm) (taken approximately 9cm from the ileo-caecal junction) from female guinea pigs (Dunkin-Hartley, 250-500g) were suspended under 1g tension in oxygenated (95% O₂/5% CO₂) Krebs-Henseleit solution routinely containing methysergide (1μM). A 50mM potassium solution was administered for 3 min, washed out and the tissues allowed to equilibrate for 1 hour; 2 bolus doses of 5-hydroxytryptamine (5-HT) (10⁻⁶M) were then added 15 min apart before the non-cumulative concentration response curves to agonist drugs were established using a 1 min contact time and an 11 min dose cycle. All experiments were repeated at least once using 4 tissues per experiment.

The administration of the 5-HT₃ receptor agonist 2-methyl-5-HT (10⁻⁷-10⁻⁵M) caused concentration related contraction responses (maximum changes in tissue tension 1.8-2.5g). Following the work of Craig & Clarke (1990), the prior (30 min) and continuing exposure of tissues to a bathing solution containing 2-methyl-5-HT (10⁻⁵M) abolished the contraction responses to subsequent challenge with 2-methyl-5-HT (10⁻⁷-10⁻³M); responses to exepanol (10⁻⁷-10⁻⁴M) and renzapride (10⁻⁷-10⁻⁵M) were not antagonised. In subsequent experiments using Krebs-Henseleit solution containing methysergide (1μM) and the 5-HT₃ receptor antagonist ondansetron (5μM), the administration of the 5-HT₄ receptor agonist 5-methoxytryptamine (5-MOT) (10⁻⁷-10⁻⁵M) caused concentration related contraction responses (maximum changes in tissue tension 1.3-1.4g). Desensitisation of the 5-HT₄ receptors using a high concentration of 5-MOT (10⁻⁵M) prior to (30 min) and a continuing exposure, antagonised the contractions induced by 5-MOT (10⁻⁷-10⁻³M) and renzapride (10⁻⁷-10⁻⁵M) but not exepanol (10⁻⁷-10⁻⁴M). The 5-HT₃ and 5-HT₄ receptor antagonist ICS 205-930 (10μM) antagonised the contractions induced by renzapride and 5-HT but not by exepanol.

Selective 5-HT₃ or 5-HT₄ receptor desensitisation or blockade antagonised the contractions induced by 5-HT₃ and 5-HT₄ receptor agonists respectively, but all such treatments failed to modify the contractions induced by exepanol. It is concluded that exepanol does not mediate its effects via a 5-HT₃ or 5-HT₄ receptor mechanism in the guinea pig ileum.

Craig, D.A. & Clarke, D.E. (1990) Br. J. Pharmacol. 99, 215P

Wolf, K.-U. (1985) Drug Res. 35, 1, 136-137

RELAXANT EFFECTS OF PINACIDIL ON THE LONGITUDINAL MUSCLE OF THE RAT ILEUM

Davies, M.P., McCurrie, J.R. and Wood, D., Postgraduate Studies in Pharmacology, School of Pharmacy, University of Bradford, Bradford, West Yorkshire, BD7 1DP

The potassium channel opening agents have been shown to cause relaxation in various smooth muscle preparations, particularly vascular (Hamilton and Weston, 1989). In the present study we investigated the relaxant effects on rat ileum of pinacidil, as a representative of this group of agents, and the antagonism of the relaxation by tetraethylammonium (TEA) and glibenclamide (GBC).

Longitudinal muscle-myenteric plexus preparations were derived from the distal ileum of male rats and suspended under 1g tension in Krebs' solution (37°C, 95% O₂/5% CO₂). Following equilibration, isometric contractions were elicited in response to 20mM KCl (approximately 75% E_{max}). At the plateau of contraction, pinacidil (PIN, 0.1-13μM) or vehicle was applied cumulatively. Relaxation was expressed as % reversal of the initial contraction. The procedure was repeated following incubation of the tissue for 20 minutes with a single concentration of TEA (0.3-3mM) or GBC (30nM-3μM) or antagonist vehicle.

PIN produced a concentration dependent relaxation, complete reversal of contraction occurring with higher concentrations. The apparent IC₅₀ value was 0.9±0.09μM (n = 15) when the vehicle for PIN was ethanol/water and 1.02±0.11μM (n = 5) when the vehicle was 0.5M HCl. However, it was noted that tissues exposed to vehicle alone relaxed during the experiment. Both TEA and GBC caused parallel rightward shifts of the PIN concentration-response curve whilst having no effect on the action of the vehicle. The apparent pA₂ values were 2.92±0.5 (n = 13) for TEA and 6.86±0.18 (n = 14) for GBC (mean ± 95% confidence limits). GBC was without direct effect on the tissue while TEA caused a small increase in baseline tension which was concentration dependent, the highest concentration of TEA (3mM) causing an increase <20% of the KCl contraction. To ascertain whether this contractile effect could offset the action of PIN in a non-specific manner, theophylline (6.4-800μM) was used to relax KCl contractions: TEA was without antagonist effect (n = 5).

Contractile responses to electrical field stimulation (0.1Hz, 5msec pulse width, supramaximal voltage) were reduced in a concentration-dependent manner by PIN (0.1-13μM). Higher concentrations of PIN virtually abolished responses to stimulation: the vehicle (ethanol/water) was without effect. The IC₅₀ for PIN in these experiments was 1.17±0.16μM (n = 6).

The IC₅₀ values reported here for PIN are comparable with those quoted for other smooth muscles and indicate no marked difference in potency to inhibit nerve-mediated or direct muscle responses in intestinal muscle. Similarly the antagonist potencies for TEA and GBC are comparable to those reported for other types of smooth muscle (Cavero *et al.*, 1989; Wilson *et al.*, 1988).

Cavero, I., Mondot, S. & Mestre, M. (1989) J. Pharmacol. Exp. Ther. 248 (3), 1261-8

Hamilton, T.C. & Weston, A.H. (1989) Gen. Pharmac. 20 (1), 1-9

Wilson, C., Coldwell, M.C., Howlett, D.R., Cooper, S.M. & Hamilton, T.C. (1988) Eur. J. Pharmac. 152, 331-39

AN EXAMINATION OF THE CONTRIBUTION MADE BY THE CONSTITUENTS OF PEPPERMINT OIL (PO) TO THE RELAXATION OF GASTROINTESTINAL SMOOTH MUSCLE

J.M. Hills, H.J. Potts, B.A. Carlin and M.E. Parsons, Smith Kline & French Research Limited, The Frythe, Welwyn, Hertfordshire, AL6 9AR, U.K.

Peppermint oil (PO) is used in the therapy of Irritable Bowel Syndrome. The efficacy of this natural substance is attributed to its ability to reduce muscle spasm and the constituent thought to be responsible for this action is menthol. While menthol is present in PO, and relaxes gut smooth muscle *in vitro* (Taylor et al., 1984), many of the other constituents of PO have not been tested. Here we have examined the activity of PO in the guinea-pig taenia coli (gptc) and guinea-pig colon, and have investigated the activity of most of the known constituents of PO in the (gptc). Male guinea-pigs (250–400g) were killed, and either taenia-coli or proximal colon removed into Krebs. Preparations were mounted in organ baths containing Krebs solution, gassed with 5% O₂/95% CO₂. The taenia and colon preparations were suspended under 1 and 2g isometric tension respectively. Taenia relaxations were assessed as the % inhibition of carbachol (100–300nM) contractions and colon relaxations as % inhibition of spontaneous contraction frequency and mean amplitude. PO relaxed the taenia in a concentration dependent manner (IC₅₀ 22.1 µg/ml). At IC₅₀ concentrations, the relaxation persisted for at least 20 mins. PO also inhibited spontaneous activity in the colon. Mean contraction amplitude (IC₅₀ 30.7 µg/ml) was inhibited more readily than contraction frequency (IC₅₀ 84.6 µg/ml).

Table 1	Constituent	IC ₅₀ gptc relax. Mean±SEM (µM) (n=4)	Approx. amount in PO
	Jasmone	4.2 ± 0.5	<0.1%
	3-octanol	24.9 ± 3.1	2.0%
	neomenthol	88.1 ± 32	6.0%
	pulegone	105.0 ± 18	0.9%
	isomenthone	125.0 ± 18	9.0%
	menthol	154.0 ± 24	43.0%
	cineole	237.0 ± 41	3.0%
	menthone	473.0 ± 1–3	19.0%
	menthyl acetate	696.0 ± 220	4.0%
	(-)-limonene	>1000	
	(+)-limonene	>1000	1.0%

When the relative potencies of the constituents of PO (Table 1) are considered with the data on the proportion of the constituents present, it appears that menthol, due to its abundance in the oil, is likely to be the constituent responsible for much of the relaxant activity. This observation therefore supports the previously held suggestion that menthol is the active ingredient of PO (Taylor et al., 1985).

Taylor, B.A., Luscombe, D.K. and Duthie, H.L. (1984), Br. J. Surg. 71, 385.

Taylor, B.A., Duthie, H.L. and Luscombe, D.K. (1985), J. Pharm. Pharmacol., 37, 104P.

A METHOD FOR DETERMINING BLADDER OR GUT SELECTIVITY AND POTENCY OF ANTIMUSCARINIC COMPOUNDS IN THE CONSCIOUS MOUSE

S. Broadbent, P. O. Andersson, A. J. Carter, W. W. Keighley and M. G. Wyllie, Pfizer Central Research, Sandwich, Kent, CT13 9NJ.

Antimuscarinic agents showing selective receptor interaction for the urinary bladder over other systems (eg. gut, salivary glands, CNS) may have a potential use in urinary incontinence. We report here a procedure for testing the effects of compounds on the urinary tract and gastro-intestinal function in the conscious animal.

Male, Albino, CD1 mice (25–27g) starved for four hours prior to the experiment, received 0.5ml charcoal suspension orally (2% charcoal in 0.5% gum tragacanth in distilled water) and an i.v. injection (tail vein) of 0.2ml compound or vehicle. Twenty minutes after dosing, the mice were killed by cervical dislocation, a laparotomy performed and the bladder was removed and weighed. The gut was removed and the distance travelled by the charcoal measured. The endpoint for an effect on bladder was urinary retention (Tita et al, 1988) and data are presented as the dose producing 50% of the maximal attainable increase in weight of bladder plus contents (200mg). Impairment of gut motility was measured as a reduction in charcoal transit (ED₅₀ = 50% reduction). Table 1 shows the effects of a range of antimuscarinic compounds in this model.

All compounds with the exception of dicyclomine and secoverine display bladder versus ileum selectivity which is consistent with radioligand binding studies (³H-QNB; [Nilvebrandt and Sparf, 1983]). However, secoverine was more active on the gut than the bladder *in vivo*. Further, dicyclomine actually caused slight gastro-intestinal stimulation. The apparent divergence of functional and radioligand binding data for these agents might be due to either pharmacokinetics or affinity for muscarinic receptor subtypes. It remains, however, that the model described here can be used for the simultaneous assessment of muscarinic antagonists on gastrointestinal and urogenital function and might thus be useful in the search for tissue-selective antimuscarinic agents.

Table 1	BLADDER ED ₅₀ (mg/kg)	GUT ED ₅₀ (mg/kg)
ATROPINE	0.26	3.0
PIRENZEPINE	2.0	>10
4-DAMP	0.9	>5
PROPANTHELINE	0.11	4.0
DICYCLOMINE	2.6	stimulation
SECOVERINE	>10	3.5

Nilvebrandt, L. & Sparf, B. (1983) Acta. Pharmacol. Toxicol. 53, 304–313.

Tita, B. Bolle, P. Mazzanti, G & Silvestrini, B (1988) Pharmacol. Res. Commun. 20, Suppl 2,44.

INFLUENCE OF NON-SMOOTH MUSCLE ELEMENTS ON BRADYKININ-INDUCED CONTRACTIONS OF GUINEA-PIG GALLBLADDER *IN VITRO*

A.W. Baird, Department of Pharmacology, University College Dublin, Dublin 4, Ireland.

Bradykinin (BK) stimulates bicarbonate secretion by guinea pig isolated gallbladder and is more potent when applied mucosally than serosally (Baird & Margolius, 1989). This suggests a principal site of action of BK in the epithelial layer. The aim of this study is to determine the effect of epithelium removal on contractile responses of gallbladder smooth muscle to BK and to other agonists. Furthermore, since BK is known to stimulate sensory nerve endings in gallbladder (Ordway & Longhurst, 1983) the possibility that BK stimulation of gallbladder smooth muscle contraction involves neurons was examined.

Tension was recorded isotonically from gallbladder strips suspended in tissue baths containing Krebs-Henseleit solution gassed with 95% O₂ / 5% CO₂ at 37°C. Matched preparations were obtained from individual female Dunkin-Hartley guinea pigs and the mucosal layer of one of each pair was removed by dissection. Complete separation of smooth muscle and epithelial layers was assessed by histological examination. Drugs were added sequentially to the bathing solution. Differences between groups of results were compared by paired t-test. Full concentration-response curves were obtained for BK, prostaglandin (PG) E₂ and acetylcholine (ACh) in matched pairs of intact and epithelial-denuded strips of gallbladder smooth muscle and EC₅₀ values (μM) were calculated for each agonist.

Table 1.	BK (n=6)	PGE ₂ (n=7)	ACh (n=5)
+EPI	0.34 ± 0.09	0.13 ± 0.05	1.09 ± 0.35
-EPI	0.32 ± 0.11	0.09 ± 0.04	0.96 ± 0.45

EC₅₀ values (mean ± s.e.m.) were not significantly different in intact (+EPI) and epithelial deprived (-EPI) preparations.

In separate experiments to determine whether nerves are involved in the response of intact gallbladder preparations to BK, neurogenic contractile responses were obtained to electrical field stimulation (EFS; 30V., 1ms., 50Hz., for 20s) via platinum field electrodes. The BK antagonist [Thi^{5,8},DPhe⁷]-BK (6μM) which reduced responses to 0.1μM BK by 32.8 ± 8.2% (n=6, P<0.05) did not alter contractions induced by EFS which, in the presence of the antagonist were 108.5 ± 5.6% of control responses. Tetrodotoxin (TTX, 1μM) which reduced the response to EFS by 90.2 ± 3.3% (n=7, P<0.05) had no effect on responses to BK (0.1μM) which, in the presence of TTX were 110.5 ± 11.4% of responses in untreated control tissues (n=7).

The influence of non-smooth muscle components on BK-induced contraction of gallbladder has been studied. Responses to BK were unaffected by epithelial removal suggesting that this peptide, as well as the other agonists, has a direct action on smooth muscle cells which is not detectably altered by mucosal elements. Also, since BK-induced contractions were not affected by TTX and [Thi^{5,8},DPhe⁷]-BK did not alter EFS-induced contractions, it appears unlikely that neurons are involved in this action of BK on gallbladder smooth muscle *in vitro*.

Baird, A.W. & Margolius, H.S. (1989) *J. Pharm. Exp. Ther.* **248**, 268-272.
Ordway, G.A. & Longhurst, J.C. (1983) *Circ. Res.* **52**, 26-35.

EFFECTS OF CIMETIDINE HYDROCHLORIDE ON SUBMANDIBULAR BLOOD FLOW AND SECRETION IN DOGS

M.A. Lung (introduced by C. W. Ogle), Department of Physiology, Faculty of Medicine, University of Hong Kong, Hong Kong.

Little attempt has been made to investigate the action of H₂ antihistaminic drugs on salivary secretion. This study demonstrates the action of cimetidine hydrochloride, a H₂ antihistamine, on the blood flow and secretion of the submandibular gland.

In sodium pentobarbitone anaesthetized dogs (n=6), we measured with electromagnetic and Doppler flow sensors the submandibular arterial inflow (Qa) from the first glandular branch of the facial artery and salivary secretion (Qs) from the submandibular duct (Lung & Wang, 1990). Cimetidine was given intra-arterially, at the rate of 0.1 ml min⁻¹, via a catheter retrogradely inserted into the facial artery.

Table 1

Doses of drug (mg kg ⁻¹ min ⁻¹)	Qa (ml min ⁻¹)	Qs (ml min ⁻¹)
0.25	4.5±0.43	0
0.5	6.0±0.40*	0.1±0.05
2.5	13±1.2*	0.5±0.06*
5	16±1.6*	1.0±0.09*

Results are means ± s.e. means. * P < 0.05, when compared with resting flow.

The resting arterial inflow was 4.0±0.42 ml min⁻¹. Cimetidine infusion caused salivary secretion and an increase in blood flow. Atropine (1 mg, i.a.) abolished the secretory response and significantly weakened the vascular response. Thus, cimetidine, apart from a direct vasodilatory action, induces salivary secretion and vasodilatation via a cholinergic mechanism.

Supported by HKU Research Grants (337/034/0011 & 377/030/7840). Cimetidine hydrochloride was a gift from SK&F Research Ltd.

Lung, M.A. & Wang, J.C.C. (1990). *J. Physiol.* **422**, 80P.

ADENOSINE INHIBITS ACID PRODUCTION BY HUMAN ISOLATED PARIETAL CELLS

S. England^{*}, M.J. Daly¹, S. Jacob, K.D. Bardhan², Department of Biomedical Science, University of Sheffield, Western Bank, Sheffield S10 2TN, ¹Astra Clinical Research Unit, 10 York Place, Edinburgh EH1 3EP, and ²District General Hospital, Moorgate Road, Rotherham S60 2UD.

Pharmacological studies have shown that adenosine (Aden) can exhibit both stimulatory and inhibitory effects. In a human glioma cell line, Aden stimulated adenylate cyclase (Clark & Seney, 1976), yet inhibited cAMP formation in human sub-cutaneous adipocytes (Ohisalo et al, 1983). These effects are mediated via stimulatory (Ra/A₂) and inhibitory (Ri/A₁) receptors respectively. The present study has investigated the effect of Aden on human isolated parietal cells (PC).

Biopsies were taken from the gastric fundus of patients during routine endoscopy. Approximately 50mg of pooled tissue was collected from three or four subjects. Exclusion criteria were age >60 years, overt inflammation of the mucosa, tumour, and medication with proton-pump inhibitors. All drug treatment was suspended at least 14 hours prior to examination. A PC suspension (17% PC) was prepared following sequential pronase and collagenase digestion and filtration. Cells showed >85% viability by trypan blue. Cell suspensions (300ul total volume) were incubated for 140 mins in 96 well microtitre filtration plates (Millipore) and maintained in an oxygenated and heated (37°C) chamber. The [¹⁴C] aminopyrine uptake (APU) technique was used as an index of acid production by the PC. The incubation was terminated by simultaneous vacuum filtration of the wells, and APU assessed by scintillation counting of the filters upon which the cells were sedimented.

Histamine (10nM-100uM) stimulated APU in a concentration-dependent manner (EC₅₀ 2.4uM, max response 56.8 ± 10.3% increase over basal. Mean ± s.e.mean, n=6). Aden (10,100uM, 1mM) inhibited the maximum response to histamine by 24.5%, 33.7% and 43.1% respectively. Downward displacement of the curve suggested non-competitive antagonism. Theophylline (Theo), a non-specific Aden receptor antagonist, was without effect on basal or histamine-stimulated (10uM) APU. However, Theo (100nM-100uM) antagonised the inhibitory response to 1mM Aden on maximally-stimulated APU (100uM histamine). Dipyridamole (10,100uM) and 2-deoxyaden (10nM-10uM), Aden uptake inhibitor, and P-site agonist respectively, were without effect on basal or stimulated cells.

In conclusion, adenosine has been shown to inhibit histamine-stimulated APU in human isolated PC. Theophylline overcame the inhibition by adenosine. This effect appeared to be independent of phosphodiesterase inhibition since theophylline alone did not alter APU. It is suggested that adenosine inhibits acid production by human isolated PC by interaction at a specific Ri adenosine receptor.

Clark, R.B. & Seney, M.N. (1976) J. Biol. Chem. 251, 4239-4246

Ohisalo, J.J., Ranta, S., Huhtaniemi, I.T. (1983) J. Clin. Endocrin. Metab. 58, 32-35

COMMUNICATIONS

The author who intended to present the work
is indicated by an asterisk (*)

- 494P **Smith K & O'Boyle KM*** Post-natal changes in D-2 dopamine receptors in rat and post-mortem human brain.
- 495P **Dexter DO*, Wells FR, Javoy-Agid F, Agid Y, Daniels SE, Marsden CD & Jenner P** No alterations in brain iron, copper, manganese or zinc levels in presymptomatic Parkinson's disease
- 496P **Attwell PJE, Rose S*, Jenner P & Marsden CD** Effect of carbidopa dose on pharmacokinetic and metabolic handling of an oral bolus of L-DOPA in rats
- 497P **Taberner PV* & Watson CJ** Effects of chronic ethanol consumption on GABA_B mediated responses in the isolated mouse vas deferens
- 498P **Frow H, Whittington MA & Little HJ*** Changes in long term potentiation in hippocampal slices following chronic barbitol treatment
- 499P **Donaghy K* & Scholfield CN** Adenosine enhances recovery of synaptic transmission in rat hippocampus after anoxia
- 500P **Bagetta G* & Constanti A** Carbachol-induced suppression of the N-wave in guinea-pig olfactory cortex slices: weak antagonism by M₃-selective muscarinic antagonists, HHSiD and p-F-HHSiD
- 501P **Berrie CP* & Elliott AC** The phorbol ester TPA inhibits muscarinic responses in rat lacrimal acinar cells but not in rabbit salivary acinar cells
- 502P **Waterfall AH*, Clarke RW & Bennett GW** The development of microdialysis for the measurement of thyrotrophin-releasing hormone in rat brain *in vivo*
- 503P **Cowell AM*, Loxley HD & Buckingham JC** *In vitro* studies on the mechanisms by which cytokines activate the hypothalamal-pituitary-adrenal axis
- 504P **Nally JE*, Guild SB & Muir TC** Phosphatidyl choline metabolism and contraction in arteriolar smooth muscle
- 505P **McHale NG*, Harty HR & Thornbury KD** Post-synaptic α -adrenoceptors do not mediate the response to field stimulation in sheep mesenteric lymphatic vessels
- 506P **Fuglsang A*, Pollock D & Stone TW** Functional evidence for the existence of postsynaptic α_2 adrenoceptors in the rat isolated tail artery
- 507P **Dainty IA*, Steptoe JE, O'Connor SE & Leff P** Is 2-methylthio-ATP an appropriate tool for the identification of P_{2Y}-purinoceptors?
- 508P **Antunes E, Marangoni RA, Borges NCC, Fontana MD & de Nucci G*** Pharmacological profile of *phoneutria nigriventer* venom on rabbit vascular smooth muscle
- 509P **Huang YT*, Hamilton CA, Howie CA & Reid JL** Responses to endothelin in hypertensive rabbits
- 510P **D'Orleans-Juste*, Lidbury PS, Capper SJ, Warner TD & Vane JR** Exogenous human big endothelin is converted to endothelin-1 in the rabbit *in vivo*
- 511P **Ridley PD*, Yacoub MH & Curtis MJ** Membrane permeability is a determinant of arrhythmogenesis following anion substitution
- 512P **Marshall KG*, Albano JDM & Waller DG** The effect of dopamine on kinin release from rat and human isolated renal cortical cells
- 513P **McGlynn H* & Ryan MP** Gentamicin nephrotoxicity in primary rat renal proximal tubular cells
- 514P **McGuinness S* & Ryan MP** Investigation of cisplatin toxicity in rat renal proximal tubular fragments
- 515P **Cheetham SC*, Viggers JA, Slater NA & Buckett WR.** Inhibition of [³H]-paroxetine binding by sibutramine, its metabolites and other antidepressants correlates with inhibition of [³H]-5-HT uptake
- 516P **Moulton B & Morinan A*** The effect of RS-30199 on anxiety and hippocampal monoamine oxidase activity in the rat
- 517P **Barrett RP* & Rowan MJ** Low dose interaction of the 5-HT_{1A} ligand gepirone with atropine on spatial learning in the rat
- 518P **Redfern WS* & Williams A** Anxiogenic effects are associated with yohimbine but not with RS-15385-197 or idazoxan in the rat
- 519P **Lawrence AJ* & Marsden CA** The effect of systemic 5-carboxamidotryptamine on extracellular levels of 5-HT in the freely moving guinea-pig
- 520P **Shepherd S*, Jordan D & Ramage AG** Action of some tryptamine analogues that are agonists at 5-HT₁ receptors on central autonomic outflow in anaesthetized cats
- 521P **Barradas MA*, O'Donoghue S & Mikhailidis DP** Shape changes: a novel method for assessing the effect of agonists and antagonists on human platelets?

- 522P **Jones RL* & Wilson NH** An EP₃-receptor may mediate prostaglandin E-induced potentiation of aggregation in human platelets
- 523P **Faller D*, Higgins G & Ryan MP** Chloride transport in human placental brush border membrane vesicles
- 524P **Keen M*, Pickering SAW & Hunt JA** Modulation of the bradykinin-stimulated release of prostacyclin from endothelial cells
- 525P **Hunt JA* & Keen M** A comparison of the thromboxane receptor ligands [¹²⁵I]-PTAOH and [³H]-SQ29548 binding in cultured bovine aortic endothelial cells
- 526P **Rabe K*, Glembycz MA, Dent G & Barnes PJ** Induction of thromboxane biosynthesis in guinea-pig eosinophils stimulated with leukotriene B₄
- 527P **Armstrong RA*, Matthews JS & Jones RL** Potentiation of FMLP-induced plasma exudation by PGE analogues: effect of the thromboxane receptor antagonist GR 32191
- 528P **Whelan CJ* & Johnson M** The anti-inflammatory effects of inhaled salmeterol and salbutamol in guinea-pig lung
- 529P **Martin F & Ryan F*** Glucocorticoid induction of rat growth hormone gene promoter function

POSTER COMMUNICATIONS

- 530P **Pleass RD* & Westwick J** Modulation of IL-8 generation in the pre-monocytic cell line, U937P1
- 531P **Wood BE, O'Connor SE & Leff P** α,β -Methylene-ADP potentiates ATP responses in the rabbit ear artery
- 532P **Schwarze J, Guild SB, Craig JW & Muir TC** The mechanical and biochemical interactions of individual co-transmitters in rat tail artery
- 533P **Sharifi AM, Morrison KJ & Pollock D** Alterations in sensitivity, phosphoinositide hydrolysis and cyclic nucleotide synthesis in isolated aortic rings from spontaneously hypertensive rats
- 534P **Jenkinson S, Guild SB & Muir TC** Differences in inositol phosphate accumulation in response to noradrenaline in tail arteries from spontaneously hypertensive rats
- 535P **Aidulis DM & Pollock D** Effects of reserpine and 6-hydroxydopamine on field stimulation-induced responses of the rat isolated tail artery
- 536P **Parkinson NA, Thom SMC & Sever PS** Adrenaline and noradrenaline activation of α_2 -adrenoceptors in human resistance arteries
- 537P **Connaughton S, Walsh T, Moore D, Shank G, Sugrue M, Prendiville E, Burke P & Docherty JR** Further investigation of subtypes of pre- and postjunctional α_2 adrenoceptors in the periphery
- 538P **Borton M, Connaughton S & Docherty JR** 8-OH-DPAT discriminates between subtypes of α_2 adrenoceptor
- 539P **Harty H, Allen JM, McHale NG & Thornbury KD** β -inhibition of spontaneous rhythm but not contractility in smooth muscle of the sheep lymph node
- 540P **Delpón E, Carrón R, Pérez-Vizcaino F & Tamargo J** Effects of propafenone on ⁴⁵Ca movements and contractile responses in rat isolated vascular smooth muscle
- 541P **Carron R, Pérez-Vizcaino F, Delpon E & Tamargo J** Effects of nafenodone on guinea-pig atrial and ventricular muscle fibres
- 542P **Arnott MR & Struthers AD** The development of an *in vitro* animal model to examine myocardial noradrenaline uptake: preliminary results using a short duration angiotensin II infusion
- 543P **McLeod JD & Piper PJ** Effect of leukotriene D₄ on the responses of cysteinyl leukotrienes and U46619 in guinea-pig heart
- 544P **Hassan N, Hamilton CA, Howle CA & Reid JL** Effects of simvastatin on plasma cholesterol and fat deposition and endothelium damage in large arteries from cholesterol-fed rabbits
- 545P **Campbell EA & Perkins MN** Effect of morphine and Ruthenium Red on a C-fibre evoked blood pressure reflex in the anaesthetised rat
- 546P **Marrs TC, Wood SG, Fitzpatrick K, Inns RH & Bright JE** Pharmacokinetics and metabolism of 4-aminopropiophenone in the rat
- 547P **Roberts SA, McCormack A, Gunraj P, MacKenzie RE & Facchini V** Comparison of the hepatic clearance of (\pm) RP 49356 and its enantiomers in the isolated perfused liver
- 548P **Panjeshahin MR, Collis MG, Bowmer CJ & Yates MS** Amelioration of acute renal failure with 8-cyclopentyl-1, 3-dipropylxanthine: dose dependency
- 549P **Martin J, McKibben B & van den Berg HW** Modulation of interferon alpha 2c receptor expression in human breast cancer cell lines by estradiol, progestins and anti-progestins

- 550P **van den Berg HW, Martin J & Lynch M** Progestin/anti-progestin action towards human breast cancer cell lines differing in their progesterone receptor content
- 551P **Martin F & Tait S** Tamoxifen inhibits thyrotropin releasing hormone-induced expression from a minimal rat prolactin promoter
- 552P **Hoaksey PRE, Ward SA & Edwards G** Metabolic interactions *in vitro* between albendazole and ivermectin
- 553P **Paterson SJ** Comparison of opioid binding in brain, cerebellum and spinal cord of New Zealand white rabbits
- 554P **Gray AM, Sewell RDE & Spencer PSJ** Antidepressant inhibitory activity in the abdominal constriction assay is competitively blocked by opioid antagonists
- 555P **Jackson HC & Weinberger PJ** Are opioid receptors or α_2 adrenoceptors involved in benzodiazepine-induced hypothermia in mice?
- 556P **Freeman P & Sturman G** Histamine H2 antagonists and nociception in the mouse
- 557P **O'Connor JJ & Kruk ZL** Measurement of stimulated endogenous 5-HT release in rat brain slices using fast cyclic voltammetry
- 558P **Gouldie AJ & Leathley MJ** Effects of the putative 5-HT_{1A} agonist anxiolytic, ipsapirone, on benzodiazepine withdrawal in rats
- 559P **Carey GJ, Costall B, Domeney AM & Jones DNC** The ability of 5-HT_{1A} ligands to modify feeding behaviour in the common marmoset (*callithrix jacchus*)
- 560P **Middlefell VC, Price TL & Thomson IA** 5-HT₃ receptor agonist effects of zacopride in the ferret
- 561P **Coughlan J, Costall B, Kelly ME, Naylor RJ & Tyers MB** Ondansetron does not affect hemicholinium-3 induced disruptions in a T-maze reinforced alternation task
- 562P **Coughlan J, Costall B, Kelly ME, Naylor RJ & Tyers MB** Ondansetron attenuates the scopolamine deficit in a water maze task
- 563P **Costall B, Kelly ME & Smith TW** The ability of BTG 1501 to inhibit the suppressed behaviour associated with withdrawal from drugs of abuse
- 564P **Costall B, Domeney AM, Gerrard PA, Kelly ME, Smith TW & Tomkins DM** The anxiolytic action of BTG 1501 revealed in rodent and primate tests
- 565P **Bratt AM, Costall B & Kelly ME** Use of the Stone maze as a test of cognitive function in the rat
- 566P **Barnes JM, Costall B, Hogg S, Kelly ME & McCurrie JR** Behavioural and biochemical effects of bilateral common carotid artery occlusion in the rat
- 567P **Jones CE & Symington HJE** Effects of barbiturates on the release of [³H]noradrenaline from rat brain slices
- 568P **Rabbani M & Little HJ** Changes in dihydropyridine binding in the cerebral cortex following chronic barbitol treatment
- 569P **Al-Qatari M & Taberner PV** Insulin action on 2-deoxyglucose uptake in normal and diabetic CBA/Ca mice following *in vivo* and *in vitro* ethanol
- 570P **Ebenezer IS** Does central administration of the GABA_A receptor agonist baclofen produce hyperphagia in rats?
- 571P **McGivern J & Scholfield CN** Interaction of GABA agonists and general anaesthetics on ionic currents of transmitter releasing axons of rat olfactory cortex
- 572P **Barnes NM, Cheng CHK, Costall B, Gerrard PA & Naylor RJ** Alterations of dopamine D2 receptor density following unilateral infusion of MPTP in the common marmoset
- 573P **Ebenzer IS, Parrott RF & Thornton SN** The effect of haloperidol pretreatment on vasopressin, oxytocin and cortisol release in sheep by cholecystokinin (CCK)
- 574P **O'Neill MF, Dourish CT & Iversen SD** Reversal of CCK-induced hypolocomotion in the mouse by the CCK-A antagonist devazepide but not by the CCK-B antagonist L-365,260
- 575P **Dourish CT, Hutson PH, Kitchener SJ, O'Neill MF, Suman-Chauhan N & Iversen SD** Behavioural and neurochemical evidence for an interaction of CCK with D1 dopamine receptors
- 576P **Ravard S, Dourish CT & Iversen SD** Evidence that the anxiolytic-like effects of the CCK antagonists devazepide and L-365,260 in the elevated plus-maze paradigm in rats are mediated by CCK receptors
- 577P **O'Neill MF, Tye SJ, Dourish CT & Iversen SD** Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey
- 578P **Rivest R, Jolicœur FB & Marsden CA** Lack of evidence for chemical complexation between neurotensin and dopamine
- 579P **Keegan KD, Woodruff GN & Pinnock RD** The pharmacology of neurotensin and neurotensin analogues on dopamine neurones in the rat substantia nigra pars compacta

- 580P **Aldalou AR, Irvine GB, Shaw C, Guthrie DJS, Nelson J & Walker B** Binding of neurotensin analogues to neurotensin receptors from rat brain
- 581P **Abu Shanab AA, Allen JM, Guthrie DJS, Irvine GB & Walker B** Binding of neurokinin A analogues to NK-2 receptors from guinea-pig brain
- 582P **Treanor JJS, Allen SJ, MacGowan SH, Wilcock GK & Dawbarn D** Nerve growth factor receptor binding in normal and Alzheimer's disease basal forebrain
- 583P **Gonzales-Mora JL, Crespi F, Mobius C, Guadelupe T & Mas M** Separation of the *in vivo* voltammetric oxidation peak of serotonin, 5-hydroxy-indolacetic acid and uric acid: a numerical method versus normal recordings
- 584P **Dickie BGM & Davies JA** Effects of calcium channel-blocking drugs on veratridine-evoked release (overflow) of glutamate from cerebellar slices of Wistar rats
- 585P **Beckett SRG, Marsden CA & Marshall P** Microinjections of DLH into the rat periaqueductal grey matter induce a dose-dependant defence response attenuated by midazolam
- 586P **Wayman CP & Wilson JF** Characterisation of the NMDA receptor that stimulates release of α -melanocyte-stimulating hormone from the rat hypothalamus
- 587P **Dawson GR, Banks R, Bentley G, McCreary A, Dourish CT & Iversen SD** The effect of chronic administration of cocaine on locomotor activity and on a cognitive task: evidence for differential development of tolerance and sensitization
- 588P **Banks RJA, Dourish CT & Iversen SD** The angiotensin converting enzyme inhibitors enalapril and captopril inhibit apomorphine-induced oral stereotypy
- 589P **Amon EA, Dietz KR & Bauer FW** Inhibition of histamine release from human basophilic leukocytes by the protein kinase C inhibitor staurosporine
- 590P **Pendry YD & MacLagan J** Vagally-released acetylcholine inhibits sympathetic neurotransmission in the guinea-pig trachea
- 591P **Cooper J & MacLagan J** The effect of potassium channel opening drugs on guinea-pig pulmonary nerves
- 592P **Paciorek PM, Cowrick IS, Spence AM, Taylor JC & Waterfall JF** Comparison of the bronchodilator properties of Ro 31-6930, lemakalim and salmeterol in the guinea-pig
- 593P **Conroy DM, Samhoun MN & Piper PJ** Comparative effects of endothelin-1 and leukotriene D₄ on human and guinea-pig airway preparations
- 594P **Wang JCC & Lung MA** Dose-related effects of alpha, beta-methylene ATP on canine nasal vascular and airway resistances
- 595P **Thorne JR & Broadley KJ** Adenosine-induced bronchoconstriction in the conscious guinea-pig
- 596P **Prentice DJ & Black JW** 9-methyl adenine analogues are selective α_1 adenosine receptor antagonists
- 597P **Alyami AM, Patel IA & Wood D** The influence of electrical field stimulation on GABA-induced ileal contractions
- 598P **Barnes JM, Ellender DM & Naylor RJ** Differences in the mechanisms of action between exepanol and 5-HT₃ and 5-HT₄ receptor agonists to cause contractions in the guinea-pig ileum
- 599P **Davies MP, McCurrie JR & Wood D** Relaxant effects of pinacidil on the longitudinal muscle of the rat ileum
- 600P **Hills JM, Potts HJ, Carlin BA & Parsons ME** An examination of the contribution made by the constituents of peppermint oil (PO) to the relaxation of gastrointestinal smooth muscle
- 601P **Broadbent S, Andersson PO, Carter AJ, Kelghley WW & Wylie MG** A method for determining bladder or gut selectivity and potency of antimuscarinic compounds in the conscious mouse
- 602P **Baird AW** Influence of non-smooth muscle elements on bradykinin-induced contractions of guinea-pig gallbladder *in vitro*
- 603P **Lung MA** Effects of cimetidine hydrochloride on submandibular blood flow and secretion in dogs
- 604P **England S, Daly MJ, Jacob S & Bardhan KD** Adenosine inhibits acid production by human isolated parietal cells

British Journal of Pharmacology

Proceedings Supplement

Proceedings of the British Pharmacological Society Meeting

University of Belfast

12th–14th September 1990

INDEX TO PROCEEDINGS SUPPLEMENTS TO VOLUMES 99, 100 and 101

AUTHOR INDEX

- ABU SHANAB, A.A., ALLEN, J.M., GUTHRIE, D.J.S., IRVINE, G.B. & WALKER, B. Binding of neurokinin A analogues to NK-2 receptors from guinea-pig brain, 101, 581P
- ADAMS, D., CROME, R., LAD, N., MANNING, A.S. & MACKENZIE, I. Failure of the ATP-dependent K⁺ channel inhibitor, glibenclamide, to reduce reperfusion-induced or ischaemic arrhythmias in rat hearts, 100, 438P
- AGID, Y. see DEXTER, D.T., 99, 81P
- - - see DEXTER, D.O., 101, 495P
- AIDULIS, D.M. & POLLOCK, D. Effects of reserpine and 6-hydroxydopamine on field stimulation-induced responses of the rat isolated tail artery, 101, 535P
- AITKEN, C.C. & CUTLER, M.G. The 5-HT₃ receptor antagonist, BRL 43694, modifies behavioural responses to yohimbine in the mouse, 100, 413P
- ALBANO, J.D.M. see MARSHALL, K.G., 101, 512P
- ALDALOU, A.R., IRVINE, G.B., SHAW, C., GUTHRIE, D.J.S., NELSON, J. & WALKER, B. Binding of neurotensin analogues to neurotensin receptors from rat brain, 101, 580P
- ALEXANDER, S.P.H., HILL, S.J. & KENDALL, D.A. Ca²⁺ elevations differentially affect receptor-stimulated inositol phosphates accumulation in mouse and rat cortex, 99, 89P
- - - A23187 and 2-chloroadenosine increase guinea-pig brain histamine-induced inositol phosphates accumulation by different mechanisms, 100, 390P
- ALLEN, J. see SCHOEMAKER, H., 100, 316P
- ALLEN, J.D. see SPIERS, J.P., 99, 234P
- ALLEN, J.M. see ABU SHANAB, A.A., 101, 581P
- - - see HARTY, H., 101, 539P
- ALLEN, S.J. see TREANOR, J.J.S., 101, 582P
- ALLERTON-ROSS, G., CLAPP, L.H. & GURNEY, A.M. Direct relaxation of rabbit pulmonary arterial strips by flash photolysis of caged cyclic GMP, 99, 198P
- AL-QATARI, M. & TABERNER, P.V. Insulin action on 2-deoxyglucose uptake in normal and diabetic CBA/Ca mice following in vivo and in vitro ethanol, 101, 569P
- AL-QATTAN, K.K. & JOHNS, E.J. Inter-action of angiotensin II and perfusion pressure on renal function in the 2K-1C Goldblatt hypertensive rat, 100, 435P
- AL-TAJIR, G., STARR, M.S., CHANDLER, C. J. & STARR, B.S. Opposing effects of dopamine D₁ and D₂ receptor stimulation on the propagation of motor seizures in mice and rats, 99, 261P
- ALYAMI, A.M., PATEL, I.A. & WOOD, D. The influence of electrical field stimulation on GABA-induced ileal contractions, 101, 597P
- AMEEN, M., BLOOMFIELD, J. & ARONSON, J. K. The effects of a low extracellular concentration of potassium for 72 h on Na/K pump numbers and activity in human lymphoblasts and their reversal within 24 h, 100, 470P
- AMON, E.A., DIETZ, K.R. & BAUER, F.W. Inhibition of histamine release from human basophilic leukocytes by the protein kinase C inhibitor staurosporine, 101, 589P
- ANDERSON, B. see KEY, B.J., 100, 467P
- ANDERSON, G.P. see HULTKVIST-BENGTTSSON, U., 99, 83P
- ANDERSON, S.M.P., CHRISTODOULOU, M.S. & GRAHAME-SMITH, D.G. The effects of phorbol esters on 5-HT release from rat hippocampal slices after chronic lithium treatment, 99, 23P
- ANDERSSON, P.O. see BROADBENT, S., 101, 601P

- ANDREWS, M. see CUNNINGHAM, F.M., 99, 85P
- ANGGARD, E. see MITCHELL, J.A., 99, 101P
- ANSON, J., COLLINS, G.G.S. & GREEN, S. C. Possible interactions of 1,2,3,4-tetrahydroamino acridine with N-methyl-D-aspartate receptors, 100, 379P
- ANTUNES, E., CICALA, C., CIRINO, G. & DE NUCCI, G. Polycations induce rat hind-paw oedema, 99, 146P
- ANTUNES, E., MARANGONI, R.A., BORGES, N. C.C., FONTANA, M.D. & DE NUCCI, G. Pharmacological profile of phoentria nigriventer venom on rabbit vascular smooth muscle, 101, 508P
- ANWYL, R. see MANAHAN-VAUGHAN, D., 99, 29P
- ARMAH, B.I., STENZEL, W., RAAP, A., BRUCKNER, R. & MUSTER, D. BDF 9148: a cAMP independent positive inotropic agent that activates sodium channels without prolonging Q-T duration, 100, 321P
- ARMSTRONG, F.H., FURMIDGE, B.A. & LOWE, K.C. Effects of a novel perfluoro-chemical emulsion on liver enzymes and the response to pentobarbital anaesthesia in rats, 100, 490P
- ARMSTRONG, F.H., SHAW, S.T. & LOWE, K.C. Effects of emulsified perfluoro-chemicals on rat liver aryl esterase activity, 99, 300P
- ARMSTRONG, P.W. see FORSTER, C., 99, 122P
- - - see FORSTER, C., 99, 16P
- ARMSTRONG, R.A., LUMLEY, P. & HUMPHREY, P.P.A. Reduction in the number of thromboxane P-receptors (B_{max}) on human platelets after exposure to GR 32191, 99, 113P
- ARMSTRONG, R.A., MATTHEWS, J.S. & JONES, R.L. Potentiation of FMLP-induced plasma exudation by PGE analogues: effect of the thromboxane receptor antagonist GR 32191, 101, 527P
- ARNOTT, M.R. & STRUTHERS, A.D. The development of an *in vitro* animal model to examine myocardial noradrenaline uptake: preliminary results using a short duration angiotensin II infusion, 101, 542P
- ARONSON, J.K. see AMEEN, M., 100, 470P
- ASHBY, M.J. see DAVENPORT, A.P., 99, 127P
- ASHFORTH, E.I.L., CHENERY, R.J. & HOUSTON, J.B. Prediction of *in vivo* disposition from hepatic microsomal and hepatocyte data, 99, 128P
- ASSEM, E.S.K. see PEH, K.H., 100, 449P
- ATKINSON, J. see MULLER, F., 99, 48P
- - - see THORIN-TRESCASES, N., 99, 44P
- ATTWELL, P.J.E., ROSE, S., JENNER, P. & MARSDEN, C.D. Effect of carbidopa dose on pharmacokinetic and metabolic handling of an oral bolus of L-DOPA in rats, 101, 496P
- AUSTIN, A., KELLY, E., KEEN, M. & MACDERMOT, J. Effect of morphine pretreatment on stimulation and inhibition of adenylate cyclase in NG108-15 and NCB20 cells, 100, 426P
- AUSTIN, C.E. & CHESS-WILLIAMS, R. Platelet sensitivity to adrenoceptor stimulation in short and long-term diabetic rats, 100, 444P
- BAGETTA, G. & CONSTANTINI, A. Carbachol-induced suppression of the N-wave in guinea-pig olfactory cortex slices: weak antagonism by M_3 -selective muscarinic antagonists, HHSiD and p-F-HHSiD, 101, 500P
- BAGETTA, G., NISTICO, G. & BOWERY, N.G. Evidence that the hippocampal damage produced by tetanus toxin can be prevented by the NMDA receptor antagonist, MK 801, 99, 96P
- - - Behavioural excitation and neuronal loss induced by intrahippocampal tetanus toxin in rats are prevented by CGP 37849, 100, 384P
- BAGUST, J., GARDNER, C.R., WALKER, R.J. & WARD, R.A. Studies on the efficacy of low affinity benzodiazepine receptor ligand on rat cerebellar slice activity, 99, 252P
- BAHRING, A. see RACKE, K., 99, 219P
- BAILEY, F. see IRELAND, S.J., 99, 63P
- BAIRD, A.W. Influence of non-smooth muscle elements on bradykinin-induced contractions of guinea-pig gall-bladder *in vitro*, 101, 602P
- BAIRD, J.G. & NAHORSKI, S.R. Quisqualate stimulates phosphoinositide metabolism by interaction with more than one receptor mechanism, 100, 315P
- BAKHLE, Y.S. see NAKAMURA, M., 99, 21P
- BALASUBRAMANIAN, M.K., BOESS, F., BRAMMER, M.J. & CAMPBELL, I.C. Increased formation of diacylglycerol metabolites following muscarinic cholinergic stimulation of synaptosomes, 99, 292P

- BALDWIN, B.A. see EBENEZER, I.S., 99, 130P
- - - see EBENEZER, I.S., 100, 419P
- BALDWIN, H.A., RASSNICK, S.R., KOOB, G. F. & BRITTON, K.T. Ethanol withdrawal: a role for corticotrophin-releasing factor (CRF), 100, 339P
- BALFOUR, D.J.K. see BENWELL, M.E.M., 99, 259P
- - - see MITCHELL, E.A., 99, 245P
- BALMENT, R.J. see BOBINSKI, H., 100, 361P
- BANKS, R. see DAWSON, G.R., 101, 587P
- BANKS, R.J.A., DOURISH, C.T. & IVERSEN, S.D. The angiotensin converting enzyme inhibitors enalapril and captopril inhibit apomorphine-induced oral stereotypy, 101, 588P
- BARANN, M. see SCHRODER, H., 99, 110P
- BARDHAN, K.D. see ENGLAND, S., 101, 604P
- BARDONE, M.C. see PIOT, O., 99, 133P
- BARER, G. see ODDOY, A., 100, 459P
- BARLOW, R.B. see CAULFIELD, M.P., 99, 166P
- BARNARD, E.A. see MORRIS, B.J., 99, 197P
- BARNES, J.C. & ROBERTS, F.F. Effects of muscarinic antagonists on arecoline-induced hippocampal theta rhythm and hypertension in the anaesthetised rat, 99, 155P
- BARNES, J.M. see HORNSBY, C.D., 100, 396P
- BARNES, J.M., BARNES, N.M., COSTALL, B., HOROVITZ, Z.P., IRONSIDE, J.W., NAYLOR, R.J. & WILLIAMS, T.J. The inhibition of acetylcholine release from human temporal cortex by angiotensin II, 99, 293P
- BARNES, J.M., COSTALL, B., HOGG, S., KELLY, M.E. & MCCURRIE, J.R. Behavioural and biochemical effects of bilateral common carotid artery occlusion in the rat, 101, 566P
- BARNES, J.M., ELLENDER, D.M. & NAYLOR, R.J. Differences in the mechanisms of action between exepanol and 5-HT₃ and 5-HT₄ receptor agonists to cause contractions in the guinea-pig ileum, 101, 598P
- BARNES, N.M. see BARNES, J.M., 99, 293P
- - - see HORNSBY, C.D., 100, 396P
- BARNES, N.M., CHENG, C.H.K., COSTALL, B., GERRARD, P.A. & NAYLOR, R.J. Reversible dopamine depletion following unilateral infusion of MPTP in the common marmoset, 100, 402P
- - - Alterations of dopamine D2 receptor density following unilateral infusion of MPTP in the common marmoset, 101, 572P
- BARNES, N.M., COSTALL, B., HOROVITZ, Z. P., NAYLOR, R.J. & WILLIAMS, T.J. Characterisation of [³H]-SQ29,852 recognition sites in rodent brain, 99, 142P
- BARNES, P.J. see DENT, G., 99, 163P
- - - see ELWOOD, W., 100, 473P
- - - see EVANS, P.M., 100, 446P
- - - see GIEMBYCZ, M.A., 100, 375P
- - - see KROEGEL, C., 100, 374P
- - - see RABE, K., 100, 376P
- - - see RABE, K., 101, 526P
- - - see WATSON, N., 100, 365P
- BARNES, S. see MARSHALL, F.H., 100, 350P
- BARNES, S., HUNTER, J.C., WOODRUFF, G. N. & HUGHES, J. CCK_B receptor activation causes an increase in endogenous amino acid release from the striatum and ventromedial nucleus of the hypothalamus in vitro, 100, 348P
- BARRADAS, M.A., O'DONOGHUE, S. & MIKHAILIDIS, D.P. Shape changes: a novel method for assessing the effect of agonists and antagonists on human platelets? 101, 521P
- BARRETT, R.P. & ROWAN, M.J. Low dose interaction of the 5-HT_{1A} ligand gepirone with atropine on spatial learning in the rat, 101, 517P
- BATINK, H.D. see VAN HEININGEN, P.N. M., 99, 203P
- BATTY, I.H. see CHILVERS, E.R., 100, 363P
- BAUDRIE, V. see CHAOULOFF, F., 99, 39P
- BAUER, F.W. see AMON, E.A., 101, 589P
- BAUMEYER, T. see CRESPI, F., 99, 260P
- BAX, N.D.S. see SHIELDS, K., 100, 463P
- BAXTER, G.F., JONES, K.B. & STURMAN, G. An in vitro investigation of the pepsin inhibitory properties of several bismuth compounds, 99, 226P
- BEARPARK, T.M. & TOMLINSON, D.R. Modulation of Na⁺/K⁺-ATPase in cultured bovine aortic endothelial cells by glucose and galactose, 100, 469P

- BEATS, B. & KERWIN, R.W. An autoradiographic study of forskolin binding in human hippocampus and its alterations in schizophrenia, 99, 270P
- BECKERINGH, J.J. & KORSTANJE, C. Enantiomers of niguldipine differentially inhibit α_1 -adrenoceptor-mediated hydrolysis of phosphoinositides and contraction in rat and guinea-pig vascular tissue, 99, 205P
- BECKETT, S.R.G., MARSDEN, C.A. & MARSHALL, P. Microinjections of DLH into the rat periaqueductal grey matter induce a dose-dependent defence response attenuated by midazolam, 101, 585P
- BEDFORD, J. see DAVENPORT, A.P., 99, 127P
- BEE, D. see ODDOY, A., 100, 459P
- BEER, M.S. see STANTON, J.A., 100, 395P
- BELSNER, K. see HUGTENBERG, J., 99, 20P
- BENJAMIN, N., DUTTON, J.A. & RITTER, J. M. Effects of glyceryl trinitrate and cultured vascular smooth muscle cells on platelet aggregation, 100, 326P
- BENNETT, G.W. see WATERFALL, A.H., 101, 502P
- - - see WATSON, C.D., 100, 312P
- BENNETT, T. see GARDINER, S.M., 99, 103P
- - - see GARDINER, S.M., 99, 154P
- - - see GARDINER, S.M., 99, 209P
- BENTLEY, G. see DAWSON, G.R., 101, 587P
- BENTLEY, P.K. & LOWE, K.C. Tissue retention of perfluorochemicals in rats, 100, 491P
- BENTON, D.C. & HAYLETT, D.G. Cromakalim increases the membrane permeability of frog skeletal muscle in vitro, 99, 196P
- BENWELL, M.E.M. & BALFOUR, D.J.K. The effects of nicotine and amphetamine on nucleus accumbens dopamine secretion: a microdialysis study, 99, 259P
- BERDEAUX, A. see DRIEU LA ROCHELLE, C., 99, 1P
- BERESFORD, I.J.M. see HAGAN, R.M., 99, 62P
- BERGA, P. see GRISTWOOD, R.W., 99, 18P
- BERRIE, C.P. & ELLIOTT, A.C. The phorbol ester TPA inhibits muscarinic responses in rat lacrimal acinar cells but not in rabbit salivary acinar cells, 101, 501P
- BERRINO, L., HERING, B., MARMO, E. & RACKE, K. Effects of L-glutamate (L-GLU) on the release of endogenous noradrenaline (NA) from the rat supraoptic nucleus (SON) in vitro, 99, 265P
- BERRY, J.L., BOYLE, J.P., DUTY, S., HOLLINGSWORTH, M., FOSTER, R.W. & SMALL, R.C. Effects of AH 21-132 on the mechanical and electrical activity of isolated portal vein and uterine smooth muscle, 100, 462P
- BERRY, J.L., BOYLE, J.P., ELLIOTT, K.R. F., FOSTER, R.W. & SMALL, R.C. Effects of AH 21-132, theophylline, forskolin and sodium nitrite on the cyclic nucleotide content of guinea-pig isolated trachealis, 100, 475P
- BESSER, R., VOGT, T. & WESSLER, I. Repetitive firing of the isolated rat phrenic nerve-hemidiaphragm preparation: effects of high calcium and (+)-tubocurarine, 99, 294P
- BILL, S.J., DOVER, G.M. & RHODES, K.F. Demonstration of 5-HT_{1A} agonist actions of 5-carboxamidotryptamine in the isolated transmurally stimulated ileum of the guinea-pig, 100, 483P
- BIRCH, P.J. see FERNANDEZ, L., 99, 285P
- - - see HARRISON, S.M., 99, 283P
- - - see ROGERS, H., 99, 98P
- BIRD, T.A. see O'NEILL, L.A.J., 99, 147P
- BISHOP, L.A. & WILLIAMS, B.C. Pharmacological characterisation of the aldosterone response to 5-HT in rat zona glomerulosa cells, 99, 40P
- BLACK, J.W. see PRENTICE, D.J., 101, 596P
- BLACK, M.D., BROTHIE, J.M., MITCHELL, I.J. & CROSSMAN, A.R. Potassium thiocyanate-induced increases in EAA receptor binding in the rat visualised by [³H]-L-glutamate involves NMDA receptors in addition to AMPA receptors, 100, 381P
- BLACKBURN, T.P. see GROWCOTT, J.W., 99, 217P
- BLARER, S. see FOZARD, J.R., 99, 7P
- - - see QUAST, U., 99, 6P
- BLOOMFIELD, J. see AMEEN, M., 100, 470P
- BLOWER, P.R. see BOYLE, E.A., 100, 398P
- - - see MELARANGE, R., 99, 172P
- BLUE, D.R. & CLARKE, D.E. Characterisation and modulation of vascular α -adrenoceptor responses in rat kidney, 99, 204P

- BOARDER, M.R. see JONES, J.A., 99, 159P
- - - see OWEN, P.J., 99, 91P
- BOARDER, M.R., OWEN, P.J. & JONES, J.A. P₂ purinoceptor-linked stimulation of labelled phosphatidic acid production in bovine aorta endothelial cells, 100, 343P
- BOBINSKI, H., HADLEY, H., MILLER, M., BALMENT, R.J. & WESTON, A.H. Effects of erythrocyte extracts from genetically hypertensive rats on vascular smooth muscle and on calcium uptake by human red cells, 100, 361P
- BODEN, P.R. see PINNOCK, R.D., 100, 349P
- BOECKXSTAENS, G.E., PEICKMANS, P.A., RUYTJENS, I.F., RAMPART, M., HERMAN, A.G. & VAN MAERCKE, Y.M. GABA_A-receptor mediated non-adrenergic non-cholinergic relaxations in the canine ileocolonic junction, 99, 52P
- BOESS, F. see BALASUBRAMANIAN, M.K., 99, 292P
- BOHM, M., GIERSCHIK, P., JAKOBS, K.H., SCHNABEL, P. & ERDMANN, E. Differential alterations of adenylate cyclase regulation by G₁ in human dilated and ischaemic cardiomyopathy, 99, 117P
- BOICHOT, E. see LAGENTE, V., 99, 174P
- BOIREAU, A. see PIOT, O., 99, 133P
- BOLOFO, M.L. see GILES, H., 99, 202P
- - - see GILES, H., 100, 452P
- BOM, A.H. see VILLALON, C., 99, 36P
- BOND, B.C., ROGERS, D.C. & HUNTER, A.J. A novel way of presenting the statistical analysis of locomotor activity, 100, 408P
- BOOT, J.R. see HERBERT, C.A., 100, 372P
- - - see HERBERT, C.A., 100, 373P
- BORGES, N.C.C. see ANTUNES, E., 101, 508P
- BORTON, M., CONNAUGHTON, S. & DOCHERTY, J.R. 8-OH-DPAT discriminates between subtypes of α_2 adrenoceptor, 101, 538P
- BOSWORTH, N. see WOOD, T.P., 100, 492P
- BOU, J. see GRISTWOOD, R.W., 99, 18P
- BOUGHTON-SMITH, N.K. see HUTCHESON, I. R., 99, 111P
- BOUHELAL, R. & MIR, A.K. Evidence that the cardiovascular and the hypoinsulinaemic effects of 8-OH-DPAT are mediated through different mechanisms, 99, 38P
- BOWEN, D.M. see PANGALOS, M.N., 100, 377P
- - - see STEELE, J.E., 100, 382P
- BOWMER, C.J. see KNIGHT, R.J., 100, 433P
- BOWERY, N.G. see BAGETTA, G., 99, 96P
- - - see BAGETTA, G., 100, 384P
- BOWMER, C.J. see PANJESHAHIN, M.R., 101, 548P
- - - see ROBINSON, S.C., 100, 323P
- BOWRING, N.E. Temporal differences in the effect of glibenclamide on pulmonary and cardiovascular responses to the K⁺ channel activator lemakalim (BRL38227), 100, 476P
- BOYLE, E.A., DAVEY, P.D., MARR, H.E. & BLOWER, P.R. The protective effect of BRL 43694 against cytostatic treatment in 10-13 week old ferrets, 100, 398P
- BOYLE, J.P. see BERRY, J.L., 100, 462P
- - - see BERRY, J.L., 100, 475P
- BOYLE, S.J., MEECHAM, K.G., HUNTER, J. C. & HUGHES, J. Characterisation of [³H]-CI-977 labelled κ -opioid binding sites in rodent CNS, 100, 303P
- BRADFORD, H.F. see CROUCHER, M.J., 100, 387P
- BRADING, A.F. see TOMITA, T., 99, 9P
- BRADSHAW, C.M. see SHAH, K., 99, 72P
- BRAIN, S.D. see BUCKLEY, T.L., 99, 94P
- BRAMMER, M.J. see BALASUBRAMANIAN, M. K., 99, 292P
- - - see XIANG, J-Z., 99, 297P
- - - see XIANG, J-Z., 100, 431P
- BRAMWELL, S.R. see SHARP, T., 100, 305P
- BRAQUET, P. see LAGENTE, V., 99, 174P
- - - see TOUVAY, C., 99, 190P
- BRATT, A.M., COSTALL, B. & KELLY, M.E. Use of the Stone maze as a test of cognitive function in the rat, 101, 565P
- BRAY, K.M. see LONGMORE, J., 99, 3P
- BRAY, L. see MULLER, F., 99, 48P
- BRAZELL, C. see WILLIS, C.L., 100, 317P
- BRAZELL, M.P. see MITCHELL, S.N., 99, 266P
- - - see SMITH, S.E., 100, 417P
- BRIGHT, J.E. see MARRS, T.C., 101, 546P
- BRINK, C. see NOREL, X., 99, 61P
- BRISTOW, L.J., WONG, E.H.F., KESINGLAND, A.C., TRICKLEBANK, M.D. & MIDDLEMISS, D.N. Suppression of conditioned avoidance behaviour by BMY 14802 cannot be explained by sigma opioid receptor antagonism, 100, 416P

- BRITTON, K.T. see BALDWIN, H.A., 100, 339P
- BROADBENT, S., ANDERSSON, P.O., CARTER, A.J., KEIGHLEY, W.W. & WYLLIE, M.G. A method for determining bladder or gut selectivity and potency of anti-muscarinic compounds in the conscious mouse, 101, 601P
- BROADLEY, K.J. see THORNE, J.R., 101, 595P
- BROADHEAD, T.M. see SHIELDS, K., 100, 463P
- BROADLEY, K.J. see THORNE, J.R., 99, 185P
- - - see URQUHART, R.A., 100, 322P
- BRODDE, O-E. see DEIGHTON, N.M., 99, 116P
- - - see VAN TITS, L.J.H., 99, 115P
- BROEKKAMP, C.L.E. see COLLINS, P., 99, 77P
- - - see COLLINS, P., 100, 314P
- BROTCHIE, J.M. see BLACK, M.D., 100, 381P
- BROTCHIE, J.M., MITCHELL, I.J. & CROSSMAN, A.R. Injections of EAA antagonists in the entopeduncular nucleus of the rat alleviate reserpine-induced akinesia by an action at NMDA receptors, 100, 385P
- BROWN, A.M. see KAUMANN, A.J., 100, 319P
- BROWN, C.M., CLAGUE, R.U., KILPATRICK, A.T., MACKINNON, A., MARTIN, A.B. & SPEDDING, M. Effects of RS15385-197 *in vivo* preparations, 99, 272P
- BROWN, D.A. see CAULFIELD, M.P., 99, 166P
- BROWN, M.J. see DAVENPORT, A.P., 99, 114P
- - - see DAVENPORT, A.P., 99, 127P
- - - see KAUMANN, A.J., 100, 319P
- - - see NUNEZ, D.J., 99, 105P
- BROWN, T.J. see MINSHALL, E.M., 100, 448P
- BROWNING, B.S. see WATSON, C.D., 100, 312P
- BROWNING, J.G. see HEAL, D.J., 100, 404P
- - - see MARTIN, K.F., 100, 351P
- BROWNING, J.G., REDFERN, R.J., LUSCOMBE, G.P., HUTCHINS, L.J., HEAL, D.J. & BUCKETT, W.R. Presynaptic dopamine uptake sites labelled by [³H]-GBR 12935: effects of unilateral 6-hydroxytryptamine lesions of rat substantia nigra, 100, 403P
- BRUCKDORFER, K.R. see PLANE, F., 99, 220P
- BRUCKNER, R. see ARMAH, B.I., 100, 321P
- BRUNTON, V.G., RUSSELL, S.N., GRANT, M. H. & WALLACE, H.M. Spermine toxicity in normal and transformed baby hamster kidney cells in culture, 99, 298P
- BUCHAN, K. & MARTIN, W. Bradykinin-induced elevations of cytosolic calcium in bovine aortic endothelial cells: role of intracellular and extracellular calcium, 99, 102P
- BUCKETT, W.R. see BROWNING, J.G., 100, 403P
- - - see CHEETHAM, S.C., 99, 68P
- - - see CHEETHAM, S.C., 101, 515P
- - - see HEAL, D.J., 99, 74P
- - - see HEAL, D.J., 99, 264P
- - - see HEAL, D.J., 100, 404P
- - - see LUSCOMBE, G.P., 100, 356P
- - - see MARTIN, K.F., 99, 267P
- - - see MARTIN, K.F., 100, 351P
- - - see MARTIN, K.F., 100, 405P
- BUCKINGHAM, J.C. see COVER, P.O., 100, 338P
- - - see COWELL, A.M., 101, 503P
- - - see HADLEY, A.J., 100, 337P
- BUCKLEY, T.L., BRAIN, S.D. & WILLIAMS, T.J. Oedema formation induced by IL-1 *in vivo*: interactions with the neuropeptide, calcitonin gene-related peptide (CGRP) in rabbit skin, 99, 94P
- BULL, D.R., SHEEHAN, M.J. & HAYES, A.G. 8-OH-DPAT acts at D₂ receptors to inhibit firing rate of substantia nigra zona compacta cells maintained *in vitro*, 99, 28P
- BULLOCK, R. see BUTCHER, S.P., 99, 277P
- BULT, H. see DE MEYER, G.R.Y., 99, 106P
- BUNCE, K.T. see ELSWOOD, C.J., 100, 485P
- - - see HILL, J.M., 99, 182P
- BURDEN, D.T. & BURKE, Y.M. Effects of benoxaprofen on myeloperoxidase (MPO) activity in ischaemic/reperfused rat kidneys, 100, 437P
- BURKE, P. see CONNAUGHTON, S., 101, 537P
- BURKE, Y.M. see BURDEN, D.T., 100, 437P
- BURLEIGH, D.E. Regional sensitivity of human colon to neurohumoral agents, 99, 183P
- - - Electrically evoked short circuit responses in human isolated colonic mucosa are reduced by loperamide but not by morphine, 100, 478P

- - - [4-Cl-D-Phe⁶,Leu¹⁷] VIP is not an effective VIP antagonist in preparations of rat colonic mucosa, 100, 480P
- BURNS, E. see SHIELDS, K., 100, 463P
- BURTON, G.A., HAYLOR, J. & DE JONGE, A. EDRF and vascular responsiveness in the perfused kidney of the spontaneously hypertensive rat, 100, 328P
- BUTCHER, S.P., BULLOCK, R., GRAHAM, D. I. & MCCULLOCH, J. Release of neuro-excitatory amino acids from rat brain following middle cerebral artery occlusion, 99, 277P
- BUTCHERS, P.R. see NIALS, A.T., 99, 120P
- BUTLER, A. see KILPATRICK, G.J., 99, 32P
- CAIRNS, H.S., ROGERSON, M.E., NEILD, G. H. & WESTWICK, J. Effect of endothelium-dependent and independent vasodilators on renal function in the anaesthetised rabbit, 99, 109P
- CALCUTT, N.A. see CARRINGTON, A.L., 100, 429P
- CALDWELL, J. see D'SOUZA, G.A., 99, 50P
- CALLOW, D.C. see LEATHARD, H.L., 100, 330P
- CAMPBELL, A.M. see MINSHALL, E.M., 100, 448P
- - - see ROBINSON, C., 100, 471P
- CAMPBELL, A.M., HOLGATE, S.T. & ROBINSON, C. Characterisation of cysteinyl leukotriene release in human lung mast cells, 99, 170P
- CAMPBELL, E.A. & PERKINS, M.N. Effect of morphine and Ruthenium Red on a C-fibre evoked blood pressure reflex in the anaesthetised rat, 101, 545P
- CAMPBELL, I.C. see BALASUBRAMANIAN, M.K., 99, 292P
- - - see TWIST, E.C., 100, 397P
- - - see XIANG, J-Z., 99, 297P
- - - see XIANG, J-Z., 100, 431P
- CANFIELD, P. & GILLEN, D. Colloidal bismuth subcitrate and arachidonic acid protect guinea-pig isolated gastric cells from damage by ammonia, 99, 225P
- CANFIELD, P. & HARBORD, M. Effect of luminal NH₃ on alkaline secretion by guinea-pig stomach in vitro, 99, 223P
- CAPDEVILLE, C. see MULLER, F., 99, 48P
- - - see THORIN-TRESCASES, N., 99, 44P
- CAPPER, S.J. see DAVENPORT, A.P., 99, 127P
- - - see D'ORLEANS-JUSTE, P., 101, 510P
- CAPRON, M. see LAGENTE, V., 99, 174P
- CAREY, F. see FORDER, R.A., 99, 164P
- CAREY, G.J. see JONES, D.N.C., 100, 309P
- CAREY, G.J., COSTALL, B., DOMENEY, A.M. & JONES, D.N.C. The ability of 5-HT_{1A} ligands to modify feeding behaviour in the common marmoset (*callithrix jacchus*), 101, 559P
- CARLIN, B.A. see HILLS, J.M., 101, 600P
- CARR, R.D., KILLINGBACK, P.G., HIGGS, L., MITCHELL, P.D., O'CONNOR, S.E., ROBSON, A. & WELLS, E. Differences in tissue ACE-inhibitory profile between FPL 63547 and enalapril after chronic dosing to spontaneously hypertensive rats, 99, 17P
- CARRE, C. see TOUVAY, C., 99, 190P
- CARRINGTON, A.L., ETTLINGER, C.B., TOMLINSON, D.R. & CALCUTT, N.A. Effects of myo-inositol and D-myo-inositol 1,2,6-trisphosphate (PP56) on neuronal dysfunction in streptozotocin-diabetic rats, 100, 429P
- CARRON, R. see DELPON, E., 101, 540P
- CARRON, R., PEREZ-VIZCAINO, F., DELPON, E. & TAMARGO, J. Effects of nafenodone on guinea-pig atrial and ventricular muscle fibres, 101, 541P
- CARTER, A.J. see BROADBENT, S., 101P, 601P
- CARTER, C.M. see MINSHALL, E.M., 100, 448P
- CATTELL, V., COOK, H.T. & MONCADA, S. Glomeruli synthesise nitrite in experimental nephrotoxic nephritis, 99, 108P
- CAULFIELD, M.P., BARLOW, R.B. & BROWN, D.A. Pharmacological studies of pre- and post-synaptic neuronal nicotinic receptors, 99, 166P
- CAVERO, I. see LE MONNIER DE GOUVILLE, A-C., 99, 152P
- CESERANI, R. see PIETRA, C., 99, 177P
- CHALLISS, R.A.J. see CHILVERS, E.R., 100, 363P
- - - see CHILVERS, E.R., 100, 364P
- - - see KROEGEL, C., 100, 374P
- - - see WHITHAM, E.M., 99, 140P
- - - see WOJCIKIEWIECZ, R.J.H., 99, 144P

- CHAOULOFF, F., BAUDRIE, V. & LAUDE, D.
Adrenaline-releasing effects of the 5-HT_{1A} receptor agonists 8-OH-DPAT, buspirone and ipsapirone in the conscious rat, 99, 39P
- CHAPMAN, I., MAZZONI, L. & MORLEY, J.
An anomalous effect of salbutamol in sensitised guinea-pigs, 99, 66P
- CHEETHAM, S.C. see DE PAERMENTIER, F. 99, 271P
- - - see HEAL, D.J., 100, 404P
- - - see LAWRENCE, K.M., 99, 237P
- - - see MARTIN, K.F., 99, 267P
- - - see MARTIN, K.F., 100, 405P
- CHEETHAM, S.C., VIGGERS, J.A., SLATER, N.A. & BUCKETT, W.R. Inhibition of [³H]-paroxetine binding by sibutramine, its metabolites and other antidepressants correlates with inhibition of [³H]-5-HT uptake, 101, 515P
- CHEETHAM, S.C., VIGGERS, J.A., SLATER, N.A., LUSCOMBE, G.P., HEAL, D.J. & BUCKETT, W.R. Important methodological considerations in re-uptake experiments using [³H]-monoamines, 99, 68P
- CHENERY, R.J. see ASHFORTH, E.I.L., 99, 128P
- CHENG, C.H.K. see BARNES, N.M., 100, 402P
- - - see BARNES, N.M., 101, 572P
- CHESS-WILLIAMS, R. see AUSTIN, C.E., 100, 444P
- CHESTER, M. see MOODY, C.J., 99, 210P
- CHEUNG, C.Y. see SEED, M.P., 99, 161P
- CHILVERS, E.R. see KROEGEL, C., 100, 374P
- - - see OFFER, G.J., 100, 362P
- CHILVERS, E.R., CHALLISS, R.A.J., BATTY, I.H. & NAHORSKI, S.R. Is the transient accumulation of inositol (1,4,5) trisphosphate in muscarinic-stimulated airway smooth muscle due to transient formation or enhanced metabolism? 100, 363P
- CHILVERS, E.R., GIEMBYCZ, M.A., CHALLISS, R.A.J. & NAHORSKI, S.R. Zaprinast does not influence methacholine-induced tone or inositol (1,4,5) trisphosphate accumulation in bovine airway smooth muscle, 100, 364P
- CHOPRA, L.C., TWORT, C.H.C. & WARD, J.P. T. Effects of BRL 38227 on calcium uptake by intracellular stores in cultured rabbit airway smooth muscle cells, 100, 368P
- CHOUDRY, N.B., MCEWAN, J., LAVENDER, E., WILLIAMS, A. & FULLER, R.W.
The effect of BRL 43694A (granisetron) on capsaicin-induced cough in man, 99, 41P
- CHRISTODOULOU, M.S. see ANDERSON, S. M.P., 99, 23P
- CHUNG, K.F. see ELWOOD, W., 100, 473P
- - - see EVANS, P.M., 100, 446P
- CICALA, C. see ANTUNES, E., 99, 146P
- CIRINO, G. see ANTUNES, E., 99, 146P
- CLAGUE, R.U. see BROWN, C.M., 99, 272P
- CLAPHAM, J.C., HAMILTON, T.C. & TRAIL, B.K. Comparison of the relaxant profiles of BRL 38227 and dazodipine in rat isolated aorta precontracted by endothelin, 99, 213P
- CLAPP, L.H. see ALLERTON-ROSS, G., 99, 198P
- CLARK, A.H. & GARLAND, C.J. 5-HT stimulates diacylglycerol production in rabbit isolated cerebral arteries, 99, 218p
- - - Endothelium-dependent contraction to 5-HT in rabbit isolated cerebral arteries, 100, 453P
- CLARK, R., SPEDDING, M. & MACFARLANE, C.B. RS-15385-197, a potent and selective α_2 -adrenoceptor antagonist, 99, 123P
- CLARKE, D.E. see BLUE, D.R., 99, 204P
- - - see CRAIG, D.A., 99, 215P
- CLARKE, R.W. see WATERFALL, A.H., 101, 502P
- CLARKSON, P.N. see GROWCOTT, J.W., 99, 217P
- CLARKSON, P.N., GROWCOTT, J.W. & COX, B. Lack of effect with ICI 170809 at the 5-HT₃ receptor in the isolated rabbit heart, 99, 214P
- CLAYTON, J.K., MARSHALL, K., SANGHA, R., SENIOR, J. & GARDINER, P.J. Inhibition of the spontaneous activity of myometrial strips in vitro by prostaglandin E analogues and isoprenaline, 99, 180P
- CLAYTON, J.K., MARSHALL, K., SENIOR, J. & GARDINER, P.J. The response of the human uterus in vitro to leukotrienes, 100, 487P
- CLOSE, S.P. & ELLIOTT, P.J.
Haloperidol-induced bradykinesia in the marmoset, 99, 262P
- COKER, S.J. see HOLBROOK, M., 100, 324P

- - - see SHAHID, M., 100, 443P
- COLEMAN, R.A. see NIALS, A.T., 99, 120P
- COLEMAN, R.A., JOHNSON, M., NIALS, A. T. & SUMNER, M.J. Salmeterol, but not formoterol, persists at β_2 -adrenoceptors in vitro, 99, 121P
- COLLINS, G.G.S. see ANSON, J., 100, 379P
- COLLINS, G.G.S. & PRESCOTT, S. A study of the possible mechanisms by which polymixin B selectively antagonizes responses evoked by N-methyl-D-aspartate, 100, 383P
- COLLINS, G.G.S. & VALENTINE, D.J. Exogenous glycine and D-serine potentiate an N-methyl-D-aspartate receptor-mediated synaptic potential in mouse olfactory cortex slices, 100, 378P
- COLLINS, P., BROEKKAMP, C.L.E., JENNER, P. & MARSDEN, C.D. Purposeless chewing and facial tremor in rats: an electro-myographical investigation, 99, 77P
- - - Drug manipulation reveals different pathways for the induction of purposeless chewing and facial tremor in rats, 100, 314P
- COLLIS, M.G. see KNIGHT, R.J., 100, 433P
- - - see PANJESHAHIN, M.R., 101, 548P
- COLQUHOUN, L., HOLDEN-DYE, L. & WALKER, R.J. The pharmacology of cholinergic receptors on the somatic muscle cells of the parasitic nematode *Ascaris suum*, 99, 253P
- COMPTON, A.M. see GARDINER, S.M., 99, 103P
- - - see GARDINER, S.M., 99, 154P
- - - see GARDINER, S.M., 99, 209P
- CONNAUGHTON, S. see BORTON, M., 101, 538P
- CONNAUGHTON, S. & DOCHERTY, J.R. Evidence for subtypes of peripheral prejunctional α_2 -adrenoceptors, 100, 358P
- CONNAUGHTON, S., WALSH, T., MOORE, D., SHANIK, G., SUGRUE, M., PRENDIVILLE, E., BURKE, P. & DOCHERTY, J.R. Further investigation of subtypes of pre- and postjunctional α_2 -adrenoceptors in the periphery, 101, 537P
- CONNOR, H.E. see TRESIZE, D., 100, 464P
- CONROY, D.M., SAMHOUN, M.N. & PIPER, P. J. Relations of guinea-pig trachea induced by platelet-activating factor are epithelium-dependent and are antagonised by WEB 2086, 99, 58P
- - - Comparative effects of endothelin-1 and leukotriene D₄ on human and guinea-pig airway preparations, 101, 593P
- CONSTANTI, A. see BAGETTA, G., 101, 500P
- COOK, H.T. see CATTELL, V., 99, 108P
- COOK, M. & WICKENDEN, A.D. The effect of NPY and some NPY C-terminal fragments on the field stimulated rat vas deferens, 100, 481P
- COOK, N.S. see FOZARD, J.R., 99, 7P
- - - see QUAST, U., 99, 6P
- COOKE, A.M. see SAFRANY, S.T., 99, 88P
- COOPER, J. & MACLAGAN, J. The effect of potassium channel opening drugs on guinea-pig pulmonary nerves, 101, 591P
- COOPER, S.J. see VAN DER HOEK, G.A., 99, 238P
- COOPER, S.J. see VAN DER HOEK, G.A., 100, 414P
- CORDEIRO, R. see SILVA, P., 99, 82P
- CORN, T.H. see TWIST, E.C., 100, 397P
- CORNETT, C.M. see EGLEN, R.M., 99, 56P
- CORRELA-DE-SA, P., FOUGO, J.L., SEBASTIAO, A.M. & RIBEIRO, J.A. Evidence that phrenic nerve endings possess inhibitory and excitatory adenosine receptors, 99, 227P
- COSTALL, B. see BARNES, J.M., 99, 293P
- - - see BARNES, J.M., 101, 566P
- - - see BARNES, N.M., 99, 142P
- - - see BARNES, N.M., 100, 402P
- - - see BARNES, N.M., 101, 572P
- - - see BRATT, A.M., 101, 565P
- - - see CAREY, G.J., 101, 559P
- - - see COUGHLAN, J., 101, 561P
- - - see COUGHLAN, J., 101, 562P
- - - see HORNSBY, C.D., 100, 396P
- - - see JONES, D.N.C., 100, 309P
- COSTALL, B., DOMENEY, A.M., GERRARD, P.A., KELLY, M.E., SMITH, T.W. & TOMKINS, D.M. The anxiolytic action of BTG 1501 revealed in rodent and primate tests, 101, 564P
- COSTALL, B., KELLY, M.E. & SMITH, T.W. The ability of BTG 1501 to inhibit the suppressed behaviour associated with withdrawal from drugs of abuse, 101, 563P
- COSTALL, B., KELLY, M.E. & TOMKINS, D. M. An automated dark/light box to assess anxiolytic potential, 99, 249P

- COUGHLAN, J., COSTALL, B., KELLY, M.E., NAYLOR, R.J. & TYERS, M.B. Ondansetron does not affect hemicholinium-3 induced disruptions in a T-maze reinforced alternation task, 101, 561P
- - - Ondansetron attenuates the scopolamine deficit in a water maze task, 101, 562P
- COVER, P.O., LAYCOCK, J.F., GARTSIDE, I.B. & BUCKINGHAM, J.C. Evidence that vasopressin contributes to the stress-induced suppression of gonadotrophin release, 100, 338P
- COWELL, A.M., LOXLEY, H.D. & BUCKINGHAM, J.C. *In vitro* studies on the mechanisms by which cytokines activate the hypothalamal-pituitary-adrenal axis, 101, 503P
- COWEN, P.J. see GARTSIDE, S.E., 99, 31P
- COWLRICK, I.S. see PACIOREK, P.M., 101, 592P
- COX, B. see CLARKSON, P.N., 99, 214P
- - - see GROWCOTT, J.W., 99, 217P
- CRAIG, D.A. & CLARKE, D.E. 5-Methoxytryptamine and 2-methyl-5-hydroxytryptamine as discriminative tools for excitatory neuronal receptors (5-HT₃ and novel site) in guinea-pig ileum, 99, 215P
- CRAIG, J.W. see SCHWARZE, J., 101, 532P
- CRAWFORD, M. see ROBERTS, P.J., 99, 284P
- CRESPI, F. see GONZALES-MORA, J.L., 101, 583P
- - - see HASSONI, A.A., 100, 400P
- CRESPI, F., BAUMEYER, T., MOBIUS, C. & DITTRICH, J. Differential square pulse conditioning voltammetry: a new method for voltammetric analysis with micro biosensors, 99, 260P
- CRICK, H. & WALLIS, D.I. Effect of 5-HT on reflex responses of neonate rat spinal motoneurons, 100, 308P
- CROME, R. see ADAMS, D., 100, 438P
- CROMPTON, M.R. see DE PAERMENTIER, F., 99, 271P
- - - see LAWRENCE, K.M., 99, 237P
- CROOK, T.J. & EBENEZER, I.S. Is pica in rats a sensitive measure of drug-induced nausea? 100, 421P
- CROSS, A.J. see MURRAY, T.K., 99, 246P
- - - see ROBERTSON, C., 99, 281P
- - - see STEELE, J.E., 100, 382P
- CROSS, A.R. see DE SOUZA, R.J., 100, 401P
- CROSSMAN, A.R. see BLACK, M.D., 100, 381P
- - - see BROTHIE, J.M., 100, 385P
- CROUCHER, M.J. & BRADFORD, H.F. Anticonvulsant and antiepileptogenic actions of a strychnine-insensitive glycine receptor antagonist in the kindling model of epilepsy, 100, 387P
- CRUWYS, S.C. & PETTIPHER, E.R. Interaction between interleukin 1 and the fibrinolytic system in the degradation of collagen by rabbit chondrocytes, 99, 148P
- CRUZ MARTINEZ, M. see MARTIN DE AGUILERA, E., 99, 212P
- CUNNINGHAM, F. see FOSTER, A.P., 99, 86P
- CUNNINGHAM, F.M. see MOORE, H.D., 99, 160P
- CUNNINGHAM, F.M., FOSTER, A.P., ANDREWS, M. & LEES, P. WEB 2086 inhibits PAF-induced platelet aggregation and plasma protein extravasation in the horse, 99, 85P
- CUNNINGHAM, J.R. see EKWURU, M.O., 99, 251P
- CURTIS, M.J. see RIDLEY, P.D., 101, 511P
- - - see TSUCHIHASHI, K., 99, 231P
- CURZON, G. see KENNETT, G.A., 99, 241P
- - - see SARNA, G.S., 99, 240P
- CUTLER, M.G. see AITKEN, C.C., 100, 413P
- CUTLER, M.G., TURNER, J.M. & MOORE, M.R. Comparison of the effects of δ -aminolaevulinic acid and muscimol in rat jejunal preparations, 100, 486P
- DAHLOF, C. see SUN, X., 99, 118P
- DAINTY, I.A. see LEFF, P., 99, 158P
- DAINTY, I.A., STEPTOE, J.E., O'CONNOR, S.E. & LEFF, P. Is 2-methylthio-ATP an appropriate tool for the identification of P₂Y-purinoceptors? 101, 507P
- DALY, C.J. see MACDONALD, A., 99, 53P
- DALY, C.J., MCGRATH, J.C. & WILSON, V. G. Activation of venous α_2 -adrenoceptors by UK-14304 in the presence of low extracellular Ca²⁺ is associated with an initial transient contraction, 100, 465P
- DALY, M.J. see ENGLAND, S., 101, 604P
- DANIELS, S.E. see DEXTER, D.O., 101, 495P

- DA PRADA, M. see SAURA MARTI, J., 99, 69P
- DASCOMBE, M.J. see REDFORD, E.J., 99, 162P
- DASHWOOD, M. see MOODY, C.J., 99, 210P
- DAVENPORT, A.P., ASHBY, M.J., EASTON, P., ELLA, S., BEDFORD, J., DICKERSON, C., NUNEZ, D.J., CAPPER, S.J. & BROWN, M.J. Endothelin-like immuno-reactivity in human plasma: development of a radioimmunoassay and comparison of levels in hypertension, 99, 127P
- DAVENPORT, A.P., NUNEZ, D.J. & BROWN, M.J. Comparison of binding sites for ¹²⁵I-endothelin-1,2,3, big endothelin, sarafotoxin and mouse vasoactive intestinal contractor in rat, pig and human tissues, 99, 114P
- DAVEY, P.D. see BOYLE, E.A., 100, 398P
- DAVIDSON, J., MILTON, A.S. & ROTONDO, D. The immunostimulatory actions of tumour necrosis factor are suppressed by dexamethasone, 100, 445P
- DAVIDSON, J., MILTON, A.S., ROTONDO, D., SALMON, J.A. & WATT, G. The effect of the lipoxxygenase inhibitor BW A797C on eicosanoid formation following pyrogen administration, 100, 447P
- DAVIES, J.A. see DICKIE, B.G.M., 101, 584P
- DAVIES, M.P., MCCURRIE, J.R. & WOOD, D. Relaxant effects of pinacidil on the longitudinal muscle of the rat ileum, 101, 599P
- DAVIES, R.J. see ROBINSON, C., 100, 471P
- DAWBARN, D. see TREANOR, J.J.S., 101, 582P
- DAWSON, G.R., BANKS, R., BENTLEY, G., MCCREARY, A., DOURISH, C.T. & IVERSEN, S.D. The effect of chronic administration of cocaine on locomotor activity and on a cognitive task: evidence for differential development of tolerance and sensitization, 101, 587P
- DAWSON, I.M. see LAWRENCE, J.A., 99, 35P
- DAYAM, A.D. see SUNDARAM, S., 99, 287P
- DEACON, R.M.J. Benzodiazepine receptor inverse agonists improve acquisition of a multi-trial passive avoidance task, 100, 423P
- DEIGHTON, N.M., MOTOMURA, S., SOHLMANN, W., ZERKOWSKI, H-R. & BRODDE, O-E. β -Adrenoceptor-mediated inotropic effects of dopamine and epinine in human isolated right atrium, 99, 116P
- DE JONGE, A. see BURTON, G.A., 100, 328P
- DELACROIX, M-F. see KERAIVIS, T.M., 100, 344P
- DELANNEY, L.E. see SCOTCHER, K.P., 100, 335P
- DE LA RIVA, C. see EBENEZER, I.S., 100, 419P
- DELGADO, C. see DELPON, E., 99, 233P
- DELPON, E. see CARRON, R., 101, 541P
- - - see TAMARGO, J., 99, 232P
- DELPON, E., CARRON, R., PEREZ-VIZCAINO, F. & TAMARGO, J. Effects of propafene on ⁴⁵Ca movements and contractile responses in rat isolated vascular smooth muscle, 101, 540P
- DELPON, E., TAMARGO, J., VALENZUELA, C. & DELGADO, C. Effects of the combination of mexiletine and flecainide in guinea-pig papillary muscles, 99, 233P
- DE MEYER, G.R.Y., BULT, H., VAN HOYDONCK, A-E. & HERMAN, A.G. Early atherosclerosis induced by a perivascular collar impairs muscarinic endothelium-dependent relaxation in the rabbit carotid artery, 99, 106P
- DE MIGUEL, E. see TAMARGO, J., 99, 232P
- DEN BOER, M.O. see VILLALON, C., 99, 36P
- DEN BOER, M., VILLALON, C., HEILIGERS, J., SAXENA, P.R. & HUMPHREY, P.P.A. The craniovascular effects of sumatriptan in the pig, 99, 37P
- DEN DAAS, I., TEPPER, P.G. & HORN, A. S. The activity of the dopamine agonist N-0437 and eight ester prodrugs after oral and transdermal administration in the 6-OHDA turning model, 100, 352P
- DENT, G. see GIEMBYCZ, M.A., 100, 375P
- - - see RABE, K., 100, 376P
- - - see RABE, K., 101, 526P
- DENT, G., GIEMBYCZ, M.A. & BARNES, P. J. Inhibition of eosinophil oxygen radical production by type 1V- but not type 111-selective cAMP phosphodiesterase inhibitors, 99, 163P
- DE NUCCI, G. see ANTUNES, E., 99, 146P
- - - see ANTUNES, E., 101, 508P

- DE PAERMENTIER, F. see LAWRENCE, K.M. 99, 237P
- DE PAERMENTIER, F., CHEETHAM, S.C., CROMPTON, M.R., KATONA, C.L.E. & HORTON, R.W. Sub-cortical β -adrenoceptor binding sites in post-mortem brain samples from depressed suicide victims, 99, 271P
- DE SOUZA, R.J. see MURRAY, T.K., 99, 246P
- DE SOUZA, R.J., SARNA, G.S., GREEN, A.R., ROBINSON, T.N. & CROSS, A.J. Extracellular dopamine concentration in rat striatum following tetrahydroamino-acridine administration, 100, 401P
- DESQUAND, S., RUFFLE, C., LEFORT, J. & VARGAFTIG, B.B. Interference of a novel PAF antagonist compound, PCA 4248, with active anaphylactic shock in vivo and hyperresponsiveness to PAF in perfused guinea-pig lungs, 99, 84P
- DETTMAR, P.W. see MICKLETHWAITE, A.V., 100, 479P
- - - see YOUNG, A., 100, 482P
- DEVALIA, J.L. see ROBINSON, C., 100, 471P
- DEVISSAGUET, M. see MULLER, F., 99, 48P
- DEXTER, D.T., WELLS, F.R., JAVOY-AGID, F., AGID, Y., MARSDEN, C.D. & JENNER, P. Alterations in brain iron and ferritin levels in multiple system atrophy and Huntington's chorea, 99, 81P
- DEXTER, D.O., WELLS, F.R., JAVOY-AGID, F., AGID, Y., DANIELS, S.E., MARSDEN, C.D. & JENNER, P. No alterations in brain iron, copper, manganese or zinc levels in presymptomatic Parkinson's disease, 101, 495P
- DI BONA, G. see LAVIAN, G., 99, 70P
- DICKERSON, C. see DAVENPORT, A.P., 99, 127P
- DICKIE, B.G.M. & DAVIES, J.A. Effects of calcium channel-blocking drugs on veratridine-evoked release (overflow) of glutamate from cerebellar slices of Wistar rats, 101, 584P
- DICKINSON, S.L. see JACKSON, H.C., 100, 392P
- DICKINSON, S.L., GADIE, B., HAYNE, M.J., LANE, A.C., WALTER, D.S. & WALTHAM, K. Neurochemical effects of idazoxan given continuously by osmotic minipump in the rat, 99, 274P
- DIETZ, K.R. see AMON, E.A., 101, 589P
- DI MONTE, A. see SCOTCHER, K.P., 100, 335P
- DITTRICH, J. see CRESPI, F., 99, 260P
- DOBLE, A. see PIOT, O., 99, 133P
- DOCHERTY, J.R. Peripheral actions of pertussis toxin pretreatment in the rat, 99, 124P
- - - see BORTON, M., 101, 538P
- - - see CONNAUGHTON, S., 100, 358P
- - - see CONNAUGHTON, S., 101, 537P
- DOKTOR, H.S. see RITTER, J.M., 99, 200P
- DOLIN, S.J. see SMITH, M.B., 99, 282P
- DOLPHIN, A.C. see HUSTON, E., 99, 129P
- DOMENEY, A.M. see CAREY, G.J., 101, 559P
- - - see COSTALL, B., 101, 564P
- - - see JONES, D.N.C., 100, 309P
- DONAGHY, K. & SCHOLFIELD, C.N. Adenosine enhances recovery of synaptic transmission in rat hippocampus after anoxia, 101, 499P
- DOODS, H.N. In vivo cardioselectivity of the anti-muscarinic drug AQ-RA 741, 99, 295P
- D'ORLEANS-JUSTE, P., LIDBURY, P.S., CAPPER, S.J., WARNER, T.D. & VANE, J. R. Exogenous human big endothelin is converted to endothelin-1 in the rabbit in vivo, 101, 510P
- D'ORLEANS-JUSTE, P., WOOD, E.G., MITCHELL, J.A. & VANE, J.R. Endothelin, EDRF and prostacyclin are released from bovine venous as well as arterial endothelial cells, 99, 100P
- DOUGALL, I.G. see LEFF, P., 99, 158P
- DOURISH, C.T. see BANKS, R.J.A., 101, 588P
- - - see DAWSON, G.R., 101, 587P
- - - see HENDRIE, C.A., 99, 138P
- - - see HENDRIE, C.A., 99, 139P
- - - see O'NEILL, M.F., 99, 137P
- - - see O'NEILL, M.F., 101, 574P
- - - see O'NEILL, M.F., 101, 577P
- - - see RAVARD, S., 101, 576P
- DOURISH, C.T., HUTSON, P.H., KITCHENER, S.J., O'NEILL, M.F., SUMAN-CHAUHAN, N. & IVERSEN, S.D. Behavioural and neurochemical evidence for an interaction of CCK with D1 dopamine receptors, 101, 575P
- DOVER, G.M. see BILL, S.J., 100, 483P
- DOWDALL, M.J. see GREEN, A.C., 99, 55P
- DOWNING, S.J. & HOLLINGSWORTH, M. Antagonism of relaxin by glibenclamide in the uterus of the rat in vivo, 99, 10P

- - - Uterine tolerance to relaxants in vivo: lack of cross tolerance between relaxin, salbutamol and cromakalim, 100, 488P
- DRETELER, G.H. Cardiorespiratory effects of microinjections of 5-HT_{1A} agonists into the raphe obscurus of the anaesthetised rat, 99, 30P
- DREWETT, I.J. & RODGER, I.W. Assessment of bronchodilator effect of rolipram in the anaesthetised cat, 99, 192P
- DRIEU LA ROCHELLE, C., RIOU, B., BERDEAUX, A. & GUIDICELLI, J.F. K⁺ channel openers dilate both large and small coronary arteries in conscious dogs, 99, 1P
- D'SOUZA, G.A., CALDWELL, J., SMITH, R. L., HORNER, M. & MOSS, M.S. The effect of frusemide on the metabolism and detectability of theophylline in the horse, 99, 50P
- DUBUQUE, L.K. see EGMEN, R.M., 99, 216P
- DUGAS, B. see LAGENTE, V., 99, 174P
- DUNSDON, R.M. see MACKENZIE, I., 100, 320P
- DUTTON, J.A. see BENJAMIN, N., 100, 326P
- DUTY, S. see BERRY, J.L., 100, 462P
- DUTY, S., PACIOREK, P.M., WATERFALL, J.F. & WESTON, A.H. Comparison of the regional haemodynamic profiles of Ro 31-6930, cromakalim and nifedipine using pulsed Doppler flowmetry in the anaesthetised normotensive rat, 100, 329P
- DUTY, S. & WESTON, A.H. Analysis of the mechanisms involved in the contractile response to cromakalim in isolated strips of rabbit aorta under Ca²⁺-free conditions, 99, 2P
- EASTON, P. see DAVENPORT, A.P., 99, 127P
- EBENEZER, I.S. Does central administration of the GABA_B receptor agonist baclofen produce hyperphagia in rats? 101, 570P
- EBENEZER, I.S. see CROOK, T.J., 100, 421P
- - - see PRINGLE, A.K., 100, 420P
- EBENEZER, I.S. & BALDWIN, B.A. Does pharmacological stimulation of central GABA_A receptors stimulate feeding in satiated pigs? 99, 130P
- EBENEZER, I.S., MISSION, B.H., DE LA RIVA, C., THORNTON, S.N. & BALDWIN, B.A. The effect of cholecystokinin (CCK) on oxytocin and cortisol release in pigs during operant feeding, 100, 419P
- EBENEZER, I.S., PARROTT, R.F. & THORNTON, S.N. The effect of haloperidol pretreatment on vasopressin, oxytocin and cortisol release in sheep by cholecystokinin (CCK), 101, 573P
- ECCLES, N.K. see LEATHARD, H.L., 99, 201P
- EDWARDS, D. see HERBERT, C.A., 100, 372P
- - - see HERBERT, C.A., 100, 373P
- EDWARDS, G. see HOAKSEY, P.R.E., 101, 552P
- - - see MILTON, K.A., 99, 296P
- EDWARDS, R.J. see STORCH, J., 99, 173P
- EGLEN, R.M., CORNETT, C.M. & WHITING, R.L. Anomalous pA₂ values for parafluorohexahydrosiladifenidol (pFHHSiD) at tracheal muscarinic receptors, 99, 56P
- EGLEN, R.M., SWANK, S.R., DUBUQUE, L.K. & WHITING, R.L. Characterisation of 5-HT receptors mediating contractions of guinea-pig ileum, in vitro, 99, 216P
- EIGENHUIS, J.J., LEEUWIN, P., MANTEL, P. & VAN WILGENBURG, H. Pre- and post-synaptic effects of midazolam on respiratory skeletal muscle, 99, 256P
- EKWURU, M.O. & CUNNINGHAM, J.R. Phaclofen increases GABA release from valproate treated rats, 99, 251P
- ELLA, S. see DAVENPORT, A.P., 99, 127P
- ELLENDER, D.M. see BARNES, J.M., 101, 598P
- ELLIOTT, A.C. see BERRIE, C.P., 101, 501P
- ELLIOTT, J.M. see PAYVANDI, N., 99, 268P
- - - see PAYVANDI, N., 100, 346P
- ELLIOTT, K.R.F. see BERRY, J.L., 100, 475P
- ELLIOTT, P.J. see CLOSE, S.P., 99, 262P
- - - see HIGGINS, G.A., 99, 244P
- ELLIOTT, P.J., MASON, G.S., STEPHENS-SMITH, M. & HAGAN, R.M. Use of a rotational model to demonstrate the existence of neurokinin NK-2 receptors in the rat substantia nigra, 100, 347P
- ELLIOTT, P. & WALLIS, D.I. Preliminary studies of the action of 5-HT on single lumbar motoneurons in the spinal cord of the neonate rat, 100, 394P

- EL-MAS, M., & HUGHES, I.E. Influence of cocaine on electrically evoked [^3H]-NA overflow from noradrenergic nerves: tissue dependent effect, 99, 178P
- EL NAHAS, A.M. see EL SAYED, A.A., 100, 327P
- EL SAYED, A.A., EL NAHAS, A.M., TOWERS, J.D. & HAYLOR, J. Effect of nitro-arginine methyl ester on renal function in the isolated perfused rat kidney, 100, 327P
- ELSWOOD, C.J. & BUNCE, K.T. Investigation of the 5-HT receptor mechanism mediating relaxation of guinea-pig ascending colon, 100, 485P
- ELWOOD, W., BARNES, P.J. & CHUNG, K.F. Inhibition of neurally mediated contraction of guinea-pig airway smooth muscle by frusemide and bumetanide *in vitro*, 100, 473P
- EMERY, C. see ODDOY, A., 100, 459P
- ENGLAND, S., DALY, M.J., JACOB, S. & BARDHAN, K.D. Adenosine inhibits acid production by human isolated parietal cells, 101, 604P
- ERDMANN, E. see BOHM, M., 99, 117P
- ESPLUGUES, J.V. see RAMOS, E.G., 99, 222P
- ETTLINGER, C.B. see CARRINGTON, A.L., 100, 429P
- EVANS, P.M., BARNES, P.J. & CHUNG, K.F. Inhibition of human eosinophil superoxide anion production by dexamethasone, 100, 446P
- EWAN, G. see HAGAN, R.M., 99, 62P
- FABREGUES, E. see JOHN, G.W., 99, 45P
- FACCHINI, V. see ROBERTS, S.A., 101, 547P
- FALLER, D., HIGGINS, G. & RYAN, M.P. Chloride transport in human placental brush membrane vesicles, 101, 523P
- FAN, T-PD. see SMITHER, R.L., 99, 87P
- FAU DE CASA-JUANA, M. see ORTEGA, M.P., 99, 175P
- FEAR, M.T. see WOOD, B.E., 100, 342P
- FEELY, M. see PICARDO, A., 99, 131P
- FENG, Q., HEDNER, T., HEDNER, J. & PETTERSSON, A. Clonidine restores the renal response to atrial natriuretic peptide in rats with chronic ischaemic heart failure, 99, 49P
- FENIUK, W. see TRESIZE, D., 100, 464P
- FERNANDEZ, L. & BIRCH, P.J. Rotenone- and iodoacetate-induced depolarisation of neonatal rat spinal cord: an *in vitro* model of ischaemia? 99, 285P
- FERNANDEZ-GALLARDO, S. see ORTEGA, M.P., 99, 175P
- FERRI, N. see ONGINI, E., 99, 78P
- FILE, S.E. see HITCHCOTT, P.K., 100, 354P
- FILE, S.E. & TOTH, E. Characterisation of spatial learning in a helical maze in the absence of intra- or extra-maze clues, 99, 254P
- FILE, S.E., ZHARKOVSKY, A. & GULATI, K. Baclofen reverses the signs of ethanol withdrawal in rats, 100, 340P
- FINBERG, J.P.M. see LAVIAN, G., 99, 70P
- FITZPATRICK, K. see MARRS, T.C., 101, 546P
- FLACK, J.D. see HADLEY, A.J., 100, 337P
- FLEMING, I. see GRAY, G.A., 99, 107P
- FLETCHER, A. see FORSTER, E.A., 100, 410P
- FLOR, B. see MARTIN DE AGUILERA, E., 99, 212P
- FOLLENFANT, R.L., NAKAMURA-CRAIG, M. & GARLAND, L.G. Sustained hyperalgesia in rats evoked by 15-hydroperoxyeicosatetraenoic acid is attenuated by the protein kinase inhibitor H-7, 99, 289P
- FONE, K.C.F. see WATSON, C.D., 100, 312P
- FONTANA, M.D. see ANTUNES, E., 101, 508P
- FORD, A.J., GREEN, D.J. & LONGRIDGE, D.J. Effects of dosing regimen of tissue plasminogen activator on the extent and dynamics of fibrinolysis, 99, 149P
- FORDER, R.A., SUDLOW, A.W., STONE, M. A., HAWORTH, D. & CAREY, F. Glucocorticoid induction of the anti-phospholipase protein, lipocortin 1, in the rat, 99, 164P
- FORLANI, A. see MONOPOLI, A., 99, 228P
- FORSTER, C. & ARMSTRONG, P.W. Coronary vascular responsiveness to angiotensin in pacing-induced heart failure: effect of enalapril, 99, 16P
- FORSTER, C., WANES, D. & ARMSTRONG, P.W. Vascular contractions to isoprenaline are mediated by an α_2 -adrenoceptor, 99, 122P
- FORSTER, E.A. & FLETCHER, A. Effects of the 5-HT₂ receptor ligands, DOI and ritanserin, on 5-HT_{1A} receptor-mediated behaviour in the rat, 100, 410P

- FORSYTHE, I.D., LAMBERT, D.G., LINSDELL, P. & NAHORSKI, S.R. Nicotine but not muscarinic receptor agonists depolarize SH-SY5Y human neuroblastoma cells, 100, 427P
- FOSTER, A.C. see WILLIS, C.L., 100, 317P
- FOSTER, A.P. see CUNNINGHAM, F.M., 99, 85P
- FOSTER, A.P., CUNNINGHAM, F. & LEES, P. The inflammatory effects of PAF in equine skin, 99, 86P
- FOSTER, K.A. & THODY, V.E. Inhibition of noradrenaline-stimulated ^{45}Ca uptake in rat aorta by cromakalim and its (-) enantiomer, lemakalim (BRL 38227), 100, 456P
- FOSTER, R.W. see BERRY, J.L., 100, 462P
- - - see BERRY, J.L., 100, 475P
- - - see MURRAY, M.A., 100, 367P
- FOSTER, R.W. & RAKSHI, K. Bronchodilator potency, effectiveness and time course of inhaled nebulised AH 21-132 in normal human subjects, 99, 193P
- FOUGO, J.L. see CORREIA-DE-SA, P., 99, 227P
- FOULKES, R., SHAW, N. & HUGHES, B. The vasodilatory effect of repeated CGRP and nitrate administration in small pig coronary artery rings, 100, 461P
- FOX, A.J. & MORTON, I.K.M. Comparison of opioid inhibition of 5-HT₃ and NK-3 evoked release of [^3H]-ACh from the guinea-pig ileum myenteric plexus, 99, 51P
- FOZARD, J.R. see QUAST, U., 99, 6P
- FOZARD, J.R., MENNINGER, K., COOK, N.S., BLARER, S. & QUAST, U. The cardiovascular effects of SDZ PCO 400 in vivo: comparison with cromakalim, 99, 7P
- FRANCIS, H.P., GREENHAM, A., PATEL, U., THOMPSON, A.M. & GARDINER, P.J. Bay u3405 antagonises U46619-induced bronchoconstriction in the anaesthetised guinea-pig, 99, 60P
- FRANCIS, P.T. see PANGALOS, M.N., 100, 377P
- - - see STEELE, J.E., 100, 382P
- FRANKLAND, A.T.J. see HEAL, D.J., 99, 264P
- FREEMAN, P. & STURMAN, G. Are histamine-H₂ antagonists proconvulsant? 99, 275P
- - - Histamine H₁ antagonists modulate seizure pattern induced by electroshock in mice, 100, 389P
- - - Histamine H₂ antagonists and nociception in the mouse, 101, 556P
- FRITZ, S. see TURNER, J.D., 99, 79P
- FRODSHAM, G., JONES, R.B. & SIM, M.F. Effect of flosequinan and its major metabolite, BTS 53 554, on phosphodiesterase (PDE) iso-enzyme types I, II, and III from guinea-pig ventricle, 100, 441P
- FROM, H., WHITTINGTON, M.A. & LITTLE, H.J. Changes in long term potentiation in hippocampal slices following chronic barbitol treatment, 101, 498P
- FUGLSANG, A., POLLOCK, D. & STONE, T. W. Functional evidence for the existence of postsynaptic α_2 -adrenoceptors in the rat isolated tail artery, 101, 506P
- FULLER, R.W. see CHOUDRY, N.B., 99, 41P
- FURMAN, B.L. see GUC, M.P., 99, 47P
- FURMIDGE, B.A. see ARMSTRONG, F.H., 100, 490P
- GADIE, B. see DICKINSON, S.L., 99, 274P
- GALZIN, A.M., PONCET, V. & LANGER, S. Z. 5-HT₃ receptor agonists enhance the electrically-evoked release of [^3H]-5-HT in guinea-pig frontal cortex slices, 100, 307P
- GARCIA, M.C. see ORTEGA, M.P., 99, 175P
- GARD, P.R. & TURNIDGE, R. Repeated administration of desipramine, but not fluvoxamine or idazoxan, results in attenuation of isoprenaline-induced drinking in rats, 100, 418P
- GARDINER, P.J. see CLAYTON, J.K., 99, 180P
- - - see CLAYTON, J.K., 100, 487P
- - - see FRANCIS, H.P., 99, 60P
- - - see MCKENNIFF, M.G., 99, 59P
- GARDINER, P. see NOREL, X., 99, 61P
- GARDINER, S.M., COMPTON, A.M. & BENNETT, T. Effects of indomethacin on regional haemodynamic responses to endothelins and sarafotoxin-S6b in conscious rats, 99, 154P
- GARDINER, S.M., COMPTON, A.M., BENNETT, T., PALMER, R.M.J. & MONCADA, S. Haemodynamic effects of prolonged infusions of M^G-monomethyl-L-arginine (L-NMMA) in conscious rats, 99, 103P

- GARDINER, S.M., COMPTON, A.M., KEMP, P. A. & BENNETT, T. Effects of endothelin-1 and sarafotoxin S6b on cardiac output in conscious rats, 99, 209P
- GARDNER, C.R. see BAGUST, J., 99, 252P
- GARDNER, C.J. & TWISSELL, D.J. Use of a commercially available signal processing centre for 'on-line' analysis of haemodynamic data, 99, 301P
- GARLAND, C.J. see CLARK, A.H., 99, 218P
- - - see CLARK, A.H., 100, 453P
- GARLAND, L.G. see FOLLENFANT, R.L., 99, 289P
- GARRATT, J.C., MASON, R. & MARSDEN, C.A. Electrophysiological study on the effects of DOI on dorsal raphe 5-HT neuronal firing, 100, 306P
- GARTSIDE, I.B. see COVER, P.O., 100, 338P
- GARTSIDE, S.E. & COWEN, P.J. Evidence that prolactin and ACTH responses to 5-HTP in the rat are mediated by 5-HT₂ receptors, 99, 31P
- GAUDIBERT, A. see LE MONNIER DE GOUVILLE, A-C., 99, 152P
- GAVIRAGHI, G. see MICHELI, D., 100, 332P
- - - see PIETRA, C., 99, 177P
- - - see TRIST, D., 100, 442P
- GENT, J.P. see PICARDO, A., 99, 131P
- GENTRY, C. see MELARANGE, R., 99, 172P
- GERRARD, P.A. see BARNES, N.M., 100, 402P
- - - see BARNES, N.M., 101, 572P
- - - see COSTALL, B., 101, 564P
- - - see JONES, D.N.C., 100, 309P
- GIBBONS, S.J. & ROBERTS, P.J. 2-Amino-4-phosphonobutyrate (AP4) has non-specific stimulatory effects on guinea-pig brain phosphoinositide turnover, 99, 90P
- GIEMBYCZ, M.A. see CHILVERS, E.R., 100, 364P
- - - see DENT, G., 99, 163P
- - - see KROEGEL, C., 100, 374P
- - - see RABE, K., 100, 376P
- - - see RABE, K., 101, 526P
- GIEMBYCZ, M.A., KROEGEL, C., DENT, G. & BARNES, P.J. Induction of thromboxane and E-series prostaglandin biosynthesis in guinea-pig eosinophils stimulated with platelet activating factor, 100, 375P
- GIERSECHIK, P. see BOHM, M., 99, 117P
- GIL, L. see RAMOS, E.G., 99, 222P
- GILES, H., BOLOFO, M.L. & LEFF, P. Rabbit jugular vein contains three different relaxant prostaglandin receptors, 99, 202P
- GILES, H., BOLOFO, M.L. & MARTIN, G.R. Agonist- and tissue-dependence of susceptibility of endothelium-dependent relaxations to L-NAME, 100, 452P
- GILL, B.K. see NAKAMURA-CRAIG, M., 99, 288P
- GILLARD, J. see KNIGHT, A.R., 100, 304P
- GILLEN, D. see CANFIELD, P., 99, 225P
- GILLHAM, B. see NORMAN, J-C., 99, 126P
- GIUDICELLI, J.F. see DRIEU LA ROCHELLE, C., 99, 1P
- GLEN, J.B. see GROWCOTT, J.W., 100, 439P
- GONZALEZ, M.A. see TAMARGO, J., 99, 232P
- GONZALES-MORA, J.L., CRESPI, F., MOBIUS, C., GUADELUPE, T. & MAS, M. Separation of the *in vivo* voltammetric oxidation peak of serotonin, 5-hydroxy-indolacetic acid and uric acid: a numerical method versus normal recordings, 101, 583P
- GONZALEZ-MORA, J.J., MAS, M., O'CONNOR, J., TROUT, S.J. & KRUK, Z.L. Qualitative and quantitative estimation of dopamine and 5-HT in mixtures assessed by fast cyclic voltammetry (FCV) and numeric analysis, 100, 399P
- GOODWIN, G.M. see LAWRENCE, J.A., 99, 35P
- GOSDEN, J. see HEAL, D.J., 99, 264P
- GOSLING, M. see YOUNG, A., 100, 482P
- GOUDIE, A.J. see LEATHLEY, M., 99, 243P
- GOUDIE, A.J. & LEATHLEY, M.J. Effects of the putative 5-HT_{1A} agonist anxiolytic, ipsapirone, on benzo-diazepine withdrawal in rats, 101, 558P
- GOUGH, M.J. see HARDY, S.C., 100, 451P
- GOUW, M.A.M., WILFFERT, B., WERMELSKIRCHEN, D. & VAN ZWIETEN, P. A. Noradrenaline-induced Ca²⁺ influx in the isolated guinea-pig aorta, 99, 43P
- GRAHAM, D.I. see BUTCHER, S.P., 99, 277P
- GRAHAME-SMITH, D.G. see ANDERSON, S. M.P., 99, 23P

- - - see GRASBY, P.M., 99, 27P
- - - see SHARP, T., 100, 305P
- - - see WANG, H., 99, 239P
- - - see WANG, H., 100, 411P
- GRANT, M.H. see BRUNTON, V.G., 99, 298P
- GRANT, T.L. see WICKENDEN, A.D., 99, 5P
- GRASBY, P.M., SHARP, T. & GRAHAME-SMITH, D.G. The effect of gepirone, ipsapirone and buspirone on local cerebral glucose utilisation in the rat, 99, 27P
- GRAY, A.M., SEWELL, R.D.E. & SPENCER, P. S.J. Antidepressant inhibitory activity in the abdominal constriction assay is competitively blocked by opioid antagonists, 101, 554P
- GRAY, D.W. & MARSHALL, I. Calcitonin gene-related peptide (CGRP) endothelium-dependent relaxation in rat aorta is inhibited by L-NMMA, 99, 104P
- GRAY, G.A. see GUC, M.P., 99, 47P
- GRAY, G.A., FLEMING, I., JULOU-SCHAEFFER, G., PARRATT, J.R. & STOCLET, J-C. NG monomethyl-L-arginine restores pressor responses to noradrenaline in endotoxin-treated rats, 99, 107P
- GRAY, J.A. see MITCHELL, S.N., 99, 266P
- - - see SMITH, S.E., 100, 417P
- GREEN, A.R. see DE SOUZA, R.J., 100, 401P
- - - see ROBERTSON, C., 99, 281P
- GREEN, A.C. & DOWDALL, M.J. The presynaptic muscarinic autoreceptor of Torpedo electric organ exhibits the M₂ subtype pharmacology: evidence from direct binding studies, 99, 55P
- GREEN, A.R. see STEELE, J.E., 100, 382P
- GREEN, D.J. see FORD, A.J., 99, 149P
- GREEN, S.C. see ANSON, J., 100, 379P
- GREENHAM, S. see FRANCIS, H.P., 99, 60P
- GRISTWOOD, R.W., LLENAS, J., BOU, J., PUIG, C. & BERGA, P. Flosequinan (BTS 49465) behaves as an inhibitor of phosphodiesterase type III, 99, 18P
- GROSSE-WILDE, H. see VAN TITS, L.J.H., 99, 115P
- GROUHEL, A. see MOODLEY, I., 100, 380P
- GROWCOTT, J.W. see CLARKSON, P.N., 99, 214P
- - - see LEWIS, P.E., 99, 194P
- GROWCOTT, J.W., COX, B., CLARKSON, P.N. & BLACKBURN, T.P. ICI 170809: apparent antagonist affinity differences for 5-HT between rabbit aorta, rat caudal artery and pig coronary artery, 99, 217P
- GROWCOTT, J.W., WILSON, C. & GLEN, J. B. Investigation of the bradycardic effects of propofol on the guinea-pig isolated right atrium, 100, 439P
- GUADELUPE, T. see GONZALES-MORA, J.L. 101, 583P
- GUC, M.P., FURMAN, B.L., GRAY, G.A. & PARRATT, J.R. Endotoxin depresses vascular reactivity to vasodilators in the pithed rat, 99, 47P
- GUIDICELLI, J.F. see RICHER, C., 99, 8P
- GUILD, S.B. see JENKINSON, S., 101, 534P
- - - see NALLY, J.E., 101, 504P
- - - see SCHWARZE, J., 101, 532P
- GULATI, K. see FILE, S.E., 100, 340P
- GUNN, L.K. & PIPER, P.J. Limitations of the co-axial bioassay, 100, 371P
- - - Does the guinea-pig trachea continuously release a smooth muscle relaxing factor? 100, 472P
- GUNRAJ, P. see ROBERTS, S.A., 101, 547P
- GURNEY, A.M. see ALLERTON-ROSS, G., 99, 198P
- - - see NORMAN, J-C., 99, 126P
- GUTHRIE, D.J.S. see ABU SHANAB, A.A., 101, 581P
- - - see ALDALOU, A.R., 101, 580P
- GWILT, M. see KING, R.C., 99, 230P
- GWILT, M., MILNE, A.A., SOICA, A.M. & KING, R.C. UK-68,798, a potent and selective class III anti-arrhythmic agent, reduces dispersion of repolarisation in canine hearts in situ induced by rapid pacing, 99, 15P
- HADLEY, A.J., FLACK, J.D. & BUCKINGHAM, J.C. Modulation of corticotrophin (ACTH) release in vitro by methylxanthines and adenosine analogues, 100, 337P
- HADLEY, H. see BOBINSKI, H., 100, 361P
- HAGAN, R.M. see ELLIOTT, P.J., 100, 347P
- - - see IRELAND, S.J., 99, 63P
- - - see PIETRA, C., 99, 177P
- HAGAN, R.M., IRELAND, S.J., JORDAN, C. C., BERESFORD, I.J.M., STEPHENS-SMITH, M.L., EWAN, G. & WARD, P. GR71251, a novel, potent and highly selective antagonist at neurokinin NK-1 receptors, 99, 62P
- HALES, T.G. see STURGESS, N.C., 99, 278P

- HALKET, J. see PLUMMER, C.J., 99, 67P
- HALLIWELL, R.F., LAMBERT, J.J. & PETERS, J.A. Modulation of NMDA-induced currents recorded from rat hippocampal neurones by 1-hydroxy-3-aminopyrrolidone-2 (HA-966), 99, 280P
- HAMBLETON, P. & MCMAHON, S. Site-dependent differences in inflammatory oedema formation in the rat, 99, 167P
- HAMILTON, C.A. see HASSAN, N., 101, 544P
- - - see HUANG, Y.T., 101, 509P
- - - see NIXON, G.F., 99, 125P
- HAMILTON, T.C. see CLAPHAM, J.C., 99, 213P
- HANAHOE, T.H.P. see PURCELL, W.M., 100, 334P
- HARBORD, M. see CANFIELD, P., 99, 223P
- HARDING, S.E. see MOODY, C.J., 99, 210P
- HARDY, S.C., HOMER, S. & GOUGH, M.J. EDRF mimetic improves reperfusion injury but not in the presence of superoxide and hydroxyl free radical scavengers - the second EDRF? 100, 451P
- HARLEY, E.A., POAT, J.A. & WOODRUFF, G. N. Predicting activity at the D-2 dopamine receptor using the [^3H]-sulpiride/[^3H]-NO437 ratio, 99, 263P
- HARPER, D. see LEFF, P., 99, 158P
- HARRISON, S.M., ROGERS, H., HAYES, A. G. & BIRCH, P.J. Anoxia- and hypoglycaemia-induced neurodegeneration in neonatal rat hippocampal slices, 99, 283P
- HARRON, D.W.G. see SPIERS, J.P., 99, 234P
- HARTY, H.R. see MCHALE, N.G., 101, 505P
- HARTY, H., ALLEN, J.M., MCHALE, N.G. & THORNBURY, K.D. β -inhibition of spontaneous rhythm but not contractility in smooth muscle of the sheep lymph node, 101, 539P
- HASSAN, N., HAMILTON, C.A., HOWIE, C. A. & REID, J.L. Effects of simvastatin on plasma cholesterol and fat deposition and endothelium damage in large arteries from cholesterol-fed rabbits, 101, 544P
- HASSONI, A.A., MARSDEN, C.A. & CRESPI, F. In vitro analysis of striatal electroactive compounds with differential pulse voltammetry and carbon fibre micro electrodes, 100, 400P
- HAWORTH, D. see FORDER, R.A., 99, 164P
- HAYES, A.G. see BULL, D.R., 99, 28P
- - - see HARRISON, S.M., 99, 283P
- - - see ROGERS, H., 99, 98P
- HAYLETT, D.G. see BENTON, D.C., 99, 196P
- HAYLOR, J. see BURTON, G.A., 100, 328P
- - - see EL SAYED, A.A., 100, 327P
- HAYNE, M.J. see DICKINSON, S.L., 99, 274P
- HAZELWOOD, R. see WOOTTON, R., 99, 236P
- HEAL, D.J. see BROWNING, J.G., 100, 403P
- - - see CHEETHAM, S.C., 99, 68P
- - - see MARTIN, K.F., 100, 351P
- - - see MARTIN, K.F., 100, 405P
- - - see PAYVANDI, N., 100, 346P
- HEAL, D.J., CHEETHAM, S.C., VIGGERS, J. A., SLATER, N.A., MARTIN, K.F., PHILLIPS, I., BROWNING, J.G., REDFERN, R.J., LUSCOMBE, G.P. & BUCKETT, W.R. A comparison of the monoamine re-uptake inhibition and α_1 - and muscarinic receptor binding properties of dothiepin, its metabolites and other antidepressants, 100, 404P
- HEAL, D.J., FRANKLAND, A.T.J., GOSDEN, J., HUTCHINS, L.J., LUSCOMBE, G.P. & BUCKETT, W.R. Effects on central dopaminergic function are not involved in the pharmacological actions of the novel antidepressant sibutramine HCl, 99, 264P
- HEAL, D.J., PROW, M.R. & BUCKETT, W.R. Effects of antidepressants including sibutramine HCl and electroconvulsive shock on pre- and post-synaptic α_2 -adrenoceptors assessed by clonidine hypoactivity and mydriasis, 99, 74P
- HECKER, M. see MITCHELL, J.A., 99, 101P
- HEDNER, J. see FENG, Q., 99, 49P
- HEDNER, T. see FENG, Q., 99, 49P
- - - see SUN, X., 99, 118P
- HEIJNIS, J.B., MATHY, M-J. & VAN ZWIETEN, P.A. Effects of various calcium antagonists and of calcium ions in isolated hearts of diabetic and normal rats, 99, 229P
- HEILIGERS, J. see DEN BOER, M., 99, 37P
- - - see VILLALON, C., 99, 36P
- HEILWIG, H. see WESSLER, I., 99, 54P

- HENDRIE, C.A. & DOURISH, C.T.
Anxiolytic profile of the cholecyst-
okinin antagonist devazepide in mice, 99, 138P
- - - Evidence for the involvement of
CCK-A receptors in the mediation of
opioid social conflict analgesia in
mice, 99, 139P
- HERBERT, C.A. see ROBINSON, C.,
100, 471P
- HERBERT, C.A., EDWARDS, D., BOOT, J.R.
& ROBINSON, C. Eosinophil activation
elicits an enhancement in the
permeability of the bronchial mucosa
to albumin, 100, 372P
- - - Modulation of the eosinophil-
induced enhancement of bronchial
epithelial permeability, 100, 373P
- HERBERT, C.A. & ROBINSON, C. Comparat-
ive regional distribution of lipid
mediator metabolising enzymes in
bovine lung, 99, 189P
- HERBERT, C.A., SUMMERS, J.A. & ROBINSON,
C. In vitro techniques for the study
of transepithelial protein flux in
the airways and its modulation by
inflammatory cells and mediators,
100, 477P
- HERING, B. see BERRINO, L., 99, 265P
- HERMAN, A.G. see BOECKSTAENS, G.E.,
99, 52P
- - - see DE MEYER, G.R.Y., 99, 106P
- HEYWORTH, J. see KIRKMAN, E., 99,
22P
- HICKS, R. see OLUFSEN, A.S., 99,
168P
- HIGGINS, A.J. see KING, R.C., 99,
230P
- HIGGINS, G. see FALLER, D., 101,
523P
- HIGGINS, G.A. & ELLIOTT, P.J. Differ-
ences in open-field behaviour of rats
after injection of 5-HT_{1A} selective
compounds into dorsal and median
raphe nuclei, 99, 244P
- HIGGS, L. see CARR, R.D., 99, 17P
- HIGMAN, M. see LEATHARD, H.L., 99,
302P
- HILEY, C.R. see KERAVIDIS, T.M., 100,
344P
- - - see MACLEAN, M.R., 99, 199P
- HILEY, C.R. & JONES, C.R. Heterogeneity
of [¹²⁵I]-sarafotoxin S6B binding
sites in rat tissues, 100, 455P
- HILL, J.M., BUNCE, K.T. & HUMPHREY, P.
P.A. Investigation of the neuronal
"non-5-HT₃" receptor mediating
contraction of guinea-pig ileum, 99,
182P
- HILL, S.J. see ALEXANDER, S.P.H., 99,
89P
- - - see ALEXANDER, S.P.H., 100,
390P
- HILLIER, K. see WILSON, G., 99,
169P
- HILLS, J.M., POTTS, H.J., CARLIN, B.
A. & PARSONS, M.E. An examination
of the contribution made by the
constituents of peppermint oil (PO)
to the relaxation of gastrointest-
inal smooth muscle, 101, 600P
- HIMMEL, H.M. & RAVENS, U. The
putative intracellular calcium
antagonist TMB-8 nonselectively
reduces the membrane conductances
for Ca²⁺, Na⁺ and K⁺ ions, 99, 12P
- HIRJI, M.R. & MUCKLOW, J.C. Trans-
epithelial water movement in
response to arginine-vasopressin,
carbamezapine, chlorpropamide and
demeclocycline in toad (*Bufo*
marinus) urinary bladder, 100,
434P
- HITCHCOTT, P.K., ZHARKOVSKY, A. &
FILE, S.E. Acute CGS 8216 reverses,
and concurrent verapamil prevents,
diazepam withdrawal-induced anxiety
in rats, 100, 354P
- HOAKSEY, P.R.E., WARD, S.A. & EDWARDS,
G. Metabolic interactions in vitro
between albendazole and ivermectin,
101, 552P
- HOGG, S. see BARNES, J.M., 101,
566P
- HOLBROOK, M. see SHAHID, M., 100,
443P
- HOLBROOK, M., SHAHID, M. & COKER, S.J.
Platelet aggregation and the effects
of rolipram on ischaemia- and
reperfusion-induced arrhythmias in
anaesthetized rabbits, 100, 324P
- HOLDEN-DYE, L. see COLQUHOUN, L.,
99, 253P
- HOLGATE, S.T. see CAMPBELL, A.M.,
99, 170P
- HOLLINGSWORTH, M. see BERRY, J.L.,
100, 462P
- - - see DOWNING, S.J., 99, 10P
- - - see DOWNING, S.J., 100, 488P
- HOMER, S. see HARDY, S.C., 100,
451P
- HORN, A.S. see DEN DAAS, I., 100,
352P
- HORNE, A.L. see PRIESTLEY, T., 99,
95P
- HORNER, M. see D'SOUZA, G.A., 99,
50P
- HORNSBY, C.D., BARNES, J.M., BARNES,
N.M., COSTALL, B. & NAYLOR, R.J.
Pharmacological comparison of the
rat and guinea-pig cortical high

- affinity 5-HT uptake system, 100, 396P
 HOROVITZ, Z.P. see BARNES, N.M., 99, 142P
 - - - see BARNES, J.M., 99, 293P
 HORTON, R.W. see DE PAERMENTIER, F., 99, 271P
 - - - see LAWRENCE, K.M., 99, 237P
 HORWELL, D.C. see HUNTER, J.C., 99, 24P
 HOUSTON, J.B. see ASHFORTH, E.I.L., 99, 128P
 HOWIE, C.A. see HASSAN, N., 101, 544P
 - - - see HUANG, Y.T., 101, 509P
 HUANG, Y.T., HAMILTON, C.A., HOWIE, C.A., & REID, J.L. Responses to endothelin in hypertensive rabbits, 101, 509P
 HUDSON, A.L. & NUTT, D.J. In vitro autoradiography of [³H]-RX821002 in the rat CNS, a new ligand for identifying α_2 -adrenoceptors, 100, 345P
 HUGGINS, J.P., TOPOUZIS, S. & MILLER, R.C. Rat aortic rings denuded of endothelium are more sensitive to sodium nitroprusside after precontraction by sarafotoxin S6b than by endothelin-1, 99, 208P
 HUGHES, B. see FOULKES, R., 100, 461P
 HUGHES, I.E. see EL-MAS, M., 99, 178P
 HUGHES, J. see BARNES, S., 100, 348P
 - - - see BOYLE, S.J., 100, 303P
 - - - see HUNTER, J.C., 99, 24P
 - - - see MARSHALL, F.H., 99, 136P
 - - - see MARSHALL, F.H., 100, 350P
 HUGTENBERG, J., BELSNER, K., MOSES, A., SCHEUFLE, E. & WILFFERT, B. Effect of nifedipine, miflozine and dipyrindamole on interstitial adenine nucleotide catabolites during global ischaemia in guinea-pig hearts, 99, 20P
 HULTKVIST-BENGTSSON, U., ANDERSON, G.P. & MORLEY, J. PAF-induced intrathoracic neutrophil accumulation in anaesthetised guinea-pigs, 99, 83P
 HUMPHREY, P.P.A. see ARMSTRONG, R.A., 99, 113P
 - - - see DEN BOER, M., 99, 37P
 - - - see HILL, J.M., 99, 182P
 HUNT, J.A. see KEEN, M., 101, 524P
 HUNT, J.A. & KEEN, M. A comparison of the thromboxane receptor ligands [¹²⁵I]-PTAOH and [³H]-SQ29548 binding in cultured bovine aortic endothelial cells, 101, 525P
 HUNT, S.P. see MORRIS, B.J., 99, 197P
 HUNTER, A.J. see BOND, B.C., 100, 408P
 - - - see MURRAY, T.K., 99, 246P
 - - - see ROGERS, D.C., 100, 409P
 HUNTER, J.C. see BARNES, S., 100, 348P
 - - - see BOYLE, S.J., 100, 303P
 - - - see MARSHALL, F.H., 100, 350P
 HUNTER, J.C., LEIGHTON, G.E., HORWELL, D.C., REES, D.C. & HUGHES, J. CI-977, a novel and selective agonist for the kappa opioid receptor, 99, 24P
 HURST, P.R. see WHELPON, R., 100, 493P
 HUSTON, E. & DOLPHIN, A.C. The effect of the isomers of 202-791 and the GABA_B agonist baclofen on glutamate release from depolarised cultured rat cerebellar neurones, 99, 129P
 HUTCHESON, I.R., WHITTLE, B.J.R. & BOUGHTON-SMITH, N.K. Endotoxin-induced intestinal damage in the rat is enhanced by L-NMMA, an inhibitor of nitric oxide formation, 99, 111P
 HUTCHINS, L.J. see BROWNING, J.G., 100, 403P
 - - - see HEAL, D.J., 99, 264P
 HUTSON, P.H. see DOURISH, C.T., 101, 575P
 HUTSON, P.H., SEMARK, J.E. & MIDDLEMISS, D.N. The TRH analogue MK-771 increases rat hippocampal but not striatal acetylcholine release in vivo, 100, 310P
 IMAIZUMI, A., LEFORT, J. & VARGAFTIG, B.B. Pertussis toxin induces bronchopulmonary hyperreactivity to histamine, 5-HT and antigen in guinea-pigs, but suppresses responses to fMLP, 99, 65P
 INNS, R.H. see MARRS, T.C., 101, 546P
 IRAVANI, M.M., SAMTANEY, N. & ZAR, M. A. Pharmacological actions of neuropeptide Y (NPY) on human myometrium in vitro, 99, 179P
 IRELAND, S.J. see HAGAN, R.M., 99, 62P
 IRELAND, S.J., HAGAN, R.M., BAILEY, F., JORDAN, C. & STEPHENS-SMITH, M. L. Receptors mediating neurokinin-induced contraction of the guinea-pig isolated trachea, 99, 63P
 IRESON, J.C. see WOOD, T.P., 100, 492P
 IRONSIDE, J.W. see BARNES, J.M., 99, 293P
 IRURZUN, A. see MARTIN DE AGUILERA, E., 99, 212P
 IRVINE, G.B. see ABU SHANAB, A.A., 101, 581P

- - - see ALDALOU, A.R., 101, 580P
- IRWIN, I. see SCOTCHER, K.P., 100, 335P
- ISMAIL, H. see WRIGHT, I.K., 100, 357P
- IVERSEN, S.D. see BANKS, R.J.A., 101, 588P
- - - see DAWSON, G.R., 101, 587P
- - - see DOURISH, C.T., 101, 575P
- - - see O'NEILL, M.F., 99, 137P
- - - see O'NEILL, M.F., 101, 574P
- - - see O'NEILL, M.F., 101, 577P
- - - see RAVARD, S., 101, 576P

- JACKSON, H.C., DICKSON, S.L. & NUTT, D. J. Non- α_2 -adrenoceptor idazoxan binding sites are not involved in the pro-convulsant action of idazoxan, 100, 392P
- JACKSON, H.C., RIPLEY, T.L. & NUTT, D.J. Behavioural profile of the δ -opioid receptor antagonist naltrindole in mice, 99, 290P
- JACKSON, H.C. & WEINBERGER, P.J. Are opioid receptors or α_2 -adrenoceptors involved in benzodiazepine-induced hypothermia in mice? 101, 555P
- JACOB, S. see ENGLAND, S., 101, 604P
- JACOBS, M. see PLANE, F., 99, 220P
- JAKOBS, K.H. see BOHM, M., 99, 117P
- JANIAN, P. see MULLER, F., 99, 48P
- JAVOY-AGID, F. see DEXTER, D.T., 99, 81P
- - - see DEXTER, D.O., 101, 495P
- JENKINSON, S., GUILD, S.B. & MUIR, T.C. Differences in inositol phosphate accumulation in response to noradrenaline in tail arteries from spontaneously hypertensive rats, 101, 534P
- JENNER, P. see ATTWELL, P.J.E., 101, 496P
- - - see COLLINS, P., 99, 77P
- - - see COLLINS, P., 100, 314P
- - - see DEXTER, D.T., 99, 81P
- - - see DEXTER, D.O., 101, 495P
- - - see LANGE, K.W., 99, 156P
- - - see LANGE, K.W., 100, 313P
- - - see LOESCHMANN, P-A., 100, 336P
- - - see ROSE, S., 99, 80P
- - - see SCOTCHER, K.P., 100, 335P
- JOHN, G.W., FABREGUES, E. & MASSINGHAM, R. Calcium antagonists differentially inhibit caffeine-induced contractions in vascular smooth muscle, 99, 45P
- JOHNS, E.J. see AL-QATTAN, K.K., 100, 435P
- JOHNS, E.J. & PALMER, R.E. Effect of cromakalim on regional blood flow through the kidney, 99, 195P
- JOHNSON, M. see COLEMAN, R.A., 99, 121P
- - - see NIALS, A.T., 99, 120P
- - - see WHELAN, C.J., 101, 528P
- JOHNSON, P.R. see MINSHALL, E.M., 100, 448P
- JOLICOEUR, F.B. see RIVEST, R., 100, 353P
- - - see RIVEST, R., 101, 578P
- JONES, A.J. see RAY, N.J., 99, 186P
- JONES, C.A. The effect of methohexit-one on the release of [3 H]-noradrenaline from rat brain slices, 100, 393P
- JONES, C.E. & SYMINGTON, H.J.E. Effects of barbiturates on the release of [3 H] noradrenaline from rat brain slices, 101, 567P
- JONES, C.R. see HILEY, C.R., 100, 455P
- JONES, D.N.C. see CAREY, G.J., 101, 559P
- JONES, D.N.C., CAREY, G.J., COSTALL, B., DOMENEY, A.M., GERRARD, P.A., NAYLOR, R.J. & TYERS, M.B. Scopolamine-induced deficits in a primate object discrimination task are reversed by ondansetron (GR38032F), 100, 309P
- JONES, J.A. see BOARDER, M.R., 100, 343P
- JONES, J.A., OWEN, P.J. & BOARDER, M.R. Influence of phorbol ester and other protein kinase C-related drugs on agonist-stimulated inositol phosphate accumulation in cultures of adrenal chromaffin cells, 99, 159P
- JONES, K.B. see BAXTER, G.F., 99, 226P
- JONES, P.S. see MACKENZIE, I., 100, 320P
- JONES, R.B. see FRODSHAM, G., 100, 441P
- JONES, R.B. & SIM, M.F. Effect of flosequinan on ischaemic arrhythmias in anaesthetised rats, 100, 440P
- JONES, R.L. see ARMSTRONG, R.A., 101, 527P
- JONES, R.L. & WILSON, N.H. An EP $_3$ -receptor may mediate prostaglandin E-induced potentiation of aggregation in human platelets, 101, 522P
- JONES, R.S.G. & LAMBERT, J.D.C. Simultaneous intracellular recording from neurones of origin and termination of the perforant path during Mg $^{2+}$ -free induced epileptogenesis in vitro, 100, 318P
- JONES, S.M. see MOODY, C.J., 99, 210P
- JORDAN, C.C. see HAGAN, R.M., 99, 62P

- - - see IRELAND, S.J., 99, 63P
- - - see PIETRA, C., 99, 177P
- JORDAN, D. see SHEPHEARD, S., 101, 520P
- JOSEPH, M.H. see SMITH, K.M., 99, 75P
- JULOU-SCHAEFFER, G. see GRAY, G.A., 99, 107P
- JUNIEN, J.L. see MOODLEY, I., 100, 380P

- KATONA, C.L.E. see DE PAERMENTIER, F., 99, 271P
- - - see LAWRENCE, K.M., 99, 237P
- KATSURA, M. see MITCHELL, J.A., 99, 101P
- KAUMANN, A.J., SANDERS, L., BROWN, A.M., MURRAY, K.J. & BROWN, M.J. Human atrial 5-HT receptors: similarity to rodent neuronal 5-HT₄ receptors, 100, 319P
- KEEGAN, K.D., WOODRUFF, G.N. & PINNOCK, R.D. The pharmacology of neurotensin and neurotensin analogues on dopamine neurones in the rat substantia nigra pars compacta, 101, 579P
- KEEN, M. see AUSTIN, A., 100, 426P
- - - see HUNT, J.A., 101, 525P
- - - see KRANE, A., 99, 171P
- - - see WILTSHIRE, R., 100, 425P
- KEEN, M., KELLY, E. & MACDERMOT, J. Guanine nucleotide sensitivity of [³H]-iloprost binding sites, 99, 145P
- KEEN, M., PICKERING, S.A.W. & HUNT, J.A. Modulation of the bradykinin-stimulated release of prostacyclin from endothelial cells, 101, 524P
- KEEN, P. see RAY, N.J., 99, 186P
- - - see SMITH, W.J., 100, 430P
- KEIGHLEY, W.W. see BROADBENT, S., 101, 601P
- KELLY, E. see AUSTIN, A., 100, 426P
- - - see KEEN, M., 99, 145P
- - - see WILTSHIRE, R., 100, 425P
- KELLY, J.S. see LAWRENCE, J.A., 99, 35P
- KELLY, M.E. see BARNES, J.M., 101, 566P
- - - see BRATT, A.M., 101, 565P
- - - see COSTALL, B., 99, 249P
- - - see COSTALL, B., 101, 563P
- - - see COSTALL, B., 101, 564P
- - - see COUGHLAN, J., 101, 561P
- - - see COUGHLAN, J., 101, 562P
- KEMP, J.A. see PRIESTLEY, T., 99, 95P
- KEMP, P.A. see GARDINER, S.M., 99, 209P

- KENDALL, D.A. see ALEXANDER, S.P.H., 99, 89P
- - - see ALEXANDER, S.P.H., 100, 390P
- - - see ROBINSON, J.P., 99, 71P
- - - see ROBINSON, J.P., 99, 273P
- - - see YOUNG, N.J., 100, 391P
- KENNETT, G.A., WHITTON, P. & CURZON, G. ID₅₀ values of antagonists versus mCPP-induced hypophagia and 5-HT₂-mediated head shakes indicate 5-HT_{1C} sites mediate the hypophagia in rats, 99, 241P
- KENNY, B.A., MACKINNON, A.C., KILPATRICK, A.T. & SPEDDING, M. Species differences in the sensitivity to [³H]-PK11195, a potential marker of neuronal damage, 100, 355P
- KENTISH, J.C. & PALMER, S. Evidence that the sensitising action of caffeine on myofibrils is not due to a direct effect on the Ca²⁺ affinity of troponin C, 99, 11P
- KERAVIS, T.M., NEHLIG, H., DELACROIX, M-F., REGOLI, D., HILEY, C.R. & STOCLET, J-C. Characterization of guanine nucleotide-sensitive bradykinin (BK) binding sites in bovine aortic endothelial cells, 100, 344P
- KERWIN, R.W. see BEATS, B., 99, 270P
- KERWIN, R., MELDRUM, B.S. & PATEL, S. The glutamate receptor system in schizophrenic hippocampal formation: a post-mortem receptor autoradiographic study, 99, 97P
- KESINGLAND, A.C. see BRISTOW, L.J., 100, 416P
- KETTLER, R. see SAURA MARTI, J., 99, 69P
- KEY, B.J., ANDERSON, B. & PRYKE, J. 5-HT-induced dilatation in the rat tail vasculature, 100, 467P
- KILLINGBACK, P.G. see CARR, R.D., 99, 17P
- KILPATRICK, A.T. see BROWN, C.M., 99, 272P
- - - see KENNY, B.A., 100, 355P
- KILPATRICK, G.J. see LUMMIS, S.C.R., 99, 33P
- KILPATRICK, G.J., BUTLER, A. & OXFORD, A.W. m-Chloro-phenylbiguanide is a potent high affinity 5-HT₃ receptor agonist, 99, 32P
- KING, A.T., MULLIGAN, B.J. & LOWE, K. C. Comparison of surfactant-mediated changes in microbial membrane permeability, 99, 299P

- KING, R.C. see GWILT, M., 99, 15P
- KING, R.C., MILNE, A.A., PACKMAN, F., GWILT, M. & HIGGINS, A.J. Estimation of synchrony of cardiac repolarisation by simultaneous on-line acquisition of 31 local electrocardiograms from the dog heart in situ using a microcomputer, 99, 230P
- KIRKMAN, E., MARSHALL, H.W., HEYWORTH, J. & LITTLE, R.A. Ethanol potentiates the reflex bradycardia elicited by stimulating cardiac C-fibre afferents in the anaesthetised dog, 99, 22P
- KITCHEN, I. see PEACHEY, J.A., 99, 184P
- KITCHENER, S.J. see DOURISH, C.T., 101, 575P
- - - see O'NEILL, M.F., 99, 137P
- KNIGHT, A.R., GILLARD, J. & WONG, E.H. F. Characterization of the pharmacology of sigma opioid sites in guinea-pig brain and NCB20 cell membranes, 100, 304P
- KNIGHT, R.J., WATSON, W.P., COLLIS, M. G., BOWMER, C.J. & YATES, M.S. Amelioration of cisplatin-induced acute renal failure in the rat with 8-cyclopentyl-1,3-dipropylxanthine, 100, 433P
- KNOWLER, J.T. see MCLAUGHLIN, M., 99, 269P
- KONDO, K. see MITCHELL, J.A., 100, 450P
- KOOB, G.F. see BALDWIN, H.A., 100, 339P
- KORBUT, R., LIDBURY, P.S., THIEMERMANN, C. & VANE, J.R. Nitrovasodilators modulate blood fibrinolytic activity, 99, 206P
- KORSTANJE, C. see BECKERINGH, J.J., 99, 205P
- KOSTERLITZ, H.W. & PATERSON, S.J. D-Phe-Cye-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH₂ is a highly selective μ -ligand with low in vitro antagonist activity, 99, 291P
- KRANE, A., KEEN, M. & MACDERMOT, J. Characterisation of a putative photo-affinity label of the prostacyclin receptor, 99, 171P
- KRANEVELD, A.D. & TREVETHICK, M.A. 12(s)-hydroxyeicosatetraenoic acid induced relaxation of dog isolated coronary artery, 99, 46P
- KROEGEL, C. see GIEMBYCZ, M.A., 100, 375P
- KROEGEL, C., CHILVERS, E.R., GIEMBYCZ, M.A., CHALLISS, R.A.J. & BARNES, P.J. Receptor-mediated accumulation of D-myoinositol (1,4,5) trisphosphate mass in guinea-pig eosinophils, 100, 374P
- KRUK, Z.L. see GONZALEZ-MORA, J.J., 100, 399P
- - - see O'CONNOR, J.J., 101, 557P
- - - see TROUT, S.J., 99, 258P
- KSOLL, E. see PARSONS, A.A., 100, 331P
- - - see PARSONS, A.A., 100, 457P
- LABAT, C. see NOREL, X., 99, 61P
- LAD, N. see ADAMS, D., 100, 438P
- LAGENTE, V., DUGAS, B., BOÏCHOT, E., PICQUOT, S., CAPRON, M., MENCIA-HUERTA, J.M. & BRAQUET, P. Increased expression of Fc ϵ R11/CCD23 on rat alveolar macrophages by PAF and antigen, 99, 174P
- LAGRASTA, C. see MONOPOLI, A., 99, 228P
- LAMBERT, D.G. see FORSYTHE, I.D., 100, 427P
- LAMBERT, D.G. & NAHORSKI, S.R. Effect of pertussis toxin on carbachol-stimulated rises in [Ca²⁺]_i and inositol phosphate accumulation in SH-SY5Y neuroblastoma cells, 99, 143P
- - - Inhibitory effects of phorbol esters on muscarinic receptor-linked inositol phosphate accumulation and intracellular Ca²⁺ homeostasis in SH-SY5Y human neuroblastoma cells, 100, 311P
- LAMBERT, J.D.C. see JONES, R.S.G., 100, 318P
- LAMBERT, J.J. see HALLIWELL, R.F., 99, 280P
- - - see STURGESS, N.C., 99, 278P
- LANE, A.C. see DICKINSON, S.L., 99, 274P
- LANGE, K.W., WELLS, F.R., ROSSOR, M.N., JENNER, P. & MARSDEN, C.D. Cortical and hippocampal muscarinic receptors are differentially affected in Alzheimer's disease and Parkinson's disease, 99, 156P
- - - Nicotinic receptors in the cerebral cortex in Alzheimer's disease and Parkinson's disease, 100, 313P
- LANGER, S.Z. see GALZIN, A.M., 100, 307P
- - - see SCHOEMAKER, H., 100, 316P
- LANGSTON, J.W. see SCOTCHER, K.P., 100, 335P
- LAUDE, D. see CHAOULOFF, F., 99, 39P
- LAURIE, D.J. & PRATT, J.A. Local cerebral glucose utilisation during

- spontaneous and "flimazenil-precipitated" withdrawal from diazepam, 99, 134P
- LAVENDER, E. see CHOUDRY, N.B., 99, 41P
- LAVIAN, G., DI BONA, G. & FINBERG, J. P.M. Inhibition of sympathetic nerve activity by tricyclic and monoamine oxidase-inhibitor antidepressants, 99, 70P
- LAWRENCE, A.J. & MARSDEN, C.A. The effect of systemic 5-carboxamidotryptamine on extracellular levels of 5-HT in the freely moving guinea-pig, 101, 519P
- LAWRENCE, J.A., DAWSON, I.M., OLVERMAN, H.J., GOODWIN, G.M., WILSON, N.H. & KELLY, J.S. Binding characteristics of 8-OH-DPAT analogues suitable for iodination, 99, 35P
- LAWRENCE, K.M., DE PAERMENTIER, F., CHEETHAM, S.C., CROMPTON, M.R., KATONA, C.L.E. & HORTON, R.W. Symmetrical hemispheric distribution of brain [³H]-paroxetine binding sites in post-mortem samples from depressed suicides and controls, 99, 237P
- LAWSON, A. Differential effects of ouabain on K⁺-induced contractions of guinea-pig tracheal and aortic smooth muscle, 99, 4P
- LAYCOCK, J.F. see COVER, P.O., 100, 338P
- LEATHARD, H.L., CALLOW, D.C. & METAXAS, K.E. Does progesterone-evoked suppression of human intracranial artery contractility involve potassium channel activation? 100, 330P
- LEATHARD, H.L., ECCLES, N.K. & YEATS, D.A. Rhythmical contractility in vitro of human uterine blood vessel circular muscle strips, 99, 201P
- LEATHARD, H.L. & HIGMAN, M. Computer programme including animated sequences to illustrate the principles of mechanisms by which drugs may alter intestinal propulsion, 99, 302P
- LEATHLEY, M.J. see GOUDIE, A.J., 101, 558P
- LEATHLEY, M., TAYLOR, M.A.I. & GOUDIE, A.J. Effects of the 5-HT₃ antagonist GR38032F on benzodiazepine withdrawal in rats, 99, 243P
- LEATHWOOD, P. see SARNA, G.S., 99, 240P
- LEE, C. & RODGERS, R.J. Influence of diazepam on the analgesic effects of elevated plus-maze exposure in mice, 99, 135P
- - - Elevated plus-maze: effects of buspirone on antinociception and behaviour, 100, 412P
- LEES, G. see PEARSON, H.A., 99, 250P
- LEES, G.M. Coping with rapid changes in the rate of submissions to the British Journal of Pharmacology, 99, 157P
- LEES, P. see CUNNINGHAM, F.M., 99, 85P
- - - see FOSTER, A.P., 99, 86P
- LEEUWIN, P. see EIGENHUIS, J.J., 99, 256P
- LEFF, P. see DAINITY, I.A., 101, 507P
- - - see GILES, H., 99, 202P
- - - see O'CONNOR, S.E., 100, 341P
- - - see WOOD, B.E., 100, 342P
- - - see WOOD, B.E., 101, 531P
- LEFF, P., HARPER, D., DAINITY, I.A. & DOUGALL, I.G. A test to detect possible errors in agonist affinity estimation, 99, 158P
- LEFORT, J. see DESQUAND, S., 99, 84P
- - - see IMAIZUMI, A., 99, 65P
- LEIGHTON, G.E. see HUNTER, J.C., 99, 24P
- LEJEUNE, V. see TOUVAY, C., 99, 190P
- LE MONNIER DE GOUVILLE, A-C., THIRY, C., GAUDIBERT, A. & CAVERO, I. Hypotension produced by endothelins undergoes crossed tachyphylaxis in both anaesthetised and conscious rats, 99, 152P
- LEWIS, P.E., GROWCOTT, J.W. & WILSON, C. Potassium channel blockade: effects on cromakalim-induced relaxation of the guinea-pig tracheal chain, 99, 194P
- LEWIS, S.A. & RAEBURN, D. Preferential pre-junctional site of inhibition of non-cholinergic bronchospasm by potassium channel openers, 100, 474P
- LIDBURY, P.S. see D'ORLEANS-JUSTE, P., 101, 510P
- - - see KORBUT, R., 99, 206P
- LINDELL, P. see FORSYTHE, I.D., 100, 427P
- LITTLE, H.J. see FROW, H., 101, 498P
- - - see RABBANI, M., 100, 422P
- - - see RABBANI, M., 101, 568P
- - - see WHITTINGTON, M.A., 99, 276P
- LITTLE, R.A. see KIRKMAN, E., 99, 22P
- LITTLE, R.A., LYTHGOE, D.J., O'SHAUGHNESSY, C.T. & STEWARD, M.C. Effect of U74006F on oedema and infarct volumes following permanent

- occlusion of the middle cerebral artery in the rat, 100, 454P
- LIU, G. see RAVENS, U., 99, 13P
- LLENAS, J. see GRISTWOOD, R.W., 99, 18P
- LLUCH, S. see MARTIN DE AGUILERA, E., 99, 212P
- LOESCHMANN, P.-A., WACHTELL, H., JENNER, P. & MARSDEN, C.D. Behavioural effects of rolipram in MPTP-treated common marmosets, 100, 336P
- LONGMORE, J., BRAY, K.M. & WESTON, A.H. The relationship between the effects of cromakalim and diazoxide on K⁺ and Rb⁺ efflux, membrane potential and tension in bovine tracheal smooth muscle, 99, 3P
- LONGRIDGE, D.J. see FORD, A.J., 99, 149P
- LOPEZ-BELMONTE, J. & WHITTLE, B.J.R. Inhibition of endothelin-1-induced rat gastric damage by calcitonin gene-related peptide, 99, 153P
- LOPEZ-SENDON, J. see TAMARGO, J., 99, 232P
- LOWE, K.C. see ARMSTRONG, F.H., 99, 300P
- - - see ARMSTRONG, F.H., 100, 490P
- - - see BENTLEY, P.K., 100, 491P
- - - see KING, A.T., 99, 299P
- LOXLEY, H.D. see COWELL, A.M., 101, 503P
- LUHESHI, G.N., WEBB, R.J. & ZAR, M.A. Presence of an atropine resistant component in the motor transmission of the isolated human detrusor muscle, 99, 181P
- LUMLEY, P. see ARMSTRONG, R.A., 99, 113P
- - - see PIKE, N.B., 99, 112P
- LUMMIS, S.C.R., KILPATRICK, G.J., NIELSEN, M. & MARTIN, I.L. Molecular target size of 5-HT₃ receptors in N1E115 neuroblastoma cells and brain differ by a factor of two, 99, 33P
- LUNG, M.A. Effects of cimetidine hydrochloride on submandibular blood flow and secretion in dogs, 101, 603P
- - - see WANG, J.C.C., 101, 594P
- LUSCOMBE, G.P. see BROWNING, J.G., 100, 403P
- - - see CHEETHAM, S.C., 99, 68P
- - - see HEAL, D.J., 99, 264P
- - - see HEAL, D.J., 100, 404P
- LUSCOMBE, G.P., MAZURKIEWICZ, S.E. & BUCKETT, W.R. Evaluation of tricyclic antidepressants in the elevated plus-maze in rats: anxiolytic effect of dothiepin and doxepin, 100, 356P
- LYNCH, M. see VAN DEN BERG, H.W., 101, 550P
- LYTHGOE, D.J. see LITTLE, R.A., 100, 454P
- MACDERMOT, J. see AUSTIN, A., 100, 426P
- - - see KEEN, M., 99, 145P
- - - see KRANE, A., 99, 171P
- - - see STORCH, J., 99, 173P
- - - see WILTSHIRE, R., 100, 425P
- MACDONALD, A. see MCLAUGHLIN, D.P., 99, 119P
- MACDONALD, A., DALY, C.J., WILSON, V.G. & MCGRATH, J.C. Effects of prejunctional α -adrenoceptor activation on neurotransmission in the rabbit saphenous artery, 99, 53P
- MACFARLANE, C.B. see CLARK, R., 99, 123P
- MACGOWAN, S.H. see TREANOR, J.J.S., 101, 582P
- MACKENZIE, I. see ADAMS, D., 100, 438P
- MACKENZIE, I., WATERFALL, J.F., JONES, P.S. & DUNSDON, R.M. Comparison of Class III antiarrhythmics and glibenclamide on action potentials from guinea-pig papillary muscle under normoxic and hypoxic conditions, 100, 320P
- MACKENZIE, R.E. see ROBERTS, S.A., 101, 547P
- MACKERT, J.R.L. see PARSONS, A.A., 100, 331P
- - - see PARSONS, A.A., 100, 457P
- MACKINNON, A. see BROWN, C.M., 99, 272P
- - - see KENNY, B.A., 100, 355P
- MACLAGAN, J. see COOPER, J., 101, 591P
- - - see PENDRY, Y.D., 101, 590P
- - - see WATSON, N., 100, 365P
- MACLEAN, M.R. & HILEY, C.R. Effect of neuropeptide Y on the mesenteric arterial bed of the pithed rat: effect of low ventilation volume, 99, 199P
- MACLENNAN, S.J. & MARTIN, G.R. Comparison of the effects of methysergide and methylergometrine with GR43175 on feline carotid blood flow distribution, 99, 221P
- MAHONEY, A. see MAKINDE, V., 100, 432P
- MAKINDE, V., MAHONEY, A., SAAID, A.H. & WALI, F.A. Comparative effects of pancuronium and vecuronium on rat isolated diaphragm and kidney, 100, 432P

- MALLARD, N.J., MARSHALL, R.W. & SPRIGGS, T.L.B. Neuronally-released noradrenaline acts at different α_1 -adrenoceptors to exogenous noradrenaline in rat vas deferens, 100, 359P
- MANAHAN-VAUGHAN, D., O'CONNOR, J.J., ROWAN, M.J. & ANWYL, R. Comparison of the effects of buspirone analogues and 1-(2-pyrimidinyl)-piperazine on synaptic transmission in the rat hippocampus *in vivo*, 99, 29P
- MANLEY, P.W. *see* QUAST, U., 99, 6P
- MANNAIONI, P.F. *see* SALVEMINI, D., 100, 333P
- MANNING, A.S. *see* ADAMS, D., 100, 438P
- MANTEL, P. *see* EIGENHUIS, J.J., 99, 256P
- MARANGONI, R.A. *see* ANTUNES, E., 101, 508P
- MARCON, C. *see* TRIST, D., 100, 442P
- MARMO, E. *see* BERRINO, L., 99, 265P
- MARR, H.E. *see* BOYLE, E.A., 100, 398P
- MARRS, T.C., WOOD, S.G., FITZPATRICK, K., INNS, R.H. & BRIGHT, J.E. Pharmacokinetics and metabolism of 4-aminopropiophenone in the rat, 101, 546P
- MARSDEN, C.A. *see* BECKETT, S.R.G., 101, 585P
- - - *see* GARRATT, J.C., 100, 306P
- - - *see* HASSONI, A.A., 100, 400P
- - - *see* LAWRENCE, A.J., 101, 519P
- - - *see* RIVEST, R., 100, 353P
- - - *see* RIVEST, R., 101, 578P
- - - *see* WRIGHT, I.K., 100, 357P
- MARSDEN, C.D. *see* ATTWELL, P.J.E., 101, 496P
- - - *see* COLLINS, P., 99, 77P
- - - *see* COLLINS, P., 100, 314P
- - - *see* DEXTER, D.T., 99, 81P
- - - *see* DEXTER, D.O., 101, 495P
- - - *see* LANGE, K.W., 99, 156P
- - - *see* LANGE, K.W., 100, 313P
- - - *see* LOESCHMANN, P-A., 100, 336P
- - - *see* ROSE, S., 99, 80P
- MARSHALL, F.H., BARNES, S., HUNTER, J.C. & HUGHES, J. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms, 100, 350P
- MARSHALL, F.H., PINNOCK, R.D. & HUGHES, J. Characterisation of cholecystokinin octapeptide stimulated endogenous dopamine release from rat nucleus accumbens *in vitro*, 99, 136P
- MARSHALL, H.W. *see* KIRKMAN, E., 99, 22P
- MARSHALL, I. *see* GRAY, D.W., 99, 104P
- MARSHALL, K. *see* CLAYTON, J.K., 99, 180P
- - - *see* CLAYTON, J.K., 100, 487P
- MARSHALL, K.G., ALBANO, J.D.M. & WALLER, D.G. The effect of dopamine on kinin release from rat and human isolated renal cortical cells, 101, 512P
- MARSHALL, P. *see* BECKETT, S.R.G., 101, 585P
- MARSHALL, R.W. *see* MALLARD, N.J., 100, 359P
- MARTEN, P. *see* TURNER, J.D., 99, 79P
- MARTIN, A.B. *see* BROWN, C.M., 99, 272P
- MARTIN, D., MORRISETT, R.A., SWARTZWEIDER, H.S. & WILSON, W.A. Acute effects of ethanol on rat hippocampal excitatory amino acid receptors, 99, 279P
- MARTIN, F. & RYAN, F. Glucocorticoid induction of rat growth hormone gene promoter function, 101, 529P
- MARTIN, F. & TAIT, S. Tamoxifen inhibits thyrotropin releasing hormone-induced expression from a minimal rat prolactin promoter, 101, 551P
- MARTIN, G.R. *see* GILES, H., 100, 452P
- - - *see* MACLENNAN, S.J., 99, 221P
- MARTIN, I.L. *see* LUMMIS, S.C.R., 99, 33P
- MARTIN, J. *see* VAN DEN BERG, H.W., 101, 550P
- MARTIN, J., MCKIBBEN, B. & VAN DEN BERG, H.W. Modulation of interferon α_2C receptor expression in human breast cancer cell lines by estradiol, progestins and anti-progestins, 101, 549P
- MARTIN, K.F. *see* HEAL, D.J., 100, 404P
- MARTIN, K.F., BROWNING, J.G., REDFERN, J., HEAL, D.J. & BUCKETT, W.R. Electroconvulsive shock increases dopamine D_1 receptor-mediated adenylate cyclase activity in rat striatal homogenates, 100, 351P
- MARTIN, K.F., PHILLIPS, I., CHEETHAM, S.C. & BUCKETT, W.R. Sodium dependent binding of [3H]-raclopride to rat striatal membranes, 99, 267P
- MARTIN, K.F., PHILLIPS, I., CHEETHAM, S.C., HEAL, D.J. & BUCKETT, W.R. Only antidepressants with marked effects on central dopamine function decrease rat striatal D_2 receptor number, 100, 405P

- MARTIN, W. see BUCHAN, K., 99, 102P
- MARTIN DE AGUILERA, E., VILA, J.M.,
IRURZUN, A., CRUZ MARTINEZ, M., FLOR,
B. & LLUCH, S. Endothelin-induced
contraction of human omental arteries,
99, 212P
- MARTINS, M.A. see SILVA, P., 99, 82P
- MAS, M. see GONZALEZ-MORA, J.J.,
100, 399P
- - - see GONZALES-MORA, J.L., 101,
583P
- MASINI, E. see SALVEMINI, D., 100,
333P
- MASON, G.S. see ELLIOTT, P.J., 100,
347P
- MASON, R. see GARRATT, J.C., 100,
306P
- MASSINGHAM, R. see JOHN, G.W., 99,
45P
- MATHY, M-J. see HEIJNIS, J.B., 99,
229P
- MATTHEWS, J.S. see ARMSTRONG, R.A.,
101, 527P
- MAZURKIEWICZ, S.E. see LUSCOMBE, G.P.,
100, 356P
- MAZZONI, L. see CHAPMAN, I., 99, 66P
- MCBAIN, J. see SAFRANY, S.T., 99,
88P
- MCCORMACK, A. see ROBERTS, S.A.,
101, 547P
- MCCREARY, A. see DAWSON, G.R., 101,
587P
- MCCULLOCH, J. see BUTCHER, S.P., 99,
277P
- - - see MCLAUGHLIN, M., 99, 269P
- MCCURRIE, J.R. see BARNES, J.M., 101,
566P
- - - see DAVIES, M.P., 101, 599P
- MCEWAN, J. see CHOUDRY, N.B., 99,
41P
- MCGIVERN, J. & SCHOLFIELD, C.N.
Interaction of GABA agonists and
general anaesthetics on ionic currents
of transmitter releasing axons of rat
olfactory cortex, 101, 571P
- MCGLYNN, H. & RYAN, M.P. Gentamicin
nephrotoxicity in primary rat renal
proximal tubular cells, 101, 513P
- MCGRATH, J.C. see DALY, C.J., 100,
465P
- - - see MACDONALD, A., 99, 53P
- MCGUINNESS, S. & RYAN, M.P. Investig-
ation of cisplatin toxicity in rat
renal proximal tubular fragments,
101, 514P
- MCHALE, N.G. see HARTY, H., 101,
539P
- MCHALE, N.G., HARTY, H.R. & THORNBURY,
K.D. Post-synaptic α -adrenoceptors
do not mediate the response to field
stimulation in sheep mesenteric
lymphatic vessels, 101, 505P
- MCILHINNEY, R.A.J. see SMITH, A.L.,
100, 386P
- MCKENNIFF, M.G., NORMAN, P. & GARDINER,
P.J. Bay u3405, a novel thromboxane
receptor antagonist: activity on
isolated airway tissues, 99, 59P
- MCKERNAN, R. see PRIESTLEY, T., 99,
95P
- MCKIBBEN, B. see MARTIN, J., 101,
549P
- MCLAUGHLIN, D.P. & MACDONALD, A.
'Atypical' β -adrenoceptors in the
rat gastric fundus, 99, 119P
- MCLAUGHLIN, M., ROSS, B.M., KNOWLER, J.
T., MILLIGAN, G. & MCCULLOCH, J.
Immunoblot analysis of the α subunit
of G proteins in control and
Alzheimer diseased brains, 99, 269P
- MCLEOD, J.D. & PIPER, P.J. The
effects of endothelin-1 on guinea-pig
isolated working hearts, 99, 151P
- - - Effect of leukotriene D₄ on the
responses of cysteinyl leukotrienes
and U46619 in guinea-pig heart, 101,
543P
- MCMAHON, S. see HAMBLETON, P., 99,
167P
- MEECHAM, K.G. see BOYLE, S.J., 100,
303P
- MELARANGE, R., BLOWER, P.R., GENTRY, C.
& O'CONNELL, C. Nabumetone, and
effective anti-inflammatory agent,
lacks the gastric irritancy potential
of piroxicam or ibuprofen, 99, 172P
- MELDRUM, B.S. see KERWIN, R., 99,
97P
- MENCIA-HUERTA, J.M. see LAGENTE, V.,
99, 174P
- - - see TOUVAY, C., 99, 190P
- MENNINGER, K. see FOZARD, J.R., 99,
7P
- METAXAS, K.E. see LEATHARD, H.L.,
100, 330P
- MICHEL, A.D. & WHITING, R.L. Gallamine
as a pharmacological tool to aid the
identification of muscarinic receptor
subtypes, 100, 366P
- MICHEL, M.C., POLIZZI, S. & MOTULSKY,
H.J. Inhibition of lymphocyte
proliferation and activation by
ketotifen and cyclosporin A, 99,
165P
- MICHELI, D. see TRIST, D., 100,
442P
- MICHELI, D., RATTI, E., TOSON, G.,
TRIST, D. & GAVIRAGHI, G. Pharmacol-
ogical profile of taludipine
(GR53992B), a new long-acting calcium
entry blocker, 100, 332P

- MICKLETHWAITE, A.V., YOUNG, A., DETTMAR, P.W. & WHITE, J.P.N. The effects of idazoxan on fluid transport and transit in rat colon *in vivo*, 100, 479P
- MIDDLEFELL, V.C., PRICE, T.L. & THOMSON, I.A. 5-HT₃ receptor agonist effects of zacopride in the ferret, 101, 560P
- MIDDLEMISS, D.N. *see* BRISTOW, L.J., 100, 416P
- - - *see* HUTSON, P.H., 100, 310P
- - - *see* PANGALOS, M.N., 100, 377P
- MIKHAILIDIS, D.P. *see* BARRADAS, M.A., 101, 521P
- MILLER, M. *see* BOBINSKI, H., 100, 361P
- MILLER, R.C. *see* HUGGINS, J.P., 99, 208P
- - - *see* TSCHIRHART, E., 99, 57P
- MILLIGAN, G. *see* MCLAUGHLIN, M., 99, 269P
- MILNE, A.A. *see* GWILT, M., 99, 15P
- - - *see* KING, R.C., 99, 230P
- MILTON, A.S. *see* DAVIDSON, J., 100, 445P
- - - *see* DAVIDSON, J., 100, 447P
- MILTON, K.A., WARD, S.A. & EDWARDS, G. Lack of effect of the antimalarial agent halofantrine on hepatic drug metabolism, 99, 296P
- MINSHALL, E.M., JOHNSON, P.R., CAMPBELL, A.M., BROWN, T.J. & CARTER, C.M. The influence of extracellular calcium and different loading concentrations of fura-2/am on the calcium response to PAF in guinea-pig eosinophils, 100, 448P
- MIR, A.K. *see* BOUHELAL, R., 99, 38P
- MISSION, B.H. *see* EBENEZER, I.S., 100, 419P
- MITCHELL, E.A., PRATT, J.A. & BALFOUR, D.J.K. Aversive environmental stimuli do not evoke behavioural responses to GR38032F following chronic treatment and withdrawal, 99, 245P
- MITCHELL, I.J. *see* BLACK, M.D., 100, 381P
- - - *see* BROTHIE, J.M., 100, 385P
- MITCHELL, J.A. *see* D'ORLEANS-JUSTE, P., 99, 100P
- MITCHELL, J.A., HECKER, M., KATSURA, M., ANGGARD, E. & VANE, J.R. Relationship between L-arginine concentration and EDRF release in bovine aortic endothelial cells, 99, 101P
- MITCHELL, J.A., KONDO, K. & VANE, J.R. The role of calcium in the release from endothelial cells of EDRF and prostacyclin induced by different agonists, 100, 450P
- MITCHELL, P.D. *see* CARR, R.D., 99, 17P
- MITCHELL, S.N. *see* SMITH, S.E., 100, 417P
- - - *see* TWIST, E.C., 100, 397P
- MITCHELL, S.N., BRAZELL, M.P. & GRAY, J.A. Nicotine-stimulated noradrenaline release in the hippocampus of freely moving rats, 99, 266P
- MOBIUS, C. *see* CRESPI, F., 99, 260P
- - - *see* GONZALES-MORA, J.L., 101, 583P
- MOLLACE, V. *see* SALVEMINI, D., 100, 325P
- MONCADA, S. *see* CATTELL, V., 99, 108P
- - - *see* GARDINER, S.M., 99, 103P
- MONOPOLI, A. *see* ONGINI, E., 99, 78P
- MONOPOLI, A., FORLANI, A., ONGINI, E., LAGRASTA, C., RICCI, R. & OLIVETTI, G. Effects of long-term administration of dilevalol and pindolol on blood pressure and myocardial hypertrophy in young spontaneously hypertensive rats, 99, 228P
- MOODY, C.J., DASHWOOD, M., SYKES, R., CHESTER, M., JONES, S.M., YACOB, M. & HARDING, S.E. Endothelin receptors on human and rat cardiac myocytes: a comparison with isolated smooth muscle cells, 99, 210P
- MOODLEY, I., GROUHEL, A., WITKO, V. & JUNIEN, J.L. Effects of PCP and sigma ligands on NMDA- and DTG-induced convulsions and mortality in mice, 100, 380P
- MOORE, A. *see* SALVEMINI, D., 100, 325P
- MOORE, D. *see* CONNAUGHTON, S., 101, 537P
- MOORE, H.D. & CUNNINGHAM, F.M. Mediators of primary irritant dermatitis in miniature swine, 99, 160P
- MOORE, M.R. *see* CUTLER, M.G., 100, 486P
- MOREL, E. *see* PERRAULT, G., 99, 255P
- MORGAN, G.P. & SIMMONDS, M.A. The peripheral-type site for benzodiazepines may be associated with the uptake carrier for adenosine, 99, 132P
- MORICE, A. *see* ODDOY, A., 100, 459P
- - - *see* ROGERS, T., 100, 458P
- - - *see* STEWART, A.G., 100, 460P
- MORINAN, A. *see* MOULTON, B., 101, 516P
- MORLEY, J. *see* CHAPMAN, I., 99, 66P

- - - see HULTKVIST-BENGTSSON, U., 99, 83P
- - - see SANJAR, S., 99, 64P
- MORRIS, B.J., WISDEN, W., HUNT, S.P. & BARNARD, E.A. Localisation of mRNAs encoding subunits of the nicotinic acetylcholine receptor to distinct cell groups in the rat spinal cord, 99, 197P
- MORRISETT, R.A. see MARTIN, D., 99, 279P
- MORRISON, K.J. see SHARIFI, A.M., 101, 533P
- MORTON, I.K.M. see FOX, A.J., 99, 51P
- MORTON, J. see XIANG, J-Z., 99, 297P
- MOSER, P.C. Effect of endothelin-1 on pupil diameter following injection into the anterior pretectal nucleus of the rat, 99, 211P
- - - The effect of novel anxiolytics on the head-twitch response in mice, 99, 248P
- MOSES, A. see HUGTENBERG, J., 99, 20P
- MOSS, M.S. see D'SOUZA, G.A., 99, 50P
- MOSS, S. see SMART, T.G., 100, 388P
- MOTOMURA, S. see DEIGHTON, N.M., 99, 116P
- MOTULSKY, H.J. see MICHEL, M.C., 99, 165P
- MOULTON, B. & MORINAN, A. The effect of RS-30199 on anxiety and hippocampal monoamine oxidase activity in the rat, 101, 516P
- MUCKLOW, J.C. see HIRJI, M.R., 100, 434P
- - - see TAN, C.K., 100, 436P
- MUIR, T.C. see JENKINSON, S., 101, 534P
- - - see NALLY, J.E., 101, 504P
- - - see SCHWARZE, J., 101, 532P
- MULDER, P. see RICHER, C., 99, 8P
- MULLER, F., JANIAN, P., BRAY, L., ATKINSON, J., SCALBERT, E., DEVISSAGUET, M. & CAPDEVILLE, C. Effect of perindopril on cerebral blood flow in awake renovascular hypertensive and normotensive rats, 99, 48P
- MULLIGAN, B.J. see KING, A.T., 99, 299P
- MUNSEY, T.S. see ROBINSON, S.C., 100, 323P
- MURRAY, K.J. see KAUMANN, A.J., 100, 319P
- MURRAY, M.A., FOSTER, R.W. & SMALL, R.C. Effects of the K⁺ channel openers cromakalim and RP 49356 on the cyclic nucleotide content of guinea-pig isolated trachealis muscle, 100, 367P
- MURRAY, T.K., HUNTER, A.J., DE SOUZA, R.J. & CROSS, A.J. Manipulation of central 5-HT function disrupts performance of a delayed-non-match-to-sample task in rats, 99, 246P
- MUSTER, D. see ARMAH, B.I., 100, 321P
- NAHORSKI, S.R. see BAIRD, J.G., 100, 315P
- - - see CHILVERS, E.R., 100, 363P
- - - see CHILVERS, E.R., 100, 364P
- - - see FORSYTHE, I.D., 100, 427P
- - - see LAMBERT, D.G., 99, 143P
- - - see LAMBERT, D.G., 100, 311P
- - - see OFFER, G.J., 100, 362P
- - - see SAFRANY, S.T., 99, 88P
- - - see WHITHAM, E.M., 99, 140P
- - - see WOJCIKIEWIECZ, R.J.H., 99, 144P
- NAKAMURA, M. & BAKHLE, Y.S. Nafazatrom and Ph CL 28A inhibit prostaglandin E₂ catabolism and prostanoid synthesis in rat isolated heart, 99, 21P
- NAKAMURA-CRAIG, M. see FOLLENFANT, R. L., 99, 289P
- NAKAMURA-CRAIG, M. & GILL, B.K. Possible involvement of neurokinin-A, substance P and calcitonin gene-related peptide in peripheral hyperalgesia in the rat, 99, 288P
- NALLY, J.E., GUILD, S.B. & MUIR, T.C. Phosphatidyl choline metabolism and contraction in arteriolar smooth muscle, 101, 504P
- NAYEEM, N. see SMART, T.G., 100, 388P
- NAYLOR, R.J. see BARNES, N.M., 99, 142P
- - - see BARNES, J.M., 99, 293P
- - - see BARNES, N.M., 100, 402P
- NAYLOR, R.J. see BARNES, N.M., 101, 572P
- - - see BARNES, J.M., 101, 598P
- - - see COUGHLAN, J., 101, 561P
- - - see COUGHLAN, J., 101, 562P
- - - see HORNSBY, C.D., 100, 396P
- - - see JONES, D.N.C., 100, 309P
- - - see RUDD, J.A., 99, 247P
- NAYLOR, R.J. & RUDD, J.A. Midbrain section in the ferret modifies drug-induced emesis, 100, 406P
- NEHLIG, H. see KERAVIDIS, T.M., 100, 344P
- NEILD, G.H. see CAIRNS, H.S., 99, 109P

- NELSON, J. see ALDALOU, A.R., 101, 580P
- NEY, P. & SCHROR, K. Stimulus-dependent inhibition of human polymorphonuclear leukocyte (PMN) activation by the PGD₂ mimetic ZK 110.841, 99, 93P
- NIALS, A.T. see COLEMAN, R.A., 99, 121P
- NIALS, A.T., BUTCHERS, P.R., COLEMAN, R.A., JOHNSON, M. & VARDEY, C.J. Salmeterol and formoterol: are they both long-acting β_2 -adrenoceptor agonists? 99, 120P
- NICHOLSON, C.D. see SHAHID, M., 100, 443P
- NIELSEN, M. see LUMMIS, S.C.R., 99, 33P
- NISTICO, G. see BAGETTA, G., 99, 96P
- - - see BAGETTA, G., 100, 384P
- NIXON, G.F., HAMILTON, C.A. & REID, J.L. Inositol phosphate formation in developing and established perinephritis hypertension in the rabbit, 99, 125P
- NOREL, X., LABAT, C., GARDINER, P. & BRINK, C. An evaluation of the inhibitory activity of Bay u3405 on the U46619 response in human isolated bronchial muscle preparations, 99, 61P
- NORMAN, J.-C., GURNEY, A.M. & GILLHAM, B. Type-2 glucocorticoid receptors differentially regulate the release of adrenocorticotrophin variants from anterior pituitary cells, 99, 126P
- NORMAN, P. see MCKENNIFF, M.G., 99, 59P
- NUNEZ, D.J. see DAVENPORT, A.P., 99, 114P
- - - see DAVENPORT, A.P., 99, 127P
- NUNEZ, D.J., TAYLOR, E.A., SCHOFIELD, J.P., OH, V.M.S. & BROWN, M.J. Endothelin-1 mRNA in the rat kidney, 99, 105P
- NUNN, D.L. & TAYLOR, C.W. Properties of inositol (1,4,5)trisphosphate receptors in liver and cerebellum, 99, 92P
- NUTT, D.J. see HUDSON, A.L., 100, 345P
- - - see JACKSON, H.C., 99, 290P
- - - see JACKSON, H.C., 100, 392P
- O'BOYLE, K.M. see SMITH, K., 101, 494P
- O'BOYLE, K.M. & WASSINGTON, J.L. Interaction of CY 208-243 with D₁ dopamine receptors: influence of Gpp(NH)p, 99, 76P
- O'CONNELL, C. see MELARANGE, R., 99, 172P
- O'CONNOR, J. see GONZALEZ-MORA, J.J., 100, 399P
- O'CONNOR, J.J. see MANAHAN-VAUGHAN, D., 99, 29P
- - - see TROUT, S.J., 99, 258P
- O'CONNOR, J.J. & KRUK, Z.L. Measurement of stimulated endogenous 5-HT release in rat brain slices using fast cyclic voltammetry, 101, 557P
- O'CONNOR, S.E. see CARR, R.D., 99, 17P
- - - see DAINTY, I.A., 101, 507P
- - - see WOOD, B.E., 100, 342P
- - - see WOOD, B.E., 101, 531P
- O'CONNOR, S.E., WOOD, B.E. & LEFF, P. Relative agonist potencies of methylene substitutes ATP analogues for P_{2x}-purinoceptors in the rabbit ear artery, 100, 341P
- ODDOY, A., EMERY, C., BEE, D., BARER, G. & MORICE, A. Pulmonary vasodilation by ligustrazine, 100, 459P
- O'DONOGHUE, S. see BARRADAS, M.A., 101, 521P
- OFFER, G.J., CHILVERS, E.R. & NAHORSKI, S.R. Muscarinic receptor-mediated phosphoinositide hydrolysis is inhibited by isoprenaline and IBMX in bovine tracheal smooth muscle, 100, 362P
- OH, V.M.S. see NUNEZ, D.J., 99, 105P
- OLEN, R.J. see TRICKLEBANK, M.D., 99, 73P
- OLEN, R.J., SINGH, L. & TRICKLEBANK, M. D. Differential effects on the behavioural and anticonvulsant properties of MK-801 following repeated administration in the mouse, 99, 286P
- OLIVETT, G. see MONOPOLI, A., 99, 228P
- OLUFSEN, A.S. & HICKS, R. Myofibroblast-like contracture of fibrotic rat lung-strip preparations provoked by oxidising agents, 99, 168P
- OLVERMAN, H.J. see LAWRENCE, J.A., 99, 35P
- O'NEILL, L.A.J., BIRD, T.A. & SAKLATVALA, J. Interleukin-1 activates a G-protein in EL4.NOB1 murine thymoma cells: a possible signal transduction mechanism, 99, 147P
- O'NEILL M.F. see DOURISH, C.T., 101, 575P
- O'NEILL, M.F., DOURISH, C.T. & IVERSEN, S.D. Reversal of CCK-induced hypo-locomotion in the mouse by the CCK-A antagonist devazepide but not by the CCK-B antagonist L-365,260, 101, 574P

- O'NEILL, M.F., KITCHENER, S.J., DOURISH, C.T. & IVERSEN, S.D. The CCK antagonists devazepide and L-365,260 promote weight gain in weaning rats, 99, 137P
- O'NEILL, M.F., TYE, S.J., DOURISH, C.T. & IVERSEN, S.D. Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey, 101, 577P
- ONGINI, E. see MONOPOLI, A., 99, 228P
- ONGINI, E., TRAMPUS, M., FERRI, N. & MONOPOLI, A. Blockade of D₁ dopamine receptors by SCH 23390 leads to enhancement of REM sleep in the rat, 99, 78P
- ORTEGA, M.P., FERNANDEZ-GALLARDO, S., GARCIA, M.C., FAU DE CASA-JUANA, M., PRIEGO, J.G., SUNKEL, C. & SANCHEZ-CRESPO, M. 1,4-dihydropyridines, a new class of PAF receptor antagonists, 99, 175P
- O'SHAUGHNESSY, C.T. see LITTLE, R.A., 100, 454P
- OSTER, L. see THORIN-TRESCASES, N., 99, 44P
- OWEN, P.J. see BOARDER, M.R., 100, 343P
- - - see JONES, J.A., 99, 159P
- OWEN, P.J. & BOARDER, M.R. Evidence that bradykinin stimulation of phosphatidic acid production in adrenal chromaffin cell cultures may be by direct activation of phospholipase D, 99, 91P
- OXFORD, A.W. see KILPATRICK, G.J., 99, 32P
- PACIOREK, P.M. see DUTY, S., 100, 329P
- PACIOREK, P.M., COWLRICK, I.S., SPENCE, A.M., TAYLOR, J.C. & WATERFALL, J.F. Comparison of the bronchodilator properties of Ro 31-6930, lemakalim and salmeterol in the guinea-pig, 101, 592P
- PACKMAN, F. see KING, R.C., 99, 230P
- PAGE, C.P. see SPINA, D., 99, 187P
- PALLY, C. see QUAIST, U., 99, 6P
- PALMER, R.E. see JOHNS, E.J., 99, 195P
- PALMER, R.M.J. see GARDINER, S.M., 99, 103P
- PALMER, S. see KENTISH, J.C., 99, 11P
- PANGALOS, M.N., PEARSON, R.C.A., FRANCIS, P.T., MIDDLEMISS, D.N. & BOWEN, D.M. Selective destruction of a sub-population of cortical neurones by suicide transport of volkensin, a lectin from Adenia volkensii, 100, 377P
- PANJESHAHIN, M.R., COLLIS, M.G., BOWMER, C.J. & YATES, M.S. Amelioration of acute renal failure with 8-cyclopentyl-1,3-dipropylxanthine dose dependency, 101, 548P
- PARKINSON, N.A., THOM, S.McG. & SEVER, P.S. Adrenaline and noradrenaline activation of α_2 -adrenoceptors in human resistance arteries, 101, 536P
- PARRATT, J.H. see WAINWRIGHT, C.L., 99, 14P
- PARRATT, J.R. see GRAY, G.A., 99, 107P
- - - see GUC, M.P., 99, 47P
- - - see VEGH, A., 99, 19P
- PARROTT, R.F. see EBENEZER, I.S., 101, 573P
- PARSONS, A.A., KSOLL, E., MACKERT, J. R.L., SCHILLING, L. & WAHL, M. Comparison of cromakalim-, pinacidil- and nicorandil-induced relaxation of rat isolated basilar artery, 100, 331P
- - - Effect of sulfonylureas on cromakalim-induced relaxation of KCl pre-contracted rabbit, cat and rat isolated cerebral arteries, 100, 457P
- PARSONS, M.E. see HILLS, J.M., 101, 600P
- PATEL, I.A. see ALYAMI, A.M., 101, 597P
- PATEL, M. see SPRAGGS, C.F., 100, 360P
- PATEL, M.K., SCHACHTER, M. & SEVER, P. S. Preliminary pharmacological characterisation of cultured human prostatic stromal cells, 99, 176P
- PATEL, S. see KERWIN, R., 99, 97P
- PATEL, U. see FRANCIS, H.P., 99, 60P
- PATERSON, G. see SWALES, N., 100, 489P
- PATERSON, S.J. Comparison of opioid binding in brain, cerebellum and spinal cord of New Zealand white rabbits, 101, 553P
- - - see KOSTERLITZ, H.W., 99, 291P
- PAYNE, A.N. see YEADON, M., 99, 191P
- PAYVANDI, N. & ELLIOTT, J.M. Treatment with DSP-4 selectively increases β_1 -adrenoceptor number in rat cerebral cortex, 99, 268P

- PAYVANDI, N., ELLIOTT, J.M. & HEAL, D. J. Radioligand binding to presynaptic α_2 -adrenoceptors in rat cortex revealed by short-term DSP-4 lesioning, 100, 346P
- PEACHEY, J.A. & KITCHEN, I. Comparison of endothelin responses in rat and guinea-pig trachea and their modulation by peptidase inhibitors, 99, 184P
- PEARSON, H.A., LEES, G. & WRAY, D.W. Lack of effect of avermectin on calcium channels in muscle fibres from moth larvae, 99, 250P
- PEARSON, J.D. see TOOTHILL, V.J., 99, 42P
- PEARSON, R.C.A. see PANGALOS, M.N., 100, 377P
- PEERS, S.H. 5-HT and bradykinin pleurisy in the rat is insensitive to dexamethasone pretreatment, 99, 150P
- PEH, K.H., WAN, B.Y.C., ASSEM, E.S.K. & THORNTON, P.C. Effects of sulphasalazine and balsalazide on cell membrane stability and histamine release, 100, 449P
- PEICKMANS, P.A. see BOECKXSTAENS, G. E., 99, 52P
- PELTON, J.T. see ZREIKA, M., 99, 207P
- PENDRY, Y.D. & MACLAGAN, J. Vagally-released acetylcholine inhibits sympathetic neurotransmission in the guinea-pig trachea, 101, 590P
- PEREZ-VIZCAINO, F. see CARRON, R., 101, 541P
- - - see DELPON, E., 101, 540P
- PERKINS, M.N. see CAMPBELL, E.A., 101, 545P
- PEROUTKA, S.J. see SLEIGHT, A.J., 99, 25P
- PERRAULT, G., MOREL, E., SANGER, D.J. & ZIVKOVIC, B. Comparison of the pharmacological profiles of four hypnotics with different chemical structures: quazepam, brotizolam, zopiclone and zolpidem, 99, 255P
- PETERS, J.A. see HALLIWELL, R.F., 99, 280P
- - - see STURGESS, N.C., 99, 278P
- PETTERSSON, A. see FENG, Q., 99, 49P
- PETTIPHER, E.R. see CRUWYS, S.C., 99, 148P
- PHILLIPS, I. see HEAL, D.J., 100, 404P
- - - see MARTIN, K.F., 99, 267P
- - - see MARTIN, K.F., 100, 405P
- PHILLIPSON, O.T. see PLUMMER, C.J., 99, 67P
- PICARDO, A., GENT, J.P. & FEELY, M. Anticonvulsant tolerance and recovery during repeated administration of the GABA uptake inhibitor NO-328, 99, 131P
- PICKERING, S.A.W. see KEEN, M., 101, 524P
- PICQUOT, S. see LAGENTE, V., 99, 174P
- PIETRA, C., ZIVIANI, L., CESERANI, R., GAVIRAGHI, G., HAGAN, R.M. & JORDAN, C.C. Effects of selective neurokinin agonists on rat bladder motility in vitro and in vivo, 99, 177P
- PIKE, N.B., WATTS, I.S. & LUMLEY, P. Effects of guanylate cyclase activation and type I phosphodiesterase inhibition upon human platelet aggregation, 99, 112P
- PINNOCK, R.D. see KEEGAN, K.D., 101, 579P
- - - see MARSHALL, F.H., 99, 136P
- PINNOCK, R.D., WOODRUFF, G.N. & BODEN, P.R. Cholecystokinin excites dorsal raphe neurones via a CCK_A receptor, 100, 349P
- PIOT, O., BARDONE, M.C., ZUNDEL, J.L., STUTZMANN, J.M., BOIREAU, A. & DOBLE, A. RP 59037, a novel partial agonist at the GABA-benzodiazepine receptor: binding and behavioural studies in the rodent, 99, 133P
- PIPER, P.J. see CONROY, D.M., 99, 58P
- - - see CONROY, D.M., 101, 593P
- - - see GUNN, L.K., 100, 371P
- - - see GUNN, L.K., 100, 472P
- - - see MCLEOD, J.D., 99, 151P
- - - see MCLEOD, J.D., 101, 543P
- PLANE, F., BRUCKDORKER, K.R. & JACOBS, M. The effect of LDL on the contractile response to 5-HT in rabbit aorta, 99, 220P
- PLEASS, R.D. & WESTWICK, J. Modulation of IL-8 generation in the pre-monocytic cell line, U937P1, 101, 530P
- PLUMMER, C.J., HALKET, J. & PHILLIPSON, O.T. Identification and distribution of N-methyladrenaline in the central nervous system of the rat, 99, 67P
- POAT, J.A. see HARLEY, E.A., 99, 263P
- POLIZZI, S. see MICHEL, M.C., 99, 165P
- POLLOCK, D. see AIDULIS, D.M., 101, 535P
- - - see FUGLSANG, A., 101, 506P
- - - see SHARIFI, A.M., 100, 466P
- - - see SHARIFI, A.M., 101, 533P
- PONCET, V. see GALZIN, A.M., 100, 307P

- POTTER, B.V.L. see SAFRANY, S.T., 99, 88P
- POTTS, H.J. see HILLS, J.M., 101, 600P
- PRATT, J.A. see LAURIE, D.J., 99, 134P
- - - see MITCHELL, E.A., 99, 245P
- PRENDIVILLE, E. see CONNAUGHTON, S., 101, 537P
- PRENTICE, D.J. & BLACK, J.W. 9-Methyladenine analogues are selective A_1 adenosine receptor antagonists, 101, 596P
- PRESCOTT, S. see COLLINS, G.G.S., 100, 383P
- PRICE, T.L. see MIDDLEFELL, V.C., 101, 560P
- PRIEGO, J.G. see ORTEGA, M.P., 99, 175P
- PRIESTLEY, T., HORNE, A.L., MCKERNAN, R. & KEMP, J.A. Glycine site antagonists protect against hypoxia-induced injury to rat cortical cell cultures, 99, 95P
- PRINGLE, A.K. & EBENEZER, I.S. The effects of baclofen on operant and non-operant food intake in rats, 100, 420P
- PROW, M.R. see HEAL, D.J., 99, 74P
- PRYKE, J. see KEY, B.J., 100, 467P
- PUIG, C. see GRISTWOOD, R.W., 99, 18P
- PURCELL, W.M. & HANAHOE, T.H.P. Human placenta: a novel source of mast cells, 100, 334P
- QUAST, U. see FOZARD, J.R., 99, 7P
- QUAST, U., BLARER, S., MANLEY, P.W., COOK, N.S., PALLY, C. & FOZARD, J.R. The cardiovascular effects of SDZ PCO 400, a novel K^+ channel opener, 99, 6P
- RAAP, A. see ARMAH, B.I., 100, 321P
- RABBANI, M. & LITTLE, H.J. Increased action of the partial inverse agonist, FG7142, during barbiturate withdrawal: protective effect of the calcium channel antagonist nitrendipine, 100, 422P
- - - Changes in dihydropyridine barbitol treatment, 101, 568P
- RABE, K., GIEMBYCZ, M.A., DENT, G. & BARNES, P.J. Leukotriene B_4 stimulates hydrogen peroxide generation in guinea-pig eosinophils: possible role of protein kinase C, 100, 376P
- - - Induction of thromboxane biosynthesis in guinea-pig eosinophils stimulated with leukotriene B_4 , 101, 526P
- RACKE, K. see BERRINO, L., 99, 265P
- - - see WESSLER, I., 99, 54P
- RACKE, K., BAHRING, A. & WESSLER, I. Effects of 5-HT, metitepine and ketanserin on the release of endogenous noradrenaline (NA) from the rat trachea *in vitro*, 99, 219P
- RADZISZEWSKI, W. see SALVEMINI, D., 100, 325P
- RAEBURN, D. see LEWIS, S.A., 100, 474P
- RAKSHI, K. see FOSTER, R.W., 99, 193P
- RAMAGE, A.G. see SHEPHEARD, S., 101, 520P
- RAMOS, E.G., ESPLUGUES, J.V., GIL, L. & ESPLUGUES, J. Involvement of capsaicin-sensitive afferent neurones in the acid secretory responses of the rat stomach, 99, 222P
- RAMPART, M. see BOECKXSTAENS, G.E., 99, 52P
- RASSNICK, S.R. see BALDWIN, H.A., 100, 339P
- RATTI, E. see MICHELI, D., 100, 332P
- RAVARD, S., DOURISH, C.T. & IVERSEN, S. D. Evidence that the anxiolytic-like effects of the CCK antagonists devazepide and L-365,260 in the elevated plus-maze paradigm in rats are mediated by CCK receptors, 101, 576P
- RAVENS, U. see HIMMEL, H.M., 99, 12P
- RAVENS, U. & LIU, G. Mioflazine and lidoflazine protect atrial muscle against calcium overload damage: a study of ultrastructure, cytochemistry and function, 99, 13P
- RAY, N.J., JONES, A.J. & KEEN, P. Ruthenium red: selective, reversible inhibition of capsaicin-stimulated substance P release from primary afferent neurons in rat trachea, 99, 186P
- REAVILL, C.A. see ROGERS, D.C., 100, 409P
- REDFERN, J. see MARTIN, K.F., 100, 351P
- REDFERN, P.H. & SINGH, A. Inhibition of 5-HT $_{1B}$ autoreceptors by methiothepin does not reveal a circadian variation in autoreceptor sensitivity in the cerebral cortex of the rat, 99, 242P
- REDFERN, R.J. see BROWNING, J.G., 100, 403P

- - - see HEAL, D.J., 100, 404P
- REDFERN, W.S. & WILLIAMS, A. Anxiogenic effects are associated with yohimbine but not with RS-15385-197 or idazoxan in the rat, 101, 518P
- REDFERN, E.J. & DASCOMBE, M.J. Comparative study of the pyrogenicities of interleukin 1 β and interleukin 6 in conscious rats, 99, 162P
- REES, D.C. see HUNTER, J.C., 99, 24P
- REGOLI, D. see KERAVALIS, T.M., 100, 344P
- REID, J.L. see HASSAN, N., 101, 544P
- - - see HUANG, Y.T., 101, 509P
- - - see NIXON, G.F., 99, 125P
- RHODES, K.F. see BILL, S.J., 100, 483P
- - - see SAVILLE, V.L., 100, 484P
- RIBEIRO, J.A. see CORREIA-DE-SA, P., 99, 227P
- - - see SEBASTIAO, A.M., 99, 141P
- RICCI, R. see MONOPOLI, A., 99, 228P
- RICHARDS, J.G. see SAURA MARTI, J., 99, 69P
- RICHER, C., MULDER, P. & GUIDICELLI, J. F. Interactions between K⁺ channel openers and the sympathetic nervous system in pithed spontaneously hypertensive rats, 99, 8P
- RIDLEY, P.D., YACOB, M.H. & CURTIS, M. J. Membrane permeability is a determinant of arrhythmogenesis following anion substitution, 101, 511P
- RIOU, B. see DRIEU LA ROCHELLE, C., 99, 1P
- RIPLEY, T.L. see JACKSON, H.C., 99, 290P
- RITTER, J.M. see BENJAMIN, N., 100, 326P
- RITTER, J.M., DOKTOR, H.S. & STRATTON, P. Effect of bradykinin B₁ receptor selective peptides on thymidine uptake by rabbit coeliac artery smooth muscle cells, 99, 200P
- RIVEST, R., JOLICOEUR, F.B. & MARSDEN, C.A. Atypical neuroleptic-like properties of neurotensin: an *in vivo* neurochemical study, 100, 353P
- - - Lack of evidence for chemical complexation between neurotensin and dopamine, 101, 578P
- ROBERTS, F.F. see BARNES, J.C., 99, 155P
- ROBERTS, M.H.T. see SIZER, A.R., 99, 26P
- ROBERTS, P.J. see GIBBONS, S.J., 99, 90P
- ROBERTS, P.J., CRAWFORD, M. & STRIKE, C. Glycine - a putative co-transmitter at glutamate-operated synapses: uptake and release by rat striatal slices, 99, 284P
- ROBERTS, S.A., MCCORMACK, A., GUNRAJ, P., MACKENZIE, R.E. & FACCHINI, V. Comparison of the hepatic clearance of (+) RP 49356 and its enantiomers in the isolated perfused liver, 101, 547P
- ROBERTSON, C., ROBINSON, T.N., CROSS, A.J. & GREEN, A.R. The effects of polyamines on the binding of [³H]-MK-801 to rat cortical membranes, 99, 281P
- ROBINSON, C. see CAMPBELL, A.M., 99, 170P
- - - see HERBERT, C.A., 99, 189P
- - - see HERBERT, C.A., 100, 372P
- - - see HERBERT, C.A., 100, 373P
- - - see HERBERT, C.A., 100, 477P
- ROBINSON, C., CAMPBELL, A.M., HERBERT, C.A., SAPSFORD, R., DEVALIA, J.L. & DAVIES, R.J. Calcium-dependent release of eicosanoids in human cultured bronchial epithelial cells, 100, 471P
- ROBINSON, J.P. & KENDALL, D.A. Niguldipine differentiates between α_1 -adrenoceptor subtypes linked to inositol phospholipid hydrolysis and potentiation of cyclic AMP formation in rat brain, 99, 71P
- - - Effect of corticosterone and steroid antagonist RU38486 on noradrenaline-stimulated cyclic AMP in rat cortex and hippocampus slices, 99, 273P
- ROBINSON, S.C., WORMALD, A.D., MUNSEY, T.S., BOWMER, C.J. & YATES, M.S. Myocardial energy production in rats with acute renal failure, 100, 323P
- ROBINSON, T.N. see DE SOUZA, R.J., 100, 401P
- - - see ROBERTSON, C., 99, 281P
- ROBSON, A. see CARR, R.D., 99, 17P
- RODGER, I.W. see DREWETT, I.J., 99, 192P
- RODGERS, R.J. see LEE, C., 99, 135P
- - - see LEE, C., 100, 412P
- RODGERS, R.J. & SHEPHARD, J.K. Stereo-selective effect of 5-HT_{1A} ligand, MDL 72832, on non-opioid defeat analgesia in mice, 99, 34P
- - - Evidence for a peripheral component in the inhibitory actions of 5-HT₃ antagonists on defeat analgesia, 100, 415P
- ROGERS, D.C. see BOND, B.C., 100, 408P

- ROGERS, D.C., REAVILL, C.A. & HUNTER, A.J. Comparison of the effects of selective D₁ agonists on dopamine-mediated behaviour, 100, 409P
- ROGERS, H. see HARRISON, S.M., 99, 283P
- ROGERS, H., BIRCH, P.J. & HAYES, A.G. The gerbil hippocampal slice: an in vitro model of ischaemia? 99, 98P
- ROGERS, T. & MORICE, A. Ligustrazine is a vasorelaxant of pulmonary artery and pulmonary resistance vessels, 100, 458P
- ROGERSON, M.E. see CAIRNS, H.S., 99, 109P
- ROSE, S. see ATTWELL, P.J.E., 101, 496P
- ROSE, S., JENNER, P. & MARSDEN, C.D. Carbidopa pretreatment prevents the alterations in L-DOPA pharmacokinetics after chronic treatment of rats with L-DOPA plus carbidopa, 99, 80P
- ROSS, B.M. see MCLAUGHLIN, M., 99, 269P
- ROSSOR, M.N. see LANGE, K.W., 99, 156P
- - - see LANGE, K.W., 100, 313P
- ROTHAUL, A.L. see URQUHART, R.A., 100, 322P
- ROTONDO, D. see DAVIDSON, J., 100, 445P
- - - see DAVIDSON, J., 100, 447P
- ROWAN, M.J. see BARRETT, R.P., 101, 517P
- - - see MANAHAN-VAUGHAN, D., 99, 29P
- RUDD, J.A. see NAYLOR, R.J., 100, 406P
- RUDD, J.A. & NAYLOR, R.J. Preliminary assessment of feverfew (*Tanacetum Parthenium*) to antagonise cisplatin-induced emesis in the ferret, 99, 247P
- RUFFLE, C. see DESQUAND, S., 99, 84P
- RUSSELL, S.N. see BRUNTON, V.G., 99, 298P
- RUYTJENS, I.F. see BOECKXSTAENS, G. E., 99, 52P
- RYAN, F. see MARTIN, F., 101, 529P
- RYAN, M.P. see FALLER, D., 101, 523P
- - - see MCGLYNN, H., 101, 513P
- - - see MCGUINNESS, S., 101, 514P
- SAAID, A.H. see MAKINDE, V., 100, 432P
- SAFRANY, S.T. see WOJCIKIEWIECZ, R.J. H., 99, 144P
- SAFRANY, S.T., WOJCIKIEWIECZ, R.J.H., MCBAIN, J., COOKE, A.M., POTTER, B.V.L. & NAHORSKI, S.R. Evaluation of calcium-mobilising properties of phosphorothioate-containing analogues of inositol (1,4,5)trisphosphate in SH-SY5Y human neuroblastoma cells, 99, 88P
- SAKLATVALA, J. see O'NEILL, L.A.J., 99, 147P
- SALMON, J.A. see DAVIDSON, J., 100, 447P
- SALVEMINI, D., MASINI, E., MANNAIONI, P. F. & VANE, J. Formation of nitric oxide-like activity from L-arginine in rat mast cells, 100, 333P
- SALVEMINI, D., RADZISZEWSKI, W., MOLLACE, V., MOORE, A. & VANE, J. Diphenylene iodonium, a potent inhibitor of free radical production, possesses anti-platelet activity and interacts with modulators of platelet cyclic nucleotides, 100, 325P
- SAMHOUN, M.N. see CONROY, D.M., 99, 58P
- - - see CONROY, D.M., 101, 593P
- SAMTANEY, N. see IRAVANI, M.M., 99, 179P
- SANCHEZ CRESPO, M. see ORTEGA, M.P., 99, 175P
- SANDERS, L. see KAUMANN, A.J., 100, 319P
- SANGER, D.J. see PERRAULT, G., 99, 255P
- SANGHA, R. see CLAYTON, J.K., 99, 180P
- SANJAR, S. & MORLEY, J. The effect of peptides on tracheal mucus velocity (TMV) in the anaesthetised ferret, 99, 64P
- SAPSFORD, R. see ROBINSON, C., 100, 471P
- SARNA, G.S. see DE SOUZA, R.J., 100, 401P
- SARNA, G.S., WHITTON, P., CURZON, G. & LEATHWOOD, P. Effect of 5-HT₁ agonists on carbohydrate/protein dietary selection of rats, 99, 240P
- SAURA MARTI, J., KETTLER, R., DA PRADA, M. & RICHARDS, J.G. Selective inhibition of MAO-B in rat by Ro 19-6327: correlation with binding in vivo, 99, 69P
- SAVILLE, V.L. & RHODES, K.F. Differences in the effects of 5-HT₃ receptor antagonists against the 5-HT₃ mediated responses to 5-HT and 2-Me 5-HT in the guinea-pig ileum longitudinal muscle, 100, 484P
- SAXENA, P.R. see DEN BOER, M., 99, 37P

- - - see VILLALON, C., 99, 36P
 SCALBERT, E. see MULLER, F., 99, 48P
 SCHACHTER, M. see PATEL, M.K., 99, 176P
 SCHEUFLE, E. see HUGTENBERG, J., 99, 20P
 SCHILLING, L. see PARSONS, A.A., 100, 331P
 - - - see PARSONS, A.A., 100, 457P
 SCHMIDT, J. & SZELENYI, I. Inhibition of guinea-pig alveolar macrophage superoxide anion generation by azelastine, 99, 188P
 SCHNABEL, P. see BOHM, M., 99, 117P
 SCHNEIDER, H.H. see TURNER, J.D., 99, 79P
 SCHOEMAKER, H., ALLEN, J. & LANGER, S. Z. Characterization of [³H]-ifenprodil binding to the rat cerebral cortex, 100, 316P
 SCHOFIELD, J.P. see NUNEZ, D.J., 99, 105P
 SCHOLFIELD, C.N. see DONAGHY, K., 101, 499P
 - - - see MCGIVERN, J., 101, 571P
 SCHRODER, H., BARANN, M. & SCHROR, K. Vasopressin increases cyclic GMP in LLC-PK₁ kidney epithelial cells via the L-arginine/nitric oxide pathway, 99, 110P
 SCHROR, K. see NEY, P., 99, 93P
 - - - see SCHRODER, H., 99, 110P
 SCHWARZE, J., GUILD, S.B., CRAIG, J. W. & MUIR, T.C. The mechanical and biochemical interactions of individual co-transmitters in rat tail artery, 101, 532P
 SCOTCHER, K.P., JENNER, P., IRWIN, I., DELANNEY, L.E., LANGSTON, J.W. & DI MONTE, A. MPTP-induced ATP depletion in synaptosomes is inhibited by selegiline but not mazindol, 100, 335P
 SEBASTIAO, A.M. see CORREIA-DE-SA, P., 99, 227P
 SEBASTIAO, A.M. & RIBEIRO, J.A. Xanthine affinities for the adenosine receptor mediating inhibition of transmission at the rat hippocampus, 99, 141P
 SEED, M.P. & CHEUNG, C.Y. Sodium aurothiomalate inhibits recombinant human interleukin-1 β -induced degradation of rat femoral head articular cartilage *in vitro*, 99, 161P
 SEMARK, J.E. see HUTSON, P.H., 100, 310P
 SENIOR, J. see CLAYTON, J.K., 99, 180P
 - - - see CLAYTON, J.K., 100, 487P
 SEVER, P.S. see PARKINSON, N.A., 101, 536P
 - - - see PATEL, M.K., 99, 176P
 SEWELL, R.D.E. see GRAY, A.M., 101, 554P
 SHAH, K., BRADSHAW, C.M. & SZABADI, E. Interaction between antidepressants and d-amphetamine on operant behaviour, 99, 72P
 SHAHID, M. see HOLBROOK, M., 100, 324P
 SHAHID, M., HOLBROOK, M., COKER, S.J. & NICHOLSON, C.D. Characterisation of human platelet cyclic nucleotide phosphodiesterase (PDE) iso-enzymes and their sensitivity to a variety of selective inhibitors, 100, 443P
 SHANIK, G. see CONNAUGHTON, S., 101, 537P
 SHARIFI, A.M., MORRISON, K.J. & POLLOCK, D. Alterations in sensitivity, phosphoinositide hydrolysis and cyclic nucleotide synthesis in isolated aortic rings from spontaneously hypertensive rats, 101, 533P
 SHARIFI, A.M. & POLLOCK, D. Inhibition of noradrenaline-induced hydrolysis of phosphatidylinositol by cAMP and cGMP in rat isolated aorta, 100, 466P
 SHARMA, S.C. Oestradiol increases histamine levels and acid content of mouse stomach, 99, 224P
 SHARP, T. see GRASBY, P.M., 99, 27P
 - - - see WANG, H., 100, 411P
 SHARP, T., BRAMWELL, S.R. & GRAHAME-SMITH, D.G. Short-term lithium increases the release of hippocampal 5-HT evoked by electrical stimulation of the dorsal raphe nucleus in the rat *in vivo*, 100, 305P
 SHAW, C. see ALDALOU, A.R., 101, 580P
 SHAW, N. see FOULKES, R., 100, 461P
 SHAW, S.T. see ARMSTRONG, F.H., 99, 300P
 SHEEHAN, M.J. see BULL, D.R., 99, 28P
 SHEPHEARD, S., JORDAN, D. & RAMAGE, A.G. Action of some tryptamine analogues that are agonists at 5-HT₁ receptors on central autonomic outflow in anaesthetised cats, 101, 520P
 SHEPHERD, J.K. see RODGERS, R.J., 99, 34P
 - - - see RODGERS, R.J., 100, 415P
 SHIELDS, K., BROADHEAD, T.M., BURNS, E. & BAX, N.D.S. The effect of ethanol on portal venous pressure in the

- rat, 100, 463P
- SIAN, J. & STURMAN, G. Involvement of central dopamine and CCK_A receptors in the apomorphine-induced hypotensive response in the anaesthetised rat, 100, 407P
- SILVA, P., MARTINS, M.A., CORDEIRO, R. & VARGAFTIG, B.B. Generation in the PAF-injected rat pleural cavity of eosinophilin, a chemoattractant for eosinophils, 99, 82P
- SIM, M.F. see FRODSHAM, G., 100, 441P
- - - see JONES, R.B., 100, 440P
- SIMMONDS, M.A. see MORGAN, G.P., 99, 132P
- SINDEN, J. see SMITH, S.E., 100, 417P
- SINGH, A. see REDFERN, P.H., 99, 242P
- SINGH, L. see OLES, R.J., 99, 286P
- - - see TRICKLEBANK, M.D., 99, 73P
- SIZER, A.R. & ROBERTS, M.H.T. 5-HT attenuates glutamate-evoked responses of rat entorhinal cortical neurons in vitro, 99, 26P
- SLATER, N.A. see CHEETHAM, S.C., 99, 68P
- - - see CHEETHAM, S.C., 101, 515P
- - - see HEAL, D.J., 100, 404P
- SLEIGHT, A.J. & PEROUTKA, S.J. Effect of central and peripheral injections of sumatriptan on extracellular levels of 5-HT in guinea-pig frontal cortex, 99, 25P
- SMALL, R.C. see BERRY, J.L., 100, 462P
- - - see BERRY, J.L., 100, 475P
- - - see MURRAY, M.A., 100, 367P
- SMART, T.G., MOSS, S. & NAYEEM, N. 'Stable' expression of functional α_1 and β_1 subunits for the vertebrate neuronal GABA_A receptor in Chinese hamster ovary cells, 100, 388P
- SMITH, A.L. & MCILHINNEY, R.A.J. Synthesis and characterization of two novel agonists for the kainate receptor, 100, 386P
- SMITH, K.M. & JOSEPH, M.H. Contrasting effects of chronic nicotine on tyrosine hydroxylase activity in noradrenaline and dopaminergic neurones in the rat brain, 99, 75P
- SMITH, K. & O'BOYLE, K.M. Post-natal changes in D-2 dopamine receptors in rat and post-mortem human brain, 101, 494P
- SMITH, M.B. & DOLIN, S.J. Propofol anaesthesia is associated with seizure-like behaviour, 99, 282P
- SMITH, R.L. see D'SOUZA, G.A., 99, 50P
- SMITH, S.E., SINDEN, J., MITCHELL, S.N., BRAZELL, M.P. & GRAY, J.A. Effect of chronic nicotine administration on step-through passive avoidance behaviour in the rat, 100, 417P
- SMITH, T.W. see COSTALL, B., 101, 563P
- - - see COSTALL, B., 101, 564P
- SMITH, W.J., TOMLINSON, D.R., WALKER, J. & KEEN, P. Altered neuropeptide gene expression in experimental diabetes, 100, 430P
- SMITHER, R.L. & FAN, T-PD. PAF antagonists inhibit angiogenesis in a rat sponge model, 99, 87P
- SOHLMANN, W. see DEIGHTON, N.M., 99, 116P
- SOICA, A.M. see GWILT, M., 99, 15P
- SOULARD, C. see TOUVAY, C., 99, 190P
- SPEDDING, M. see BROWN, C.M., 99, 272P
- - - see CLARK, R., 99, 123P
- - - see KENNY, B.A., 100, 355P
- SPENCE, A.M. see PACIOREK, P.M., 101, 592P
- SPENCER, P.S.J. see GRAY, A.M., 101, 554P
- SPICER, B.A. see TAYLOR, S.G., 100, 370P
- - - see WARD, J.S., 100, 369P
- SPIERS, J.P., HARRON, D.W.G., WILSON, R. & ALLEN, J.D. Effect of α_1 -adrenoceptor modulation and UK-52,046 on atrio-ventricular conduction in the anaesthetised dog, 99, 234P
- SPINA, D. & PAGE, C.P. Lack of an effect of peptidases on vascular responses to epithelium-derived inhibitory factor, 99, 187P
- SPRAGGS, C.F. & PATEL, M. Functional comparisons of L-365,260 and other gastrin/CCK receptor antagonists in gastric mucosa and ileum in vitro, 100, 360P
- SPRIGGS, T.L.B. see MALLARD, N.J., 100, 359P
- STANTON, J.A., WATLING, K.J. & BEER, M. S. The effect of Ca^{2+} and Mg^{2+} ions on the binding of [^3H]-Q ICS 205-930 to the 5-HT₃ recognition site in rat brain whole cortex, 100, 395P
- STARR, M.S. see AL-TAJIR, G., 99, 261P
- STEELE, J.E., BOWEN, D.M., FRANCIS, P.T. GREEN, A.R. & CROSS, A.J. Spermidine enhancement of [^3H]-MK-801 binding to the NMDA receptor complex in human brain, 100, 382P

- STENZEL, W. see ARMAH, B.I., 100, 321P
- STEPHENS-SMITH, M. see ELLIOTT, P. J., 100, 347P
- - - see HAGAN, R.M., 99, 62P
- - - see IRELAND, S.J., 99, 63P
- STEPTOE, J.E. see DAINTY, I.A., 101, 507P
- STEWART, M.C. see LITTLE, R.A., 100, 454P
- STEWART, A.G. & MORICE, A.H. Effects of atrial natriuretic peptide in hypoxia adapted rats, 100, 460P
- STEWART, B.R. see WILKINS, S.C., 100, 424P
- STOCLET, J-C. see GRAY, G.A., 99, 107P
- - - see KERAIVIS, T.M., 100, 344P
- STONE, M.A. see FORDER, R.A., 99, 164P
- STONE, T.W. see FUGLSANG, A., 101, 506P
- STORCH, J., EDWARDS, R.J. & MACDERMOT, J. f-Met-Leu-Phe or platelet activating factor, but not IgE-antigen complexes, release TXB₂ from differentiated U937 monocyte cells, 99, 173P
- STRATTON, P. see RITTER, J.M., 99, 200P
- STRIKE, C. see ROBERTS, P.J., 99, 284P
- STRONG, P. & SUMNER, M.J. Receptor-mediated adenylate cyclase inhibition and cellular responses, 100, 468P
- STRUPICH, J. see WOJCIKIEWIECZ, R.J. H., 99, 144P
- STRUTHERS, A.D. see ARNOTT, M.R., 101, 542P
- STUBBS, C.M. see TRESIZE, D., 100, 464P
- STURGESS, N.C., PETERS, J.A., HALES, T. G. & LAMBERT, J.J. The actions of alphaxalone and pentobarbitone on inhibitory and excitatory amino acid receptors, 99, 278P
- STURMAN, G. see BAXTER, G.F., 99, 226P
- - - see FREEMAN, P., 99, 275P
- - - see FREEMAN, P., 100, 389P
- - - see FREEMAN, P., 101, 556P
- - - see SIAN, J., 100, 407P
- STUTZMANN, J.M. see PIOT, O., 99, 133P
- SUDLOW, A.W. see FORDER, R.A., 99, 164P
- SUGRUE, M. see CONNAUGHTON, S., 101, 537P
- SUMAN-CHAUHAN, N. see DOURISH, C.T., 101, 575P
- SUMMERS, J.A. see HERBERT, C.A., 100, 477P
- SUMNER, M.J. see COLEMAN, R.A., 99, 121P
- - - see STRONG, P., 100, 468P
- SUN, X., DAHLOF, C. & HEDNER, T. Does endothelin 1 or 3 facilitate pressor responses mediated by postjunctional α -adrenoceptors? 99, 118P
- SUNDARAM, S. & DAYAM, A.D. The role of cholecystokinin in raw soya flour-induced trophic lesions in rat pancreas, 99, 287P
- SUNKEL, C. see ORTEGA, M.P., 99, 175P
- SWALES, N. & PATERSON, G. The actions of salmeterol and two non-selective β -adrenoceptor agonists, isoxsuprine and nylicrin, on β_1 - and β_2 -adrenoceptors, 100, 489P
- SWANK, S.R. see EGLIN, R.M., 99, 216P
- SWANN, K. see WOOD, T.P., 100, 492P
- SWARTZWEIDER, H.S. see MARTIN, D., 99, 279P
- SYKES, R. see MOODY, C.J., 99, 210P
- SYMINGTON, H.J.E. see JONES, C.E., 101, 567P
- SZABADI, E. see SHAH, K., 99, 72P
- SZEKERES, L. see VEGH, A., 99, 19P
- SWELNYL, I. see SCHMIDT, J., 99, 188P
- TABERNER, P.V. see AL-QATARI, M., 101, 569P
- TABERNER, P.V. & WATSON, C.J. Effects of chronic ethanol consumption on GABA_B mediated responses in the isolated mouse vas deferens, 101, 497P
- TAIT, S. see MARTIN, F., 101, 551P
- TAMARGO, J. see CARRON, R., 101, 541P
- - - see DELPON, E., 99, 233P
- - - see DELPON, E., 101, 540P
- TAMARGO, J., LOPEZ-SENDON, J., DELPON, E., GONZALEZ, M.A. & DE MIGUEL, E. Cardiovascular effects of elgodipine, a new dihydropyridine derivative, 99, 232P
- TAN, C.K. & MUCKLOW, J.C. Isolation of tubule segments rich in arginine-vasopressine (AVP) receptors, 100, 436P
- TAYLOR, C.W. see NUNN, D.L., 99, 92P
- TAYLOR, E.A. see NUNEZ, D.J., 99, 105P
- TAYLOR, J.C. see PACIOREK, P.M., 101, 592P
- TAYLOR, M.A.I. see LEATHLEY, M., 99, 243P
- TAYLOR, S.G. see WARD, J.S., 100, 369P

- TAYLOR, S.G. & SPICER, B.A. Effects of 5-HT and carbachol on small and large pulmonary arteries from hyper-responsive and normal rats, 100, 370P
- TEPPER, P.G. see DEN DAAS, I., 100, 352P
- THIEMERMANN, C. see KORBUT, R., 99, 206P
- THIRY, C. see LE MONNIER DE GOUVILLE, A-C., 99, 152P
- THODY, V.E. see FOSTER, K.A., 100, 456P
- THOM, S.McG. see PARKINSON, N.A., 101, 536P
- THOMAS, D.R. see WILKINS, S.C., 100, 424P
- THOMPSON, A.M. see FRANCIS, H.P., 99, 60P
- THOMSON, I.A. see MIDDLEFELL, V.C., 101, 560P
- THORIN-TRESCASES, N., OSTER, L., ATKINSON, J. & CAPDEVILLE, C. Cytosolic free calcium and vasoconstriction in the normotensive rat tail artery, 99, 44P
- THORNBURY, K.D. see HARTY, H., 101, 539P
- - - see MCHALE, N.G., 101, 505P
- THORNE, J.R. & BROADLEY, K.J. Examination of the effect of adenosine on superfused trachea from normal and sensitised guinea-pigs, 99, 185P
- - - Adenosine-induced bronchoconstriction in the conscious guinea-pig, 101, 595P
- THORNTON, P.C. see PEH, K.H., 100, 449P
- THORNTON, S.N. see EBENEZER, I.S., 100, 419P
- - - see EBENEZER, I.S., 101, 573P
- TOMITA, T. & BRADING, A.F. The effect of cromakalim in guinea-pig stomach cannot be ascribed solely to opening K⁺ channels, 99, 9P
- TOMKINS, D.M. see COSTALL, B., 99, 249P
- - - see COSTALL, B., 101, 564P
- TOMLINSON, D.R. see BEARPARK, T.M., 100, 469P
- - - see CARRINGTON, A.L., 100, 429P
- - - see SMITH, W.J., 100, 430P
- TOOTHILL, V.J. & PEARSON, J.D. Neutrophil-endothelial cell interactions in the acute inflammatory response: detection of novel adhesive ligands, 99, 42P
- TOPOUZIS, S. see HUGGINS, J.P., 99, 208P
- TOSON, G. see MICHELI, D., 100, 332P
- TOTH, E. see FILE, S.E., 99, 254P
- TOUVAY, C., VILAIN, B., LEJEUNE, V., CARRE, C., SOULARD, C., MENICA-HUERTA, J.M. & BRAQUET, P. Hypereosinophilia and bronchial reactivity in the rat, 99, 190P
- TOWERS, J.D. see EL SAYED, A.A., 100, 327P
- TOWERS, P. see WOOD, T.P., 100, 492P
- TRAIL, B.K. see CLAPHAM, J.C., 99, 213P
- TRAMPUS, M. see ONGINI, E., 99, 78P
- TREANOR, J.J.S., ALLEN, S.J., MACGOWAN, S.H., WILCOCK, G.K. & DAWBARN, D. Nerve growth factor receptor binding in normal and Alzheimer's disease basal forebrain, 101, 582P
- TRESIZE, D., STUBBS, C.M., CONNOR, H.E. & FENIUK, W. α_1 -Adrenoceptor antagonist effects of the 5-HT_{1A} agonist 8-OH-DPAT, 100, 464P
- TREVETHICK, M.A. see KRANEVELD, A.D., 99, 46P
- TRICKLEBANK, M.D. see BRISTOW, L.J., 100, 416P
- - - see OLES, R.J., 99, 286P
- TRICKLEBANK, M.D., OLES, R.J. & SINGH, L. Reversal by inositol of the proconvulsant action of lithium in pilocarpine-treated mice, 99, 73P
- TRIST, D. see MICHELI, D., 100, 332P
- TRIST, D., MICHELI, D., MARCON, C. & GAVIRAGHI, G. The potency of taludipine (GR53992B) in the guinea-pig papillary muscle is augmented in conditions which mimic ischaemia, 100, 442P
- TROUT, S.J. see GONZALEZ-MORA, J.J., 100, 399P
- TROUT, S.J., O'CONNOR, J.J., WIECZOREK, W. & KRUK, Z.L. Regional differences in evoked striatal dopamine overflow measured using fast cyclic voltammetry in brain slices, 99, 258P
- TSCHIRHART, E. & MILLER, R. Airway epithelium actively metabolises endothelin and modulates endothelin-induced contraction in guinea-pig trachea, 99, 57P
- TSUCHIHASHI, K. & CURTIS, M.J. Tedisamil possesses direct defibrillatory activity during myocardial ischaemia and during reperfusion, 99, 231P
- TURNER, J.D., SCHNEIDER, H.H., MARTEN, P. & FRITZ, S. *In vivo* binding of the reportedly selective D₂ agonist N-0437 is not displaced by dopaminergic ligands, 99, 79P

- TURNER, J.M. see CUTLER, M.G., 100, 486P
- TURNIDGE, R. see GARD, P.R., 100, 418P
- TWISSELL, D.J. see GARDNER, C.J., 99, 301P
- TWIST, E.C., MITCHELL, S.N., CORN, T. H. & CAMPBELL, I.C. Effect of a chronic ritanserin regimen on amine and metabolite levels in rat frontal cortex and cerebellum, 100, 397P
- TWORT, C.H.C. see CHOPRA, L.C., 100, 368P
- TYE, S.J. see O'NEILL, M.F., 101, 577P
- TYERS, M.B. see COUGHLAN, J., 101, 561P
- - - see COUGHLAN, J., 101, 562P
- - - see JONES, D.N.C., 100, 309P
- UPTON, N. see WILKINS, S.C., 100, 424P
- - - see WRIGHT, I.K., 100, 357P
- URQUHART, R.A., ROTHAU, A.L. & BROADLEY, K.J. Antagonism of adenosine P and muscarinic receptor activation of ⁸⁶Rubidium efflux from guinea-pig left atria, 100, 322P
- VALENTINE, D.J. see COLLINS, G.G.S., 100, 378P
- VALENZUELA, C. see DELPON, E., 99, 233P
- VAN BELLE, H. see WAINWRIGHT, C.L., 99, 14P
- VAN DEN BERG, H.W. see MARTIN, J., 101, 549P
- VAN DEN BERG, H.W., MARTIN, J. & LYNCH, M. Progestin/anti-progestin action towards human breast cancer cell lines differing in their progesterone receptor content, 101, 550P
- VAN DER HOEK, G.A. & COOPER, S.J. Microstructural analysis of the effects of the selective 5-HT₃ antagonist, ondansetron, on feeding and other behavioural responses, 99, 238P
- - - Antagonism of amphetamine-induced sniffing, but not hyperlocomotion, by the selective 5-HT₃ antagonist, ondansetron, 100, 414P
- VANE, J.R. see D'ORLEANS-JUSTE, P., 99, 100P
- - - see D'ORLEANS-JUSTE, P., 101, 510P
- - - see KORBUT, R., 99, 206P
- - - see MITCHELL, J.A., 99, 101P
- - - see MITCHELL, J.A., 100, 450P
- - - see SALVEMINI, D., 100, 325P
- - - see SALVEMINI, D., 100, 333P
- VAN HEININGEN, P.N.M., BATINK, H.D. & VAN ZWIETEN, P.A. Angiotensin 11-induced increases in ⁴⁵Ca²⁺ uptake and contractile responses in guinea-pig aorta, 99, 203P
- VAN HOYDONCK, A-E. see DE MEYER, G.R. Y., 99, 106P
- VAN MAERCKE, Y.M. see BOECKXSTAENS, G. E., 99, 52P
- VAN TITS, L.J.H., GROSSE-WILDE, H. & BRODDE, O-E. Effect of chronic β -adrenoceptor-antagonist treatment on isoprenaline-evoked changes in function and subset composition of circulating mononuclear leukocytes, 99, 115P
- VAN WILGENBURG, H. see EIGENHUIS, J.J. 99, 256P
- VAN ZWIETEN, P.A. see GOUW, M.A.M., 99, 43P
- - - see HEIJNIS, J.B., 99, 229P
- - - see VAN HEININGEN, P.N.M., 99, 203P
- VARDEY, C.J. see NIALS, A.T., 99, 120P
- VARGAFTIG, B.B. see DESQUAND, S., 99, 84P
- - - see IMAIZUMI, A., 99, 65P
- - - see SILVA, P., 99, 82P
- VEGH, A., SZEKERES, L. & PARRATT, J.R. Preconditioning of the ischaemic myocardium: role of the cyclooxygenase pathway, 99, 19P
- VIGGERS, J.A. see CHEETHAM, S.C., 99, 68P
- - - see CHEETHAM, S.C., 101, 515P
- - - see HEAL, D.J., 100, 404P
- VILA, J.M. see MARTIN DE AGUILERA, E., 99, 212P
- VILAIN, B. see TOUVAY, C., 99, 190P
- VILLALON, C. see DEN BOER, M., 99, 37P
- VILLALON, C., BOM, A.H., HEILIGERS, J., DEN BOER, M.O. & SAXENA, P.R. Reduction of porcine carotid arterio-venous shunting by indorenate is unrelated to 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1C} or 5-HT_{1D} receptor subtype, 99, 36P
- VOGT, T. see BESSER, R., 99, 294P
- WACHTELL, H. see LOESCHMANN, P-A., 100, 336P
- WADDINGTON, J.L. see O'BOYLE, K.M., 99, 76P
- WAHL, M. see PARSONS, A.A., 100, 331P
- - - see PARSONS, A.A., 100, 457P

- WAINWRIGHT, C.L., PARRATT, J.H. & VAN BELLE, H. The effects of a nucleoside transport inhibitor, R75231, on ischaemic arrhythmias in anaesthetised pigs, 99, 14P
- WALI, F.A. Comparative effects of atracurium and lignocaine at the rat neuromuscular junction, 99, 235P
- - - Effect of atracurium on twitch relaxation rate in the rat diaphragm preparation, 100, 428P
- - - see MAKINDE, V., 100, 432P
- WALKER, B. see ABU SHANAB, A.A., 101, 581P
- - - see ALDALOU, A.R., 101, 580P
- WALKER, J. see SMITH, W.J., 100, 430P
- WALKER, R.J. see BAGUST, J., 99, 252P
- - - see COLQUHOUN, L., 99, 253P
- WALLACE, H.M. see BRUNTON, V.G., 99, 298P
- WALLER, D.G. see MARSHALL, K.G., 101, 512P
- WALLIS, D.I. see CRICK, H., 100, 308P
- - - see ELLIOTT, P., 100, 394P
- WALSH, T. see CONNAUGHTON, S., 101, 537P
- WALTER, D.S. see DICKINSON, S.L., 99, 274P
- WALTHAM, K. see DICKINSON, S.L., 99, 274P
- WAN, B.Y.C. see PEH, K.H., 100, 449P
- WANES, D. see FORSTER, C., 99, 122P
- WANG, H. & GRAHAME-SMITH, D.G. Effects of rubidium on 5-HT-mediated behaviour in rat and mouse, 99, 239P
- WANG, H., GRAHAME-SMITH, D.G. & SHARP, T. Effects of caesium on 5-HT mediated behaviour in rat and mouse, 100, 411P
- WANG, J.C.C. & LUNG, M.A. Dose-related effects of α , β -methylene ATP on canine nasal vascular and airway resistances, 101, 594P
- WARD, J.P.T. see CHOPRA, L.C., 100, 368P
- WARD, J.S., SPICER, B.A. & TAYLOR, S.G. Effects of lemakalim (BRL 38227) and salbutamol on hyperresponsive lung parenchyma, 100, 369P
- WARD, P. see HAGAN, R.M., 99, 62P
- WARD, R.A. see BAGUST, J., 99, 252P
- WARD, S.A. see HOAKSEY, P.R.E., 101, 552P
- - - see MILTON, K.A., 99, 296P
- WARNER, T.D. A new method to compare the responses of the arterial and venous vessels within the isolated perfused superior mesenteric vascular bed of the rat, 99, 99P
- - - see D'ORLEANS-JUSTE, P., 101, 510P
- WATERFALL, A.H., CLARKE, R.W. & BENNETT, G.W. The development of microdialysis for the measurement of thyrotrophin-releasing hormone in rat brain *in vivo*, 101, 502P
- WATERFALL, J.F. see DUTY, S., 100, 329P
- - - see MACKENZIE, I., 100, 320P
- - - see PACIOREK, P.M., 101, 592P
- WATLING, K.J. see STANTON, J.A., 100, 395P
- WATSON, C.D., BROWNING, B.S., FONE, K. C.F. & BENNETT, G.W. Effects of chronic administration of a TRH analogue (RX77368) and atropine on cognitive behaviour and brain biochemistry in the rat, 100, 312P
- WATSON, C.J. see TABERNER, P.V., 101, 497P
- WATSON, N., BARNES, P.J. & MACLAGAN, J. Evidence for an effect of methoctramines on ganglionic nicotinic cholinceptors in the guinea-pig trachea *in vitro*, 100, 365P
- WATSON, W.P. see KNIGHT, R.J., 100, 433P
- WATT, G. see DAVIDSON, J., 100, 447P
- WATTS, I.S. see PIKE, N.B., 99, 112P
- WAYMAN, C.P. & WILSON, J.F. Characterisation of the NMDA receptor that stimulates release of α -melanocyte-stimulating hormone from the rat hypothalamus, 101, 586P
- WEBB, R.J. see LUHESHI, G.N., 99, 181P
- WEINBERGER, P.J. see JACKSON, H.C., 101, 555P
- WELLS, E. see CARR, R.D., 99, 17P
- WELLS, F.R. see DEXTER, D.T., 99, 81P
- - - see DEXTER, D.O., 101, 495P
- - - see LANGE, K.W., 99, 156P
- - - see LANGE, K.W., 100, 313P
- WERMELSKIRCHEN, D. see GOUW, M.A.M., 99, 43P
- WESSLER, I. see BESSER, R., 99, 294P
- - - see RACKE, K., 99, 219P
- WESSLER, I., HEILWIG, H. & RACKE, K. Stimulation-induced overflow of [3 H]-acetylcholine from the isolated guinea-pig trachea: inhibitory role of the epithelium, 99, 54P

- WESTON, A.H. see BOBINSKI, H., 100, 361P
- - - see DUTY, S., 99, 2P
- - - see DUTY, S., 100, 329P
- - - see LONGMORE, J., 99, 3P
- WESTWICK, J. see CAIRNS, H.S., 99, 109P
- - - see PLEASS, R.D., 101, 530P
- WHELAN, C.J. & JOHNSON, M. The anti-inflammatory effects of inhaled salmeterol and salbutamol in guinea-pig lung, 101, 528P
- WHELPTON, R. & HURST, P.R. In vitro metabolism of physostigmine by human plasma: interactions with other drugs, 100, 493P
- WHITE, J.P.N. see MICKLETHWAITE, A. V., 100, 479P
- WHITHAM, E.M., CHALLISS, R.A.J. & NAHORSKI, S.R. Muscarinic receptor mediated phosphoinositide metabolism in cerebellar granule cells, 99, 140P
- WHITING, R.L. see EGLEN, R.M., 99, 56P
- - - see EGLEN, R.M., 99, 216P
- - - see MICHEL, A.D., 100, 366P
- WHITTINGTON, M.A. see FROW, H., 101, 498P
- WHITTINGTON, M.A. & LITTLE, H.J. Actions of Bay K 8644 stereoisomers on the changes in hippocampal field potential during ethanol withdrawal, 99, 272P
- WHITTLE, B.J.R. see HUTCHESON, I.R., 99, 111P
- - - see LOPEZ-BELMONTE, J., 99, 153P
- WHITTON, P. see KENNETT, G.A., 99, 241P
- - - see SARNA, G.S., 99, 240P
- WICKENDEN, A.D. see COOK, M., 100, 481P
- WICKENDEN, A.D. & GRANT, T.L. 2-Deoxy-D-glucose, an inhibitor of glycolysis, inhibits cromakalim but not sodium nitroprusside induced vasorelaxation, 99, 5P
- WIECZOREK, W. see TROUT, S.J., 99, 258P
- WILCOCK, G.K. see TREANOR, J.J.S., 101, 582P
- WILFFERT, B. see GOUW, M.A.M., 99, 43P
- - - see HUGTENBERG, J., 99, 20P
- WILKINS, S.C., THOMAS, D.R., STEWART, B.R. & UPTON, N. Inhibition of rearing behaviour in rats by anxiogenic agents correlates with their ability to potentiate [³⁵S]-TBPS binding in vitro, 100, 424P
- WILKINSON, D. see YEADON, M., 99, 191P
- WILLIAMS, A. see CHOUDRY, N.B., 99, 41P
- - - see REDFERN, W.S., 101, 518P
- WILLIAMS, B.C. see BISHOP, L.A., 99, 40P
- WILLIAMS, T.J. see BARNES, N.M., 99, 142P
- - - see BARNES, J.M., 99, 293P
- - - see BUCKLEY, T.L., 99, 94P
- WILLIS, C.L., BRAZELL, C. & FOSTER, A.C. Determination of plasma and CSF levels of MK-801 required for neuroprotection in the quinolinate-injected rat striatum following intravenous infusion of the drug, 100, 317P
- WILSON, C. see GROWCOTT, J.W., 100, 439P
- - - see LEWIS, P.E., 99, 194P
- WILSON, G. & HILLIER, K. Phospholipid fatty acid profiles in human colon mucosa, 99, 169P
- WILSON, J.F. see WAYMAN, C.P., 101, 586P
- WILSON, N.H. see JONES, R.L., 101, 522P
- - - see LAWRENCE, J.A., 99, 35P
- WILSON, R. see SPIERS, J.P., 99, 234P
- WILSON, V.G. see DALY, C.J., 100, 465P
- - - see MACDONALD, A., 99, 53P
- - - see YOUNG, N.J., 100, 391P
- WILSON, W.A. see MARTIN, D., 99, 279P
- WILTSHIRE, R., KEEN, M., KELLY, E. & MACDERMOT, J. Effect of pretreatment with forskolin or 8-bromo-cAMP on adenylate cyclase stimulation in NG108-15 and NCB20 cells, 100, 425P
- WISDEN, W. see MORRIS, B.J., 99, 197P
- WITKO, V. see MOODLEY, I., 100, 380P
- WOJCIKIEWIECZ, R.J.H. see SAFRANY, S.T., 99, 88P
- WOJCIKIEWIECZ, R.J.H., SAFRANY, S.T., CHALLISS, R.A.J., STRUPICH, J. & NAHORSKI, S.R. Intracellular stores of Ca²⁺ in electrically permeabilised SH-SY5Y cells are discharged following muscarinic receptor and G-protein activation, 99, 144P
- WONG, E.H.F. see BRISTOW, L.J., 100, 416P
- - - see KNIGHT, A.R., 100, 304P
- WOOD, B.E. see O'CONNOR, S.E., 100, 341P
- WOOD, B.E., O'CONNOR, S.E., FEAR, M.T. & LEFF, P. Suramin is a slowly equilibrating but competitive

- antagonist at P_{2x}-purinoceptors in the rabbit ear artery, 100, 342P
- WOOD, B.E., O'CONNOR, S.E. & LEFF, P. α , β -Methylene-ADP potentiates ATP responses in the rabbit ear artery, 101, 531P
- WOOD, D. see ALYAMI, A.M., 101, 597P
- - - see DAVIES, M.P., 101, 599P
- WOOD, E.G. see D'ORLEANS-JUSTE, P., 99, 100P
- WOOD, S.G. see MARRS, T.C., 101, 546P
- WOOD, T.P., TOWERS, P., SWANN, K., IRESON, J.C., BOSWORTH, N. & WYLLIE, M.G. Radioligand binding technology which eliminates the requirement for separation of free and bound radio-label, 100, 492P
- WOODRUFF, G.N. see BARNES, S., 100, 348P
- - - see HARLEY, E.A., 99, 263P
- - - see KEEGAN, K.D., 101, 579P
- - - see PINNOCK, R.D., 100, 349P
- WOOTTON, R. & HAZELWOOD, R. 8-OH-DPAT labels two sites in the raphe nucleus area of rat brains, 99, 236P
- WORMALD, A.D. see ROBINSON, S.C., 100, 323P
- WRAY, D.W. see PEARSON, H.A., 99, 250P
- WRIGHT, I.K., ISMAIL, H., UPTON, N. & MARSDEN, C.A. Effect of isolation-rearing on performance in the elevated plus-maze and open field behaviour, 100, 357P
- WYLLIE, M.G. see BROADBENT, S., 101, 601P
- - - see WOOD, T.P., 100, 492P
- XIANG, J-Z., BRAMMER, M.J. & CAMPBELL, I.C. Clonidine inhibits ⁴⁵Ca entry into synaptosomes and, in addition, reduces exchangeable intracellular Ca²⁺ pools, 100, 431P
- XIANG, J-Z., MORTON, J., BRAMMER, M.J. & CAMPBELL, I.C. Synaptosomal studies of the regulation of total and free calcium concentrations, 99, 297P
- YACoub, M. see MOODY, C.J., 99, 210P
- - - see RIDLEY, P.D., 101, 511P
- YATES, M.S. see KNIGHT, R.J., 100, 433P
- - - see PANJESHAHIN, M.R., 101, 548P
- - - see ROBINSON, S.C., 100, 323P
- YEADON, M., WILKINSON, D. & PAYNE, A.N. Ozone induces bronchial hyperreactivity to inhaled substance P by functional inhibition of enkephalinase, 99, 191P
- YEATS, D.A. see LEATHARD, H.L., 99, 201P
- YOUNG, A. see MICKLETHWAITE, A.V., 100, 479P
- YOUNG, A., GOSLING, M. & DETTMAR, P.W. Differential involvement of K opioid receptors in regulating fluid transport in the rat small and large intestine *in vivo*, 100, 482P
- YOUNG, N.J., WILSON, V.G. & KENDALL, D. A. Effects of a crude bovine brain extract of clonidine-displacing substance on [³H]-myo inositol uptake and phosphoinositide hydrolysis in rat brain slices, 100, 391P
- ZAR, M.A. see IRAVANI, M.M., 99, 179P
- - - see LUHESHI, G.N., 99, 181P
- ZERKOWSKI, H-R. see DEIGHTON, N.M., 99, 116P
- ZHARKOVSKY, A. Flumazenil suppresses, and CGS8216 enhances, physical signs of diazepam withdrawal in rats, 99, 257P
- - - see FILE, S.E., 100, 340P
- - - see HITCHCOTT, P.K., 100, 354P
- ZIVIANI, L. see PIETRA, C., 99, 177P
- ZIVKOVIC, B. see PERRAULT, G., 99, 255P
- ZREIKA, M. & PELTON, J.T. Radio-immunoassay for endothelin-1: antibody cross-reactivity with endothelins, some analogues of endothelin-1 and sarafotoxin S6b, 99, 207P
- ZUNDEL, J.L. see PIOT, O., 99, 133P

SUBJECT INDEX

- Acetylcholine, 99, 227P; 100, 310P; 101, 590P
³H]-acetylcholine release, 99, 54P, 293P
ACTH, 99, 31P; 100, 337P
Acute renal failure, 100, 323P, 433P; 101, 548P
Adenine nucleotide metabolites, 99, 20P
Adenosine, 99, 14P, 132P, 185P; 100, 322P, 390P; 101, 499P, 595P, 596P, 604P
Adenosine antagonism, 101, 548P
Adenosine 3',5'-monophosphate, cyclic, 99, 273P
Adenosine receptors, 99, 141P, 227P; 100, 337P
Adenylate cyclase, 99, 117P; 100, 351P, 425P, 426P, 468P
Adrenaline, 99, 39P; 101, 536P
 β_2 -Adrenoceptor agonists, 99, 121P, 163P
 α_1 -Adrenoceptor antagonist, 100, 464P
 α_2 -Adrenoceptor antagonist, 99, 123P, 272P; 100, 358P, 392P
 β -Adrenoceptor antagonist, 99, 115P
 α_2 -Adrenoceptor feedback, 99, 53P
 α -Adrenoceptors, 99, 71P, 118P, 273P; 101, 537P
 α_1 -Adrenoceptors, 99, 204P, 234P
 α_2 -Adrenoceptors, 99, 122P, 124P; 100, 345P, 346P, 358P, 391P, 431P, 465P; 101, 506P, 518P, 536P, 537P, 538P, 555P
 α_{2B} -Adrenoceptors, 101, 538P
 β -Adrenoceptors, 99, 116P, 268P, 271P; 100, 418P, 489P; 101, 539P
 β -Adrenoceptors, 'atypical', 99, 119P
Adrenoceptor subtypes, 101, 537P
 α -Adrenoceptor subtypes, 100, 359P
 α_2 -Adrenoceptor subtypes, 100, 358P
 α_2 -Adrenoceptors, central, 99, 74P
Adrenocorticotrophin, 99, 126P
Afferent neurons, 99, 222P
Agonist affinity, 99, 158P; 101, 507P
Agonist interactions, 99, 76P
Agonist potency order, 100, 341P
AH21-132, 99, 193P; 100, 462P
Airway epithelium, 99, 57P, 187P
Airways, 100, 372P, 373P, 473P, 477P; 101, 593P
Airway smooth muscle, 99, 3P, 192P; 100, 362P, 363P, 364P, 368P, 473P
Albendazole, 101, 552P
Albumin, 100, 372P, 477P
Aldosterone response, 99, 40P
Alkaline secretion, 99, 223P
Alphaxalone, 99, 278P
Alveolar macrophage, 99, 188P
Alzheimer's disease, 99, 156P, 269P; 100, 313P; 101, 582P
Amines, 100, 397P
Amino acids, 99, 277P; 100, 348P
 γ -Aminobutyric acid, 99, 52P, 130P, 133P, 251P, 252P; 100, 486P; 101, 597P
 γ -Aminobutyric acid agonists, 101, 571P
 γ -Aminobutyric acid_A receptor, 99, 278P; 100, 388P
 γ -Aminobutyric acid_B receptor, 99, 129P; 101, 497P, 570P
 γ -Aminobutyric acid receptor agonist, 100, 340P
 γ -Aminobutyric acid uptake inhibitor, 99, 131P
 δ -Aminolaevulinic acid, 100, 486P
2-Amino-4-phosphonobutyrate, 99, 90P
4-Aminopropiophenone, 101, 546P
Ammonia, 99, 225P
Amphetamine, 99, 72P, 259P; 100, 414P
Analgesia, 99, 24P; 100, 412P
Anaesthesia, 99, 282P
Anaesthetic, i.v., 100, 439P
Anaesthetised rats, 100, 440P
Analgesia, 101, 577P
Anaphylaxis, 99, 84P
Angiogenesis, 99, 87P
Angiotensin I, 99, 16P
Angiotensin II, 99, 203P; 100, 435P; 101, 542P
Angiotensin converting enzyme, 99, 142P
Angiotensin converting enzyme inhibitor, 99, 48P; 101, 588P
Anions, 101, 511P
Anoxia, 101, 499P
Antagonists, 99, 62P; 100, 480P, 487P; 101, 581P, 596P
 μ -Antagonist, 99, 291P
 α_2 -Antagonists, 99, 274P
Anterior pretectal nucleus, 99, 211P
Anti-arrhythmics, 99, 234P; 100, 320P

Anticonvulsant tolerance, 99, 131P
 Antidepressant treatments, 100, 405P
 Antidepressants, 99, 72P, 74P, 123P, 264P, 272P; 100, 404P, 418P; 101, 515P, 554P
 Antigen, 99, 66P
 Antihypertensive activity, 99, 7P; 100, 332P
 Anti-inflammatory, 99, 172P; 101, 528P
 Antimuscarinic, 101, 601P
 Antinociception, 101, 554P
 Antioxidant, 100, 332P
 Anti-proteinase, 100, 373P
 Anxiety, 99, 135P, 138P, 249P; 100, 354P, 356P, 357P, 413P, 424P; 101, 516P, 518P, 564P, 576P
 Anxiolytics, 99, 29P, 248P
 Aorta, guinea-pig, 99, 43P, 203P
 Aorta, rat, 99, 5P; 100, 456P, 466P; 101, 533P
 Apomorphine hypotension, 100, 407P
 AQ-RA 741, 99, 295P
 Arachidonate, 99, 169P
 Arachidonic acid, 99, 225P
 L-Arginine, 99, 101P, 107P
 Arginine-vasopressin, 100, 434P, 436P
 Arrhythmias, 99, 19P; 100, 324P, 440P; 101, 511P
 Arterial and venous vasculatures, 99, 99P
 Arterial muscle, 99, 198P
 Arteries, human, 99, 212P; 101, 536P
 Arthritis, 99, 148P
 Ascaris, 99, 253P
 Asthma, 101, 592P
 ATP, 100, 335P; 101, 531P
 ATPase, 100, 469P
 Atracurium, 99, 235P; 100, 428P
 Atria, left, 100, 322P
 Atrial muscle fibres, 101, 540P
 Atrial natriuretic peptide, 99, 49P; 100, 460P
 Atrium, guinea-pig, 100, 439P
 Atrium, human, 99, 116P; 100, 319P
 Atropine, 99, 181P; 100, 312P; 101, 517P
 Aurothiomalate, 99, 161P
 Automated system, 99, 249P
 Autoradiography, 99, 210P; 100, 345P
 Autoreceptor, 99, 242P; 101, 519P
 Avermectin, 99, 250P
 Aversive environment, 99, 245P
 Azelastine, 99, 188P

 Baclofen, 100, 340P, 420P; 101, 570P
 Barbiturate withdrawal, 100, 422P; 101, 498P, 568P
 Barbiturates, 101, 567P

BAY u3405, 99, 59P, 60P, 61P
 BDF 9148, 100, 321P
 Behaviour, 99, 290P; 100, 413P, 414P, 417P; 101, 575P
 Behavioural syndrome, 100, 410P
 Benzodiazepine receptors, 99, 255P; 100, 423P
 Benzodiazepine withdrawal, 101, 558P
 Benzodiazepines, 99, 132P, 133P, 243P, 252P, 254P, 256P; 101, 558P
 Benzodiazepine-induced hypothermia, 101, 555P
 Bicuculline, 100, 486P
 Big-endothelin, 101, 510P
 Binding, 99, 113P
 Binding assay, 100, 386P
 Binding sites, 100, 344P
 Binding studies, 101, 525P
 Binding *in vivo*, 99, 69P, 79P
 Bismuth compounds, 99, 226P
 Bladder, mouse, 101, 601P
 Bladder, rat, 99, 177P
 Bladder, toad, 100, 434P
 Blood flow, 99, 221P
 Blood pressure, 99, 155P, 228P; 101, 520P, 545P
 Blood vessels, 99, 46P; 100, 326P; 101, 504P, 532P, 534P
 BMY 14802, 100, 416P
 Bolus, 99, 149P
 Bradycardia, 99, 22P
 Bradykinesia, 99, 262P
 Bradykinin, 99, 91P, 102P, 200P; 100, 344P; 101, 602P
 Brain, human, 100, 382P; 101, 494P
 Brain, rodent, 99, 142P, 268P; 100, 346P
 Brain slice, rat, 101, 557P, 567P
 BRL 38227, 99, 213P; 100, 369P, 476P
 BRL 43694, 100, 398P, 413P
 Bronchial hyperreactivity, 99, 191P
 Bronchial reactivity, 99, 190P
 Bronchoconstriction, 99, 41P
 Bronchodilatation, 99, 192P, 193P
 Bronchus, rabbit, 99, 187P
 BTG 1501, 101, 563P, 564P
 Bumetanide, 100, 473P
 Buspirone, 99, 248P; 100, 412P
 BW A797C, 100, 447P

 Caesium, 100, 411P
 Caffeine, 99, 11P, 45P
 Calcitonin gene-related peptide, 99, 94P, 104P, 153P, 288P; 100, 461P
 Calcium, 99, 11P, 89P, 102P, 232P, 297P; 100, 361P, 390P, 448P, 450P, 465P; 101, 584P
⁴⁵Ca accumulation, 100, 431P
 Ca⁺⁺ antagonism, 100, 439P

Calcium antagonists, 99, 45P, 229P
 Calcium channel antagonist, 100, 422P
 Calcium channel ligand, 99, 129P
 Calcium channels, 99, 250P, 276P
 Calcium entry blocker, 100, 332P
⁴⁵Ca⁺⁺ influx, 99, 43P
 Calcium mobilization, 99, 88P, 144P
⁴⁵Ca⁺⁺-uptake, 99, 203P; 100, 456P
 Capsaicin, 99, 186P, 222P; 101, 545P
 Carbamazepine, 100, 434P
 Carbidopa, 101, 496P
 5-Carboxamidotryptamine, 100, 483P
 Cardiac electrophysiology, 99, 15P, 230P
 Cardiac myocytes, 99, 210P
 Cardiac output, 99, 209P
 Cardiac receptors, 99, 22P
 Cardiorespiratory effects, 99, 30P
 Cardiosselective muscarinic antagonist, 99, 295P
 Cardiotonic, 99, 18P
 Carotid artery blood flow, 99, 36P
 Carotid occlusion, 101, 566P
 Cartilage, 99, 161P
 Catecholaminergic neurones, 99, 75P
 Catecholamines, 99, 67P
 Cell culture, 99, 95P
 Cell lines, 100, 388P
 Cell proliferation, 99, 200P
 Central dopamine effects, 99, 264P
 Central nervous system, 99, 67P, 89P, 239P, 246P, 281P; 100, 305P, 345P, 411P
 Cerebellar granule cells, 99, 140P
 Cerebellum, 99, 92P, 252P; 101, 584P
 Cerebral arteries, 100, 331P, 457P
 Cerebral blood flow autoregulation, 99, 48P
 Cerebral cortex, 99, 26P; 100, 315P, 393P
 Cerebral glucose use, 99, 134P
 Cerebral ischaemia, 100, 454P
 C-fibre evoked reflex, 101, 545P
 CGP 37849, 100, 384P
 CGS 8216, 99, 257P
 Chemotaxis, 99, 82P
 Chloride channels, 101, 523P
 Chloroethylclonidine, 100, 359P
 7-Chlorokynurenic acid, 100, 387P
 m-Chloro-phenylbiguanide, 99, 32P
 Cholecystokinin, 99, 136P, 138P, 287P; 100, 348P, 349P, 350P, 407P, 419P; 101, 575P
 Cholecystokinin octapeptide antagonists, 99, 137P, 287P; 101, 577P
 Cholecystokinin octapeptide receptors, 101, 574P, 576P
 Cholecystokinin-A receptors, 99, 139P
 Cholesterol, 101, 544P
 Cholinergic, 99, 254P; 100, 314P
 Cholinergic receptors, 100, 427P
 Cholinoceptors, 99, 253P; 100, 365P
 Chondrocytes, 99, 148P
 Chronic MK-801 behaviour, 99, 286P
 Cimetidine hydrochloride, 101, 603P
 Circadian, 99, 242P
 Cisplatin, 99, 247P; 100, 433P
 Cisplatin nephrotoxicity, 101, 514P
 Class III antiarrhythmics, 99, 15P
 Classification, 99, 202P
 Clonidine, 99, 49P
 Clonidine displacing substance, 100, 391P
 Clorgyline, 99, 70P
 Co-axial bioassay, 100, 472P
 Co-axial trachea, 100, 371P
 Cocaine, 99, 178P; 100, 493P; 101, 587P
 Cognition, 101, 587P
 Colloidal bismuth sub-citrate, 99, 225P
 Colon, 99, 169P, 183P; 100, 479P, 485P
 Computer, 99, 301P, 302P
 Computer methods, 99, 230P
 Conditioned avoidance, 100, 416P
 Convulsions, 100, 380P, 422P
 Coronary arteries, 99, 1P; 100, 461P
 Correlations, 99, 128P
 Cortex, 100, 379P, 383P, 396P
 Corticosteroids, 100, 446P
 Corticosterone, 99, 273P
 Corticotroph, 99, 126P
 Corticotropin-releasing factor, 100, 339P
 Cortisol, 100, 419P
 Co-transmission, 99, 53P; 101, 506P, 532P, 534P
 Cough, 99, 41P
 Craniovascular effects, 99, 37P
 Cromakalim, 99, 2P, 3P, 9P, 194P, 195P, 196P; 100, 329P, 368P, 456P
 Cross-tolerance, 100, 488P
 Cyclic nucleotide phosphodiesterase inhibition, 99, 192P
 Cyclic nucleotides, 100, 325P
 Cyclo-oxygenase, 99, 154P
 8-Cyclopentyl-1, 3-dipropylxanthine, 100, 433P; 101, 548P
 Cyclosporin A, 99, 165P
 Cysteinyl leukotrienes, 101, 543P
 Cytochrome P-450, 101, 552P
 Cytokines, 101, 503P
 Cytosolic calcium, 99, 102P
 D1 receptors, 99, 76P, 78P, 79P; 100, 351P, 409P; 101, 575P
 D-2 receptors, 99, 263P, 267P; 100, 405P; 101, 494P, 572P

Data-capture, 99, 301P
 Dazodipine, 99, 213P
 Decrement-increment, 99, 294P
 Defeat analgesia, 99, 34P; 100, 415P
 Defence reaction, 101, 585P
 Dentate gyrus, 100, 318P
 2-Deoxy-D-glucose, 99, 5P
 Depression, 99, 271P
 Desensitization, 100, 425P, 426P
 Desipramine, 99, 70P
 Dexamethasone, 99, 150P; 100, 445P
 Diabetes mellitus, 100, 429P, 430P
 Diabetic hearts, 99, 229P
 Diacylglycerol, 99, 218P, 292P
 Dialysis, 100, 310P
 Diaphragm, rat, 99, 235P; 100, 428P, 432P
 Diazepam, 99, 257P; 100, 354P
 Diazepam-withdrawal, 99, 134P
 Diazoxide, 99, 3P
 Differential pulse stripping voltammetry, 99, 260P
 Dihydropyridine binding, 101, 568P
 1,4-dihydropyridines, 99, 175P
 Dilevalol, 99, 228P
 2,5-Dimethoxy-4-iodophenylisopropylamine, 100, 306P
 Dopamine, 99, 28P, 79P, 116P, 136P, 258P, 260P, 261P; 100, 350P, 399P, 400P, 401P, 402P, 407P; 101, 512P, 573P, 578P, 588P
 Dopamine neurones, 101, 579P
 Dopamine prodrugs, 100, 352P
 Dopamine uptake sites, 100, 403P
 Dopaminergic, 100, 314P
 Drugs of abuse, 101, 563P
 DSP-4, 99, 268P; 100, 346P
 Duration of action, 99, 120P, 121P

 EAA, 100, 385P
 Ear artery, rabbit, 100, 341P, 342P
 Editorial board, 99, 157P
 Eicosanoid formation, 100, 447P
 Electrical field stimulation, 101, 597P
 Electroconvulsive shock, 100, 351P
 Electrophysiology, 99, 28P, 29P
 Electroshock, 100, 389P
 Elevated plus-maze, 100, 356P, 357P, 412P; 101, 518P
 Elgodipine, 99, 232P
 Emesis, 99, 247P; 100, 398P, 406P
 Emulsified perfluorochemicals, 99, 300P; 100, 490P, 491P
 Enalapril, 99, 16P, 17P
 Endothelial cell, 99, 101P, 102P; 100, 343P, 344P, 450P, 469P; 101, 525P
 Endothelin, 99, 57P, 100P, 105P, 114P, 118P, 127P, 152P, 153P, 154P, 184P, 208P, 210P, 213P; 100, 455P; 101, 509P
 Endothelin-1, 99, 151P, 207P, 209P, 211P; 101, 510P, 593P
 Endothelium, 99, 42P, 103P, 109P, 212P; 100, 453P; 101, 507P, 524P, 544P
 Endothelium-dependent relaxations, 99, 124P
 Endothelium-derived relaxing factor, 99, 100P, 101P, 104P, 109P, 146P, 220P; 100, 328P, 450P, 451P, 452P; 101, 524P
 Endotoxin, 99, 47P, 107P, 111P
 Enkephalinase, 99, 57P
 Entopeduncular nucleus, 100, 385P
 Entorhinal cortex, 100, 318P
 Eosinophils, 99, 82P, 163P; 100, 372P, 373P, 374P, 375P, 376P, 446P, 448P; 101, 526P
 Epileptiform activity, 100, 318P
 Epinephrine, 99, 116P
 Epithelium, 99, 58P; 100, 372P, 373P, 471P, 477P
 Epithelium, derived relaxation factor, 100, 371P, 472P
 Epithelium-mediated inhibition, 99, 54P
 Equine skin, 99, 86P
 Ergot alkaloids, 99, 221P
 Erythrocytes, 100, 361P
 Estradiol, 101, 549P
 Ethanol, 99, 22P, 279P; 100, 463P
 Ethanol dependence, 101, 497P, 569P
 Ethanol withdrawal, 99, 276P; 100, 339P, 340P
 Evoked release, 99, 178P
 Excitatory amino acids, 99, 279P, 281P; 100, 315P
 Excitatory innervation, 100, 474P
 Exepanol, 101, 598P
 Experimental diabetes, 99, 229P
 Extracellular Ca²⁺ load, 99, 13P

 Facial tremor, 99, 77P
 Fast cyclic voltammetry, 100, 399P; 101, 557P
 Fatty acids, 99, 169P
 Feeding, 99, 130P, 238P, 240P
 Feeding behaviour, 101, 559P
 Ferret, 99, 64P
 Ferritin, 99, 81P
 Fever few, 99, 247P
 Fibrinolytic activity, 99, 206P
 Fibrinolysis, 99, 149P
 Field stimulation, 101, 505P
 Flosequinan, 100, 440P, 441P
 Flumazenil, 99, 134P, 257P
 Food intake, 100, 420P; 101, 570P

Force of contraction, 99, 13P
 Formoterol, 99, 120P
 Forskolin, 99, 270P; 100, 425P
 FPL 63547, 99, 17P
 Fragments, 100, 481P
 Free radicals, 100, 325P, 454P; 101, 495P
 Frontal cortex, 99, 269P; 100, 307P
 Frusemide, 99, 50P; 100, 473P
 Frusemide/bumetanide, 100, 473P

Gallamine, 100, 366P
 Gallbladder, 101, 602P
 Ganglia, 99, 166P
 Gastric acid, 99, 222P
 Gastric damage, 99, 153P, 172P, 225P
 Gastric fundus, 99, 119P
 Gastric mucosa, rat, 100, 360P
 Gastrin/CCK, 100, 360P
 Gastrointestinal, 99, 224P
 Gastrointestinal smooth muscle, 101, 600P
 Gene expression, 100, 430P
 Gentamicin, 101, 513P
 Gepirone, 101, 517P
 G_i , 99, 117P
 Glibenclamide, 99, 10P; 100, 320P, 438P, 476P
 Global ischaemia, 99, 20P
 Glucocorticoid, 99, 126P, 164P; 101, 529P
 Glucose, 99, 39P; 100, 469P
 Glucose uptake, 101, 569P
 Glucose utilization, 99, 27P
 Glutamate, 99, 97P, 284P; 100, 381P; 101, 584P
 Glutamate receptors, 99, 265P; 100, 382P, 386P
 Glutathione, 99, 298P
 Glyceryl trinitrate, 100, 326P
 Glycine, 99, 280P, 284P; 100, 378P
 Glycine receptors, 100, 387P
 Gonadotrophins, 100, 338P
 Gpp(NH)p, 99, 76P
 G proteins, 99, 269P
 GR 38032F, 99, 238P, 243P; 100, 309P, 414P
 GR 43175, 99, 221P
 GR71251, 99, 62P, 63P
 Guanine nucleotides, 99, 145P
 Guanosine 3',5'monophosphate, cyclic, 99, 110P, 198P, 208P; 100, 364P
 Gut, mouse, 101, 601P

Head-twitches, 99, 248P
 Heart, guinea-pig, 99, 151P, 233P; 101, 543P
 Heart, rat, 99, 21P
 Heart failure, 99, 16P, 49P, 122P
 Hemicholinium-3, 101, 561P
 HHSiD and p-F-HHSiD, 101, 500P
 High affinity uptake, 100, 396P
 Hippocampus, 99, 90P, 97P, 98P, 141P, 270P, 276P, 279P; 100, 384P; 101, 498P, 499P
 Histamine, 99, 224P; 100, 390P; 101, 589P
 Histamine-H2 antagonists, 99, 275P; 101, 556P
 Histamine release, 100, 449P
 Histamine secretion, 100, 334P
 D.L.Homocysteic acid, 101, 585P
 Human breast cancer cell, 101, 549P, 550P
 Human parietal cells, 101, 604P
 Human subjects, 99, 193P
 Huntington's chorea, 99, 81P
 Hybridisation, in situ, 99, 105P, 197P
 Hydrogen peroxide, 100, 376P
 Hydrolysis of phosphoinositides, 99, 205P
 15-Hydroperoxyeicosatetraenoic acid, 99, 289P
 8-Hydroxy-2-(di-n-propylamino)tetralin, 99, 28P, 35P, 38P, 236P; 100, 464P; 101, 538P
 6-Hydroxydopamine, 101, 535P
 12 Hydroxyeicosatetraenoic acid, 99, 46P
 5-Hydroxyindolacetic acid, 101, 583P
 15-Hydroxyprostaglandin dehydrogenase, 99, 189P
 5-Hydroxytryptamine, 99, 26P, 27P, 40P, 41P, 216P, 218P, 220P, 239P, 240P, 242P, 243P, 246P, 260P; 100, 305P, 308P, 319P, 349P, 394P, 396P, 399P, 411P, 453P, 467P; 101, 516P, 519P, 557P, 583P
 5-Hydroxytryptamine_{1A}, 99, 29P, 34P, 236P, 244P; 101, 559P
 5-Hydroxytryptamine₁ agonists, 101, 520P
 5-Hydroxytryptamine_{1A} agonists, 99, 30P, 39P; 100, 410P
 5-Hydroxytryptamine₃, 99, 51P, 214P; 100, 395P
 5-Hydroxytryptamine₃ agonists, 101, 560P
 5-Hydroxytryptamine₄, 99, 215P
 5-Hydroxytryptamine₃ agonists, 99, 32P
 5-Hydroxytryptamine₂ antagonism, 99, 217P
 5-Hydroxytryptamine₃ antagonists, 99, 245P
 5-Hydroxytryptamine₂ ligands, 100, 410P
 5-Hydroxytryptamine₁-like receptors, 99, 221P; 100, 483P
 5-Hydroxytryptamine₃ receptor antagonists, 100, 309P, 484P

H1 antagonists, 100, 389P
 HA-966, 99, 280P
 Haemodynamics, 99, 301P; 100, 463P
 Halofantrine, 99, 296P

5-Hydroxytryptamine receptors, 99, 31P, 182P, 219P; 100, 485P
 5-Hydroxytryptamine_{1A} receptors, 99, 27P
 5-Hydroxytryptamine_{1C} receptors, 99, 241P
 5-Hydroxytryptamine_{1D} receptors, 99, 25P
 5-Hydroxytryptamine₂ receptors, 99, 241P; 100, 306P, 397P
 5-Hydroxytryptamine₃ receptors, 99, 32P, 33P, 238P; 100, 307P, 398P; 101, 598P
 5-Hydroxytryptamine₄ receptors, 99, 216P; 100, 319P; 101, 598P
 5-Hydroxytryptamine receptor subtypes, 99, 36P
 5-Hydroxytryptamine release, 99, 23P, 25P
 5-Hydroxytryptamine terminal autoreceptor, 99, 25P
 5-Hydroxytryptamine uptake, 99, 237P; 101, 515P
 Hypereosinophilia, 99, 190P
 Hyperresponsiveness, 99, 65P, 84P; 100, 369P, 370P
 Hypertension, 99, 18P; 100, 328P, 361P; 101, 533P
 Hypertensive rabbits, 101, 509P
 Hypertensive rat, 99, 48P
 Hypnotics, 99, 255P
 Hypoinsulinaemic effects, 99, 38P
 Hypophagia, 99, 241P
 Hypotension, 99, 152P
 Hypothalamo-pituitary-adrenal axis, 101, 503P
 Hypothalamus, 99, 265P; 101, 502P, 586P
 Hypoxia, 100, 320P, 459P, 460P

 ICI 170809, 99, 214P, 217P
 Idazoxan, 99, 274P; 100, 418P
 Ifenprodil, 100, 316P
 Ileocolonic junction, 99, 52P
 Ileum, guinea-pig, 99, 51P, 182P, 216P; 100, 360P, 484P; 101, 597P, 598P
 [³H]-Iloprost, 99, 145P
 Imidazoline agonists, 100, 465P
 Indorenate, 99, 36P
 Inflammation, 99, 42P, 86P, 108P, 146P, 147P, 167P; 101, 527P
 Inhibition, 100, 468P
 Inhibitor H-7, 99, 289P
 Inhibitory factor, 99, 187P
 IIIIn-neutrophils, 99, 83P
 Inositol phosphates, 99, 89P, 90P, 125P, 140P, 159P; 100, 311P, 362P; 101, 501P
 Inositol phospholipid, 100, 390P
 [³H]-Inositol polyphosphates, 100, 315P
 Inositol (1,4,5)trisphosphate, 99, 92P; 100, 364P, 374P
 Inotropic agent, 100, 321P
 Ins(1,4,5)P₃ analogues, 99, 88P
 Insulin, 101, 569P
 Interferon α₂-receptor, 101, 549P
 Interleukin-1, 99, 94P, 147P, 148P, 160P
 Interleukin 1β, 99, 162P
 Interleukin 6, 99, 162P
 Interleukin-8, 101, 530P
 Interstitial fluid, 99, 20P
 Intestinal propulsion, 99, 302P
 Intestinal smooth muscle, 101, 599P
 Intestine, 99, 111P; 100, 482P
 Intracellular calcium, 99, 44P, 176P; 100, 311P, 427P; 101, 501P
 Intracellular Ca²⁺ antagonist, 99, 12P
 Intracellular Ca release, 99, 2P
 Intracellular Ca²⁺ stores, 100, 368P
 Intracellular recording, 99, 26P
 Intracerebral dialysis, 100, 401P
 In vitro model, 101, 547P
 In vitro: in vivo metabolism, 99, 128P
 Ions, 100, 395P
 Ipsapirone, 101, 558P
 Iron, 101, 495P
 Irritant dermatitis, 99, 160P
 Ischaemia, 99, 19P, 98P, 277P, 283P, 285P; 100, 355P, 437P, 438P, 442P
 Ischaemia, global, 99, 20P
 Ischaemic arrhythmias, 99, 14P
 Ischaemic cardiomyopathy, 99, 117P
 Isolated tissues, 99, 217P
 Isomerisation mechanism, 99, 158P
 Isoprenaline, 99, 115P, 122P
 Ivermectin, 101, 552P

 Jejunum, rat, 100, 486P
 Journal statistics, 99, 157P
 Journal submissions, 99, 157P

 Ketotifen, 99, 165P
 Kidney, human, 101, 512P
 Kidney, rat, 100, 328P, 432P, 436P
 Kidney epithelial cells, 99, 110P
 Kidney function, 99, 195P; 100, 327P
 Kindling, 100, 387P
 Kinin, 101, 512P

 Lack of effect, 99, 214P
 L-DOPA, 101, 496P
 L-DOPA plus carbidopa, 99, 80P
 Learning, 99, 254P; 101, 517P

Learning and memory, 99, 246P
 Lemakalim, 100, 369P, 476P
 Leptazol, 99, 275P
 Lesioning, 100, 403P
 Leukocytes, 99, 150P
 Leukotriene B₄, 100, 376P; 101, 526P
 Leukotriene D₄, 101, 593P
 Leukotriene D₄ antagonists, 101, 543P
 Leukotrienes, 99, 170P; 100, 477P, 487P
 LiCl, 100, 421P
 Ligand binding, 99, 121P
 Lignocaine, 99, 235P
 Lipocortin 1, 99, 164P
 Lithium, 99, 23P, 73P; 100, 305P
 Liver, 99, 92P, 296P; 100, 463P
 Liver aryl esterase, 99, 300P
 Liver enzymes, 100, 490P
 Liver perfusion, 101, 547P
 Locomotor activity, 100, 408P, 409P; 101, 574P
 Long-term potentiation, 101, 498P
 Luminal NH₃, 99, 223P
 Lung, 99, 189P
 Lungs, guinea-pig, 99, 65P
 Lymph node, sheep, 101, 539P
 Lymphoblasts, 100, 470P
 Lymphocytes, 99, 165P

 Macrophages, 99, 108P, 174P
 MAO-B inhibition, 99, 69P
 Marmoset, 99, 262P; 101, 572P
 Mast cells, 99, 170P; 100, 333P, 334P
 M&B 22,948, 99, 112P
 MDL 72832, 99, 34P; 100, 415P
 Meclofenamate, 99, 19P
 α-Melanocyte-stimulating hormone, 101, 586P
 Membrane currents, 99, 12P
 Membrane permeability, 99, 299P; 101, 511P
 Memory, 100, 417P
 Menthol, 101, 600P
 Mesenteric lymphatic vessels, 101, 505P
 Mesenteric vascular bed, 99, 199P
 Mesolimbic dopamine, 99, 259P
 Metabolism, 99, 296P; 101, 552P
 Methodology, 99, 68P
 Methohexitone, 100, 393P
 5-Methoxytryptamine, 99, 215P
 N-methyladrenaline, 99, 67P
 N-methyl-D-aspartate, 99, 95P, 280P, 283P; 100, 380P, 381P
 N-methyl-D-aspartate receptor, 99, 281P; 100, 316P, 317P, 378P, 379P, 382P, 383P; 101, 586P
 N-methyl-D-aspartate receptor antagonism, 99, 96P
 α,β-Methylene ATP, 101, 594P
 2-Methyl-5-HT, 99, 215P; 100, 484P
 1-Methyl-4-phenylpyridinium (MPP⁺), 100, 335P
 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 100, 402P; 101, 572P
 MPTP-treated marmosets, 100, 336P
 Methylxanthines, 100, 337P
 Mice, 99, 139P
 Microdialysis, 101, 502P, 519P
 Micturition reflex, 99, 177P
 Midazolam, 99, 256P; 101, 585P
 Midbrain section, ferret, 100, 406P
 Middle cerebral artery, 100, 454P
 MK801, 99, 285P, 286P; 100, 317P
 Monoamine oxidase, 101, 516P
 [³H]-Monoamines, 99, 68P
 NG-monomethyl L-arginine, 99, 104P
 Mononuclear leukocytes, 99, 115P
 Morphine, 100, 426P; 101, 556P
 Morris water maze, 100, 312P
 Motoneurons, 100, 308P, 394P
 Mucosa, 100, 478P, 480P
 Multiple system atrophy, 99, 81P
 Muscarinic, 99, 292P
 Muscarinic agonists, 99, 155P
 Muscarinic receptors, 99, 55P, 56P, 140P, 156P; 100, 362P, 363P, 452P; 101, 500P
 Muscarinic receptor subtypes, 100, 366P
 Muscimol, 100, 486P
 Muscle, 99, 196P, 250P
 Muscle contraction, 99, 11P
 Myeloperoxidase, 100, 437P
 Myenteric plexus, 99, 291P
 Myocardial adenine nucleotides, 100, 323P
 Myocardial hypertrophy, 99, 228P
 Myocardial ischaemia, 99, 231P
 Myocardium, 99, 12P; 101, 542P
 Myocardium, human, 99, 13P
 Myofibroblasts, 99, 168P
 Myo-inositol, 100, 429P
 Myometrium, human, 99, 179P, 180P

 N-0437, 100, 352P
 Nafazatrom, 99, 21P
 Nafenodone, 101, 540P
 Naftidrofuryl oxalate, 101, 521P
 Naltrindole, 99, 290P
 Nasal airway resistance, 101, 594P
 Nasal vascular resistance, 101, 594P
 Nausea, 100, 421P; 101, 573P
 Nephrotoxicity, 101, 513P
 Nerve conduction, 100, 429P
 Nerve growth factor, 101, 582P
 Neuroblastoma cells, 99, 33P
 Neurochemistry, 99, 274P

Neurodegeneration, 99, 96P; 100, 384P
 Neurohumoral agents, 99, 183P
 Neurokinin-A, 99, 288P; 101, 581P
 Neurokinin receptors, 99, 63P
 Neurokinins, 99, 177P; 100, 347P
 Neuromuscular junction, 99, 227P
 Neuronal, 99, 182P
 Neuropeptide Y, 99, 179P, 199P
 Neuropeptides, 100, 353P
 Neuroprotection, 99, 95P; 100, 317P
 Neurotensin, 101, 578P, 579P, 580P
 Neurotransmission, 100, 473P
 Neurotransmitter release, 100, 348P
 Neutrophil adhesion, 99, 42P
 Nicotine, 99, 75P, 253P, 259P, 266P; 100, 417P
 Nicotinic receptors, 99, 166P, 197P; 100, 313P
 Niculdipine, 99, 205P
 Nigra, 99, 28P, 261P
 Niguldipine, 99, 71P
 Nitrates, 100, 461P
 Nitric oxide, 99, 103P, 106P, 107P, 108P, 110P, 111P; 100, 326P, 327P, 333P
 Nitro-arginine, 100, 327P
 N^G-nitro-L-arginine methyl ester, 100, 452P
 Nitroprusside, 99, 208P
 Nitrovasodilators, 99, 106P, 112P
 NK-1 receptors, 99, 62P
 Nociception, 101, 556P
 Non-adrenergic, non-cholinergic, 99, 52P
 Non-cholinergic transmission, 99, 181P
 Non- α_2 -idazoxan binding sites, 100, 392P
 Non-opioid analgesia, 99, 135P
 Noradrenaline, 99, 43P; 101, 536P, 542P
 Noradrenaline overflow, 99, 178P
 Noradrenaline release, 99, 219P, 265P, 266P; 100, 393P; 101, 567P
 NPY, 100, 481P
 Nucleoside transport inhibitor, 99, 14P
 Nucleotide phosphodiesterase, cyclic, 100, 443P
 Nucleotides, cyclic, 100, 367P, 466P, 475P
 Nucleus accumbens, 99, 136P

 Oedema formation, 99, 94P
 Oestradiol, 99, 224P
 Olfactory cortex slices, 101, 500P, 571P
 Ondansetron, 99, 238P; 100, 309P, 414P; 101, 561P, 562P
 Operant behaviour, 99, 72P

 Opioid analgesia, 99, 139P
 Opioid antagonists, 101, 554P
 Opioid binding, 99, 291P
 κ -opioid receptor, 99, 24P; 101, 553P
 Opioid receptors, 101, 555P
 δ -Opioid receptor antagonist, 99, 290P
 Opioids, 99, 51P; 100, 478P, 482P; 101, 553P
 Ovabain, 99, 4P
 Oxidative phosphorylation, 100, 323P
 Oxidising agents, 99, 168P
 Oxytocin, 100, 419P
 Ozone, 99, 191P

 Pancuronium, 100, 432P
 Parafluorohexahydrosiladifenidol, 99, 56P
 Parenchyma, 100, 369P
 Parkinson's disease, 99, 156P, 262P; 100, 313P, 336P; 101, 495P
 Parkinsonism, 100, 385P
 [³H]-Paroxetine, 99, 237P; 101, 515P
 Patch clamp, 100, 388P
 Pentobarbital metabolism, 100, 490P
 Pentobarbitone, 99, 278P
 Peppermint oil, 101, 600P
 Pepsin, 99, 226P
 Peptide analogues, 101, 580P
 Peptides, 99, 127P, 184P
 Perfused mesentery, rat, 100, 464P
 Perfusion, 100, 467P
 Parietal cells, 101, 604P
 Perinephritis hypertension, 99, 125P
 Peripheral hyperalgesia, 99, 288P
 Permeability, 100, 372P, 477P
 Permeabilized cells, 99, 144P
 Pertussis, 99, 65P
 Pertussis toxin, 99, 124P, 143P
 pH, 99, 226P
 Phaclofen, 99, 251P; 101, 570P
 Pharmacokinetics, 99, 128P; 101, 496P, 546P
 Ph CL 28A, 99, 21P
 Phorbol esters, 99, 159P; 100, 311P; 101, 501P
 Phosphatidic acid, 99, 91P
 Phosphatidylcholine, 101, 504P
 Phosphatidylinositol, 99, 73P
 Phosphatidylinositol hydrolysis, 100, 466P
 Phosphodiesterase I, II, III, 100, 441P
 Phosphodiesterase inhibitors, 99, 18P, 163P; 100, 324P, 336P, 364P, 475P
 Phosphodiesterase isoenzyme selective inhibitors, 100, 443P
 Phosphoinositide hydrolysis, 101, 533P

Phosphoinositide metabolism, 100, 363P
 Phosphoinositides, 100, 391P; 101, 504P, 532P, 534P
 Phospholipase D, 99, 91P; 100, 343P
 Photoaffinity label, 99, 171P
 Physostigmine, 100, 493P
 Pica, 100, 421P
 Picrotoxin, 99, 275P
 Pilocarpine-seizures, 99, 73P
 Pinacidil, 101, 599P
 Pindolol, 99, 228P
 [³H]PK11195, 100, 355P
 Placenta, 100, 334P
 Plasma cholesterol, 101, 544P
 Plasma esterases, 100, 493P
 Placental brush border, 101, 523P
 Plasma protein extravasation, 99, 85P
 Platelet, human, 99, 112P; 100, 443P
 Platelet activating factor, 99, 58P, 82P, 83P, 86P, 87P, 173P, 174P; 100, 374P, 375P, 448P
 PAF-acether, 99, 175P
 PAF-antagonist, 99, 84P, 85P, 87P, 175P
 Platelets, 99, 83P, 113P; 100, 324P, 325P, 444P; 101, 522P
 Platelet shape change, 101, 521P
 Plethysmography, 101, 595P
 Pleurisy, 99, 150P
 Plus-maze, 99, 135P
 Polyamines, 100, 382P
 Polycations, 99, 146P
 Polymerase chain reaction, 99, 105P
 Polymorphonuclear leukocyte, 99, 93P
 Polymyxin B, 100, 383P
 Porcine skin, 99, 160P
 Portal vein, 100, 462P
 Post-mortem human brain, 99, 237P, 271P; 101, 494P
 Post-natal, 101, 494P
 Potassium, 99, 4P, 196P; 100, 458P
 K⁺ channel openers, 99, 1P, 8P; 100, 329P, 331P, 367P, 457P, 474P; 101, 592P, 599P
 Potassium channels, 99, 5P, 6P, 7P, 9P, 194P; 100, 330P; 101, 591P
 Potassium thiocyanate, 100, 381P
 Potency, 100, 442P
 Potentiation, 101, 531P
 Prazosin pA₂, 99, 204P
 Presynaptic, 99, 55P
 Primate, 101, 577P
 Progesterone, 100, 330P
 Progestins and anti-progestines, 101, 549P, 550P
 Prolactin, 99, 31P; 101, 551P
 Propafenone, 101, 541P
 Prostacyclin, 99, 100P; 101, 524P
 Prostacyclin receptors, 99, 145P, 171P
 Prostaglandin₂, 99, 93P; 100, 471P
 Prostaglandin E analogues, 99, 180P
 Prostaglandins, 99, 21P, 109P, 189P, 202P; 101, 522P, 527P
 Prostate, 99, 176P
 Protein kinase C, 99, 23P, 159P; 101, 530P, 589P
 Pulmonary artery pressure, 100, 460P
 Pulmonary arterioles, 100, 370P
 Pulmonary circulation, 100, 458P, 459P
 Pulmonary nerves, 101, 591P
 Pupil diameter, 99, 211P
 Purinoceptors, 101, 507P, 531P
 P_{2X}-receptor antagonist, competitive, 100, 342P
 P_{2X}-receptors, 100, 341P, 343P; 101, 531P
 Purposeless chewing, 99, 77P; 100, 314P
 Pyramidal neurones, 100, 377P
 Pyrogen, 99, 162P; 100, 447P
 Raclopride binding, 99, 267P
 Radioimmunoassay, 99, 127P, 207P
 Radioligand binding, 100, 395P, 492P
 Raphe nucleus, 99, 236P, 244P; 100, 349P
 Raphe obscurus, 99, 30P
 Rapid eye movement sleep, 99, 78P
 Rat tail artery, 99, 44P
 Rat tail vasculature, 100, 467P
 Raw soya flour, 99, 287P
⁸⁶Rb⁺ efflux, 99, 6P; 100, 322P
 Rearing, 100, 424P
 Receptor activation, 99, 144P
 Receptor binding, 99, 263P; 100, 403P, 404P; 101, 580P, 581P, 582P
 Receptors, 99, 114P; 100, 436P, 455P; 101, 521P
 α-Receptors, 101, 505P
 Recombinant tissue plasminogen activator, 99, 149P
 Recovery, 99, 131P
 Regional hemodynamics, 99, 8P; 100, 329P
 Relaxation, 99, 46P
 Relaxation rate, 100, 428P
 Relaxants, 100, 488P
 Relaxin, 99, 10P
 Release, 99, 277P
 Renal blood flow, 99, 195P
 Renal failure, 100, 433P
 Renal function, 99, 109P; 100, 435P, 437P
 Renal proximal tubular cells, 101, 513P
 Renal tubular fragments, 101, 514P
 Reperfusion, 99, 231P; 100, 438P, 451P

Repetitive nerve firing, 99, 294P
 Repolarisation, 99, 15P, 230P
 Respiratory burst, 101, 526P
 Responses, 100, 468P
 Re-uptake, 99, 68P
 Re-uptake inhibition, 100, 404P
 Ritanserin, 100, 397P
 Ro 19-6327, 99, 69P
 Ro 31-6930, 101, 592P
 Rodents, 101, 563P
 Rolipram, 100, 336P
 Rotation, 100, 347P
 RS-15385-197, 99, 123P, 272P
 [³H] RX821002, 100, 345P
 Rubidium, 99, 239P
 Ruthenium red, 99, 186P

Salbutamol, 99, 66P; 101, 528P
 Salivary secretion, 101, 603P
 Salmeterol, 99, 120P; 100, 489P
 Saphenous artery, 99, 53P
 Sarafotoxin, 99, 114P, 154P, 207P, 209P
 Sarafotoxin S6b, 100, 455P
 SCH 23390, 99, 78P
 Schizophrenia, 99, 97P, 270P
 Scopolamine, 100, 309P; 101, 562P, 565P
 Second messengers, 99, 71P, 143P
 Secretion, 100, 479P
 Seizure threshold, 100, 392P
 Seizures, 99, 261P, 282P
 Selective, 101, 596P
 M₂-Selective antagonist, 99, 295P
 Sensitized guinea-pigs, 101, 595P
 SH-SY5Y cells, 99, 88P
 SH-SY5Y neuroblastoma cells, 99, 143P
 Sibubramine HCl, 99, 74P, 264P
 Sigma, 100, 380P, 416P
 Signal transduction, 99, 147P
 Silicotic-fibrosis, 99, 168P
 Simvastatin, 101, 544P
 Skeletal muscle, 99, 256P
 SKF 38393, 99, 77P
 Smooth muscle, 99, 2P, 176P, 212P; 101, 539P, 602P
 Smooth vascular muscle, 99, 45P
 Sodium dependency, 99, 267P
 Sodium excretion, 100, 435P
 Sodium/potassium, 100, 469P, 470P
 Spermine, 99, 298P
 Spinal cord, rabbit, 101, 553P
 Spinal cord, rat, 99, 197P; 100, 308P, 394P
 Spontaneous rhythm, 101, 539P
 Spontaneously hypertensive rats, 99, 7P, 228P
 [³H]SQ29,852, 99, 142P

Statistical analysis, 100, 408P
 Staurosporine, 101, 589P
 Stereoselective hepatic clearance, 101, 547P
 Stereotypy, 101, 588P
 Steroid receptor, 100, 446P
 Stereospecificity, 100, 415P
 Stimulus modulation, 99, 204P
 Stomach, guinea-pig, 99, 9P, 223P
 Stone maze, 101, 565P
 Stress, 100, 338P
 Striatum, 99, 258P, 284P; 100, 348P, 353P, 405P
 Submandibular blood flow, 101, 603P
 Substance P, 99, 64P, 186P, 191P; 100, 430P
 Substantia nigra, 100, 347P; 101, 579P
 Suicide, 99, 271P
 Suicide transport, 100, 377P
 Sulfonylurea's, 100, 331P, 457P
 Sulphasalazine, 100, 449P
 Sulpiride/NO437 ratio, 99, 263P
 Sumatriptan, 99, 37P
 Superoxide anion, 99, 188P
 Suramin, 100, 342P
 Surfactants, 99, 299P
 Sustained hyperalgesia, 99, 289P
 Sympathetic nerve, 99, 70P
 Sympathetic nerve activity, 101, 520P
 Sympathetic neurotransmission, 101, 590P
 Sympathoinhibitory effects, 99, 8P
 Synaptic transmission, 100, 378P; 101, 499P
 Synaptosomes, 99, 292P, 297P; 100, 335P, 431P
 Synthesis, 100, 386P

Tachyphylaxis, 99, 152P
 Tail artery, 101, 506P, 535P
 Taludipine, 100, 332P, 442P
 Tamoxifen, 101, 551P
 Ternary complex, 99, 158P
 [³⁵S] Tertiary butyl bicyclopophosphorothionate, 100, 424P
 Tetanus toxin, 99, 96P; 100, 384P
 Tetrahydroaminoacridine, 100, 379P, 401P
 Theophylline, 99, 50P
 Theta rhythm, 99, 155P
 Thromboxane, 99, 113P
 Thromboxane B₂, 99, 173P
 Thromboxane antagonists, 101, 527P
 Thromboxane biosynthesis, 100, 375P
 Thromboxane receptor antagonist, 99, 59P, 60P, 61P
 Thromboxane receptors, 101, 525P
 Thyrotrophin-releasing hormone, 100, 310P; 101, 502P, 551P

Thyrotrophin-releasing hormone analogue, 100, 312P
 Tissue ACE, 99, 17P
 Tissue retention, 100, 491P
 T-Maze, 101, 561P
 Tocolysis, 99, 180P
 Tolerance, 101, 587P
 Torpedo, 99, 55P
 Toxicity, 99, 298P
 Trachea, 99, 56P
 Trachea, co-axial, 100, 371P
 Trachea, guinea-pig, 99, 4P, 58P, 63P, 184P, 194P; 100, 365P, 367P, 371P, 472P, 475P, 590P
 Trachea, isolated, 99, 54P
 Trachea, rat, 99, 219P
 Trachea, superfused, 99, 185P
 Tracheal mucus velocity, 99, 64P
 Transit, 100, 479P
 Transmitter release, 99, 129P, 136P
 Transmitter releasing axons, 101, 571P
 Tricyclic antidepressants, 100, 356P
 (+)-Tubocurarine, 99, 294P
 Tumour necrosis factor, 100, 445P
 Twitch, 100, 428P
 Tyrosine hydroxylase, 99, 75P

U937 monocyte cells, 99, 173P; 101, 530P
 U46619, 99, 59P, 60P, 61P
 UK-52,046, 99, 234P
 Uptake/release, 99, 284P
 Uric acid, 101, 583P
 Urinary bladder, 99, 181P
 Uterine blood vessel, 99, 201P
 Uterus, 99, 179P; 100, 462P, 487P
 Uterus, rat, 99, 10P; 100, 488P

Valproate, 99, 251P
 Vascular activity, 99, 47P
 Vascular bed, rat, 99, 99P
 Vascular contractions, 99, 122P
 Vascular reactivity, 99, 106P
 Vascular smooth muscle, 99, 118P, 200P, 218P; 100, 330P, 453P; 101, 508P, 541P
 Vas deferens, 99, 132P; 100, 359P, 481P
 Vasoactive intestinal peptide, 100, 480P
 Vasoconstriction, 99, 44P
 Vasodilatation, 99, 103P
 Vasodilators, 99, 47P, 198P; 100, 458P, 459P
 Vasopressin, 100, 338P; 101, 573P
 Vasorelaxation, 99, 6P
 Vasospasm, 99, 220P

Vecuronium, 100, 432P
 Venom, phoneutria nigriventer, 101, 508P
 Ventricular fibrillation, 99, 231P
 Ventricle, guinea-pig, 100, 441P
 Ventromedial nucleus of the hypothalamus, 100, 348P
 Volkensin, 100, 377P
 Voltammetry, 99, 258P; 100, 353P, 399P, 400P; 101, 578P

Water-maze, 101, 562P, 566P
 Weanling rats, 99, 137P
 Weight gain, 99, 137P
 Western blotting, 99, 164P
 Whole cell patch recording, 100, 427P
 Withdrawal, 99, 245P; 100, 354P

Xanthines, 99, 141P

Yeast, 99, 299P
 Yohimbine, 100, 413P

Zacopride, 101, 560P
 ZK 110.841, 99, 93P
 ZK 119817, 99, 171P
 Zolpidem, 99, 255P
 Zona glomerulosa cells, 99, 40P